FIELD OF THE INVENTION This invention is in the field of pharmaceutical agents and specifically relates to compounds, compositions, uses and methods for treating inflammation, angiogenesis and cancer.

BACKGROUND OF THE INVENTION Protein kinases represent a large family of proteins which play a central role in the regulation of a wide variety of cellular processes, maintaining control over cellular function. A partial list of such kinases includes abl, Akt, bcr-abl, Blk, Brk, Btk, c-kit, c-Met, c-src, c-fms, CDK1, CDK2, CDK3, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDK10, cRafl, CSF1R, CSK, EGFR, ErbB2, ErbB3, ErbB4, Erk Fak, fes, FGFR1, FGFR2, FGFR3, FGFR4, FGFR5, Fgr, flt-1, Fps, Frk, Fyn, Hck, IGF-1R, INS-R, Jak, KDR, Lck, Lyn, MEK, p38, PDGFR, PIK, PKC, PYK2, ros, tie, tie2, TRK, Yes, and Zap70. Inhibition of such kinases has become an important therapeutic target.

Certain diseases are known to be associated with deregulated angiogenesis, for example ocular neovascularisation, such as retinopathies (including diabetic retinopathy), age-related macular degeneration, psoriasis, hemangioblastoma, hemangioma, arteriosclerosis, inflammatory disease, such as a rheumatoid or rheumatic inflammatory disease, especially arthritis (including rheumatoid arthritis), or other chronic inflammatory disorders, such as chronic asthma, arterial or post-transplantational atherosclerosis, endometriosis, and neoplastic diseases, for example so-called solid tumors and liquid tumors (such as leukemias).

At the center of the network regulating the growth and differentiation of the vascular system and its components, both during embryonic development and normal growth, and in a wide number of pathological anomalies and diseases, lies the angiogenic factor known as Vascular Endothelial Growth Factor" (VEGF ; originally termed'Vascular Permeability Factor", VPF), along with its cellular receptors (see G. Breier et al. , Trends in Cell Biology, 6: 454-456 (1996)).

VEGF is a dimeric, disulfide-linked 46-kDa glycoprotein related to"Platelet-Derived Growth Factor" (PDGF); it is produced by normal cell lines and tumor cell lines; is an endothelial cell-specific mitogen; shows angiogenic activity in in vivo test systems (e. g. rabbit cornea); is chemotactic for endothelial cells and monocytes; and induces plasminogen activators in endothelial cells, which are involved in the proteolytic degradation of extracellular matrix during the formation of capillaries. A number of isoforms of VEGF are known, which show comparable biological activity, but differ in the type of cells that secrete them and in their heparin-binding capacity. In addition, there are other members of the VEGF family, such as"Placenta Growth Factor" (PIGF) and VEGF-C.

VEGF receptors (VEGFR) are transmembranous receptor tyrosine kinases. They are

characterized by an extracellular domain with seven immunoglobulin-like domains and an intracellular tyrosine kinase domain. Various types of VEGF receptor are known, e. g. VEGFR-1 (also known as flt-1), VEGFR-2 (also known as KDR), and VEGFR-3.

A large number of human tumors, especially gliomas and carcinomas, express high levels of VEGF and its receptors. This has led to the hypothesis that the VEGF released by tumor cells stimulates the growth of blood capillaries and the proliferation of tumor endothelium in a paracrine manner and through the improved blood supply, accelerate tumor growth. Increased VEGF expression could explain the occurrence of cerebral edema in patients with glioma. Direct evidence of the role of VEGF as a tumor angiogenesis factor in vivo is shown in studies in which VEGF expression or VEGF activity was inhibited. This was achieved with anti-VEGF antibodies, with dominant-negative VEGFR-2 mutants which inhibited signal transduction, and with antisense-VEGF RNA techniques. All approaches led to a reduction in the growth of glioma cell lines or other tumor cell lines in vivo as a result of inhibited tumor angiogenesis.

Angiogenesis is regarded as an absolute prerequisite for tumors which grow beyond a diameter of about 1-2 mm; up to this limit, oxygen and nutrients may be supplied to the tumor cells by diffusion.

Every tumor, regardless of its origin and its cause, is thus dependent on angiogenesis for its growth after it has reached a certain size.

Three principal mechanisms play an important part in the activity of angiogenesis inhibitors against tumors: 1) Inhibition of the growth of vessels, especially capillaries, into avascular resting tumors, with the result that there is no net tumor growth owing to the balance that is achieved between cell death and proliferation; 2) Prevention of the migration of tumor cells owing to the absence of blood flow to and from tumors; and 3) Inhibition of endothelial cell proliferation, thus avoiding the paracrine growth- stimulating effect exerted on the surrounding tissue by the endothelial cells which normally line the vessels. See R. Connell and J. Beebe, Exp. Opin. Ther. Patents, 11: 77-114 (2001).

VEGF's are unique in that they are the only angiogenic growth factors known to contribute to vascular hyperpermeability and the formation of edema. Indeed, vascular hyperpermeability and edema that is associated with the expression or administration of many other growth factors appears to be mediated via VEGF production.

Inflammatory cytokines stimulate VEGF production. Hypoxia results in a marked upregulation of VEGF in numerous tissues, hence situations involving infarct, occlusion, ischemia, anemia, or circulatory impairment typically invoke VEGF/VPF-mediated responses. Vascular hyperpermeability, associated edema, altered transendothelial exchange and macromolecular extravasation, which is often accompanied by diapedesis, can result in excessive matrix deposition, aberrant stromal proliferation, fibrosis, etc.

Hence, VEGF-mediated hyperpermeability can significantly contribute to disorders with these etiologic features. As such, regulators of angiogenesis have become an important therapeutic target.

The hepatocyte growth factor receptor ("c-Met") is a unique receptor tyrosine kinase shown to be overexpressed in a variety of malignancies. c-Met typically comprises, in its native form, a 190-kDa heterodimeric (a disulfide-linked 50-kDa a-chain and a 145-kDa P-chain) membrane-spanning tyrosine

kinase protein (Proc. Natl. Acad. Sci. USA, 84: 6379-6383 (1987) ). c-Met is mainly expressed in epithelial cells and stimulation of c-Met leads to scattering, angiogenesis, proliferation and metastasis.

(See Cytokine and Growth Factor Reviews, 13: 41-59 (2002)).

The ligand for c-Met is hepatocyte growth factor (also known as scatter factor, HGF and SF).

HGF is a heterodimeric protein secreted by cells of mesodermal origin (Nature, 327: 239-242 (1987); J.

Cell Biol. , 111: 2097-2108 (1990)).

Various biological activities have been described for HGF through interaction with c-met (Hepatocyte Growth Factor-Scatter Factor (HGF-SF) and the c-Met Receptor, Goldberg and Rosen, eds., Birkhauser Verlag-Basel, 67-79 (1993). The biological effect of HGF/SF may depend in part on the target cell. HGF induces a spectrum of biological activities in epithelial cells, including mitogenesis, stimulation of cell motility and promotion of matrix invasion (Biochem. Biophys. Res. Comm. , 122: 1450- 1459 (1984); Proc. Natl. Acad. Sci. U. S. A. , 88: 415-419 (1991) ). It stimulates the motility and invasiveness of carcinoma cells, the former having been implicated in the migration of cells required for metastasis. HGF can also act as a"scatter factor", an activity that promotes the dissociation of epithelial and vascular endothelial cells (Nature, 327: 239-242 (1987) ; J. Cell Biol., 111: 2097-2108 (1990); EMBO J. , 10: 2867-2878 (1991); Proc. Natl. Acad. Sci. USA, 90: 649-653 (1993) ). Therefore, HGF is thought to be important in tumor invasion (Hepatocyte Growth Factor-Scatter Factor (HGF-SF) and the C-Met Receptor, Goldberg and Rosen, eds. , Birkhauser Verlag-Basel, 131-165 (1993)).

HGF and c-Met are expressed at abnormally high levels in a large variety of solid tumors. High levels of HGF and/or c-Met have been observed in liver, breast, pancreas, lung, kidney, bladder, ovary, brain, prostate, gallbladder and myeloma tumors in addition to many others. The role of HGF/c-Met in metastasis has been investigated in mice using cell lines transformed with HGF/c-Met (J. Mol. Med., 74: 505-513 (1996) ). Overexpression of the c-Met oncogene has also been suggested to play a role in the pathogenesis and progression of thyroid tumors derived from follicular epithelium (Oncogene, 7: 2549- 2553 (1992) ). HGF is a morphogen (Development, 110: 1271-1284 (1990); Cell, 66: 697-711 (1991) ) and a potent angiogenic factor (J. Cell Biol. , 119: 629-641 (1992)).

Recent work on the relationship between inhibition of angiogenesis and the suppression or reversion of tumor progression shows great promise in the treatment of cancer (Nature, 390: 404-407 (1997) ), especially the use of multiple angiogenesis inhibitors compared to the effect of a single inhibitor.

Angiogenesis can be stimulated by HGF, as well as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF).

Angiogenesis, the process of sprouting new blood vessels from existing vasculature and arteriogenesis, the remodeling of small vessels into larger conduit vessels are both physiologically important aspects of vascular growth in adult tissues. These processes of vascular growth are required for beneficial processes such as tissue repair, wound healing, recovery from tissue ischemia and menstrual cycling. They are also required for the development of pathological conditions such as the growth of neoplasias, diabetic retinopathy, rheumatoid arthritis, psoriasis, certain forms of macular degeneration, and certain inflammatory pathologies. The inhibition of vascular growth in these contexts has also shown

beneficial effects in preclinical animal models. For example, inhibition of angiogenesis by blocking vascular endothelial growth factor or its receptor has resulted in inhibition of tumor growth and in retinopathy. Also, the development of pathological pannus tissue in rheumatoid arthritis involves angiogenesis and might be blocked by inhibitors of angiogenesis.

The ability to stimulate vascular growth has potential utility for treatment of ischemia-induced pathologies such as myocardial infarction, coronary artery disease, peripheral vascular disease, and stroke.

The sprouting of new vessels and/or the expansion of small vessels in ischemic tissues prevents ischemic tissue death and induces tissue repair. Certain diseases are known to be associated with deregulated angiogenesis, for example ocular neovascularization, such as retinopathies (including diabetic retinopathy), age-related macular degeneration, psoriasis, hemangioblastoma, hemangioma, arteriosclerosis, inflammatory disease, such as a rheumatoid or rheumatic inflammatory disease, especially arthritis (including rheumatoid arthritis), or other chronic inflammatory disorders, such as chronic asthma, arterial or post-transplantational atherosclerosis, endometriosis, and neoplastic diseases, for example so-called solid tumors and liquid tumors (such as leukemias). Treatment of malaria and related viral diseases may also be mediated by HGF and cMet.

Elevated levels of HGF and c-Met have also been observed in non-oncological settings, such as hypertension, myocardial infarction and rheumatoid arthritis. It has been observed that levels of HGF increase in the plasma of patients with hepatic failure (Gohda et al. , supra) and in the plasma (Hepatol., 13: 734-750 (1991)) or serum (J. Biochem. , 109: 8-13 (1991)) of animals with experimentally induced liver damage. HGF has also been shown to be a mitogen for certain cell types, including melanocytes, renal tubular cells, keratinocytes, certain endothelial cells and cells of epithelial origin (Biochem. Biophys. Res.

Commun. , 176: 45-51 (1991); Biochem. Biophys. Res. Commun., 174: 831-838 (1991); Biochem. , 30: 9768-9780 (1991); Proc. Natl. Acad. Sci. USA, 88: 415-419 (1991) ). Both HGF and the c-Met protooncogene have been postulated to play a role in microglial reactions to CNS injuries (Oncogene, 8: 219-222 (1993)).

In view of the role of HGF and/or c-Met in potentiating or promoting such diseases or pathological conditions, it would be useful to have a means of substantially reducing or inhibiting one or more of the biological effects of HGF and its receptor. Thus a compound that reduces the effect of HGF would be a useful compound.

T cells play a pivotal role in the regulation of immune responses and are important for establishing immunity to pathogens. In addition, T cells are often activated during inflammatory autoimmune diseases, such as rheumatoid arthritis, inflammatory bowel disease, type I diabetes, multiple sclerosis, Sjogren's disease, myasthenia gravis, psoriasis, and lupus. T cell activation is also an important component of transplant rejection, allergic reactions, and asthma.

T cells are activated by specific antigens through the T cell receptor (TCR) which is expressed on the cell surface. This activation triggers a series of intracellular signaling cascades mediated by enzymes expressed within the cell (Kane, LP et al. Current Opinion in Immunol. 200,12, 242). These cascades lead to gene regulation events that result in the production of cytokines, like interleukin-2 (IL-2). IL-2 is a

critical cytokine in T cell activation, leading to proliferation and amplification of specific immune responses.

One class of enzymes shown to be important in signal transduction is the kinase enzymes Members of the Src-family of tyrosine kinases include, for example: Lck, Fyn (B), Fyn (T), Lyn, Src, Yes, Hck, Fgr and Blk (for review see: Bolen, JB, and Brugge, JS Annu. Rev. Immunol 1997,15, 371). Gene disruption studies suggest that inhibition of some members of the src family of kinases would potentially lead to therapeutic benefit. Src (-/-) mice have abnormalities in bone remodeling or osteopetrosis (Soriano, P. Cell 1991,64, 693), suggesting that inhibition of this kinase might be useful in diseases of bone resorption, such as osteoporosis. Lck (-/-) mice have defects in T cell maturation and activation (Anderson, SJ et al. Adv. Immunol. 1994, 56, 151), suggesting that inhibition of this kinase might be useful in diseases of T cell mediated inflammation. In addition, human patients have been identified with mutations effecting Lck kinase activity (Goldman, FD et al. J. Clin. Invest. 1998,102, 421). These patients suffer from a severe combined immunodeficiency disorder (SCID).

Without wishing to imply that the compounds disclosed in the present invention possess pharmacological activity only by virtue of an effect on a single biological process, it is believed that the compounds modulate T cell activation by way of inhibition of one or more of the multiple protein tyrosine kinases involved in early signal transduction steps leading to T cell activation, for example by way of inhibition of Lck kinase.

Src-family kinases are also important for signaling downstream of other immune cell receptors.

Fyn, like Lck, is involved in TCR signaling in T cells (Appleby, MW et al. Cell 1992,70, 751). Hck and Fgr are involved in Fcy receptor signaling leading to neutrophil activation (Vicentini, L. et al. J. Immunol.

2002,168, 6446). Lyn and Src also participate in Fcy receptor signaling leading to release of histamine and other allergic mediators (Turner, H. and Kinet, J-P Nature 1999,402, B24). These findings suggest that Src family kinase inhibitors may be useful in treating allergic diseases and asthma.

PCT publication WO 03/000660 describes substituted phenyl compounds. Substituted quinolines are described in US patent No. 6,143, 764. WO 02/32872 describes substituted quinolines. WO 00/47212 describes substituted quinazoline derivatives.

Compounds of the current invention have not been described for the treatment of cancer and inflammation.

DESCRIPTION OF THE INVENTION A class of compounds useful in treating cancer and angiogenesis is defined by Formula I

wherein R is selected from substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, H, substituted or unsubstituted alkyl, and substituted or unsubstituted alkenyl and substituted or unsubstituted alkynyl; wherein R'is selected from substituted or unsubstituted 5-14-membered nitrogen containing heterocyclyl; wherein A is an optionally substituted ten membered bicyclic ring comprising at least one aromatic ring; wherein X is selected from O, S, NR2 and CR3R4 ; wherein Y is selected from-NRb(CR3R4)p-, -NRbC(=O)(CR3R4)p-, -NRbC(=O)NRb(CR3R4)p-, - NRbC(=O)(CR3R4)pO-, -NRbC(=O)O(CR3R4)p-, -NRbC (=S) (CR3R4)p-, -NRbC(=NR2)(CR3R4)p-, - <BR> <BR> <BR> NRbS02- (CR3R4-C (=O(CR3R4-O (CR3R4-,- (CR3R4) p-S (=O),- (CR3R4,-<BR> NR@SO2-(CR3R4)p-, -OC(=O)(CR3R4)p-, -O(CR3R4)p-, -(CR3R4)p-S(=O)t-, -(CR3R4)p-, - S(=O)2NRb(CR3R4)p-, -S(=O)t(CR3R4)p-, -C(=O)(CR3R4)p-, -C(=NRa)NH(CR3R4)p-, - C(=S)NH(CR3R4)p- and -C(=O)NH(CR3R4)p-; wherein Y is in either direction; wherein Ra and Rb is each independently selected from H, alkyl, heterocyclyl, aryl, arylalkyl, heterocyclylalkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, R5R5N-(C=O)-, and W- (=O)- ; wherein each of Ra and Rb is optionally substituted; wherein R2 is selected from H, alkyl, haloalkyl, aryl, heterocyclyl, arylalkyl, heterocyclylalkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl and R5-carbonyl ; wherein R3 and R4 is each independently selected from H, alkyl, aryl, heterocyclyl, arylalkyl, heterocyclylalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, R6 and alkyl substituted with R6 ; wherein Rus vis selected from H, alkyl, haloalkyl, arylalkyl, heterocyclylalkyl, cycloalkylalkyl, aryl, heterocyclyl, alkenyl, alkynyl and cycloalkyl ; wherein R6 is selected from cyano,-OR2,-SR2, halo,-SO2R2,-C (=O) R,-SO2NR R,-NR'C (=O) OR, NR'C (=O) NR5R2,-NR5C (=O) R2, -CO2R2, -C(=O)NR2R5 and -NR2R5 ; wherein p is 0,1, 2, or 3; and wherein t is 0,1 or 2; and pharmaceutically acceptable derivatives thereof ; provided R is not methyl when Y is-C02-.

The invention also relates to compounds of Formula I wherein R is selected from H, 6-10 membered aryl, 4-10 membered heterocyclyl, 4-6 membered cycloalkyl, C1-6-alkyl, C2-6-alkenyl and C26- alkynyl; wherein R is substituted or unsubstituted; in conjunction with any of the above or below embodiments.

The invention also relates to compounds of Formula I wherein R is phenyl or naphthyl; in conjunction with any of the above or below embodiments.

The invention also relates to compounds of Formula I wherein R is a substituted or unsubstituted heterocyclyl ring selected from pyrrolidinyl, pyrrolyl, imidazolyl, pyrazolyl, pyrazinyl, pyrimidinyl, pyridyl, quinolinyl, isoquinolinyl, 2,3-dihydrobenzofuryl, 2, 3-dihydro-1, 4-benzodioxinyl, 1,3- benzodioxolyl, isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, furanyl, and thienyl; in conjunction with any of the above or below embodiments.

The invention also relates to compounds of Formula I wherein R is 4-6 membered cycloalkyl selected from cyclobutyl, cyclopentyl and cyclohexyl; in conjunction with any of the above or below embodiments.

The invention also relates to compounds of Formula I wherein R is selected from methyl, ethyl, propyl, butyl and pentyl; in conjunction with any of the above or below embodiments.

The invention also relates to compounds of Formula I wherein R is selected from ethenyl and propenyl; in conjunction with any of the above or below embodiments.

The invention also relates to compounds of Formula I wherein R is H; in conjunction with any of the above or below embodiments.

The invention also relates to compounds of Formula I wherein A is selected from

wherein R'is selected from H, halo and C, 3-alkyl ; and pharmaceutically acceptable derivatives thereof; in conjunction with any of the above or below embodiments.

The invention also relates to compounds of Formula I wherein R'is selected from 6-membered heterocyclyl and 9-10-membered bicyclic heterocyclyl; in conjunction with any of the above or below embodiments.

The invention also relates to compounds of Formula I wherein R'is selected from 9-10- membered bicyclic heteroaryl; in conjunction with any of the above or below embodiments.

The invention also relates to compounds of Formula I wherein R'is wherein ring T is selected from phenyl and 5-6-membered heteroaryl ; wherein Z is selected from N or CH; wherein R'° is one or more substituents selected from R50-; and wherein R5 is selected from C, 6-alkyl, C, 6-haloalkyl, C, 6-alkylamino-C, 6-alkyl, aryl-C, 6-alkyl, heterocyclyl-C, 6-alkyl, cycloalkyl-C, 6- alkyl, aryl, heterocyclyl, and cycloalkyl ; in conjunction with any of the above or below embodiments.

The invention also relates to compounds of Formula I wherein R'is selected from

and wherein R'° is selected from C, 3-alkoxy, C, 3-alkylamino-C, 3-alkoxy, phenyl-C, 3-alkoxy, 5-6 membered heterocyclyl-C, 3-alkoxy and C46-cycloalkyl-C, 3-alkoxy ; in conjunction with any of the above or below embodiments.

The invention also relates to compounds of Formula I wherein R'is selected from 6,7-dimethoxy- 4-quinolinyl, 6-methoxy-7- (dimethylaminopropoxy)-4-quinolinyl, 6, 7-dimethoxy-4-quinazolinyl, and 6- methoxy-7- (dimethylaminopropoxy)-4-quinazolinyl ; in conjunction with any of the above or below embodiments.

The invention also relates to compounds of Formula I wherein Y is selected from-NH (CH2) p-, - NHC (=O) (CH2) p-, -NHC (=O) (CH2) pO-, -NHC (=O) O (CH2) p-,- (CH2) p-NHC (=O)-,-NHC (=O) NH-, - C (=O) O-,-NHSO2-, and-C (=O) NH (CH2) p- ; and wherein p is 0,1, or 2; in conjunction with any of the above or below embodiments.

The invention also relates to compounds of Formula I wherein Y is selected from-NH-,-NHCH2- ,-NH (CHz) 2-, -NH (CH2) 3-, -NHC (=O) CH2-,-NHC (=O) (CH2) 2-,-NHC (=O)-,-NHC (=O) CH20-,- NHC (=O) OCH2-,-NHC (=O) NH-,- (CH2) NHC (=O)-,-C (=O) O-,-NHSO2-, and-C (=O) NHCH2- ; in conjunction with any of the above or below embodiments.

The invention also relates to compounds of Formula I wherein R is selected from ethyl, isopropyl, (CH3) 3CCH2-, ethenyl, and an unsubstituted or substituted ring selected from phenyl, cyclobutyl, cyclopentyl, cyclohexyl, 2-pyrrolidinyl, 2-pyrrolyl, 5-imidazolyl, 5-pyrazolyl, 2-pyrazinyl, 4-pyrimidinyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 8-quinolinyl, 2,3-dihydrobenzofur-7-yl, 2, 3-dihydro-1, 4-benzodioxin-5-yl, 1, 3-benzodioxol-4-yl, 4-isoxazolyl, 3-isothiazolyl, 5-oxazolyl, 4-thiazolyl, 5-thiazolyl, 2-furanyl, 3- furanyl, 3-thienyl and 2-thienyl; wherein A is naphthyl; wherein X is-0-or-CH2- ; wherein Y is selected from-NHC (=O)-,-NHC (=O) (CH2)-,-NHC (=O) (CH2) 2-,- (CH2) p-NHC (=O)-,-NHC (=O) NH- and- NHSOz- ; and wherein R'is selected from 6, 7-dimethoxy-4-quinolinyl, 6-methoxy-7- (dimethylaminopropoxy)-4-quinolinyl, 6,7-dimethoxy-4-quinazolinyl, and 6-methoxy-7- (dimethylaminopropoxy)-4-quinazolinyl ; and pharmaceutically acceptable derivatives thereof; in conjunction with any of the above or below embodiments.

The invention also relates to compounds of Formula I and pharmaceutically acceptable salts thereof selected from N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-2-naphthalenyl)-2- (methyloxy) benzamide; N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-5-fluoro-2-naphthalenyl)-2-thiophenecarboxamide ; <BR> <BR> <BR> N- {5-fluoro-6- [6-methoxy-7- (3-morpholm-4-yl-propoxy)-qumolin-4-yloxy]-naphthalen-2-y !}- 2-methoxy-benzamide; N- (6- ( (6, 7-bis (methyloxy) -4-quinolinyl) oxy)-2-naphthalenyl)-7-fluoro-2, 3-dihydro-1, 4-benzodioxine-5- carboxamide; N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-2-naphthalenyl)-5-fluoro-2- (methyloxy) benzamide ; N- (6- ( (6, 7-bis (methyloxy) -4-quinolinyl) oxy) -2-naphthalenyl)-3-cyanobenzamide ; N- (6- ( (6, 7-bis (methyloxy) -4-quinolinyl) oxy) -2-naphthalenyl) cyclobutanecarboxamide; N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-2-naphthalenyl)-2- (2-thienyl) acetamide; N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-2-naphthalenyl)-2- (ethyloxy) benzamide; N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-2-naphthalenyl)-4- (methyloxy)-3-thiophenecarboxamide ; N- (6- ( (6, 7-bis (methyloxy) -4-quinolinyl) oxy) -2-naphthalenyl)-3-methyl-2-thiophenecarboxamide ; N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-2-naphthalenyl)-5-chloro-2- (methyloxy) benzamide; N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-2-naphthalenyl)-2- (methyloxy)-3-pyridinecarboxamide ; N- (6- ( (6, 7-bis (methyloxy) -4-quinolinyl) oxy) -2-naphthalenyl)-2-thiophenecarboxamide ; N- (6- ( (6, 7-bis (methyloxy) -4-quinolinyl) oxy) -2-naphthalenyl)-3-bromobenzamide ; N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-2-naphthalenyl)-1-methyl-I H-imidazole-5-carboxamide ; N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-2-naphthalenyl)-4- (methyloxy) benzamide; N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-5-fluoro-2-naphthalenyl)-3-thiophenecarboxamide ; N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-5-fluoro-2-naphthalenyl)-4- (methyloxy)-3- thiophenecarboxamide; N- (6- ( (6, 7-bis (methyloxy) -4-quinolinyl) oxy)-5-fluoro-2-naphthalenyl)-5-fluoro-2- (methyloxy) benzamide; N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-5-fluoro-2-naphthalenyl)-2- (methyloxy) benzamide; N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-5-fluoro-2-naphthalenyl) benzamide; N- (5-fluoro-6- ( (6- (methyloxy)-7- ( (3- (4-morpholinyl) propyl) oxy)-4-quinolinyl) oxy) -2-naphthalenyl)-2- thiophenecarboxamide; N- (5-fluoro-6- ( (6- (methyloxy)-7- ( (3- (4-morpholinyl) propyl) oxy)-4-quinolinyl) oxy)-2-naphthalenyl)-3- thiophenecarboxamide; 3- (acetylamino)-N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-2-naphthalenyl) benzamide; N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-5-fluoro-2-naphthalenyl)-2- (methyloxy)-3- pyridinecarboxamide; and N- (6- ( (6- (methyloxy)-7- ( (3- (4-morpholinyl) propyl) oxy)-4-quinolinyl) oxy)-2-naphthalenyl)-2- thiophenecarboxamide.

The invention also relates to compounds of Formula I' wherein R is selected from a) substituted or unsubstituted aryl, b) substituted or unsubstituted heterocyclyl, c) substituted or unsubstituted cycloalkyl, d) substituted or unsubstituted cycloalkenyl, e) H, f) substituted or unsubstituted alkyl, g) substituted or unsubstituted alkenyl, h) substituted or unsubstituted alkynyl, i) alkylaminocarbonyl, j) aminocarbonyl, and k) cyano; wherein R'is wherein ring T is selected from phenyl and 5-6-membered heteroaryl ; wherein Z is selected from N or CR' ; wherein R"is selected from H, CN, NHZ, F, alkylcarbonylamino, and alkylaminocarbonyl; wherein R'° is one or more substituents selected from H, C, 6-alkoxy, C, 6- haloalkoxy, C, 6-alkylamino-C, 6-alkoxy, aryl-Cl 6-alkoxy, heterocyclyl-C, 6-alkoxy, cycloalkyl- C, 6-alkoxy, heterocyclyl-C, 6-(hydroxyalkoxy), cycloalkyl-C, 6-(hydroxyalkoxy), aryl-C, 6- (hydroxyalkoxy), C, 6-alkoxyalkoxy, aryloxy-C, 6-alkoxy, heterocyclyloxy-C, 6-alkoxy, cycloalkyloxy-C, 6-alkoxy, aryloxy, heterocyclyloxy, and cycloalkyloxy; ; wherein R"is selected from amino, alkylamino, alkoxy, aminocarbonyl, alkylaminocarbonyl and H, wherein A is selected from the following:

wherein X is selected from O, S, NR2 and CR3R4 ; wherein Y is selected from-NRb (CR3R4) p-,-NRbC (=O) (CR3R4) -,-NRbC (=O) NRb (CR3R4) p-,- NRbC(=O)(CR3R4)pO-, -NRbC(=O)O(CR3R4)p-, -NRbC(=S)(CR3R4)p-, -NRbC(=NRa)(CR3R4)p-, - NRbSO2-(CR3R4)p-, -OC(=O)(CR3R4)p-, -O(CR3R4)p-, -(CR3R4)p-S(=O)t-, -(CR3R4)p-, - S(=O)2NRb(CR3R4)p-, -S(=O)t(CR3R4)p-, -C(=O)(CR3R4)p-, -C(=O)S(CR3R4)p-, - C (=NRa) NRb (CR3R4) P,-C (=S) NH (CR'R4) p- and -C(=O)NRb(CR3R4)p-; wherein Y is in either direction;

wherein Ra and Rb is each independently selected from H, alkyl, heterocyclyl, aryl, arylalkyl, heterocyclylalkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, R5R5N-(C=o)-, and R5- (=O)- ; wherein each of Ra and Rb is optionally substituted; wherein RC, Rd, Re and Rr is each independently selected from H, and C, -3-alkyl ; wherein each of RC, Rd, Re and Rf is optionally substituted; wherein R2 is selected from H, alkyl, haloalkyl, aryl, heterocyclyl, arylalkyl, heterocyclylalkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl and W-carbonyl ; wherein R3 and R4 is each independently selected from H, alkyl, aryl, heterocyclyl, arylalkyl, heterocyclylalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, R6 and alkyl substituted with R6 ; wherein Rus ils selected from H, alkyl, haloalkyl, arylalkyl, heterocyclylalkyl, cycloalkylalkyl, aryl, heterocyclyl, alkenyl, alkynyl and cycloalkyl ; wherein R6 is selected from cyano, -OR2, -SR2, halo,-SO2R2,-C (=O) R2, -SO2NR2R5, -NR5C (=O) OR2,- NR'C (=O) NR5R2, -NR5C (=O) R2,-CO2R2,-C (=O) NRzR' and-NR2R5 ; wherein R7 is selected from H, halo and C1-3-alkyl ; wherein R'° is one or more substituents selected from C, 6-alkoxy, C, 6-haloalkoxy, C, 6-alkylamino-C, 6- alkoxy, aryl-C, 6-alkoxy, heterocyclyl-C, 6-alkoxy, cycloalkyl-C, 6-alkoxy, heterocyclyl-C, 6- (hydroxyalkoxy), cycloalkyl-C, 6-(hydroxyalkoxy), aryl-C, 6-(hydroxyalkoxy), C, 6-alkoxyalkoxy, aryloxy-C, 6-alkoxy, heterocyclyloxy-C, 6-alkoxy, cycloalkyloxy-C, 6-alkoxy, aryloxy, heterocyclyloxy, and cycloalkyloxy ; wherein p is 0,1, 2, or 3; and wherein t is 0,1 or 2; wherein each alkyl, aryl, heteroaryl, cycloalkyl, alkenyl, alkynyl, heterocyclyl, and alkoxy moiety of any R, R', R2, R3, R4, R5, Ra and Rb is optionally substituted with one or more groups selected from halo,- NH2,-OH,-COzH, (C,-C6) alkylamino, (C,-C6) alkyl, C,-C6) alkoxy, C,-C6) haloalkyl, di (C,- C6) alkylamino, (C,-C6) alkylamino-(C1-C6)alkyl, (C1-C6)hydroxyalkylamino, (C1-C6)alkylamino-(C1- C6) alkylamino, phenyl, and heterocyclyl; and pharmaceutically acceptable derivatives thereof; provided R is not methyl when Y is-CO2-or-0-.

The invention also relates to compounds wherein R is selected from H, 6-10 membered aryl, 4-10 membered heterocyclyl, 3-6 membered cycloalkyl, C, 6-alkyl, C26-alkenyl and C26-alkynyl ; wherein R is substituted or unsubstituted.

The invention also relates to compounds wherein R is optionally substituted phenyl or optionally substituted naphthyl.

The invention also relates to compounds wherein R is a substituted or unsubstituted heterocyclyl ring selected from pyrrolidinyl, pyrrolyl, imidazolyl, pyrazolyl, pyrazinyl, pyrimidinyl, pyridyl, quinolinyl, isoquinolinyl, tetrahydrofuryl, 2,3-dihydrothiazolyl, 2,3-dihydrobenzofuryl, 2, 3-dihydro-1, 4- benzodioxinyl, 1,3-benzodioxolyl, benzisoxazolyl, benzthiazolyl, benzimidazolyl, benzothiadiazolyl,

indolinyl, imidazo [1, 2-a] pyridyl, isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, thiadiazolyl, furanyl, and thienyl.

The invention also relates to compounds wherein R is selected from 1-methyl-cyclopropyl, cyclopropyl, 2-fluorocyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

The invention also relates to compounds wherein R is selected from methyl, trifluoromethyl, ethyl, propyl, butyl and pentyl.

The invention also relates to compounds wherein R is selected from cyclohexenyl, ethenyl and propenyl.

The invention also relates to compounds wherein R is H.

The invention also relates to compounds wherein R is dimethylamino.

The invention also relates to compounds wherein A is selected from

and The invention also relates to compounds wherein A is i z I R\ T J N The invention also relates to compounds wherein R'is selected from R1o ;

wherein ring T is selected from phenyl and 5-6-membered heteroaryl; wherein Z is selected from N or CH; wherein R'° is one or more substituents selected from R8O-; and wherein R8 is selected from C, 6- alkyl, C, 6-haloalkyl, C, 6-alkylamino-C, 6-alkyl, aryl-C, 6-alkyl, heterocyclyl-C, 6-alkyl, cycloalkyl-C, 6- <BR> <BR> alkyl, heterocyclyl-C, 6-(hydroxyalkyl), cycloalkyl-C, 6-(hydroxyalkyl), aryl-C, 6-(hydroxyalkyl), C, 6- alkoxyalkyl, aryloxy-C, 6-alkyl, heterocyclyloxy-C, 6-alkyl, cycloalkyloxy-C, 6-alkyl, aryl, heterocyclyl, and cycloalkyl.

The invention also relates to compounds wherein R'is selected from and wherein R'° is selected from C, 3-alkoxy, C, 3-alkylamino-C, 3-alkoxy, 5-6 membered heterocyclyl-C1- 3-alkoxy, C4-6cycloalkyl-C1-3-alkoxy, 5-6 membered heterocyclyl-C1-3-(hydroxyalkoxy), C3-6-cycloalkyl- C1-3-(hydroxyalkoxy), phenyl-C1-3-(hydroxyalkoxy), C1-2-alkoxy-C1-3-alkoxy, phenyloxy-C1-3alkoxy, 5-6 membered heterocyclyloxy-C1-4-alkoxy, cycloalkyloxy-C1-3-alkoxy, 5-6 membered heterocyclyloxy, and C3-6-cycloalkyloxy.

The invention also relates to compounds wherein R'is selected from pyrrolo [2, 3-dJpyrimidin4- yl, pyrazolo [3,4-b] pyridine-4-yl, 2-amincarbonyl-4-pyridyl, 2-methylamincarbonyl-4-pyridyl, 2- methylaminopyrimidin-4-yl, 2-aminopyrimidin-4-yl, 6, 7-dimethoxy-4-quinolinyl, 6-methoxy-7-

(dimethylaminopropoxy)-4-quinolinyl, 6-methoxy-7- (4-morpholinylpropoxy)-4-quinolinyl, 6, 7- dimethoxy-4-quinazolinyl, and 6-methoxy-7- (dimethylaminopropoxy)-4-quinazolinyl.

The invention also relates to compounds wherein Y is selected from-NH (CH2) p-,- NHC (=O) (CH2) p-,-NHC (=O) (CH2) pO-,-NHC (=O) O (CH2) p-, QCH2) p-NHC (=O)-,-NHC (=O) NH-,- C (=O) O-,-NHSO2-, and-C (=O) NH (CH2) p- ; and wherein p is 0,1, or 2.

The invention also relates to compounds wherein Y is selected from-NH-,-NHCH2-,-NH (CH2) 2- ,-NH (CH2) 3-, -NHC (=O) CH2-,-NHC (=O) (CH2) 2-,-NHC (=O)-,-NHC (=O) CH20-,-NHC (=O) OCH2-,- NHC (=O) NH-,- (CH2) NHC (=O)-,-C (=O) O-,-NHSO2-, and-C (=O) NHCH2-.

The invention also relates to compounds wherein R is selected from ethyl, isopropyl, (CH3) 3CCH2-, ethenyl, and an unsubstituted or substituted ring selected from phenyl, cyclobutyl, cyclopentyl, cyclohexyl, 2-pyrrolidinyl, 2-pyrrolyl, 5-imidazolyl, 5-pyrazolyl, 2-pyrazinyl, 4-pyrimidinyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 8-quinolinyl, 2,3-dihydrobenzofur-7-yl, 2, 3-dihydro-1, 4-benzodioxin-5-yl, 1, 3-benzodioxol-4-yl, 4-isoxazolyl, 3-isothiazolyl, 5-oxazolyl, 4-thiazolyl, 5-thiazolyl, 2-furanyl, 3- furanyl, 3-thienyl and 2-thienyl; wherein A is naphthyl; wherein X is-O-or-CH2-; wherein Y is selected from-NHC (=O)-,-NHC (=O) (CH2)-,-NHC (=O) (CH2) 2-,- (CH2) p-NHC (=O)-,-NHC (=O) NH- and- NHS02- ; and wherein R'is selected from 6, 7-dimethoxy4-quinolinyl, 6-methoxy-7- (dimethylaminopropoxy)-4-quinolinyl, 6, 7-dimethoxy-4-quinazolinyl, and 6-methoxy-7- (dimethylaminopropoxy)-4-quinazolinyl.

The invention also relates to compounds selected from N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-2-naphthalenyl)-2- (methyloxy) benzamide; N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-5-fluoro-2-naphthalenyl)-2-thiophenecarboxamide ; <BR> <BR> <BR> <BR> N- {5-fluoro-6-[6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinolin -4-yloxy]-naphthalen-2-yl}-2- methoxy-benzamide; N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-2-naphthalenyl)-7-fluoro-2, 3-dihydro-1, 4-benzodioxine-5- carboxamide; N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-2-naphthalenyl)-5-fluoro-2- (methyloxy) benzamide; N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-2-naphthalenyl)-3-cyanobenzamide ; N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy) -2-naphthalenyl) cyclobutanecarboxamide ; N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-2-naphthalenyl)-2- (2-thienyl) acetamide; N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-2-naphthalenyl)-2- (ethyloxy) benzamide; N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-2-naphthalenyl)-4- (methyloxy)-3-thiophenecarboxamide ; N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-2-naphthalenyl)-3-methyl-2-thiophenecarboxamide ; N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-2-naphthalenyl)-5-chloro-2- (methyloxy) benzamide; N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-2-naphthalenyl)-2- (methyloxy)-3-pyridinecarboxamide ; N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-2-naphthalenyl)-2-thiophenecarboxamide ; N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-2-naphthalenyl)-3-bromobenzamide ; N46-((6a7-bis (methyloxy)-4-quinolinyl) oxy)-2-naphthalenyl)-1-methyl-lH-imidazole-5-carboxamide ;

N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-2-naphthalenyl)-4- (methyloxy) benzamide; N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-5-fluoro-2-naphthalenyl)-3-thiophenecarboxamide ; N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-5-fluoro-2-naphthalenyl)-4- (methyloxy)-3- thiophenecarboxamide; N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-5-fluoro-2-naphthalenyl)-5-fluoro-2- (methyloxy) benzamide; N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-5-fluoro-2-naphthalenyl)-2- (methyloxy) benzamide; N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-5-fluoro-2-naphthalenyl) benzamide; N-(5-fluoro-6-((6-(methyloxy)-7-((3-(4-morpholinyl)propyl)ox y)-4-quinolinyl)oxy)-2-=naphthalenyl)-2- thiophenecarboxamide; N- (S-fluoro-6- ( (6- (methyloxy)-7- ( (3- (4-morpholinyl) propyl) oxy)-4-quinolinyl) oxy)-2-naphthalenyl)-3- thiophenecarboxamide; 3- (acetylamino)-N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-2-naphthalenyl) benzamide; N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-5-fluoro-2-naphthalenyl)-2- (methyloxy)-3- pyridinecarboxamide; and N-(6-((6-(methyloxy)-7-((3-(4-morpholinyl)propyl)oxy)-4-quin olinyl)-2-naphthalenyl)-2- thiophenecarboxamide.

The invention also relates to compounds of Formula II wherein Xa is O or CH2 ; wherein Ya is selected from-NH (CH2) p-,-NHC (=O) (CH2) p-,-NHC (=O) (CH2) pO-,- (CH2) p-NHC (=O)-,- NHC (=O) NH-, -NHC (=O) O (CH2) p-,-C (=O) O-,-NHSO2-, and-C (=O) NH (CHZ) P ; wherein p is 0,1, 2, or 3; or Y is a bond if R is thienyl; wherein Z is CH or N; wherein R'is selected from H, C, 5-alkyl, C24-alkenyl, and an unsubstituted or substituted ring selected from phenyl, C36-cycloalkyl, pyrrolidinyl, pyrrolyl, imidazolyl, pyrazolyl, pyrazinyl, pyrimidinyl, pyridyl, quinolinyl, 2,3-dihydrobenzofuryl, 2, 3-dihydro-1, 4-benzodioxinyl, 1,3- benzodioxolyl, isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, furanyl and thienyl ; wherein R8 is selected from H, fluoro, chloro and methyl ; wherein R9 is selected from H, methyl and fluoro ; and

wherein R'° is one or more substituents selected from 5 or 6-memebered heterocyclyl-C, _3-alkoxy, C, 2-alkylamino-C,-alkoxy, and C, 4-alkoxy ; and pharmaceutically acceptable derivatives thereof ; provided R is not methyl when Y is-CO2-.

The invention also relates to compounds of Formula II wherein Xa is O ; wherein ya is selected <BR> <BR> <BR> <BR> from-NHC (=O) (CH2) p-,-NHC (=O) (CH2) pO-,- (CH2) p-NHC (=O)-,-NHC (=O) NH-, -NHC (=O) O (CH2) p- ,-NHS02-, and-C (=O) NH (CH2) p- ; wherein p is 0,1, 2, or 3; wherein R'is selected from ethyl, isopropyl, (CH3) 3CCH2-, ethenyl, and an unsubstituted or substituted ring selected from phenyl, cyclobutyl, cyclopentyl, cyclohexyl, 2-pyrrolidinyl, 2-pyrrolyl, 5-imidazolyl, 5-pyrazolyl, 2-pyrazinyl, 4- pyrimidinyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 8-quinolinyl, 2,3-dihydrobenzofur-7-yl, 2, 3-dihydro-1, 4- benzodioxin-5-yl, 1, 3-benzodioxol-4-yl, 4-isoxazolyl, 3-isothiazolyl, 5-oxazolyl, 4-thiazolyl, 5-thiazolyl, 2-furanyl, 3-furanyl, 3-thienyl and 2-thienyl; wherein R'° is one or more substituents selected from 4- morpholinopropoxy, 1-pyrrolidinylethoxy, dimethylaminoethoxy, dimethylaminopropoxy and methoxy ; wherein R8 is H; and wherein R9 is H ; methyl or fluoro; and pharmaceutically acceptable derivatives thereof ; in conjunction with any of the above or below embodiments.

The invention also relates to compounds of Formula II wherein ya is selected from-NHC (=O)-,- NHC (=O) (CH2)-,-NHC (=O) (CH2) 2-,- (CH2) p-NHC (=O)-,-NHC (=O) NH-and-NHSO2-; and pharmaceutically acceptable derivatives thereof ; in conjunction with any of the above or below embodiments.

The invention also relates to compounds of Formula II wherein Ya is-NHC (=O)- ; and pharmaceutically acceptable derivatives thereof; in conjunction with any of the above or below embodiments.

The invention also relates to compounds of Formula II wherein R'is an unsubstituted or substituted ring selected from phenyl, cyclobutyl, cyclopentyl, cyclohexyl, 2-pyrrolidinyl, 2-pyrrolyl, 5- imidazolyl, 5-pyrazolyl, 2-pyrazinyl, 4-pyrimidinyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 8-quinolinyl, 2,3- dihydrobenzofur-7-yl, 2, 3-dihydro-1, 4-benzodioxin-5-yl, 1, 3-benzodioxol-4-yl, 4-isoxazolyl, 3- isothiazolyl, 5-oxazolyl, 4-thiazolyl, 5-thiazolyl, 2-furanyl, 3-furanyl, 3-thienyl and 2-thienyl; and pharmaceutically acceptable derivatives thereof ; in conjunction with any of the above or below embodiments.

The invention also relates to compounds of Formula II wherein R8 is H; and wherein R9 is H or fluoro ; and pharmaceutically acceptable derivatives thereof ; in conjunction with any of the above or below embodiments.

The invention also relates to compounds of

wherein Ya is selected from-NH (CH2) p-, -NHC (=O) (CH2) p-,-NHC (=O) (CH2) pO-,- (CH2) p-NHC (=O)-,- NHC (=O) NH-,-NHC (=O) O (CH2) p-, -C (=O) O-,-NHSO2-, and-C (=O) NH (CH2) p- ; wherein p is 0,1, 2, or 3; or Y is a bond if R is thienyl ; wherein R'is selected from H, C1-5-alkyl, C1-3-haloalkyl, C1-3alkoxy-C1-3-alkyl, C1-3-alkoxycarbonyl-C1-3- alkyl, C1-5-cyanoalkyl, aminocarbonyl-C1-5-alkyl, C1-5-alkyl-aminocarbonyl-C1-5-alkyl, amino-C1-5- alkyl, C, 5-alkyl-amino-C, _5-alkyl, C, 5-alkylsulfonyl-C, 5-alkyl, phenyl-C, 3-alkyl, C3. 6-cycloalkyl-C, _ 3-alkyl, 5-6-membered heterocyclyl-C, 3-alkyl, and an unsubstituted or substituted ring selected from phenyl, naphthyl, 1,3-benzodioxolyl, 2, 3-dihydro-1, 4-benzodioxinyl, C3_6-cycloalkyl, CS 6- cycloalkenyl, pyrrolidinyl, pyrrolyl, imidazolyl, pyrazolyl, pyrazinyl, pyrimidinyl, pyridyl, quinolinyl, dihydrothiazolyl, 2, 3-dihydrobenzofuryl, piperidinyl, 1-methyl-oxopyridyl, tetrahydropyran-4-yl, indolinyl, imidazo [1, 2-a] pyridinyl, quinolinyl, isoquinolinyl, tetahydroisoquinolinyl, benzofuryl, benzo [1, 2,5] thiadiazolyl, benzothiazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, thiadiazolyl, furanyl and thienyl; wherein R8 is selected from H, fluoro, chloro and methyl ; wherein R9 is selected from H, methyl and fluoro; and wherein R'°a is H or methoxy; and wherein R'°b is selected from 4-morpholinopropoxy, 2-hydroxy-3-morpholin-4-yl-propoxy, pyrrolidin-1-ylpropoxy, 1-pyrrolidinylethoxy, 4-piperidinyloxypropoxy, (4-methylpiperazin-1- yl) propoxy, 3- (4-methylpiperazin-1-yl) propoxy, 3- (1, 2, 4-triazol-1-yl) propoxy, triazinylpropoxy, 3- (piperidin4-yl) propoxy, dimethylaminoethoxy, dimethylaminopropoxy and methoxy; and pharmaceutically acceptable derivatives thereof ; provided R is not methyl when Y is-CO2-.

The invention also relates to compounds wherein ya is selected from-NHC (=O)-,- NHC (=O) (CH2)-,-NHC (=O) (CH2) 2-,-CH2-NHC (=O)-,-NHC (=O) NH- and -NHSO2-.

The invention also relates to compounds wherein Y is-NHC (=O)- or-NHC (=O) NH-.

The invention also relates to compounds wherein R'°a is methoxy; and wherein R'°b is selected from 4-morpholinopropoxy, 2-hydroxy-3-morpholin-4-yl-propoxy, pyrrolidin-1-ylpropoxy, 1- pyrrolidinylethoxy, 4-piperidinyloxypropoxy, (4-methylpiperazin-1-yl) propoxy, 3-(4-methylpiperazin-1-

yl) propoxy, 3- (1, 2, 4-triazol-1-yl) propoxy, triazinylpropoxy, 3- (piperidin-4-yl) propoxy, dimethylaminoethoxy, dimethylaminopropoxy and methoxy.

The invention also relates to compounds wherein R8 is H; and wherein R9 is H, methyl or fluoro; and pharmaceutically acceptable derivatives thereof.

The invention also relates to compounds wherein R'is selected from H, methyl, ethyl, n-butyl, isobutyl, tert-butyl, isopropyl, propyl, cyanomethyl, aminocarbonylmethyl, dimethylaminocarbonylmethyl, dimethylaminoethyl, 2-methoxy-1-methylethyl, methoxycarbonylmethyl, methoxyethyl, methoxypropyl, methylsulfonylethyl, dimethylaminoethyl, methoxycarbonylmethyl, ethenyl, thiazol-2-yl-CH (CH3) -, phenyl-CH (CH3) -, 5-methylisoxazol-3-ylmethyl, pyrrolidin-1-ylethyl, tetrahydrofur-2-ylmethyl, 4-methyl-2-oxo-oxazolidin-5-yl, pyrid4-ylmethyl, pyrid-2-ylmethyl, 2- trifluoromethylpyrid-5-ylmethyl, trifluoromethyl, 2,2, 2-trifluoroethyl, 3,3, 3-trifluoropropyl, (CH3) 3CCH2-, pentafluoroethyl, CF3CH2CH2-, cyclopropylmethyl, benzyl, 4-methylbenzyl, 4-chlorobenzyl, (2- methoxyphenyl) ethyl, 1-phenylethyl, phenylethyl, cyclopropyl, 1-methylcyclopropyl, 2- fluorocyclopropyl, 2-phenylcyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 5, 5-dimethyl-3- oxocyclohexenyl, phenyl, 4-methylphenyl, 3-methylphenyl, 2-methylphenyl, 3,4-dimethylphenyl, 3,5- dimethylphenyl, 4-ethylphenyl, 3-ethylphenyl, 2-ethylphenyl, 4-isopropylphenyl, 4-isopropyl-3- methylphenyl, 3-isopropylphenyl, 4-tert-butylphenyl, 2, 3-dimethylphenyl, 3-fluorophenyl, 4- fluorophenyl, 2-fluorophenyl, 2,4-difluorophenyl, 3, 4-difluorophenyl, 2,3-difluorophenyl, 2,6- difluorophenyl, 2,5-difluorophenyl, 3, 5-difluorophenyl, 2,4, 6-trifluorophenyl, 3-bromophenyl, 4- bromophenyl, 4-chlorophenyl, 3-chlorophenyl, 2-chlorophenyl, 4-methoxyphenyl, 3-methoxyphenyl, 2- methoxyphenyl, 3,4-dimethoxyphenyl, 2,6-dichlorophenyl, 3-fluoro-5-methoxyphenyl, 3-chloro-5- methoxyphenyl, 4-chloro-2-methoxyphenyl, 2, 4-dimethoxyphenyl, 2,6-dimethoxyphenyl, 3,5- dimethoxyphenyl, 2-ethoxyphenyl, 4-hydroxyphenyl, 2-hydroxyphenyl, 2, 5-dichlorophenyl, 2,4- dichlorophenyl, 2, 3-dichlorophenyl, 3, 5-dichlorophenyl, 3, 4-dichlorophenyl, 3, 4-difluorophenyl, 3- trifluoromethoxyphenyl, 4-trifluoromethoxyphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 3,5-di (trifluoromethyl)-phenyl, 3,5-di (trifluoromethyl)-2-methylphenyl, 4-dimethylaminophenyl, 3- dimethylaminophenyl, 3-nitrophenyl, 4-nitrophenyl, 3-cyanophenyl, 4-methylthiophenyl, 3- <BR> <BR> <BR> <BR> methylsulfonylphenyl, 2-methylsulfonylphenyl, 3-chloro-4-methylphenyl, 3-chloro-4-fluorophenyl, 4- [1- isopropylpiperazinin-4-yl] phenyl, 2- [ (l-methylpyrrolidin-3-yl)-N (CH3)]-5-trifluoromethylphenyl, 5- [1- <BR> <BR> <BR> <BR> methylpiperazin4-ylmethyl]-3-trifluoromethylphenyl, 5-[2-oxopyrrolidin-1-yl]-3-trifluoromethylphenyl, 2-chloro-4-trifluoromethylphenyl, 4-chloro-3-trifluoromethylphenyl, 4-bromo-2-fluorophenyl, 2- trifluoromethoxyphenyl, 2-trifluoromethylphenyl, 4-pentafluoroethylphenyl,-fluoro-3- <BR> <BR> <BR> <BR> trifluoromethylphenyl, 2-fluoro-5-triiluoromethylphenyl, 2-methyl-3-trifluoromethylphenyl, 2-methyl-5- trifluoromethylphenyl, 3-fluoro-5-trifluoromethylphenyl, 2- [methylcarbonylamino]-5- trifluoromethylphenyl, 3- [1-methylpiperidin-4-yl]-5-trifluoromethylphenyl, 2- [1, I-dioxo-thiomorpholin- <BR> <BR> <BR> <BR> 4-yl]-5-trifluoromethylphenyl, 2- [l-oxo-thiomorpholin-4-yl]-5-trifluoromethylphenyl, 2- [thiomorpholin-<BR> <BR> <BR> <BR> <BR> <BR> 4-yl]-5-trifluoromethylphenyl, 2-piperidin-1-yl-5-trifluoromethyl-phenyl, 2- [ (3- dimethylaminopropyl) methylarnino]-5-trifluoromethylphenyl, 2-(3-dimethylamino-pyrroldin-1-yl)-5-

trifluoromethylphenyl, 3- (methylcarbonylamino) phenyl, 3- (4-methylpiperazin-1-ymethyl) phenyl, 2- (4- methylpiperazin-1-ymethyl) phenyl, 2-piperidin-1-yl-5-trifluoromethyl-phenyl, 2- [1-methylpiperidin-4- yloxy]-5-trifluoromethylphenyl, 2-methoxy-5-trifluoromethylphenyl, 2-methoxy-5-phenylphenyl, 2- [3, 3- dimethyl-2-oxo-azetidin-1-yl]-5-trifluoromethylphenyl, 2- [morpholin-4-ylethoxy]-5-tert-butylphenyl, 2- methoxy-5-fluorophenyl, 2-methoxy-5-tert-butylphenyl, 3- [dimethylaminomethylcarbonylamino]-4-tert- butylphenyl, 2-methoxy-5- [2-pyridylaminocarbonyl] phenyl, 2-methoxy-5-phenylaminocarbonylphenyl, 2- [methyl- (l-methylpyrrolidin-3-yl) amino]-5-trifluoromethylphenyl, 2, 2-difluorobenzodioxol-4-yl, biphenyl, 2-naphthyl, 2, 3-dihydro-1, 4-benzodioxin-6-yl, 7-fluoro-2, 3-dihydro-1, 4-benzodioxin-6-yl, 1,3- benzodioxol-4-yl, 1-isopropylpiperidin-4-yl, 2-pyrrolidinyl, 1-methyl-2-pyrrolidinyl, 4-piperazinyl, 1- methylpiperidin-4-yl, 3-methyl-isothiazol-5-yl, 3-isothiazolyl, 4, 5-dichloro-3-isothiazolyl, isoxazol-3-yl, 5-isoxazolyl, 4-isoxazolyl, 5-methyl-isoxazol-3-yl, 3,5-dimethyl-isoxazol-4-yl, 4, 5-dimethyl-isoxazol-3- yl, 3-methyl-isoxazol-5-yl, 5-tert-butyl-isoxazol-3-yl, 4-bromo-5-methyl-isoxazol-3-yl, 5-oxazolyl, 1- methylimidazol-5-yl, 5-imidazolyl, 2-thienyl, 3-thienyl, 2-methylcarbonyl-thien-3-yl, 2-methylcarbonyl- 5-tert-butyl-thien-3-yl, 2-aminocarbonyl-5-tert-butyl-thien-3-yl, 4-methoxy-5-chloro-3-thienyl, 3-methyl- 2-thienyl, 5-methyl-2-thienyl, 5-methylthio-2-thienyl, 5-methylsulfonyl-2-thienyl, 3-ethoxy-2-thienyl, 3- chloro-2-thienyl, 5-chloro-2-thienyl, 3-bromo-2-thienyl, 5-bromo-2-thienyl, 4-methoxy-5-bromo-3- thienyl, 4-methoxy-3-thienyl, 2-furyl, 2-cyano-5-phenylfur-3-yl, 4, 5-dimethyl-2-furyl, 5-methyl-2- trifluoromethyl-3-furyl, 3-furanyl, 1-methylpyrrol-2-yl, 2-pyrrolyl, 2-pyrazinyl, 5-methyl-2-pyrazinyl, 4- pyrimidinyl, 2, 6-dimethoxy-4-pyrimidinyl, 4-methoxy-6-methylpyrimidin-2-yl, 4-chloro-2- methylthiopyrimidin-6-yl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 4-trifluoromethylpyridin-2-yl, 2- trifluoromethylpyridin-5-yl, 2-dimethylaminopyridin-5-yl, 5-chloro-2-pyridyl, 2-fluoro-3-pyridyl, 2- chloro-3-pyridyl, 2-methoxy-3-pyridyl, 2-ethoxy-3-pyridyl, 2-chloro-4-pyridyl, 2, 5-dichloro-3-pyridyl, 2- (dimethylaminoethoxy)-3-pyridyl, 2-methoxy-5-pyridyl, 2-methyl-5-pyridyl, 4-chloro-2-pyridyl, 4- methoxy-5-pyridyl, 3-benzyloxypyridin-2-yl, 4-methylpyridin-2-yl, 4-ethylpyridin-2-yl, 2-chloropyridin- 4-yl, 3-chloropyridin-5-yl, 3-chloropyridin-6-yl, 2-chloropyridin-5-yl, 4-chloropyridin-2-yl, 1-methyl-2- oxopyrid-5-yl, tetrahydropyran-4-yl, 4,5-dihydrothiazol-2-yl, thiazol-2-yl, 5-methyl-thiazol-2-yl, 4,5- dimethyl-thiazol-2-yl, 4-tert-butyl-thiazol-2-yl, 5-tert-butyl-thiazol-2-yl, 5-nitrothiazol-2-yl, 5- bromothiazol-2-yl, 5- [4-chlorophenyl]-thiazol-2-yl, 4- [4-chlorophenyl]-thiazol-2-yl, 4- [4-nitrophenyl]- thiazol-2-yl, 4-thiazolyl, 2-methyl-4-thiazolyl, 2, 5-dimethyl-4-thiazolyl, 2, 4-dimethyl-5-thiazolyl, 5-tert- butyl-1, 3, 4-thiadiazol-2-yl, 5-trifluoromethyl-1, 3, 4-thiadiazol-2-yl, 5-ethyl-1, 3, 4-thiadiazol-2-yl, pyrazol- 5-yl, 3-pyrazolyl, 1, 3-diphenyl-pyrazol-3-yl, 1, 3-dimethyl-pyrazol-3-yl, 5-cyano4-tert-butyl-pyrazol-3- yl, 5-amino-3-methyl-pyrazol-1-yl, 3-methyl-1-tert-butyl-pyrazol-3-yl, 5-amino-3-tert-butyl-pyrazol-1-yl, 1-ethylpyrazol-5-yl, 3-tert-butyl-pyrazol-5-yl, 1-methyl-3-tert-butyl-pyrazol-5-yl, 4, 4-dimethyl-1, 2,34- tetrahydroisoquinolin-7-yl, 7-quinolinyl, 2, 3-dihydrobenzofur-7-yl, 3, 3-dimethyl-1- methylcarbonylindolin-6-yl, 3,3-dimethyl-2, 3-dihydro-indol-6-yl, 4-tert-butyl-imidazo [1, 2-a] pyridin-6-yl, 3-quinolinyl, 2-benzofuryl, benzo [1, 2,5] thiadiazol-4-yl, 7-methyl-benzothiazol-2-yl, 6-ethoxy- benzothiazol-2-yl, 6-fluoro-benzothiazol-2-yl, 5, 6-dimethyl-benzothiazol-2-yl, benzimidazol-2-yl, 1-

methyl-benzimidazol-2-yl, benzoxazol-2-yl, benzisoxazol-3-yl, 4-methoxybenzisoxazol-3-yl and 2- methylbenzothiazol-5-yl.

The invention also relates to compounds wherein R'is an unsubstituted or substituted ring selected from phenyl, cyclobutyl, cyclopentyl, cyclohexyl, 2-pyrrolidinyl, 2-pyrrolyl, 5-imidazolyl, 5- pyrazolyl, 2-pyrazinyl, 4-pyrimidinyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 8-quinolinyl, 2,3-dihydrobenzofur- 7-yl, 2, 3-dihydro-1, 4-benzodioxin-5-yl, 1, 3-benzodioxol-4-yl, 4-isoxazolyl, 3-isothiazolyl, 5-oxazolyl, 4- thiazolyl, 5-thiazolyl, 2-furanyl, 3-furanyl, 3-thienyl and 2-thienyl.

The invention also relates to compounds wherein R8 is H; and wherein R9 is H or fluoro ; and pharmaceutically acceptable derivatives thereof.

The invention also relates to compounds selected from N- (5-fluoro-6- ( (6- (methyloxy)-7- ( (3- (4-morpholinyl) propyl) oxy)-4-quinolinyl) oxy)-2-naphthalenyl)-2- thiophenecarboxamide; 5-fluoro-N- (5-fluoro-6- ( (6- (methyloxy)-7- ( (3- (4-morpholinyl) propyl) oxy)-4-quinolinyl) oxy) -2- naphthalenyl)-2- (methyloxy) benzamide; N- (6- ( (7- ( (3- (dimethylamino) propyl) oxy)-6- (methyloxy)-4-quinolinyl) oxy)-2-naphthalenyl)-3- thiophenecarboxamide; N- (6- ( (6- (methyloxy)-7- ( (3- (4-morpholinyl) propyl) oxy)-4-quinolinyl) oxy)-2-naphthalenyl)-3- thiophenecarboxamide; N-ethyl-N'- (5-fluoro-6- ( (6- (methyloxy)-7- ( (3- (4-morpholinyl) propyl) oxy)-4-quinolinyl) oxy) -2- naphthalenyl) urea; N- (6- ( (7- ( (3- (dimethylamino) propyl) oxy)-6-(methyloxy)-4-quinolinyl) oxy)-5-fluoro-2-naphthalenyl)-3- thiophenecarboxamide; N-ethyl-N'-(6-((6-(methyloxy)-7-((3-(4-morpholinyl)propyl)ox y)-4-quinolinyl) oxy) -2-naphthalenyl) urea; N-(6-((7-((2-(dimethylamino) ethyl) oxy)-6- (methyloxy)-4-quinolinyl) oxy)-2-naphthalenyl) benzamide; N- (6- ( (7- ( (3- (dimethylamino) propyl) oxy)-6- (methyloxy)-4-quinolinyl) oxy)-5-fluoro-2-naphthalenyl)-2- thiophenecarboxamide; N-(6-((6-(methyloxy)-7-((3-(4-morpholinyl) propyl) oxy)-4-quinolinyl) oxy)-2-naphthalenyl)-2- thiophenecarboxamide; <BR> <BR> <BR> <BR> N- (5-fluoro-6- ( (6- (methyloxy)-7- ( (3- (4-morpholinyl) propyl) oxy)-4-quinolinyl) oxy)-2-naphthalenyl)-3- thiophenecarboxamide; N-(5-fluoro-6-((6-(methyloxy)-7-((3-(4-morpholinyl)propyl)ox y)-4-quinolinyl)oxy)-2-naphthalenyl)-2- (methyloxy) benzamide; N-(5-fluoro-6-((7-(((2S)-2-hydroxy-3-(4-morpholinyl)propyl)o xy)-6-(methyloxy)-4-quinolinyl) oxy) -2- naphthalenyl)-3-thiophenecarboxamide ; N- (6- ( (7- ( ( (2R)-2-hydroxy-3- (4-morpholinyl) propyl) oxy)-6- (methyloxy)-4-quinolinyl) oxy) -2- naphthalenyl)-2-thiophenecarboxamide ; N- (6- ( (7- ( (3- (dimethylamino) propyl) oxy)-6- (methyloxy)-4-quinolinyl) oxy)-5-fluoro-2-naphthalenyl)-N'- (2,2, 2-trifluoroethyl) urea;

N- (6- ( (7- ( ( (2S)-2-hydroxy-3- (4-morpholinyl) propyl) oxy)-6- (methyloxy)-4-quinolinyl) oxy) -2- naphthalenyl)-2-thiophenecarboxamide ; and N- (5-fluoro-6- ( (7- ( ( (2R)-2-hydroxy-3- (4-morpholinyl) propyl) oxy)-6- (methyloxy)-4-quinolinyl) oxy) -2- naphthalenyl)-3-thiophenecarboxamide.

The invention also relates to compounds of Formula III wherein Xa is O, NR2 or CH2 ; wherein R2 is C1-3-alkyl or H; wherein ya is selected from-NH (CH2) p-,-NHC (=O) (CH2) p-,-NHC (=O) (CH2) pO-,- (CH2) p-NHC (=O)-,- NHC (=O) NH-, -NHC (=O) O (CH2) p-,-C (=O) O-, -NHSO2-, and-C (=O) NH (CH2) p- ; wherein Y is in either direction; wherein p is 0,1, 2, or 3; wherein R'is lower alkyl or an unsubstituted or substituted ring selected from phenyl, C36- cycloalkyl, pyrrolidinyl, pyrrolyl, imidazolyl, pyrazolyl, pyrazinyl, pyrimidinyl, pyridyl, quinolinyl, 2,3- dihydrobenzofuryl, 2, 3-dihydro-1, 4-benzodioxinyl, 1,3-benzodioxolyl, isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, furanyl and thienyl; wherein R'is selected from 4-quinolinyl optionally substituted with one or more substituents selected from C1-3-alkoxy, C1-3- alkylamino-C, 3-alkoxy, phenyl-C, 3-alkoxy, 5-6 membered heterocyclyl-C, 3-alkoxy and C4-6- cycloalkyl-C1-3-alkoxy, 4-quinazolinyl optionally substituted with one or more substituents selected from C, 3-alkoxy, Cl 3- alkylamino-C1-3-alkoxy, phenyl-C1-3-alkoxy, 5-6 membered heterocyclyl-C, 3-alkoxy and C46- cycloalkyl-C1-3-alkoxy, 4-pyrrolo [2,3-b] pyridinyl optionally substituted with one or more substituents selected from is Cl 3- alkyl, C, 3-alkoxy, C, 3-alkylamino-C, 3-alkoxy, phenyl-C, 3-alkoxy, 5-6 membered heterocyclyl- C, 3-alkoxy and C46-cycloalkyl-C, 3-alkoxy, 4-pyrazolo [3,4-b] pyridinyl optionally substituted with one or more substituents selected from is C1-3- alkyl, C1-3-alkoxy, C1-3-alkylamino-C1-3-alkoxy, phenyl-C1-3-alkoxy, 5-6 membered heterocyclyl- C, 3-alkoxy and C46-cycloalkyl-C, 3-alkoxy, 4-pyrimidinyl optionally substituted with one or more substituents selected from amino, methylamide and methylamino, and 4-pyridinyl optionally substituted with one or more substituents selected from methylamide and methylamino; and

wherein R8 and R9 are independently selected from H, methyl, trifluoromethyl, chloro and fluoro ; and pharmaceutically acceptable derivatives thereof.

The invention also relates to compounds of Formula III wherein V is selected from-NHC (=O)-, -NHC (=O) (CH2)-,-NHC (=O) (CH2) 2-, QCH2) p-NHC (=O)-,-NHC (=O) NH-and-NHSO2-; wherein Y is in either direction; and pharmaceutically acceptable derivatives thereof; in conjunction with any of the above or below embodiments.

The invention also relates to compounds of Formula III wherein Y'is-NHC (=O)- or-C (=O) NH- ; and pharmaceutically acceptable derivatives thereof ; in conjunction with any of the above or below embodiments.

The invention also relates to compounds of Formula III wherein R'is an unsubstituted or substituted ring selected from phenyl, cyclobutyl, cyclopentyl, cyclohexyl, n-butyl, isobutyl, tert-butyl, isopropyl, 2-pyrrolidinyl, 2-pyrrolyl, 5-imidazolyl, 5-pyrazolyl, 2-pyrazinyl, 4-pyrimidinyl, 2-pyridyl, 3- pyridyl, 4-pyridyl, 8-quinolinyl, 2,3-dihydrobenzofur-7-yl, 2, 3-dihydro-1, 4-benzodioxin-5-yl, 1,3- benzodioxol-4-yl, 4-isoxazolyl, 3-isothiazolyl, 5-oxazolyl, 4-thiazolyl, 5-thiazolyl, 2-furanyl, 3-furanyl, 3- thienyl and 2-thienyl; and pharmaceutically acceptable derivatives thereof; in conjunction with any of the above or below embodiments.

The invention also relates to compounds of Formula III wherein ya is-NHC (=O)-or-C (=O) NH- ; and R'is selected from n-butyl, isobutyl, tert-butyl, isopropyl, phenyl, 4-methylphenyl, 4-fluorophenyl, 4-bromophenyl, 4-chlorophenyl, 4-trifluoromethoxyphenyl, 4-trifluoromethylphenyl, 4-chloro-3- trifluoromethylphenyl, 3-trifluoromethylphenyl, 2-piperidin-1-yl-5-trifluoromethyl-phenyl, 2- [ (3- dimethylaminopropyl) methylamino]-5-trifluoromethylphenyl, 2- (3-dimethylamino-pyrroldin-1-yl)-5- trifluoromethylphenyl, 2- [methyl- (1-methylpyrrolidin-3-yl) amino] -5-trifluoromethylphenyl, 5-tert-butyl- isoxazol-3-yl, 5-tert-butyl-pyrazol-3-yl, and 2-methylbenzothiazol-5-yl; and pharmaceutically acceptable derivatives thereof; in conjunction with any of the above or below embodiments.

The invention also relates to compounds of Formula III wherein R8 is H; and wherein R9 is H or fluoro; and pharmaceutically acceptable derivatives thereof ; in conjunction with any of the above or below embodiments.

The invention also relates to compounds of Formula III wherein R'is selected from 2- aminopyrimidin-4-yl, 2-methylamino-pyrimidin-4-yl, 2-methylaminocarbonyl-pyridin4-yl, 4- pyrazolo [3,4-b] pyridinyl, 4-pyrrolo [2,3-b] pyridinyl, 6, 7-dimethoxy-4-quinolinyl, 6-methoxy-7- (dimethylaminopropoxy)-4-quinolinyl, 6,7-dimethoxy-4-quinazolinyl, and 6-methoxy-7- (dimethylaminopropoxy) -4-quinazolinyl; and pharmaceutically acceptable derivatives thereof ; in conjunction with any of the above or below embodiments.

The invention also relates to compounds of Formula III wherein Xa is O ; wherein R'is selected from 6,7-dimethoxy-quinolin-4-yl, 2-aminopyrimidin-4-yl, 2-methylamino-pyrimidin-4-yl, 2- methylaminocarbonyl-pyridin-4-yl, 4-pyrazolo [3,4-b] pyridinyl, and 4-pyrrolo [2,3-b] pyridinyl; wherein R8 is H; and wherein R9 is H; and pharmaceutically acceptable derivatives thereof; in conjunction with any of the above or below embodiments.

The invention also relates to compounds of

wherein Xa is O, NR2 or CH2 ; wherein R is C1-3-alkyl or H; wherein Y ils selected from-NH (CH2) p-,-NHC (=O) (CH2) p-, -NHC (=O) (CH2) pO-,- (CH2) p-NHC (=O)-,- NHC (=O) NH-, -NHC (=O) O (CH2) p-,-C (=O) O-,-NHSO2-, and-C (=O) NH (CH2) p- ; wherein Y is in either direction; wherein p is 0,1, 2, or 3; wherein R'is selected from H, C1-5-alkyl, C1-3-haloalkyl, C1-3-alkoxy-C1-3-alkyl, C1-3-alkoxycarbonyl-C1-3- alkyl, C1-5-cyanoalkyl, aminocarbonyl-C1-5-alkyl, C1-5-alkyl-aminocarbonyl-C1-5-alkyl, amino-C1-5- alkyl, Cl 5-alkyl-amino-C, 5-alkyl, C, 5-alkylsulfonyl-Cl 5-alkyl, phenyl-Cl 3-alkyl, C36-cycloalkyl-C, 3-alkyl, 5-6-membered heterocyclyl-C, 3-alkyl, and an unsubstituted or substituted ring selected from phenyl, naphthyl, 1,3-benzodioxolyl, 2, 3-dihydro-1, 4-benzodioxinyl, C36-cycloalkyl, C56- cycloalkenyl, pyrrolidinyl, pyrrolyl, imidazolyl, pyrazolyl, pyrazinyl, pyrimidinyl, pyridyl, quinolinyl, dihydrothiazolyl, 2,3-dihydrobenzofuryl, piperidinyl, 1-methyl-oxopyridyl, tetrahydropyran-4-yl, indolinyl, imidazo [1, 2-a] pyridinyl, quinolinyl, isoquinolinyl, tetahydroisoquinolinyl, benzofuryl, benzo [1, 2,5] thiadiazolyl, benzothiazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, thiadiazolyl, furanyl and thienyl; wherein R'is selected from 4-quinolinyl optionally substituted with one or more substituents selected from C1-3-alkoxy, C1-3- alkylamino-C, 3-alkoxy, aminocarbonyl, alkylaminocarbonyl, phenyl-C, 3-alkoxy, 5-6 membered heterocyclyl-C1-3-alkoxy and C4-6-cycloalkyl-C1-3-alkoxy, 4-quinazolinyl optionally substituted with one or more substituents selected from C, 3-alkoxy, Cl 3- alkylamino-C, _3-alkoxy, aminocarbonyl, alkylaminocarbonyl, phenyl-C, _3-alkoxy, 5-6 membered heterocyclyl-C, _3-alkoxy and C4-6-cycloalkyl-C1-3-alkoxy, 4-pyrrolo [2, 3-b]pyridinyl optionally substituted with one or more substituents selected from is Cl 3- alkyl, C1-3-alkoxy, C1-3-alkylamino-C1-3-alkoxy, phenyl-C1-3-alkoxy, 5-6 membered heterocyclyl- C, 3-alkoxy and C46-cycloalkyl-Cl 3-alkoxy, 4-pyrazolo [3,4-b] pyridinyl optionally substituted with one or more substituents selected from is Cl 3- alkyl, C1-3-alkoxy, C1-3-alkylamino-C1-3-alkoxy, phenyl-C1-3-alkoxy, 5-6 membered heterocyclyl- C, 3-alkoxy and C4-6-cycloalkyl-C1-3-alkoxy,

4-pyrimidinyl optionally substituted with one or more substituents selected from amino, methylamide and methylamino, and 4-pyridinyl optionally substituted with one or more substituents selected from methylamide and methylamino; wherein Ru ils selected from H, fluoro, chloro and methyl; and wherein R9 is selected from H, methyl and fluoro; and pharmaceutically acceptable derivatives thereof.

The invention also relates to compounds wherein R'is selected from H, methyl, ethyl, n-butyl, isobutyl, tert-butyl, isopropyl, propyl, cyanomethyl, aminocarbonylmethyl, dimethylaminocarbonylmethyl, dimethylaminoethyl, 2-methoxy-1-methylethyl, methoxycarbonylmethyl, methoxyethyl, methoxypropyl, methylsulfonylethyl, dimethylaminoethyl, methoxycarbonylmethyl, ethenyl, thiazol-2-yl-CH (CH3) -, phenyl-CH (CH3) -, 5-methylisoxazol-3-ylmethyl, pyrrolidin-1-ylethyl, tetrahydrofur-2-ylmethyl, 4-methyl-2-oxo-oxazolidin-5-yl, pyrid-4-ylmethyl, pyrid-2-ylmethyl, 2- trifluoromethylpyrid-5-ylmethyl, trifluoromethyl, 2,2, 2-trifluoroethyl, 3,3, 3-trifluoropropyl, (CH3) 3CCH2-, pentafluoroethyl, CF3CH2CH2-, cyclopropylmethyl, benzyl, 4-methylbenzyl, 4-chlorobenzyl, (2- methoxyphenyl) ethyl, 1-phenylethyl, phenylethyl, cyclopropyl, 1-methylcyclopropyl, 2- fluorocyclopropyl, 2-phenylcyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 5,5-dimethyl-3- oxocyclohexenyl, phenyl, 4-methylphenyl, 3-methylphenyl, 2-methylphenyl, 3, 4-dimethylphenyl, 3,5- dimethylphenyl, 4-ethylphenyl, 3-ethylphenyl, 2-ethylphenyl, 4-isopropylphenyl, 4-isopropyl-3- methylphenyl, 3-isopropylphenyl, 4-tert-butylphenyl, 2,3-dimethylphenyl, 3-fluorophenyl, 4- fluorophenyl, 2-fluorophenyl, 2, 4-difluorophenyl, 3,4-difluorophenyl, 2, 3-difluorophenyl, 2,6- difluorophenyl, 2,5-difluorophenyl, 3, 5-difluorophenyl, 2,4, 6-trifluorophenyl, 3-bromophenyl, 4- bromophenyl, 4-chlorophenyl, 3-chlorophenyl, 2-chlorophenyl, 4-methoxyphenyl, 3-methoxyphenyl, 2- methoxyphenyl, 3,4-dimethoxyphenyl, 2, 6-dichlorophenyl, 3-fluoro-5-methoxyphenyl, 3-chloro-5- methoxyphenyl, 4-chloro-2-methoxyphenyl, 2,4-dimethoxyphenyl, 2,6-dimethoxyphenyl, 3,5- dimethoxyphenyl, 2-ethoxyphenyl, 4-hydroxyphenyl, 2-hydroxyphenyl, 2, 5-dichlorophenyl, 2,4- dichlorophenyl, 2,3-dichlorophenyl, 3, 5-dichlorophenyl, 3, 4-dichlorophenyl, 3, 4-difluorophenyl, 3- trifluoromethoxyphenyl, 4-trifluoromethoxyphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 3,5-di (trifluoromethyl)-phenyl, 3,5-di (trifluoromethyl)-2-methylphenyl, 4-dimethylaminophenyl, 3- dimethylaminophenyl, 3-nitrophenyl, 4-nitrophenyl, 3-cyanophenyl, 4-methylthiophenyl, 3- methylsulfonylphenyl, 2-methylsulfonylphenyl, 3-chloro-4-methylphenyl, 3-chloro-4-fluorophenyl, 4- [1- <BR> <BR> <BR> <BR> isopropylpiperazinin-4-yl] phenyl, 2- [ (l-methylpyrrolidin-3-yl)-N (CH3)]-5-trifluoromethylphenyl, 5- [1- methylpiperazin4-ylmethyl]-3-trifluoromethylphenyl, 5-[2-oxopyrrolidin-1-yl]-3-trifluoromethylphenyl, 2-chloro-4-trifluoromethylphenyl, 4-chloro-3-trifluoromethylphenyl, 4-bromo-2-fluorophenyl, 2- trifluoromethoxyphenyl, 2-trifluoromethylphenyl, 4-pentafluoroethylphenyl,-fluoro-3- trifluoromethylphenyl, 2-fluoro-5-trifluoromethylphenyl, 2-methyl-3-trifluoromethylphenyl, 2-methyl-5- trifluoromethylphenyl, 3-fluoro-5-trifluoromethylphenyl, 2- [methylcarbonylamino]-5- trifluoromethylphenyl, 3- [1-methylpiperidin-4-yl]-5-trifluoromethylphenyl, 2- [l, l-dioxo-thiomorpholin-

4-yl]-5-trifluoromethylphenyl, 2- [1-oxo-thiomorpholin-4-yl]-5-trifluoromethylphenyl, 2- [thiomorpholin-<BR> <BR> <BR> <BR> <BR> <BR> 4-yl]-5-trifluoromethylphenyl, 2-piperidin-1-yl-5-trifluoromethyl-phenyl, 2- [ (3-<BR> <BR> <BR> <BR> <BR> <BR> dimethylaminopropyl) methylamino]-5-trifluoromethylphenyl, 2- (3-dimethylamino-pyrroldin-1-yl)-5- trifluoromethylphenyl, 3- (methylcarbonylamino) phenyl, 3- (4-methylpiperazin-1-ymethyl) phenyl, 2- (4- methylpiperazin-1-ymethyl) phenyl, 2-piperidin-1-yl-5-trifluoromethyl-phenyl, 2- [1-methylpiperidin-4- yloxy]-5-trifluoromethylphenyl, 2-methoxy-5-trifluoromethylphenyl, 2-methoxy-5-phenylphenyl, 2- [3, 3- dimethyl-2-oxo-azetidin-1-yl]-5-trifluoromethylphenyl, 2-[morpholin4-ylethoxy]-5-tert-butylphenyl, 2- methoxy-5-fluorophenyl, 2-methoxy-5-tert-butylphenyl, 3- [dimethylaminomethylcarbonylamino]-4-tert- butylphenyl, 2-methoxy-5- [2-pyridylaminocarbonyl] phenyl, 2-methoxy-5-phenylaminocarbonylphenyl, 2- [methyl- (l-methylpyrrolidin-3-yl) amino]-5-trifluoromethylphenyl, 2, 2-difluorobenzodioxol-4-yl, biphenyl, 2-naphthyl, 2, 3-dihydro-1, 4-benzodioxin-6-yl, 7-fluoro-2, 3-dihydro-1, 4-benzodioxin-6-yl, 1,3- benzodioxol-4-yl, 1-isopropylpiperidin4-yl, 2-pyrrolidinyl, 1-methyl-2-pyrrolidinyl, 4-piperazinyl, 1- methylpiperidin-4-yl, 3-methyl-isothiazol-5-yl, 3-isothiazolyl, 4, 5-dichloro-3-isothiazolyl, isoxazol-3-yl, 5-isoxazolyl, 4-isoxazolyl, 5-methyl-isoxazol-3-yl, 3, 5-dimethyl-isoxazol-4-yl, 4, 5-dimethyl-isoxazol-3- yl, 3-methyl-isoxazol-5-yl, 5-tert-butyl-isoxazol-3-yl, 4-bromo-5-methyl-isoxazol-3-yl, 5-oxazolyl, 1- methylimidazol-5-yl, 5-imidazolyl, 2-thienyl, 3-thienyl, 2-methylcarbonyl-thien-3-yl, 2-methylcarbonyl- 5-tert-butyl-thien-3-yl, 2-aminocarbonyl-5-tert-butyl-thien-3-yl, 4-methoxy-5-chloro-3-thienyl, 3-methyl- 2-thienyl, 5-methyl-2-thienyl, 5-methylthio-2-thienyl, 5-methylsulfonyl-2-thienyl, 3-ethoxy-2-thienyl, 3- chloro-2-thienyl, 5-chloro-2-thienyl, 3-bromo-2-thienyl, 5-bromo-2-thienyl, 4-methoxy-5-bromo-3- thienyl, 4-methoxy-3-thienyl, 2-furyl, 2-cyano-5-phenylfur-3-yl, 4, 5-dimethyl-2-furyl, 5-methyl-2- trifluoromethyl-3-furyl, 3-furanyl, 1-methylpyrrol-2-yl, 2-pyrrolyl, 2-pyrazinyl, 5-methyl-2-pyrazinyl, 4- pyrimidinyl, 2,6-dimethoxy-4-pyrimidinyl, 4-methoxy-6-methylpyrimidin-2-yl, 4-chloro-2- methylthiopyrimidin-6-yl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 4-trifluoromethylpyridin-2-yl, 2- trifluoromethylpyridin-5-yl, 2-dimethylaminopyridin-5-yl, 5-chloro-2-pyridyl, 2-fluoro-3-pyridyl, 2- chloro-3-pyridyl, 2-methoxy-3-pyridyl, 2-ethoxy-3-pyridyl, 2-chloro-4-pyridyl, 2, 5-dichloro-3-pyridyl, 2- (dimethylaminoethoxy) -3-pyridyl, 2-methoxy-5-pyridyl, 2-methyl-5-pyridyl, 4-chloro-2-pyridyl, 4- methoxy-5-pyridyl, 3-benzyloxypyridin-2-yl, 4-methylpyridin-2-yl, 4-ethylpyridin-2-yl, 2-chloropyridin- <BR> <BR> <BR> <BR> 4-yl, 3-chloropyridin-5-yl, 3-chloropyridin-6-yl, 2-chloropyridin-5-yl, 4-chloropyridin-2-yl, 1-methyl-2- oxopyrid-5-yl, tetrahydropyran-4-yl, 4, 5-dihydrothiazol-2-yl, thiazol-2-yl, 5-methyl-thiazol-2-yl, 4,5- dimethyl-thiazol-2-yl, 4-tert-butyl-thiazol-2-yl, 5-tert-butyl-thiazol-2-yl, 5-nitrothiazol-2-yl, 5- bromothiazol-2-yl, 5- [4-chlorophenyl]-thiazol-2-yl, 4- [4-chlorophenyl]-thiazol-2-yl, 4- [4-nitrophenyl]- thiazol-2-yl, 4-thiazolyl, 2-methyl-4-thiazolyl, 2, 5-dimethyl-4-thiazolyl, 2, 4-dimethyl-5-thiazolyl, 5-tert- butyl-1, 3, 4-thiadiazol-2-yl, 5-trifluoromethyl-1, 3, 4-thiadiazol-2-yl, 5-ethyl-1, 3, 4-thiadiazol-2-yl, pyrazol- <BR> <BR> <BR> <BR> 5-yl, 3-pyrazolyl, 1, 3-diphenyl-pyrazol-3-yl, 1, 3-dimethyl-pyrazol-3-yl, 5-cyano-4-tert-butyl-pyrazol-3- yl, 5-amino-3-methyl-pyrazol-1-yl, 3-methyl-1-tert-butyl-pyrazol-3-yl, 5-amino-3-tert-butyl-pyrazol-1-yl, I-ethylpyrazol-5-yl, 3-tert-butyl-pyrazol-5-yl, 1-methyl-3-tert-butyl-pyrazol-5-yl, 4, 4-dimethyl-1, 2,34- tetrahydroisoquinolin-7-yl, 7-quinolinyl, 2,3-dihydrobenzofur-7-yl, 3, 3-dimethyl-1- methylcarbonylindolin-6-yl, 3, 3-dimethyl-2, 3-dihydro-indol-6-yl, 4-tert-butyl-imidazo [1, 2-a] pyridin-6-yl,

3-quinolinyl, 2-benzofuryl, benzo [1, 2,5] thiadiazol-4-yl, 7-methyl-benzothiazol-2-yl, 6-ethoxy- benzothiazol-2-yl, 6-fluoro-benzothiazol-2-yl, 5,6-dimethyl-benzothiazol-2-yl, benzimidazol-2-yl, 1- methyl-benzimidazol-2-yl, benzoxazol-2-yl, benzisoxazol-3-yl, 4-methoxybenzisoxazol-3-yl and 2- methylbenzothiazol-5-yl.

The invention also relates to compounds wherein Xa is O ; The invention also relates to compounds wherein R'is selected from 2-aminopyrimidin-4-yl, 2- methylamino-pyrimidin-4-yl, 2-methylaminocarbonyl-pyridin-4-yl, 4-pyrazolo [3,4-b] pyridinyl, and 4- pyrrolo [2,3-b] pyridinyl.

The invention also relates to compounds wherein R'is wherein R°a is selected from H, methoxy, aminocarbonyl, and methylaminocarbonyl ; and wherein Rl°b is selected from 4-morpholinopropoxy, 2-hydroxy-3-morpholin-4-yl-propoxy, pyrrolidin-1-ylpropoxy, 1- pyrrolidinylethoxy, 4-piperidinyloxypropoxy, (4-methylpiperazin-1-yl) propoxy, 3- (4-methylpiperazin-1- yl) propoxy, 3- (1, 2, 4-triazol-1-yl) propoxy, triazinylpropoxy, 3- (piperidin-4-yl) propoxy, dimethylaminoethoxy, dimethylaminopropoxy and methoxy.

The invention also relates to compounds selected from N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-1-naphthalenyl) benzamide; 6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N- (4-chlorophenyl)-1-naphthalenecarboxamide ; 6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N- (3- (trifluoromethyl) phenyl)- I-naphthalenecarboxamide ; 6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N- (4- (trifluoromethyl) phenyl)-1-naphthalenecarboxamide ; 6- ( (6, 7-bis (methyloxy) 4-quinolinyl) oxy)-N-ethyl-I-naphthalenecarboxamide ; 6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-5-fluoro-N-methyl-I-naphthalenecarboxamide ; 4- (5-Carbamoyl-l-fluoro-naphthalen-2-yloxy)-7-methoxy-quinolin e-6-carboxylic acid amide; 6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N- (3-isoxazolyl)-l-naphthalenecarboxamide ; 6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N-methyl-l-naphthalenecarboxamide ; 6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-5-fluoro-1-naphthalenecarboxamide ; 6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N-phenyl-1-naphthalenecarboxamide ; 6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N- (2- (methyloxy) ethyl)-1-naphthalenecarboxamide ; 6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-5-fluoro-N-(2-(methyloxy) ethyl)-1-naphthalenecarboxamide ; 4- (5-Cyclopropylcarbamoyl-l-fluoro-naphthalen-2-yloxy)-7-metho xy-quinoline-6-carboxylic acid amide; 7- (methyloxy)-4- ( (5- ( ( (2- (methyloxy) ethyl) amino) carbonyl)-2-naphthalenyl) oxy) -6- quinolinecarboxamide; 6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N-cyclopropyl-1-naphthalenecarboxamide ; 6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-5-fluoro-N- (3-isoxazolyl)-1-naphthalenecarboxamide ;

4- ( (5- ( (cyclopropylamino) carbonyl)-2-naphthalenyl) oxy)-N-methyl-7- (methyloxy)-6- quinolinecarboxamide; 4- ( (5- ( (cyclopropylamino) carbonyl)-2-naphthalenyl) oxy)-7- (methyloxy)-6-quinolinecarboxamide ; 4- (5-Carbamoyl-naphthalen-2-yloxy)-7-methoxy-quinoline-6-carbo xylic acid amide; 6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N-cyclopropyl-1-naphthalenecarboxamide ; 6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-5-fluoro-N- (1, 3-thiazol-2-yl)-l-naphthalenecarboxamide ; 6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-l-naphthalenecarboxamide ; 6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N-cyclopropyl-5-fluoro-1-naphthalenecarboxamide ; 6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N- (6- (dimethylamino)-3-pyridinyl)-I-naphthalenecarboxamide ; 6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N- (4-chloro-3- (trifluoromethyl) phenyl)-1- naphthalenecarboxamide; and 6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N- (4- ( 1, 1-dimethylethyl) phenyl)-1-naphthalenecarboxamide.

The invention also relates to compounds of wherein Ya is selected from-(CH2) p-NH-,-(CH2) p-C (=O) NH-, QCH2) p-OC (=O) NH-, -C (=O) O-, and- C (=O) NH (CH2) p- ; wherein p is 0,1, 2, or 3; wherein Z is CR"or N; wherein R'is selected from H, C, s-alkyl, C, 3-haloalkyl, C, 3-alkoxy-C, 3-alkyl, Cl 3-alkoxycarbonyl-C, 3- alkyl, C, 5-cyanoalkyl, aminocarbonyl-C, s-alkyl, C, 5-alkyl-aminocarbonyl-C, 5-alkyl, amino-C, 5- alkyl, C, 5-alkyl-amino-C, 5-alkyl, C, 5-alkylsulfonyl-C, 5-alkyl, phenyl-C, 3-alkyl, C36-cycloalkyl-C, 3-alkyl, 5-6-membered heterocyclyl-C, 3-alkyl, and an unsubstituted or substituted ring selected from phenyl, naphthyl, 1, 3-benzodioxolyl, C36-cycloalkyl, C56-cycloalkenyl, pyrrolidinyl, pyrrolyl, imidazolyl, pyrazolyl, pyrazinyl, pyrimidinyl, pyridyl, quinolinyl, dihydrothiazolyl, 2,3- dihydrobenzofuryl, 2, 3-dihydro-1, 4-benzodioxinyl, piperidinyl, 1-methyl-oxopyridyl, tetrahydropyran-4-yl, indolinyl, imidazo [1, 2-a] pyridinyl, quinolinyl, benzofuryl, benzo [1, 2,5] thiadiazolyl, benzothiazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, thiadiazolyl, furanyl and thienyl ; wherein R8 is selected from H, fluoro, chloro and methyl; wherein R9 is selected from H, methyl and fluoro; and wherein R"is selected from H, CN, NH2, F, alkylcarbonylamino, and alkylaminocarbonyl;

wherein R'oa is H or methoxy; and wherein Rl°b is selected from 4-morpholinopropoxy, 2-hydroxy-3-morpholin4-yl-propoxy, pyrrolidin-1-ylpropoxy, I-pyrrolidinylethoxy, 4-piperidinyloxypropoxy, (4-methylpiperazin-1- yl) propoxy, 3- (4-methylpiperazin-1-yl) propoxy, 3- (1, 2, 4-triazol-1-yl) propoxy, triazinylpropoxy, 3- (piperidin-4-yl) propoxy, dimethylaminoethoxy, dimethylaminopropoxy and methoxy; and pharmaceutically acceptable derivatives thereof.

The invention also relates to compounds wherein Z is CH; wherein Rl°a is methoxy; and wherein R'°b is selected from 4-morpholinopropoxy, 2-hydroxy-3-morpholin-4-yl-propoxy, pyrrolidin-1- ylpropoxy, 1-pyrrolidinylethoxy, 4-piperidinyloxypropoxy, (4-methylpiperazin-1-yl) propoxy, 3- (4- methylpiperazin-1-yl) propoxy, 3- (1, 2,4-triazol-1-yl) propoxy, triazinylpropoxy, 3- (piperidin-4-yl) propoxy, dimethylaminoethoxy, dimethylaminopropoxy and methoxy.

The invention also relates to compounds wherein R'is selected from H, methyl, ethyl, n-butyl, isobutyl, tert-butyl, isopropyl, propyl, cyanomethyl, aminocarbonylmethyl, dimethylaminocarbonylmethyl, dimethylaminoethyl, 2-methoxy-1-methylethyl, methoxycarbonylmethyl, methoxyethyl, methoxypropyl, methylsulfonylethyl, dimethylaminoethyl, methoxycarbonylmethyl, ethenyl, thiazol-2-yl-CH (CH3)-, phenyl-CH (CH3) -, 5-methylisoxazol-3-ylmethyl, pyrrolidin-1-ylethyl, tetrahydrofur-2-ylmethyl, 4-methyl-2-oxo-oxazolidin-5-yl, pyrid-4-ylmethyl, pyrid-2-ylmethyl, 2- trifluoromethylpyrid-5-ylmethyl, trifluoromethyl, 2,2, 2-trifluoroethyl, 3,3, 3-trifluoropropyl, (CH3) 3CCH2-, pentafluoroethyl, CF3CH2CH2-, cyclopropylmethyl, benzyl, 4-methylbenzyl, 4-chlorobenzyl, (2- methoxyphenyl) ethyl, I-phenylethyl, phenylethyl, cyclopropyl, I-methylcyclopropyl, 2- fluorocyclopropyl, 2-phenylcyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 5, 5-dimethyl-3- oxocyclohexenyl, phenyl, 4-methylphenyl, 3-methylphenyl, 2-methylphenyl, 3, 4-dimethylphenyl, 3,5- dimethylphenyl, 4-ethylphenyl, 3-ethylphenyl, 2-ethylphenyl, 4-isopropylphenyl, 4-isopropyl-3- methylphenyl, 3-isopropylphenyl, 4-tert-butylphenyl, 2, 3-dimethylphenyl, 3-fluorophenyl, 4- fluorophenyl, 2-fluorophenyl, 2, 4-difluorophenyl, 3, 4-difluorophenyl, 2, 3-difluorophenyl, 2,6- difluorophenyl, 2, 5-difluorophenyl, 3,5-difluorophenyl, 2,4, 6-trifluorophenyl, 3-bromophenyl, 4- bromophenyl, 4-chlorophenyl, 3-chlorophenyl, 2-chlorophenyl, 4-methoxyphenyl, 3-methoxyphenyl, 2- methoxyphenyl, 3,4-dimethoxyphenyl, 2, 6-dichlorophenyl, 3-fluoro-5-methoxyphenyl, 3-chloro-5- methoxyphenyl, 4-chloro-2-methoxyphenyl, 2,4-dimethoxyphenyl, 2,6-dimethoxyphenyl, 3,5- dimethoxyphenyl, 2-ethoxyphenyl, 4-hydroxyphenyl, 2-hydroxyphenyl, 2, 5-dichlorophenyl, 2,4- dichlorophenyl, 2,3-dichlorophenyl, 3, 5-dichlorophenyl, 3, 4-dichlorophenyl, 3, 4-difluorophenyl, 3- trifluoromethoxyphenyl, 4-trifluoromethoxyphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 3,5-di (trifluoromethyl)-phenyl, 3,5-di (trifluoromethyl)-2-methylphenyl, 4-dimethylaminophenyl, 3- dimethylaminophenyl, 3-nitrophenyl, 4-nitrophenyl, 3-cyanophenyl, 4-methylthiophenyl, 3- <BR> <BR> <BR> methylsulfonylphenyl, 2-methylsulfonylphenyl, 3-chloro-4-methylphenyl, 3-chloro-4-fluorophenyl, 4- [1- isopropylpiperazinin-4-yl] phenyl, 2- [ (l-methylpyrrolidin-3-yl)-N (CH3)]-5-trifluoromethylphenyl, 5- [l- <BR> <BR> <BR> methylpiperazin4-ylmethyl]-3-trifluoromethylphenyl, 5-[2-oxopyrrolidin-1-yl]-3-trifluoromethylphenyl, 2-chloro-4-trifluoromethylphenyl, 4-chloro-3-trifluoromethylphenyl, 4-bromo-2-fluorophenyl, 2-

trifluoromethoxyphenyl, 2-trifluoromethylphenyl, 4-pentafluoroethylphenyl,-fluoro-3- trifluoromethylphenyl, 2-fluoro-5-trifluoromethylphenyl, 2-methyl-3-trifluoromethylphenyl, 2-methyl-5- trifluoromethylphenyl, 3-fluoro-5-trifluoromethylphenyl, 2-[methylcarbonylamino]-5- <BR> <BR> <BR> <BR> trifluoromethylphenyl, 3- [l-methylpiperidin-4-yl]-5-trifluoromethylphenyl, 2- [1, 1-dioxo-thiomorpholin-<BR> <BR> <BR> <BR> <BR> <BR> 4-yl]-5-trifluoromethylphenyl, 2- [l-oxo-thiomorpholin-4-yl]-5-trifluoromethylphenyl, 2- [thiomorpholin- 4-yl]-5-trifluoromethylphenyl, 2-piperidin-1-yl-5-trifluoromethyl-phenyl, 2- [ (3- dimethylaminopropyl) methylamino]-5-trifluoromethylphenyl, 2- (3-dimethylamino-pyrroldin-1-yl)-5- trifluoromethylphenyl, 3- (methylcarbonylamino) phenyl, 3- (4-methylpiperazin-1-ymethyl) phenyl, 2- (4- methylpiperazin-1-ymethyl) phenyl, 2-piperidin-1-yl-5-trifluoromethyl-phenyl, 2- [1-methylpiperidin-4- yloxy]-5-trifluoromethylphenyl, 2-methoxy-5-trifluoromethylphenyl, 2-methoxy-5-phenylphenyl, 2- [3, 3- dimethyl-2-oxo-azetidin-1-yl]-5-trifluoromethylphenyl, 2- [morpholin-4-ylethoxy]-5-tert-butylphenyl, 2- methoxy-5-fluorophenyl, 2-methoxy-5-tert-butylphenyl, 3- [dimethylaminomethylcarbonylamino]-4-tert- butylphenyl, 2-methoxy-5- [2-pyridylaminocarbonyl] phenyl, 2-methoxy-5-phenylaminocarbonylphenyl, 2- [methyl-(l-methylpyrrolidin-3-yl) amino]-5-trifluoromethylphenyl, 2, 2-difluorobenzodioxol-4-yl, biphenyl, 2-naphthyl, 2, 3-dihydro-1, 4-benzodioxin-6-yl, 7-fluoro-2, 3-dihydro-1, 4-benzodioxin-6-yl, 1,3- benzodioxol4-yl, 1-isopropylpiperidin4-yl, 2-pyrrolidinyl, 1-methyl-2-pyrrolidinyl, 4-piperazinyl, 1- methylpiperidin-4-yl, 3-methyl-isothiazol-5-yl, 3-isothiazolyl, 4, 5-dichloro-3-isothiazolyl, isoxazol-3-yl, 5-isoxazolyl, 4-isoxazolyl, 5-methyl-isoxazol-3-yl, 3, 5-dimethyl-isoxazol-4-yl, 4, 5-dimethyl-isoxazol-3- yl, 3-methyl-isoxazol-5-yl, 5-tert-butyl-isoxazol-3-yl, 4-bromo-5-methyl-isoxazol-3-yl, 5-oxazolyl, 1- methylimidazol-5-yl, 5-imidazolyl, 2-thienyl, 3-thienyl, 2-methylcarbonyl-thien-3-yl, 2-methylcarbonyl- 5-tert-butyl-thien-3-yl, 2-aminocarbonyl-5-tert-butyl-thien-3-yl, 4-methoxy-5-chloro-3-thienyl, 3-methyl- 2-thienyl, 5-methyl-2-thienyl, 5-methylthio-2-thienyl, 5-methylsulfonyl-2-thienyl, 3-ethoxy-2-thienyl, 3- chloro-2-thienyl, 5-chloro-2-thienyl, 3-bromo-2-thienyl, 5-bromo-2-thienyl, 4-methoxy-5-bromo-3- thienyl, 4-methoxy-3-thienyl, 2-furyl, 2-cyano-5-phenylfur-3-yl, 4,5-dimethyl-2-furyl, 5-methyl-2- trifluoromethyl-3-furyl, 3-furanyl, 1-methylpyrrol-2-yl, 2-pyrrolyl, 2-pyrazinyl, 5-methyl-2-pyrazinyl, 4- pyrimidinyl, 2, 6-dimethoxy-4-pyrimidinyl, 4-methoxy-6-methylpyrimidin-2-yl, 4-chloro-2- methylthiopyrimidin-6-yl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 4-trifluoromethylpyridin-2-yl, 2- trifluoromethylpyridin-5-yl, 2-dimethylaminopyridin-5-yl, 5-chloro-2-pyridyl, 2-fluoro-3-pyridyl, 2- chloro-3-pyridyl, 2-methoxy-3-pyridyl, 2-ethoxy-3-pyridyl, 2-chloro-4-pyridyl, 2, 5-dichloro-3-pyridyl, 2- (dimethylaminoethoxy)-3-pyridyl, 2-methoxy-5-pyridyl, 2-methyl-5-pyridyl, 4-chloro-2-pyridyl, 4- methoxy-5-pyridyl, 3-benzyloxypyridin-2-yl, 4-methylpyridin-2-yl, 4-ethylpyridin-2-yl, 2-chloropyridin- 4-yl, 3-chloropyridin-5-yl, 3-chloropyridin-6-yl, 2-chloropyridin-5-yl, 4-chloropyridin-2-yl, 1-methyl-2- oxopyrid-5-yl, tetrahydropyran-4-yl, 4,5-dihydrothiazol-2-yl, thiazol-2-yl, 5-methyl-thiazol-2-yl, 4,5- dimethyl-thiazol-2-yl, 4-tert-butyl-thiazol-2-yl, 5-tert-butyl-thiazol-2-yl, 5-nitrothiazol-2-yl, 5- bromothiazol-2-yl, 5- [4-chlorophenyl]-thiazol-2-yl, 4- [4-chlorophenyl]-thiazol-2-yl, 4- [4-nitrophenyl]- thiazol-2-yl, 4-thiazolyl, 2-methyl-4-thiazolyl, 2, 5-dimethyl-4-thiazolyl, 2, 4-dimethyl-5-thiazolyl, 5-tert- butyl-1, 3, 4-thiadiazol-2-yl, 5-trifluoromethyl-1, 3, 4-thiadiazol-2-yl, 5-ethyl-1, 3, 4-thiadiazol-2-yl, pyrazol- <BR> <BR> <BR> 5-yl, 3-pyrazolyl, 1, 3-diphenyl-pyrazol-3-yl, 1, 3-dimethyl-pyrazol-3-yl, 5-cyano-4-tert-butyl-pyrazol-3-

yl, 5-amino-3-methyl-pyrazol-1-yl, 3-methyl-l-tert-butyl-pyrazol-3-yl, 5-amino-3-tert-butyl-pyrazol-1-yl, 1-ethylpyrazol-5-yl, 3-tert-butyl-pyrazol-5-yl, 1-methyl-3-tert-butyl-pyrazol-5-yl, 4,4-dimethyl-1, 2,34- tetrahydroisoquinolin-7-yl, 7-quinolinyl, 2,3-dihydrobenzofur-7-yl, 3, 3-dimethyl-1- methylcarbonylindolin-6-yl, 3,3-dimethyl-2, 3-dihydro-indol-6-yl, 4-tert-butyl-imidazo [1, 2-a] pyridin-6-yl, 3-quinolinyl, 2-benzofuryl, benzo [1, 2,5] thiadiazol-4-yl, 7-methyl-benzothiazol-2-yl, 6-ethoxy- benzothiazol-2-yl, 6-fluoro-benzothiazol-2-yl, 5, 6-dimethyl-benzothiazol-2-yl, benzimidazol-2-yl, 1- methyl-benzimidazol-2-yl, benzoxazol-2-yl, benzisoxazol-3-yl, 4-methoxybenzisoxazol-3-yl and 2- methylbenzothiazol-5-yl.

The invention also relates to compounds wherein R'is selected from H, isopropyl, (CH3) 3CCH2-, benzyl, 4-methylphenylmethyl, 2-thiazolyl-CH (CH3) -, phenyl-CH (CH3) -, phenyl, 4-methylphenyl, 3-methylphenyl, 2-methylphenyl, 4-tert-butyl-phenyl, 4-chlorophenyl, 3-chlorophenyl, 2-chlorophenyl, 4- trifluoromethylphenyl, 3-trifluoromethylphenyl,-chloro-3-trifluoromethylphenyl, 4- dimethylaminophenyl, biphenyl, 3-isothiazolyl, and 2-thiazolyl.

The invention also relates to compounds wherein ya is-C (=O) NH-.

The invention also relates to compounds wherein R8 and R9 are both H.

The invention also relates to compounds thereof selected from 7- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy) -N-phenyl-2, 3-dihydro-4H-1, 4-benzoxazine-4-carboxamide ; 7- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N- (4-methylphenyl)-2, 3-dihydro-4H-1, 4-benzoxazine-4- carboxamide; 7- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N- (4- (dimethylamino) phenyl) -2, 3-dihydro-4H-1, 4- benzoxazine-4-carboxamide ; 7- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N- (3- (trifluoromethyl) phenyl) -2, 3-dihydro-4H-1, 4- benzoxazine-4-carboxamide ; 7-((6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N-((1 S)-1-phenylethyl)-2, 3-dihydro4H-1, 4-benzoxazine4- carboxamide; 7-((6, 7-bis (methyloxy) 4-quinolinyl) oxy)-N-(4-chlorophenyl)-2, 3-dihydro4H-1, 4-benzoxazine-4- carboxamide; 7- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N- (4- (trifluoromethyl) phenyl) -2, 3-dihydro4H-1, 4- benzoxazine-4-carboxamide ; 7- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N- (4- ( 1, 1-dimethylethyl) phenyl) -2, 3-dihydro-4H-1, 4- benzoxazine-4-carboxamide ; 7- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N- (3-isoxazolyl)-2, 3-diliydro-4H-1, 4-benzoxazine-4- carboxamide; 7- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N- (3-methylphenyl)-2, 3-dihydro-4H-1, 4-benzoxazine-4- carboxamide; and 7- ( (6, 7-bis (methyloxy) 4-quinolinyl) oxy)-N- (3-chlorophenyl)-2, 3-dihydro4H-1, 4-benzoxazine-4- carboxamide.

The invention also relates to compounds

wherein Ya is selected from-NH (CH2) p-,-NHC (=O) (CH2) p-,-NHC (=O) (CH2) pO-,- (CH2) p-NHC (=O)-,- NHC (=O) NH-, -NHC (=O) O (CH2) p-,-C (=O) O-,-NHSO2-, and-C (=O) NH (CH2) p- ; wherein p is 0,1, 2, or 3; wherein Z is CR"or N; wherein R'is selected from H, C1-5-alkyl, C1-3-haloalkyl, C1-3-alkoxy-C1-3-alkyl, C1-3-alkoxycarbonyl-C1-3- alkyl, C, 5-cyanoalkyl, aminocarbonyl-C, 5-alkyl, C, 5-alkyl-aminocarbonyl-C, 5-alkyl, amino-C, _5- alkyl, C1-5-alkyl-amino-C1-5-alkyl, C1-5-alkylsulfonyl-C1-5-alkyl, phenyl-C1-3-alkyl, C3-6-cycloalkyl-C1- 3-alkyl, 5-6-membered heterocyclyl-C, 3-alkyl, and an unsubstituted or substituted ring selected from phenyl, naphthyl, 1, 3-benzodioxolyl, C36-cycloalkyl, Cs 6-cycloalkenyl, pyrrolidinyl, pyrrolyl, imidazolyl, pyrazolyl, pyrazinyl, pyrimidinyl, pyridyl, quinolinyl, dihydrothiazolyl, 2,3- dihydrobenzofuryl, 2, 3-dihydro-1, 4-benzodioxinyl, piperidinyl, 1-methyl-oxopyridyl, tetrahydropyran-4-yl, indolinyl, imidazo [1, 2-a] pyridinyl, quinolinyl, benzofuryl, benzo [1, 2,5] thiadiazolyl, benzothiazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, thiadiazolyl, furanyl and thienyl ; wherein R8 is selected from H, fluoro, chloro and methyl; wherein R9 is selected from H, methyl and fluoro; and wherein Rx is selected from H, CN, NE2, F, alkylcarbonylamino, and alkylaminocarbonyl; wherein R'°a is H or methoxy; and wherein R'°b is selected from 4-morpholinopropoxy, 2-hydroxy-3-morpholin-4-yl-propoxy, pyrrolidin-1-ylpropoxy, 1-pyrrolidinylethoxy, 4-piperidinyloxypropoxy, (4-methylpiperazin-1- yl) propoxy, 3- (4-methylpiperazin-1-yl) propoxy, 3- (1, 2, 4-triazol-1-yl) propoxy, triazinylpropoxy, 3- (piperidin-4-yl) propoxy, dimethylaminoethoxy, dimethylaminopropoxy and methoxy; and pharmaceutically acceptable derivatives thereof.

The invention also relates to compounds wherein Z is CH; wherein R'°a is methoxy; and wherein R'°b is selected from 4-morpholinopropoxy, 2-hydroxy-3-morpholin-4-yl-propoxy, pyrrolidin-1- ylpropoxy, 1-pyrrolidinylethoxy, 4-piperidinyloxypropoxy, (4-methylpiperazin-1-yl) propoxy, 3- (4- methylpiperazin-1-yl) propoxy, 3- (1, 2,4-triazol-1-yl) propoxy, triazinylpropoxy, 3- (piperidin-4-yl) propoxy, dimethylaminoethoxy, dimethylaminopropoxy and methoxy.

The invention also relates to compounds wherein R'is selected from H, methyl, ethyl, n-butyl, isobutyl, tert-butyl, isopropyl, propyl, cyanomethyl, aminocarbonylmethyl,

dimethylaminocarbonylmethyl, dimethylaminoethyl, 2-methoxy-1-methylethyl, methoxycarbonylmethyl, methoxyethyl, methoxypropyl, methylsulfonylethyl, dimethylaminoethyl, methoxycarbonylmethyl, ethenyl, thiazol-2-yl-CH (CH3) -, phenyl-CH (CH3) -, 5-methylisoxazol-3-ylmethyl, pyrrolidin-1-ylethyl, tetrahydrofur-2-ylmethyl, 4-metbyl-2-oxo-oxazolidin-5-yl, pyrid-4-ylmethyl, pyrid-2-ylmethyl, 2- trifluoromethylpyrid-5-ylmethyl, trifluoromethyl, 2,2, 2-trifluoroethyl, 3,3, 3-trifluoropropyl, (CH3) 3CCH2-, pentafluoroethyl, CF3CH2CH2-, cyclopropylmethyl, benzyl, 4-methylbenzyl, 4-chlorobenzyl, (2- methoxyphenyl) ethyl, 1-phenylethyl, phenylethyl, cyclopropyl, 1-methylcyclopropyl, 2- fluorocyclopropyl, 2-phenylcyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 5, 5-dimethyl-3- oxocyclohexenyl, phenyl, 4-methylphenyl, 3-methylphenyl, 2-methylphenyl, 3, 4-dimethylphenyl, 3,5- dimethylphenyl, 4-ethylphenyl, 3-ethylphenyl, 2-ethylphenyl, 4-isopropylphenyl, 4-isopropyl-3- methylphenyl, 3-isopropylphenyl, 4-tert-butylphenyl, 2,3-dimethylphenyl, 3-fluorophenyl, 4- fluorophenyl, 2-fluorophenyl, 2,4-difluorophenyl, 3, 4-difluorophenyl, 2, 3-difluorophenyl, 2,6- difluorophenyl, 2,5-difluorophenyl, 3, 5-difluorophenyl, 2,4, 6-trifluorophenyl, 3-bromophenyl, 4- bromophenyl, 4-chlorophenyl, 3-chlorophenyl, 2-chlorophenyl, 4-methoxyphenyl, 3-methoxyphenyl, 2- methoxyphenyl, 3,4-dimethoxyphenyl, 2, 6-dichlorophenyl, 3-fluoro-5-methoxyphenyl, 3-chloro-5- methoxyphenyl, 4-chloro-2-methoxyphenyl, 2, 4-dimethoxyphenyl, 2, 6-dimethoxyphenyl, 3,5- dimethoxyphenyl, 2-ethoxyphenyl, 4-hydroxyphenyl, 2-hydroxyphenyl, 2, 5-dichlorophenyl, 2,4- dichlorophenyl, 2, 3-dichlorophenyl, 3, 5-dichlorophenyl, 3,4-dichlorophenyl, 3, 4-difluorophenyl, 3- trifluoromethoxyphenyl, 4-trifluoromethoxyphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 3,5-di (trifluoromethyl)-phenyl, 3,5-di (trifluoromethyl)-2-methylphenyl, 4-dimethylaminophenyl, 3- dimethylaminophenyl, 3-nitrophenyl, 4-nitrophenyl, 3-cyanophenyl, 4-methylthiophenyl, 3- methylsulfonylphenyl, 2-methylsulfonylphenyl, 3-chloro-4-methylphenyl, 3-chloro-4-fluorophenyl, 4- [1- <BR> <BR> <BR> <BR> isopropylpiperazinin-4-yl] phenyl, 2- [ (1-methylpyrrolidin-3-yl)-N (CH3)]-5-trifluoromethylphenyl, 5- [1- methylpiperazin-4-ylmethyl]-3-trifluoromethylphenyl, 5- [2-oxopyrrolidin-1-yl]-3-trifluoromethylphenyl, 2-chloro-4-trifluoromethylphenyl, 4-chloro-3-trifluoromethylphenyl, 4-bromo-2-fluorophenyl, 2- trifluoromethoxyphenyl, 2-trifluoromethylphenyl, 4-pentafluoroethylphenyl,-fluoro-3- trifluoromethylphenyl, 2-fluoro-5-trifluoromethylphenyl, 2-methyl-3-trifluoromethylphenyl, 2-methyl-5- trifluoromethylphenyl, 3-fluoro-5-trifluoromethylphenyl, 2- [methylcarbonylamino]-5- trifluoromethylphenyl, 3- [1-methylpiperidin-4-yl]-5-trifluoromethylphenyl, 2- [1, 1-dioxo-thiomorpholin- 4-yl]-5-trifluoromethylphenyl, 2- [1-oxo-thiomorpholin-4-yl]-5-trifluoromethylphenyl, 2- [thiomorpholin- <BR> <BR> <BR> <BR> 4-yl]-5-trifluoromethylphenyl, 2-piperidin-1-yl-5-trifluoromethyl-phenyl, 2- [ (3-<BR> <BR> <BR> <BR> <BR> <BR> dimethylaminopropyl) methylamino]-5-trifluoromethylphenyl, 2- (3-dimethylamino-pyrroldin-1-yl)-5- trifluoromethylphenyl, 3- (methylcarbonylamino) phenyl, 3- (4-methylpiperazin-1-ymethyl) phenyl, 2- (4- methylpiperazin-1-ymethyl) phenyl, 2-piperidin-1-yl-5-trifluoromethyl-phenyl, 2- [1-methylpiperidin-4- yloxy]-5-trifluoromethylphenyl, 2-methoxy-5-trifluoromethylphenyl, 2-methoxy-5-phenylphenyl, 2- [3, 3- dimethyl-2-oxo-azetidin-1-yl]-5-trifluoromethylphenyl, 2-[morpholin4-ylethoxy]-5-tert-butylphenyl, 2- <BR> <BR> <BR> <BR> methoxy-5-fluorophenyl, 2-methoxy-5-tert-butylphenyl, 3- [dimethylaminomethylcarbonylamino]-4-tert- butylphenyl, 2-methoxy-5-[2-pyridylaminoca : rbonyl] phenyl, 2-methoxy-5-phenylaminocarbonylphenyl, 2-

[methyl-(l-methylpyrrolidin-3-yl) amino] -5-trifluoromethylphenyl, 2, 2-difluorobenzodioxol4-yl, biphenyl, 2-naphthyl, 2, 3-dihydro-1, 4-benzodioxin-6-yl, 7-fluoro-2, 3-dihydro-1, 4-benzodioxin-6-yl, 1,3- benzodioxol4-yl, 1-isopropylpiperidin4-yl, 2-pyrrolidinyl, 1-methyl-2-pyrrolidinyl, 4-piperazinyl, 1- methylpiperidin-4-yl, 3-methyl-isothiazol-5-yl, 3-isothiazolyl, 4, 5-dichloro-3-isothiazolyl, isoxazol-3-yl, 5-isoxazolyl, 4-isoxazolyl, 5-methyl-isoxazol-3-yl, 3, 5-dimethyl-isoxazol-4-yl, 4, 5-dimethyl-isoxazol-3- yl, 3-methyl-isoxazol-5-yl, 5-tert-butyl-isoxazol-3-yl, 4-bromo-5-methyl-isoxazol-3-yl, 5-oxazolyl, 1- methylimidazol-5-yl, 5-imidazolyl, 2-thienyl, 3-thienyl, 2-methylcarbonyl-thien-3-yl, 2-methylcarbonyl- 5-tert-butyl-thien-3-yl, 2-aminocarbonyl-5-tert-butyl-thien-3-yl, 4-methoxy-5-chloro-3-thienyl, 3-methyl- 2-thienyl, 5-methyl-2-thienyl, 5-methylthio-2-thienyl, 5-methylsulfonyl-2-thienyl, 3-ethoxy-2-thienyl, 3- chloro-2-thienyl, 5-chloro-2-thienyl, 3-bromo-2-thienyl, 5-bromo-2-thienyl, 4-methoxy-5-bromo-3- thienyl, 4-methoxy-3-thienyl, 2-furyl, 2-cyano-5-phenylfur-3-yl, 4, 5-dimethyl-2-furyl, 5-methyl-2- trifluoromethyl-3-furyl, 3-furanyl, 1-methylpyrrol-2-yl, 2-pyrrolyl, 2-pyrazinyl, 5-methyl-2-pyrazinyl, 4- pyrimidinyl, 2, 6-dimethoxy4-pyrimidinyl, 4-methoxy-6-methylpyrimidin-2-yl, 4-chloro-2- methylthiopyrimidin-6-yl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 4-trifluoromethylpyridin-2-yl, 2- trifluoromethylpyridin-5-yl, 2-dimethylaminopyridin-5-yl, 5-chloro-2-pyridyl, 2-fluoro-3-pyridyl, 2- chloro-3-pyridyl, 2-methoxy-3-pyridyl, 2-ethoxy-3-pyridyl, 2-chloro4-pyridyl, 2, 5-dichloro-3-pyridyl, 2- (dimethylaminoethoxy)-3-pyridyl, 2-methoxy-5-pyridyl, 2-methyl-5-pyridyl, 4-chloro-2-pyridyl, 4- methoxy-5-pyridyl, 3-benzyloxypyridin-2-yl, 4-methylpyridin-2-yl, 4-ethylpyridin-2-yl, 2-chloropyridin- 4-yl, 3-chloropyridin-5-yl, 3-chloropyridin-6-yl, 2-chloropyridin-5-yl, 4-chloropyridin-2-yl, 1-methyl-2- oxopyrid-5-yl, tetrahydropyran4-yl, 4, 5-dihydrothiazol-2-yl, thiazol-2-yl, 5-methyl-thiazol-2-yl, 4,5- dimethyl-thiazol-2-yl, 4-tert-butyl-thiazol-2-yl, 5-tert-butyl-thiazol-2-yl, 5-nitrothiazol-2-yl, 5- bromothiazol-2-yl, 5- [4-chlorophenyl]-thiazol-2-yl, 4- [4-chlorophenyl]-thiazol-2-yl, 4- [4-nitrophenyl]- thiazol-2-yl, 4-thiazolyl, 2-methyl4-thiazolyl, 2, 5-dimethyl-4-thiazolyl, 2, 4-dimethyl-5-thiazolyl, 5-tert- butyl-1, 3, 4-thiadiazol-2-yl, 5-trifluoromethyl-1, 3,4-thiadiazol-2-yl, 5-ethyl-1, 3, 4-thiadiazol-2-yl, pyrazol- <BR> <BR> <BR> <BR> 5-yl, 3-pyrazolyl, 1, 3-diphenyl-pyrazol-3-yl, 1, 3-dimethyl-pyrazol-3-yl, 5-cyano-4-tert-butyl-pyrazol-3- yl, 5-amino-3-methyl-pyrazol-1-yl, 3-methyl-1-tert-butyl-pyrazol-3-yl, 5-amino-3-tert-butyl-pyrazol-1-yl, I-ethylpyrazol-5-yl, 3-tert-butyl-pyrazol-5-yl, 1-methyl-3-tert-butyl-pyrazol-5-yl, 4, 4-dimethyl-1, 2,34- tetrahydroisoquinolin-7-yl, 7-quinolinyl, 2,3-dihydrobenzofur-7-yl, 3, 3-dimethyl-1- methylcarbonylindolin-6-yl, 3,3-dimethyl-2, 3-dihydro-indol-6-yl, 4-tert-butyl-imidazo [1, 2-a] pyridin-6-yl, 3-quinolinyl, 2-benzofuryl, benzo [1, 2,5] thiadiazol4-yl, 7-methyl-benzothiazol-2-yl, 6-ethoxy- benzothiazol-2-yl, 6-fluoro-benzothiazol-2-yl, 5, 6-dimethyl-benzothiazol-2-yl, benzimidazol-2-yl, 1- methyl-benzimidazol-2-yl, benzoxazol-2-yl, benzisoxazol-3-yl, 4-methoxybenzisoxazol-3-yl and 2- methylbenzothiazol-5-yl.

The invention also relates to compounds wherein R'is selected from 3-isopropylphenyl, 3- fluorophenyl, 3,4-difluorophenyl, 4-chlorophenyl, 3-chlorophenyl, 3,4-dichlorophenyl, 3-methoxyphenyl, 3-trifluoromethoxyphenyl, and 3,5-di (trifluoromethyl) phenyl.

The invention also relates to compounds wherein Ya is-C (=O) NH-.

The invention also relates to compounds wherein R8 and R9 are H.

The invention also relates to compounds of

wherein Ya is selected from-NH (CH2) p-,-NHC (=O) (CH2) p-,-NHC (=O) (CH2) pO-,- (CH2) p-NHC (=O)-,- NHC (=O) NH-,-NHC (=O) O (CH2) p-,-C (=O) O-,-NHSO2-, and-C (=O) NH (CH2) p- ; wherein p is 0,1, 2, or 3; wherein Z is CR"or N; wherein R'is selected from H, C1-5-alkyl, C1-3-haloalkyl, C1-3-alkoxy-C1-3-alkyl, C1-3-alkoxycarbonyl-C1-3- alkyl, Cl s-cyanoalkyl, aminocarbonyl-C, s-alkylX Cl 5-alkyl-aminocarbonyl-C, 5-alkyl, amino-Cl 5- alkyl, C1-5-alkyl-amino-C1-5-alkyl, C1-5-alkylsufonyl-C1-5-alkyl, phenyl-C1-3-alkyl, C3-6-cycloalkyl-C1- 3-alkyl, 5-6-membered heterocyclyl-C, 3-alkyl, and an unsubstituted or substituted ring selected from phenyl, naphthyl, 1,3-benzodioxolyl, C3_6-cycloalkyl, Cs-6-cycloalkenyl, pyrrolidinyl, pyrrolyl, imidazolyl, pyrazolyl, pyrazinyl, pyrimidinyl, pyridyl, quinolinyl, dihydrothiazolyl, 2,3- dihydrobenzofuryl, 2, 3-dihydro-1, 4-benzodioxinyl, piperidinyl, 1-methyl-oxopyridyl, tetrahydropyran-4-yl, indolinyl, imidazo [1, 2-a] pyridinyl, quinolinyl, benzofuryl, benzo [1, 2,5] thiadiazolyl, benzothiazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, thiadiazolyl, furanyl and thienyl; wherein R is selected from H, fluoro, chloro and methyl; wherein R9 is selected from H, methyl and fluoro; and wherein R"is selected from H, CN, NH2, F, alkylcarbonylamino, and alkylaminocarbonyl; wherein R'°a is H or methoxy; and wherein R'°b is selected from 4-morpholinopropoxy, 2-hydroxy-3-morpholin-4-yl-propoxy, pyrrolidin-1-ylpropoxy, 1-pyrrolidinylethoxy, 4-piperidinyloxypropoxy, (4-methylpiperazin-1- yl) propoxy, 3- (4-methylpiperazin-1-yl) propoxy, 3- (1, 2, 4-triazol-1-yl) propoxy, triazinylpropoxy, 3- (piperidin-4-yl) propoxy, dimethylaminoethoxy, dimethylaminopropoxy and methoxy; and pharmaceutically acceptable derivatives thereof.

The invention also relates to compounds wherein Z is CH; wherein R'°a is methoxy; and wherein R'°b is selected from 4-morpholinopropoxy, 2-hydroxy-3-morpholin-4-yl-propoxy, pyrrolidin-1- ylpropoxy, 1-pyrrolidinylethoxy, 4-piperidinyloxypropoxy, (4-methylpiperazin-1-yl) propoxy, 3- (4- methylpiperazin-1-yl) propoxy, 3- (1, 2, 4-triazol-1-yl) propoxy, triazinylpropoxy, 3- (piperidin4-yl) propoxy, dimethylaminoethoxy, dimethylaminopropoxy and methoxy.

The invention also relates to compounds wherein R'is selected from H, methyl, ethyl, n-butyl, isobutyl, tert-butyl, isopropyl, propyl, cyanomethyl, aminocarbonylmethyl, <BR> <BR> <BR> dimethylaminocarbonylmethyl, dimethylaminoethyl, 2-methoxy-1-methylethyl, methoxycarbonylmethyl, methoxyethyl, methoxypropyl, methylsulfonylethyl, dimethylaminoethyl, methoxycarbonylmethyl, ethenyl, thiazol-2-yl-CH (CH3) -, phenyl-CH (CH3) -, 5-methylisoxazol-3-ylmethyl, pyrrolidin-1-ylethyl, tetrahydrofur-2-ylmethyl, 4-methyl-2-oxo-oxazolidin-5-yl, pyrid-4-ylmethyl, pyrid-2-ylmethyl, 2- trifluoromethylpyrid-5-ylmethyl, trifluoromethyl, 2,2, 2-trifluoroethyl, 3,3, 3-trifluoropropyl, (CH3) 3CCH2-, pentafluoroethyl, CF3CH2CH2-, cyclopropylmethyl, benzyl, 4-methylbenzyl, 4-chlorobenzyl, (2- methoxyphenyl) ethyl, I-phenylethyl, phenylethyl, cyclopropyl, 1-methylcyclopropyl, 2- fluorocyclopropyl, 2-phenylcyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 5, 5-dimethyl-3- oxocyclohexenyl, phenyl, 4-methylphenyl, 3-methylphenyl, 2-methylphenyl, 3,4-dimethylphenyl, 3,5- dimethylphenyl, 4-ethylphenyl, 3-ethylphenyl, 2-ethylphenyl, 4-isopropylphenyl, 4-isopropyl-3- methylphenyl, 3-isopropylphenyl, 4-tert-butylphenyl, 2,3-dimethylphenyl, 3-fluorophenyl, 4- fluorophenyl, 2-fluorophenyl, 2, 4-difluorophenyl, 3, 4-difluorophenyl, 2, 3-difluorophenyl, 2,6- difluorophenyl, 2, 5-difluorophenyl, 3, 5-difluorophenyl, 2,4, 6-trifluorophenyl, 3-bromophenyl, 4- bromophenyl, 4-chlorophenyl, 3-chlorophenyl, 2-chlorophenyl, 4-methoxyphenyl, 3-methoxyphenyl, 2- methoxyphenyl, 3,4-dimethoxyphenyl, 2, 6-dichlorophenyl, 3-fluoro-5-methoxyphenyl, 3-chloro-5- methoxyphenyl, 4-chloro-2-methoxyphenyl, 2,4-dimethoxyphenyl, 2,6-dimethoxyphenyl, 3,5- dimethoxyphenyl, 2-ethoxyphenyl, 4-hydroxyphenyl, 2-hydroxyphenyl, 2,5-dichlorophenyl, 2,4- dichlorophenyl, 2,3-dichlorophenyl, 3, 5-dichlorophenyl, 3, 4-dichlorophenyl, 3, 4-difluorophenyl, 3- trifluoromethoxyphenyl, 4-trifluoromethoxyphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 3,5-di (trifluoromethyl)-phenyl, 3,5-di (trifluoromethyl)-2-methylphenyl, 4-dimethylaminophenyl, 3- dimethylaminophenyl, 3-nitrophenyl, 4-nitrophenyl, 3-cyanophenyl, 4-methylthiophenyl, 3- methylsulfonylphenyl, 2-methylsulfonylphenyl, 3-chloro-4-methylphenyl, 3-chloro-4-fluorophenyl, 4- [1- <BR> <BR> <BR> isopropylpiperazinin-4-yl] phenyl, 2- [ (l-methylpyrrolidin-3-yl)-N (CH3)]-5-trifluoromethylphenyl, 5- [1-<BR> <BR> <BR> <BR> <BR> methylpiperazin-4-ylmethyl]-3-trifluoromethylphenyl, 5- [2-oxopyrrolidin-1-yl]-3-trifluoromethylphenyl, 2-chloro-4-trifluoromethylphenyl, 4-chloro-3-trifluoromethylphenyl, 4-bromo-2-fluorophenyl, 2- trifluoromethoxyphenyl, 2-trifluoromethylphenyl, 4-pentafluoroethylphenyl,-fluoro-3- trifluoromethylphenyl, 2-fluoro-5-trifluoromethylphenyl, 2-methyl-3-trifluoromethylphenyl, 2-methyl-5- trifluoromethylphenyl, 3-fluoro-5-trifluoromethylphenyl, 2- [methylcarbonylamino]-5- trifluoromethylphenyl, 3- [1-methylpiperidin-4-yl]-5-trifluoromethylphenyl, 2- [1, 1-dioxo-thiomorpholin- <BR> <BR> <BR> 4-yl]-5-trifluoromethylphenyl, 2- [1-oxo-thiomorpholin-4-yl]-5-trifluoromethylphenyl, 2- [thiomorpholin-<BR> <BR> <BR> <BR> <BR> <BR> 4-yl]-5-trifluoromethylphenyl, 2-piperidin-1-yl-5-trifluoromethyl-phenyl, 2- [ (3-<BR> <BR> <BR> <BR> <BR> dimethylaminopropyl) methylamino]-5-trifluoromethylphenyl, 2- (3-dimethylamino-pyrroldin-1-yl)-5- trifluoromethylphenyl, 3- (methylcarbonylamino) phenyl, 3- (4-methylpiperazin-1-ymethyl) phenyl, 2- (4- methylpiperazin-1-ymethyl) phenyl, 2-piperidin-1-yl-5-trifluoromethyl-phenyl, 2- [1-methylpiperidin-4- yloxy]-5-trifluoromethylphenyl, 2-methoxy-5-trfluoromethylphenyl, 2-methoxy-5-phenylphenyl, 2- [3, 3- dimethyl-2-oxo-azetidin-1-yl]-5-trifluoromethylphenyl, 2-[morpholin-4-ylethoxy]-5-tert-butylphenyl, 2-

methoxy-5-fluorophenyl, 2-methoxy-5-tert-butylphenyl, 3- [dimethylaminomethylcarbonylamino]-4-tert- butylphenyl, 2-methoxy-5- [2-pyridylaminocarbonyl] phenyl, 2-methoxy-5-phenylaminocarbonylphenyl, 2- [methyl- (l-methylpyrrolidin-3-yl) amino]-5-trifluoromethylphenyl, 2, 2-difluorobenzodioxol-4-yl, biphenyl, 2-naphthyl, 2, 3-dihydro-1, 4-benzodioxin-6-yl, 7-fluoro-2, 3-dihydro-1, 4-benzodioxin-6-yl, 1,3- benzodioxol-4-yl, 1-isopropylpiperidin-4-yl, 2-pyrrolidinyl, 1-methyl-2-pyrrolidinyl, 4-piperazinyl, 1- methylpiperidin-4-yl, 3-methyl-isothiazol-5-yl, 3-isothiazolyl, 4, 5-dichloro-3-isothiazolyl, isoxazol-3-yl, 5-isoxazolyl, 4-isoxazolyl, 5-methyl-isoxazol-3-yl, 3, 5-dimethyl-isoxazol-4-yl, 4, 5-dimethyl-isoxazol-3- yl, 3-methyl-isoxazol-5-yl, 5-tert-butyl-isoxazol-3-yl, 4-bromo-5-methyl-isoxazol-3-yl, 5-oxazolyl, 1- methylimidazol-5-yl, 5-imidazolyl, 2-thienyl, 3-thienyl, 2-methylcarbonyl-thien-3-yl, 2-methylcarbonyl- 5-tert-butyl-thien-3-yl, 2-aminocarbonyl-5-tert-butyl-thien-3-yl, 4-methoxy-5-chloro-3-thienyl, 3-methyl- 2-thienyl, 5-methyl-2-thienyl, 5-methylthio-2-thienyl, 5-methylsulfonyl-2-thienyl, 3-ethoxy-2-thienyl, 3- chloro-2-thienyl, 5-chloro-2-thienyl, 3-bromo-2-thienyl, 5-bromo-2-thienyl, 4-methoxy-5-bromo-3- thienyl, 4-methoxy-3-thienyl, 2-furyl, 2-cyano-5-phenylfur-3-yl, 4,5-dimethyl-2-furyl, 5-methyl-2- trifluoromethyl-3-furyl, 3-furanyl, 1-methylpyrrol-2-yl, 2-pyrrolyl, 2-pyrazinyl, 5-methyl-2-pyrazinyl, 4- pyrimidinyl, 2, 6-dimethoxy-4-pyrimidinyl, 4-methoxy-6-methylpyrimidin-2-yl, 4-chloro-2- methylthiopyrimidin-6-yl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 4-trifluoromethylpyridin-2-yl, 2- trifluoromethylpyridin-5-yl, 2-dimethylaminopyridin-5-yl, 5-chloro-2-pyridyl, 2-fluoro-3-pyridyl, 2- chloro-3-pyridyl, 2-methoxy-3-pyridyl, 2-ethoxy-3-pyridyl, 2-chloro-4-pyridyl, 2, 5-dichloro-3-pyridyl, 2- (dimethylaminoethoxy)-3-pyridyl, 2-methoxy-5-pyridyl, 2-methyl-5-pyridyl, 4-chloro-2-pyridyl, 4- methoxy-5-pyridyl, 3-benzyloxypyridin-2-yl, 4-methylpyridin-2-yl, 4-ethylpyridin-2-yl, 2-chloropyridin- 4-yl, 3-chloropyridin-5-yl, 3-chloropyridin-6-yl, 2-chloropyridin-5-yl, 4-chloropyridin-2-yl, 1-methyl-2- oxopyrid-5-yl, tetrahydropyran-4-yl, 4, 5-dihydrothiazol-2-yl, thiazol-2-yl, 5-methyl-thiazol-2-yl, 4,5- dimethyl-thiazol-2-yl, 4-tert-butyl-thiazol-2-yl, 5-tert-butyl-thiazol-2-yl, 5-nitrothiazol-2-yl, 5- bromothiazol-2-yl, 5- [4-chlorophenyl]-thiazol-2-yl, 4- [4-chlorophenyl]-thiazol-2-yl, 4- [4-nitrophenyl]- thiazol-2-yl, 4-thiazolyl, 2-methyl-4-thiazolyl, 2, 5-dimethyl-4-thiazolyl, 2, 4-dimethyl-5-thiazolyl, 5-tert- butyl-1, 3,4-thiadiazol-2-yl, 5-trifluoromethyl-1, 3, 4-thiadiazol-2-yl, 5-ethyl-1, 3, 4-thiadiazol-2-yl, pyrazol- 5-yl, 3-pyrazolyl, 1, 3-diphenyl-pyrazol-3-yl, 1, 3-dimethyl-pyrazol-3-yl, 5-cyano-4-tert-butyl-pyrazol-3- yl, 5-amino-3-methyl-pyrazol-1-yl, 3-methyl-1-tert-butyl-pyrazol-3-yl, 5-amino-3-tert-butyl-pyrazol-1-yl, 1-ethylpyrazol-5-yl, 3-tert-butyl-pyrazol-5-yl, 1-methyl-3-tert-butyl-pyrazol-5-yl, 4, 4-dimethyl-1, 2,34- tetrahydroisoquinolin-7-yl, 7-quinolinyl, 2, 3-dihydrobenzofur-7-yl, 3, 3-dimethyl-1- methylcarbonylindolin-6-yl, 3, 3-dimethyl-2, 3-dihydro-indol-6-yl, 4-tert-butyl-imidazo [1, 2-a] pyndin-6-yl, 3-quinolinyl, 2-benzofuryl, benzo [1, 2,5] thiadiazol-4-yl, 7-methyl-benzothiazol-2-yl, 6-ethoxy- benzothiazol-2-yl, 6-fluoro-benzothiazol-2-yl, 5, 6-dimethyl-benzothiazol-2-yl, benzimidazol-2-yl, 1- methyl-benzimidazol-2-yl, benzoxazol-2-yl, benzisoxazol-3-yl, 4-methoxybenzisoxazol-3-yl and 2- methylbenzothiazol-5-yl.

The invention also relates to compounds wherein R'is selected from methoxyethyl, cyclopropyl, 3-isopropylphenyl, 4-tert-butyl-phenyl, 4-isopropyl-3-methylphenyl, 3-chloro-4-methylphenyl, 3- fluorophenyl, 3, 4-difluorophenyl, 4-chlorophenyl, 3-chlorophenyl, 3, 4-dichlorophenyl, 3-methoxyphenyl,

4-trifluoromethoxyphenyl, 3-trifluoromethoxyphenyl, 3-trifluoromethylphenyl, 3-pyridyl, 4- trifluoromethyl-2-pyridyl, 3-isothiazolyl, and 2-thiazolyl.

The invention also relates to compounds wherein Ya is-C (=O) NH-.

The invention also relates to compounds wherein R'and R9 are H.

The invention also relates to compounds selected from 7- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N- (3-fluorophenyl)-2-naphthalenecarboxamide ; 7- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N-cyclopropyl-2-naphthalenecarboxamide ; 7- ( (6, 7-bis (methyloxy) 4-quinolinyl) oxy)-N- (3- (methyloxy) phenyl)-2-naphthalenecarboxamide ; 7- ( (6, 7-bis (methyloxy) 4-quinolinyl) oxy)-N- (3-isoxazolyl)-2-naphthalenecarboxamide ; 7- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N- (3-cblorophenyl)-2-naphthalenecarboxamide ; 7-((6, 7-bis (methyloxy) 4-quinolinyl) oxy)-N-(4-(1, 1-dimethylethyl) phenyl) -2- naphthalenecarboxamide; 7- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N- (5- (1, 1-dimethylethyl)-3-isoxazolyl)-2- naphthalenecarboxamide; 7- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N- (1, 3-thiazol-2-yl)-2-naphthalenecarboxamide ; 7- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N- (3-chloro-4-methylphenyl)-2-naphthalenecarboxamide ; 7- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N- (4- (trifluoromethyl)-2-pyridinyl)-2- naphthalenecarboxamide; 7- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N- (3- ( (trifluoromethyl) oxy) phenyl)-2- naphthalenecarboxamide; 7- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N- (3, 4-difluorophenyl)-2-naphthalenecarboxamide ; 7- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N- (3-methyl-4- (1-methylethyl) phenyl)-2- naphthalenecarboxamide ; 7- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N- (3, 4-dichlorophenyl)-2-naphthalenecarboxamide ; 7- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N- (4- ( (trifluoromethyl) oxy) phenyl)-2- naphthalenecarboxamide; 7- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N- (3- (trifluoromethyl) phenyl) -2-naphthalenecarboxamide; and 7- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N- (3-pyridinyl)-2-naphthalenecarboxamide.

The invention also relates to compounds of

wherein Ya is selected from-NH (CH2) p-, -NHC (=O) (CH2) p-,-NHC (=O) (CH2) pO-,- (CH2) p-NHC (=O)-,- NHC (=O) NH-, -NHC (=O) O (CH2) p-,-C (=O) O-,-NHSO2-, and-C (=O) NH (CH2) p-; wherein p is 0,1, 2, or 3; wherein Z is CR"or N; wherein R'is selected from H, C1-5-alkyl, C1-3-haloalkyl, C1-3-alkoxy-C1-3-alkyl, C1-3-alkoxycarbonyl-C1-3- alkyl, C, 5-cyanoalkyl, aminocarbonyl-C, 5-alkyl, C, 5-alkyl-aminocarbonyl-C, 5-alkyl, amino-C, 5- alkyl, Cl 5-alkyl-amino-Cl 5-alkyl, C, 5-alkylsulfonyl-C, 5-alkyl, phenyl-Cl 3-alkyl, C36-cycloalkyl-C, 3-alkyl, 5-6-membered heterocyclyl-C, 3-alkyl, and an unsubstituted or substituted ring selected from phenyl, naphthyl, 1,3-benzodioxolyl, C36-cycloalkyl, C56-cycloalkenyl, pyrrolidinyl, pyrrolyl, imidazolyl, pyrazolyl, pyrazinyl, pyrimidinyl, pyridyl, quinolinyl, dihydrothiazolyl, 2,3- dihydrobenzofuryl, 2, 3-dihydro-1, 4-benzodioxinyl, piperidinyl, 1-methyl-oxopyridyl, tetrahydropyran-4-yl, indolinyl, imidazo [1, 2-a] pyridinyl, quinolinyl, benzofuryl, benzo [1, 2,5] thiadiazolyl, benzothiazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, thiadiazolyl, furanyl and thienyl; wherein R is selected from H, fluoro, chloro and methyl; wherein R9 is selected from H, methyl and fluoro; and wherein R"is selected from H, CN, NH2, F, alkylcarbonylamino, and alkylaminocarbonyl; wherein R'°a is H or methoxy; and wherein R'°b is selected from 4-morpholinopropoxy, 2-hydroxy-3-morpholin-4-yl-propoxy, pyrrolidin-1-ylpropoxy, 1-pyrrolidinylethoxy, 4-piperidinyloxypropoxy, (4-methylpiperazin-1- yl) propoxy, 3- (4-methylpiperazin-1-yl) propoxy, 3- (1, 2, 4-triazol-1-yl) propoxy, triazinylpropoxy, 3- (piperidin-4-yl) propoxy, dimethylaminoethoxy, dimethylaminopropoxy and methoxy; and pharmaceutically acceptable derivatives thereof.

The invention also relates to compounds wherein Z is CH; wherein R'°a is methoxy; and wherein R'°b is selected from 4-morpholinopropoxy, 2-hydroxy-3-morpholin-4-yl-propoxy, pyrrolidin-1- ylpropoxy, 1-pyrrolidinylethoxy, 4-piperidinyloxypropoxy, (4-methylpiperazin-1-yl) propoxy, 3- (4- methylpiperazin-1-yl) propoxy, 3- (1, 2, 4-triazol-1-yl) propoxy, triazinylpropoxy, 3- (piperidin-4-yl) propoxy, dimethylaminoethoxy, dimethylaminopropoxy and methoxy.

The invention also relates to compounds wherein R'is selected from H, methyl, ethyl, n-butyl, isobutyl, tert-butyl, isopropyl, propyl, cyanomethyl, aminocarbonylmethyl, dimethylaminocarbonylmethyl, dimethylaminoethyl, 2-methoxy-1-methylethyl, methoxycarbonylmethyl, methoxyethyl, methoxypropyl, methylsulfonylethyl, dimethylaminoethyl, methoxycarbonylmethyl, ethenyl, thiazol-2-yl-CH (CH3) -, phenyl-CH (CH3) -, 5-methylisoxazol-3-ylmethyl, pyrrolidin-1-ylethyl, tetrahydrofur-2-ylmethyl, 4-methyl-2-oxo-oxazolidin-5-yl, pyrid-4-ylmethyl, pyrid-2-ylmethyl, 2- trifluoromethylpyrid-5-ylmethyl, trifluoromethyl, 2,2, 2-trifluoroethyl, 3,3, 3-trifluoropropyl, (CH3) 3CCH2-, pentafluoroethyl, CF3CH2CH2-, cyclopropylmethyl, benzyl, 4-methylbenzyl, 4-chlorobenzyl, (2- methoxyphenyl) ethyl, 1-phenylethyl, phenylethyl, cyclopropyl, 1-methylcyclopropyl, 2- fluorocyclopropyl, 2-phenylcyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 5, 5-dimethyl-3- oxocyclohexenyl, phenyl, 4-methylphenyl, 3-methylphenyl, 2-methylphenyl, 3, 4-dimethylphenyl, 3,5- dimethylphenyl, 4-ethylphenyl, 3-ethylphenyl, 2-ethylphenyl, 4-isopropylphenyl, 4-isopropyl-3- methylphenyl, 3-isopropylphenyl, 4-tert-butylphenyl, 2, 3-dimethylphenyl, 3-fluorophenyl, 4- fluorophenyl, 2-fluorophenyl, 2, 4-difluorophenyl, 3, 4-difluorophenyl, 2,3-difluorophenyl, 2,6- difluorophenyl, 2, 5-difluorophenyl, 3, 5-difluorophenyl, 2,4, 6-trifluorophenyl, 3-bromophenyl, 4- bromophenyl, 4-chlorophenyl, 3-chlorophenyl, 2-chlorophenyl, 4-methoxyphenyl, 3-methoxyphenyl, 2- methoxyphenyl, 3, 4-dimethoxyphenyl, 2,6-dichlorophenyl, 3-fluoro-5-methoxyphenyl, 3-chloro-5- methoxyphenyl, 4-chloro-2-methoxyphenyl, 2, 4-dimethoxyphenyl, 2,6-dimethoxyphenyl, 3,5- dimethoxyphenyl, 2-ethoxyphenyl, 4-hydroxyphenyl, 2-hydroxyphenyl, 2, 5-dichlorophenyl, 2,4- dichlorophenyl, 2, 3-dichlorophenyl, 3, 5-dichlorophenyl, 3, 4-dichlorophenyl, 3, 4-difluorophenyl, 3- trifluoromethoxyphenyl, 4-trifluoromethoxyphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 3,5-di (trifluoromethyl)-phenyl, 3,5-di (trifluoromethyl)-2-methylphenyl, 4-dimethylaminophenyl, 3- dimethylaminophenyl, 3-nitrophenyl, 4-nitrophenyl, 3-cyanophenyl, 4-methylthiophenyl, 3- methylsulfonylphenyl, 2-methylsulfonylphenyl, 3-chloro-4-methylphenyl, 3-chloro-4-fluorophenyl, 4- [1- <BR> <BR> <BR> <BR> isopropylpiperazinin-4-yl] phenyl, 2- [ (l-methylpyrrolidin-3-yl)-N (CH3)]-5-trifluoromethylphenyl, 5- [1-<BR> <BR> <BR> <BR> <BR> <BR> <BR> methylpiperazin-4-ylmethyl]-3-trifluoromethylphenyl, 5- [2-oxopyrrolidin-1-yl]-3-trifluoromethylphenyl, 2-chloro-4-trifluoromethylphenyl, 4-chloro-3-trifluoromethylphenyl, 4-bromo-2-fluorophenyl, 2- trifluoromethoxyphenyl, 2-trifluoromethylphenyl, 4-pentafluoroethylphenyl,-fluoro-3- trifluoromethylphenyl, 2-fluoro-5-trifluoromethylphenyl, 2-methyl-3-trifluoromethylphenyl, 2-methyl-5- trifluoromethylphenyl, 3-fluoro-5-trifluoromethylphenyl, 2- [methylcarbonylamino]-5- <BR> <BR> <BR> <BR> trifluoromethylphenyl, 3- [1-methylpiperidin-4-yl]-5-trifluoromethylphenyl, 2- [1, 1-dioxo-thiomorpholin-<BR> <BR> <BR> <BR> <BR> <BR> 4-yl]-5-trifluoromethylphenyl, 2- [1-oxo-thiomorpholin-4-yl]-5-trifluoromethylphenyl, 2- [thiomorpholin-<BR> <BR> <BR> <BR> <BR> <BR> <BR> 4-yl]-5-trifluoromethylphenyl, 2-piperidin-1-yl-5-trifluoromethyl-phenyl, 2- [ (3-<BR> <BR> <BR> <BR> <BR> <BR> dimethylaminopropyl) methylamino]-5-trifluoromethylphenyl, 2- (3-dimethylamino-pyrroldin-1-yl)-5- trifluoromethylphenyl, 3- (methylcarbonylamino) phenyl, 3- (4-methylpiperazin-1-ymethyl) phenyl, 2- (4- methylpiperazin-1-ymethyl) phenyl, 2-piperidin-1-yl-5-trifluoromethyl-phenyl, 2- [1-methylpiperidin-4- yloxy]-5-trifluoromethylphenyl, 2-methoxy-5-trifluoromethylphenyl, 2-methoxy-5-phenylphenyl, 2- [3, 3- dimethyl-2-oxo-azetidin-1-yl]-5-trifluoromethylphenyl, 2- [morpholin-4-ylethoxy]-5-tert-butylphenyl, 2-

methoxy-5-fluorophenyl, 2-methoxy-5-tert-butylphenyl, 3- [dimethylaminomethylcarbonylamino]-4-tert- butylphenyl, 2-methoxy-5-[2-pyridylaminocarbonyl] phenyl, 2-methoxy-5-phenylaminocarbonylphenyl, 2- [methyl-(l-methylpyrrolidin-3-yl) amino]-5-trifluoromethylphenyl, 2, 2-difluorobenzodioxol-4-yl, biphenyl, 2-naphthyl, 2, 3-dihydro-1, 4-benzodioxin-6-yl, 7-fluoro-2, 3-dihydro-1, 4-benzodioxin-6-yl, 1,3- benzodioxol-4-yl, 1-isopropylpiperidin-4-yl, 2-pyrrolidinyl, 1-methyl-2-pyrrolidinyl, 4-piperazinyl, 1- methylpiperidin-4-yl, 3-methyl-isothiazol-5-yl, 3-isothiazolyl, 4, 5-dichloro-3-isothiazolyl, isoxazol-3-yl, 5-isoxazolyl, 4-isoxazolyl, 5-methyl-isoxazol-3-yl, 3, 5-dimethyl-isoxazol-4-yl, 4, 5-dimethyl-isoxazol-3- yl, 3-methyl-isoxazol-5-yl, 5-tert-butyl-isoxazol-3-yl, 4-bromo-5-methyl-isoxazol-3-yl, 5-oxazolyl, 1- methylimidazol-5-yl, 5-imidazolyl, 2-thienyl, 3-thienyl, 2-methylcarbonyl-thien-3-yl, 2-methylcarbonyl- 5-tert-butyl-thien-3-yl, 2-aminocarbonyl-5-tert-butyl-thien-3-yl, 4-methoxy-5-chloro-3-thienyl, 3-methyl- 2-thienyl, 5-methyl-2-thienyl, 5-methylthio-2-thienyl, 5-methylsulfonyl-2-thienyl, 3-ethoxy-2-thienyl, 3- chloro-2-thienyl, 5-chloro-2-thienyl, 3-bromo-2-thienyl, 5-bromo-2-thienyl, 4-methoxy-5-bromo-3- thienyl, 4-methoxy-3-thienyl, 2-furyl, 2-cyano-5-phenylfur-3-yl, 4,5-dimethyl-2-furyl, 5-methyl-2- trifluoromethyl-3-furyl, 3-furanyl, 1-methylpyrrol-2-yl, 2-pyrrolyl, 2-pyrazinyl, 5-methyl-2-pyrazinyl, 4- pyrimidinyl, 2, 6-dimethoxy-4-pyrimidinyl, 4-methoxy-6-methylpyrimidin-2-yl, 4-chloro-2- methylthiopyrimidin-6-yl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 4-trifluoromethylpyridin-2-yl, 2- trifluoromethylpyridin-5-yl, 2-dimethylaminopyridin-5-yl, 5-chloro-2-pyridyl, 2-fluoro-3-pyridyl, 2- chloro-3-pyridyl, 2-methoxy-3-pyridyl, 2-ethoxy-3-pyridyl, 2-chloro-4-pyridyl, 2, 5-dichloro-3-pyridyl, 2- (dimethylaminoethoxy)-3-pyridyl, 2-methoxy-5-pyridyl, 2-methyl-5-pyridyl, 4-chloro-2-pyridyl, 4- methoxy-5-pyridyl, 3-benzyloxypyridin-2-yl, 4-methylpyridin-2-yl, 4-ethylpyridin-2-yl, 2-chloropyridin- 4-yl, 3-chloropyridin-5-yl, 3-chloropyridin-6-yl, 2-chloropyridin-5-yl, 4-chloropyridin-2-yl, 1-methyl-2- oxopyrid-5-yl, tetrahydropyran-4-yl, 4, 5-dihydrothiazol-2-yl, thiazol-2-yl, 5-methyl-thiazol-2-yl, 4,5- dimethyl-thiazol-2-yl, 4-tert-butyl-thiazol-2-yl, 5-tert-butyl-thiazol-2-yl, 5-nitrothiazol-2-yl, 5- bromothiazol-2-yl, 5- [4-chlorophenyl]-thiazol-2-yl, 4- [4-chlorophenyl]-thiazol-2-yl, 4- [4-nitrophenyl]- thiazol-2-yl, 4-thiazolyl, 2-methyl-4-thiazolyl, 2,5-dimethyl-4-thiazolyl, 2, 4-dimethyl-5-thiazolyl, 5-tert- butyl-1, 3, 4-thiadiazol-2-yl, 5-trifluoromethyl-1, 3,4-thiadiazol-2-yl, 5-ethyl-1, 3, 4-thiadiazol-2-yl, pyrazol- 5-yl, 3-pyrazolyl, 1, 3-diphenyl-pyrazol-3-yl, 1, 3-dimethyl-pyrazol-3-yl, 5-cyano-4-tert-butyl-pyrazol-3- yl, 5-amino-3-methyl-pyrazol-1-yl, 3-methyl-1-tert-butyl-pyrazol-3-yl, 5-amino-3-tert-butyl-pyrazol-1-yl, 1-ethylpyrazol-5-yl, 3-tert-butyl-pyrazol-5-yl, 1-methyl-3-tert-butyl-pyrazol-5-yl, 4,4-dimethyl-1, 2,34- tetrahydroisoquinolin-7-yl, 7-quinolinyl, 2,3-dihydrobenzofur-7-yl, 3, 3-dimethyl-1- methylcarbonylindolin-6-yl, 3, 3-dimethyl-2, 3-dihydro-indol-6-yl, 4-tert-butyl-imidazo [1, 2-a] pyridin-6-yl, 3-quinolinyl, 2-benzofuryl, benzo [1, 2,5] thiadiazol-4-yl, 7-methyl-benzothiazol-2-yl, 6-ethoxy- benzothiazol-2-yl, 6-fluoro-benzothiazol-2-yl, 5, 6-dimethyl-benzothiazol-2-yl, benzimidazol-2-yl, 1- methyl-benzimidazol-2-yl, benzoxazol-2-yl, benzisoxazol-3-yl, 4-methoxybenzisoxazol-3-yl and 2- methylbenzothiazol-5-yl.

The invention also relates to compounds wherein R'is selected from methoxyethyl, cyclopropyl, and 4-chlorophenyl.

The invention also relates to compounds wherein Ya is-C (=) NH-.

The invention also relates to compounds wherein R and R9 are H.

The invention also relates to compounds selected from 7- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N- (4-chlorophenyl)-4-quinolinecarboxamide ; 7- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N-cyclopropyl-4-quinolinecarboxamide ; and 7- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N- (2- (methyloxy) ethyl)-4-quinolinecarboxamide.

The invention also relates to compounds wherein R is not H when Y is (CH2) 0 when A is naphthyl or quinolinyl.

INDICATIONS Compounds of the present invention would be useful for, but not limited to, the prevention or treatment of angiogenesis related diseases. The compounds of the invention have kinase inhibitory activity, such as VEGFR/KDR, c-kit, abl, and/or c-Met inhibitory activity. The compounds of the invention are useful in therapy as antineoplasia agents or to minimize deleterious effects of VEGF and/or HGF. The compounds of the invention also inhibit Ick and src activity.

Compounds of the invention would be useful for the treatment of neoplasia including cancer and metastasis, including, but not limited to: carcinoma such as cancer of the bladder, breast, colon, kidney, liver, lung (including small cell lung cancer), esophagus, gall-bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin (including squamous cell carcinoma); hematopoietic tumors of lymphoid lineage (including leukemia, acute lymphocitic leukemia, acute lymphoblastic leukemia, B-cell lymphom, T-cell-lymphoma, Hodgkin's lymphom, non-Hodgkin's lymphom, hairy cell lymphom and Burkett's lymphom) ; hematopoietic tumors of myeloid lineage (including acute and chronic myelogenous leukemias, myelodysplastic syndrome and promyelocytic leukemia); tumors of mesenchymal origin (including fibrosarcoma and rhabdomyosarcoma, and other sarcomas, e. g. soft tissue and bone); tumors of the central and peripheral nervous system (including astrocytoma, neuroblastoma, glioma and schwannomas); and other tumors (including melanoma, seminoma, teratocarcinoma, osteosarcoma, xenoderoma pigmentosum, keratoctanthoma, thyroid follicular cancer and Kaposi's sarcoma).

Preferably, the compounds are useful for the treatment of neoplasia selected from lung cancer, colon cancer and breast cancer.

The compounds also would be useful for treatment of ophthalmological conditions such as corneal graft rejection, ocular neovascularization, retinal neovascularization including neovascularization following injury or infection, diabetic retinopathy, retrolental fibroplasia and neovascular glaucoma; retinal ischemia; vitreous hemorrhage; ulcerative diseases such as gastric ulcer; pathological, but non- malignant, conditions such as hemangiomas, including infantile hemaginomas, angiofibroma of the nasopharynx and avascular necrosis of bone; and disorders of the female reproductive system such as endometriosis. The compounds are also useful for the treatment of edema, and conditions of vascular hyperpermeability.

The compounds of the invention are useful in therapy of proliferative diseases. These compounds can be used for the treatment of an inflammatory rheumatoid or rheumatic disease, especially of

manifestations at the locomotor apparatus, such as various inflammatory rheumatoid diseases, especially chronic polyarthritis including rheumatoid arthritis, juvenile arthritis or psoriasis arthropathy; paraneoplastic syndrome or tumor-induced inflammatory diseases, turbid effusions, collagenosis, such as systemic Lupus erythematosus, poly-myositis, dermato-myositis, systemic sclerodermia or mixed collagenosis; postinfectious arthritis (where no living pathogenic organism can be found at or in the affected part of the body), seronegative spondylarthritis, such as spondylitis ankylosans; vasculitis, sarcoidosis, or arthrosis; or further any combinations thereof. An example of an inflammation related disorder is (a) synovial inflammation, for example, synovitis, including any of the particular forms of synovitis, in particular bursal synovitis and purulent synovitis, as far as it is not crystal-induced. Such synovial inflammation may for example, be consequential to or associated with disease, e. g. arthritis, e. g. osteoarthritis, rheumatoid arthritis or arthritis deformans. The present invention is further applicable to the systemic treatment of inflammation, e. g. inflammatory diseases or conditions, of the joints or locomotor apparatus in the region of the tendon insertions and tendon sheaths. Such inflammation may be, for example, consequential to or associated with disease or further (in a broader sense of the invention) with surgical intervention, including, in particular conditions such as insertion endopathy, myofasciale syndrome and tendomyosis. The present invention is further especially applicable to the treatment of inflammation, e. g. inflammatory disease or condition, of connective tissues including dermatomyositis and myositis.

These compounds can be used as active agents against such disease states as arthritis, atherosclerosis, psoriasis, hemangiomas, myocardial angiogenesis, coronary and cerebral collaterals, ischemic limb angiogenesis, wound healing, peptic ulcer Helicobacter related diseases, fractures, cat scratch fever, rubeosis, neovascular glaucoma and retinopathies such as those associated with diabetic retinopathy or macular degeneration. In addition, some of these compounds can be used as active agents against solid tumors, malignant ascites, hematopoietic cancers and hyperproliferative disorders such as thyroid hyperplasia (especially Grave's disease), and cysts (such as hypervascularity of ovarian stroma, characteristic of polycystic ovarian syndrome (Stein-Leventhal syndrome) ) since such diseases require a proliferation of blood vessel cells for growth and/or metastasis.

Further, some of these compounds can be used as active agents against burns, chronic lung disease, stroke, polyps, anaphylaxis, chronic and allergic inflammation, ovarian hyperstimulation syndrome, brain tumor-associated cerebral edema, high-altitude, trauma or hypoxia induced cerebral or pulmonary edema, ocular and macular edema, ascites, and other diseases where vascular hyperpermeability, effusions, exudates, protein extravasation, or edema is a manifestation of the disease.

The compounds will also be useful in treating disorders in which protein extravasation leads to the deposition of fibrin and extracellular matrix, promoting stromal proliferation (e. g. fibrosis, cirrhosis and carpal tunnel syndrome).

The compounds of the present invention are also useful in the treatment of ulcers including bacterial, fungal, Mooren ulcers and ulcerative colitis.

The compounds of the present invention are also useful in the treatment of conditions wherein undesired angiogenesis, edema, or stromal deposition occurs in viral infections such as Herpes simplex, Herpes Zoster, AIDS, Kaposi's sarcoma, protozoan infections and toxoplasmosis, following trauma, radiation, stroke, endometriosis, ovarian hyperstimulation syndrome, systemic lupus, sarcoidosis, synovitis, Crohn's disease, sickle cell anemia, Lyme disease, pemphigoid, Paget's disease, hyperviscosity syndrome, Osler-Weber-Rendu disease, chronic inflammation, chronic occlusive pulmonary disease, asthma, and inflammatory rheumatoid or rheumatic disease. The compounds are also useful in the reduction of sub-cutaneous fat and for the treatment of obesity.

The compounds of the present invention are also useful in the treatment of ocular conditions such as ocular and macular edema, ocular neovascular disease, scleritis, radial keratotomy, uveitis, vitritis, myopia, optic pits, chronic retinal detachment, post-laser complications, glaucoma, conjunctivitis, Stargardt's disease and Eales disease in addition to retinopathy and macular degeneration.

The compounds of the present invention are also useful in the treatment of cardiovascular conditions such as atherosclerosis, restenosis, arteriosclerosis, vascular occlusion and carotid obstructive disease.

The compounds of the present invention are also useful in the treatment of cancer related indications such as solid tumors, sarcomas (especially Ewing's sarcoma and osteosarcoma), retinoblastoma, rhabdomyosarcomas, neuroblastoma, hematopoietic malignancies, including leukemia and lymphom, tumor-induced pleural or pericardial effusions, and malignant ascites.

The compounds of the present invention are also useful in the treatment of diabetic conditions such as diabetic retinopathy and microangiopathy.

Accordingly, the invention relates to a method of treating inflammation in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a compound according to any one of the above embodiments.

The invention relates to a method of inhibiting T cell activation in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a compound according to any one of the above embodiments.

The invention relates to a method of treating arthritis, rheumatoid arthritis, psoriatic arthritis, or osteoarthritis in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a compound according to any one of the above embodiments.

The invention relates to a method of treating organ transplant, acute transplant or heterograft or homograft rejection, or transplantation tolerance induction in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a compound according to any one of the above embodiments.

The invention relates to a method of treating ischemic or reperfusion injury, myocardial infarction, or stroke in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a compound according to any one of the above embodiments.

The compounds of this invention may also act as inhibitors of other protein kinases, e. g. tie-2, Ick, src, fgf, c-Met, ron, and ret, and thus be effective in the treatment of diseases associated with other protein kinases. The compounds of this invention may also act as inhibitors of mutants of the above-identified tyrosine kinases, including c-kit, abl and VEGFR.

Besides being useful for human treatment, these compounds are also useful for veterinary treatment of companion animals, exotic animals and farm animals, including mammals, rodents, and the like. More preferred animals include horses, dogs, and cats.

As used herein, the compounds of the present invention include the pharmaceutically acceptable derivatives thereof.

Where the plural form is used for compounds, salts, and the like, this is taken to mean also a sindle compound, salt and the like.

DEFINITIONS "Angiogenesis"is defined as any alteration of an existing vascular bed or the formation of new vasculature which benefits tissue perfasion. This includes the formation of new vessels by sprouting of endothelial cells from existing blood vessels or the remodeling of existing vessels to alter size, maturity, direction or flow properties to improve blood perfusion of tissue.

As used herein, "HGF"refers to hepatocyte growth factor/scatter factor. This includes purified hepatocyte growth factor/scatter factor, fragments of hepatocyte growth factor/scatter factor, chemically synthesized fragments of hepatocyte growth factor/scatter factor, derivatives or mutated versions of hepatocyte growth factor/scatter factor, and fusion proteins comprising hepatocyte growth factor/scatter factor and another protein."HGF"as used herein also includes hepatocyte growth factor/scatter factor isolated from species other than humans.

As used herein"c-Met"refers to the receptor for HGF. This includes purified receptor, fragments of receptor, chemically synthesized fragments of receptor, derivatives or mutated versions of receptor, and fusion proteins comprising the receptor and another protein. "c-Met"as used herein also includes the HGF receptor isolated from a species other than humans.

As used herein, "HGF"refers to hepatocyte growth factor/scatter factor. This includes purified hepatocyte growth factor/scatter factor, fragments of hepatocyte growth factor/scatter factor, chemically synthesized fragments of hepatocyte growth factor/scatter factor, derivatives or mutated versions of hepatocyte growth factor/scatter factor, and fusion proteins comprising hepatocyte growth factor/scatter factor and another protein. "HGF"as used herein also includes hepatocyte growth factor/scatter factor isolated from species other than humans.

As used herein"c-Met"refers to the receptor for HGF. This includes purified receptor, fragments of receptor, chemically synthesized fragments of receptor, derivatives or mutated versions of receptor, and fusion proteins comprising the receptor and another protein. "c-Met"as used herein also includes the HGF receptor isolated from a species other than humans.

As used herein, the terms"hepatocyte growth factor"and"HGF"refer to a growth factor typically having a structure with six domains (finger, Kringle 1, Kringle 2, Kringle 3, Kringle 4 and serine protease domains). Fragments of HGF constitute HGF with fewer domains and variants of HGF may have some of the domains of HGF repeated; both are included if they still retain their respective ability to bind a HGF receptor. The terms"hepatocyte growth factor"and"HGF"include hepatocyte growth factor from humans ("huHGF") and any non-human mammalian species, and in particular rat HGF. The terms as used herein include mature, pre, pre-pro, and pro forms, purified from a natural source, chemically synthesized or recombinantly produced. Human HGF is encoded by the cDNA sequence published by Miyazawa et al. (1989), supra, or Nakamura et al. (1989), supra. The sequences reported by Miyazawa et al. and Nakamura et al. differ in 14 amino acids. The reason for the differences is not entirely clear; polymorphism or cloning artifacts are among the possibilities. Both sequences are specifically encompassed by the foregoing terms. It will be understood that natural allelic variations exist and can occur among individuals, as demonstrated by one or more amino acid differences in the amino acid sequence of each individual. The terms"hepatocyte growth factor"and"HGF"specifically include the delta 5 huHGF as disclosed by Seki et al. , supra.

The terms"HGF receptor"and"c-Met"when used herein refer to a cellular receptor for HGF, which typically includes an extracellular domain, a transmembrane domain and an intracellular domain, as well as variants and fragments thereof which retain the ability to bind HGF. The terms"HGF receptor" and"c-Met"include the polypeptide molecule that comprises the full-length, native amino acid sequence encoded by the gene variously known as P90MET. The present definition specifically encompasses soluble forms of HGF receptor, and HGF receptor from natural sources, synthetically produced in vitro or obtained by genetic manipulation including methods of recombinant DNA technology. The HGF receptor variants or fragments preferably share at least about 65% sequence homology, and more preferably at least about 75% sequence homology with any domain of the human c-Met amino acid sequence published in Rodrigues et al. , Mol. Cell. Biol. , 11: 2962-2970 (1991) ; Park et al., Proc. Natl. Acad. Sci. , 84: 6379- 6383 (1987); or Ponzetto et al. , Oncogene, 6: 553-559 (1991).

The terms"agonist"and"agonistic"when used herein refer to or describe a molecule which is capable of, directly or indirectly, substantially inducing, promoting or enhancing HGF biological activity or HGF receptor activation.

The terms"cancer"and"cancerous"when used herein refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth. Examples of cancer include but are not limited to, carcinoma, lymphom, sarcoma, blastoma and leukemia. More particular examples of such cancers include squamous cell carcinoma, lung cancer, pancreatic cancer, cervical cancer, bladder cancer, hepatoma, breast cancer, colon carcinoma, and head and neck cancer. While the term"cancer"as used herein is not limited to any one specific form of the disease, it is believed that the methods of the invention will be particularly effective for cancers which are found to be accompanied by increased levels of HGF or expression of c-Met in the mammal.

The terms"treating, ""treatment,"and"therapy"as used herein refer to curative therapy, prophylactic therapy, and preventative therapy.

The term"mammal"as used herein refers to any mammal classified as a mammal, including humans, cows, horses, dogs and cats. In a preferred embodiment of the invention, the mammal is a human.

Given that elevated levels of c-Met and HGF are observed in hypertension, arteriosclerosis, myocardial infarction, and rheumatoid arthritis, nucleic acid ligands will serve as useful therapeutic agents for these diseases.

The term"treatment"includes therapeutic treatment as well as prophylactic treatment (either preventing the onset of disorders altogether or delaying the onset of a pre-clinically evident stage of disorders in individuals).

A"pharmaceutically-acceptable derivative"denotes any salt, ester of a compound of this invention, or any other compound which upon administration to a patient is capable of providing (directly or indirectly) a compound of this invention, or a metabolite or residue thereof, characterized by the ability to inhibit angiogenesis.

The phrase"therapeutically-effective"is intended to qualify the amount of each agent, which will achieve the goal of improvement in disorder severity and the frequency of incidence over treatment of each agent by itself, while avoiding adverse side effects typically associated with alternative therapies.

For example, effective neoplastic therapeutic agents prolong the survivability of the patient, inhibit the rapidly-proliferating cell growth associated with the neoplasm, or effect a regression of the neoplasm.

The term"H"denotes a single hydrogen atom. This radical may be attached, for example, to an oxygen atom to form a hydroxyl radical.

Where the term"alkyl"is used, either alone or within other terms such as"haloalkyl"and "alkylamino", it embraces linear or branched radicals having one to about twelve carbon atoms. More preferred alkyl radicals are"lower alkyl"radicals having one to about six carbon atoms. Examples of such radicals include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isoamyl, hexyl and the like. Even more preferred are lower alkyl radicals having one or two carbon atoms. The term"alkylenyl"embraces bridging divalent alkyl radicals such as methylenyl and ethylenyl. The term "lower alkyl substituted with R2"does not include an acetal moiety.

The term"alkenyl"embraces linear or branched radicals having at least one carbon-carbon double bond of two to about twelve carbon atoms. More preferred alkenyl radicals are"lower alkenyl"radicals having two to about six carbon atoms. Most preferred lower alkenyl radicals are radicals having two to about four carbon atoms. Examples of alkenyl radicals include ethenyl, propenyl, allyl, propenyl, butenyl and 4-methylbutenyl. The terms"alkenyl"and"lower alkenyl", embrace radicals having"cis"and"trans" orientations, or alternatively,"E"and"Z"orientations.

The term"alkynyl"denotes linear or branched radicals having at least one carbon-carbon triple bond and having two to about twelve carbon atoms. More preferred alkynyl radicals are"lower alkynyl"

radicals having two to about six carbon atoms. Most preferred are lower alkynyl radicals having two to about four carbon atoms. Examples of such radicals include propargyl, butynyl, and the like.

The term"halo"means halogens such as fluorine, chlorine, bromine or iodine atoms.

The term"haloalkyl"embraces radicals wherein any one or more of the alkyl carbon atoms is substituted with halo as defined above. Specifically embraced are monohaloalkyl, dihaloalkyl and polyhaloalkyl radicals including perhaloalkyl. A monohaloalkyl radical, for one example, may have either an iodo, bromo, chloro or fluoro atom within the radical. Dihalo and polyhaloalkyl radicals may have two or more of the same halo atoms or a combination of different halo radicals."Lower haloalkyl" embraces radicals having 1-6 carbon atoms. Even more preferred are lower haloalkyl radicals having one to three carbon atoms. Examples of haloalkyl radicals include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl and dichloropropyl."Perfluoroalkyl"means alkyl radicals having all hydrogen atoms replaced with fluoro atoms. Examples include trifluoromethyl and pentafluoroethyl.

The term"hydroxyalkyl"embraces linear or branched alkyl radicals having one to about ten carbon atoms any one of which may be substituted with one or more hydroxyl radicals. More preferred hydroxyalkyl radicals are"lower hydroxyalkyl"radicals having one to six carbon atoms and one or more hydroxyl radicals. Examples of such radicals include hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl and hydroxyhexyl. Even more preferred are lower hydroxyalkyl radicals having one to three carbon atoms.

The term"alkoxy"embrace linear or branched oxy-containing radicals each having alkyl portions of one to about ten carbon atoms. More preferred alkoxy radicals are"lower alkoxy"radicals having one to six carbon atoms. Examples of such radicals include methoxy, ethoxy, propoxy, butoxy and tert- butoxy. Even more preferred are lower alkoxy radicals having one to three carbon atoms. Alkoxy radicals may be further substituted with one or more halo atoms, such as fluoro, chloro or bromo, to provide "haloalkoxy"radicals. Even more preferred are lower haloalkoxy radicals having one to three carbon atoms. Examples of such radicals include fluoromethoxy, chloromethoxy, trifluoromethoxy, trifluoroethoxy, fluoroethoxy and fluoropropoxy.

The term"aryl", alone or in combination, means a carbocyclic aromatic system containing one or two rings wherein such rings may be attached together in a fused manner. The term"aryl"embraces aromatic radicals such as phenyl, naphthyl, indenyl, tetrahydronaphthyl, and indanyl. More preferred aryl is phenyl. Said"aryl"group may have 1 to 3 substituents such as lower alkyl, hydroxyl, halo, haloalkyl, nitro, cyano, amino, alkoxy and lower alkylamino. Phenyl substituted with-O-CH2-O-forms the aryl benzodioxolyl substituent.

The term"heterocyclyl"embraces saturated, partially saturated and unsaturated heteroatom- containing ring radicals, where the heteroatoms may be selected from nitrogen, sulfur and oxygen. It does not include rings containing-O-O-,-O-S-or-S-S-portions. Said"heterocyclyl"group may have 1 to 3

substituents such as hydroxyl, Boc, halo, haloalkyl, cyano, lower alkyl, lower aralkyl, oxo, lower alkoxy, amino and lower alkylamino.

Examples of saturated heterocyclic radicals include saturated 3 to 6-membered heteromonocyclic groups containing 1 to 4 nitrogen atoms [e. g. pyrrolidinyl, imidazolidinyl, piperidinyl, pyrrolinyl, piperazinyl]; saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms [e. g. morpholinyl]; saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms [e. g. , thiazolidinyl]. Examples of partially saturated heterocyclyl radicals include dihydrothienyl, dihydropyranyl, dihydrofuryl and dihydrothiazolyl.

Examples of unsaturated heterocyclic radicals, also termed"heteroaryl"radicals, include unsaturated 5 to 6 membered heteromonocyclyl group containing 1 to 4 nitrogen atoms, for example, pyrrolyl, imidazolyl, pyrazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazolyl [e. g., 4H-1, 2, 4-triazolyl, 1H-1, 2, 3-triazolyl, 2H-1, 2, 3-triazolyl] ; unsaturated 5-to 6-membered heteromonocyclic group containing an oxygen atom, for example, pyranyl, 2-furyl, 3-furyl, etc.; unsaturated 5 to 6-membered heteromonocyclic group containing a sulfur atom, for example, 2-thienyl, 3- thienyl, etc.; unsaturated 5-to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms, for example, oxazolyl, isoxazolyl, oxadiazolyl [e. g. , 1,2, 4-oxadiazolyl, 1,3, 4- oxadiazolyl, 1,2, 5-oxadiazolyl]; unsaturated 5 to 6-membered heteromonocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms, for example, thiazolyl, thiadiazolyl [e. g. , 1,2, 4-thiadiazolyl, 1,3, 4- thiadiazolyl, 1,2, 5-thiadiazolyl].

The term heterocyclyl also embraces radicals where heterocyclic radicals are fused/condensed with aryl radicals: unsaturated condensed heterocyclic group containing 1 to 5 nitrogen atoms, for example, indolyl, isoindolyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl, indazolyl, benzotriazolyl, tetrazolopyridazinyl [e. g. , tetrazolo [1, 5-b] pyridazinyl] ; unsaturated condensed heterocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms [e. g. benzoxazolyl, benzoxadiazolyl] ; unsaturated condensed heterocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms [e. g., benzothiazolyl, benzothiadiazolyl]; and saturated, partially unsaturated and unsaturated condensed heterocyclic group containing 1 to 2 oxygen or sulfur atoms [e. g. benzofuryl, benzothienyl, 2,3-dihydro- benzo [1, 4] dioxinyl and dihydrobenzofuryl]. Preferred heterocyclic radicals include five to ten membered fused or unfused radicals. More preferred examples of heteroaryl radicals include quinolyl, isoquinolyl, imidazolyl, pyridyl, thienyl, thiazolyl, oxazolyl, furyl, and pyrazinyl. Other preferred heteroaryl radicals are 5-or 6-membered heteroaryl, containing one or two heteroatoms selected from sulfur, nitrogen and oxygen, selected from thienyl, furyl, pyrrolyl, indazolyl, pyrazolyl, oxazolyl, triazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, pyridyl, piperidinyl and pyrazinyl.

Particular examples of non-nitrogen containing heterocyclyl include pyranyl, 2-furyl, 3-furyl, 2- thienyl, 3-thienyl, benzofuryl, benzothienyl, and the like.

Particular examples of partially saturated and saturated heterocyclyl include pyrrolidinyl, imidazolidinyl, piperidinyl, pyrrolinyl, pyrazolidinyl, piperazinyl, morpholinyl, tetrahydropyranyl, thiazolidinyl, dihydrothienyl, 2,3-dihydro-benzo [1, 4] dioxanyl, indolinyl, isoindolinyl,

dihydrobenzothienyl, dihydrobenzofuryl, isochromanyl, chromanyl, 1,2-dihydroquinolyl, 1,2, 3,4- tetrahydro-isoquinolyl, 1,2, 3,4-tetrahydro-quinolyl, 2,3, 4,4a, 9, 9a-hexahydro-1H-3-aza-fluorenyl, 5,6, 7- trihydro-1, 2,4-triazolo [3,4-a] isoquinolyl, 3,4-dihydro-2H-benzo [l, 4] oxazinyl, benzo [1, 4] dioxanyl, 2,3- dihydro-lH-IX'-benzo [d] isothiazol-6-yl, dihydropyranyl, dihydrofuryl and dihydrothiazolyl, and the like.

The term"sulfonyl", whether used alone or linked to other terms such as alkylsulfonyl, denotes respectively divalent radicals-SO2-.

The terms"sulfamyl,""aminosulfonyl"and"sulfonamidyl,"denotes a sulfonyl radical substituted with an amine radical, forming a sulfonamide (-SO2NH2).

The term"alkylaminosulfonyl"includes"N-alkylaminosulfonyl"where sulfamyl radicals are independently substituted with one or two alkyl radical (s). More preferred alkylaminosulfonyl radicals are "lower alkylaminosulfonyl"radicals having one to six carbon atoms. Even more preferred are lower alkylaminosulfonyl radicals having one to three carbon atoms. Examples of such lower alkylaminosulfonyl radicals include N-methylaminosulfonyl, and N-ethylaminosulfonyl.

The terms"carboxy"or"carboxyl", whether used alone or with other terms, such as "carboxyalkyl", denotes-CO2H.

The term"carbonyl", whether used alone or with other terms, such as"aminocarbonyl", denotes- (C=O)-.

The term"aminocarbonyl"denotes an amide group of the formula-C (=O) NH2- The terms"N-alkylaminocarbonyl"and"N, N-dialkylaminocarbonyl" denote aminocarbonyl radicals independently substituted with one or two alkyl radicals, respectively. More preferred are"lower alkylaminocarbonyl"having lower alkyl radicals as described above attached to an aminocarbonyl radical.

The terms"N-arylaminocarbonyl"and"N-alkyl-N-arylaminocarbonyl"de note aminocarbonyl radicals substituted, respectively, with one aryl radical, or one alkyl and one aryl radical.

The terms"heterocyclylalkylenyl"and"heterocyclylalkyl"embrace heterocyclic-substituted alkyl radicals. More preferred heterocyclylalkyl radicals are"5-or 6-membered heteroarylalkyl"radicals having alkyl portions of one to six carbon atoms and a 5-or 6-membered heteroaryl radical. Even more preferred are lower heteroarylalkylenyl radicals having alkyl portions of one to three carbon atoms.

Examples include such radicals as pyridylmethyl and thienylmethyl.

The term"aralkyl"embraces aryl-substituted alkyl radicals. Preferable aralkyl radicals are"lower aralkyl"radicals having aryl radicals attached to alkyl radicals having one to six carbon atoms. Even more preferred are"phenylalkylenyl"attached to alkyl portions having one to three carbon atoms.

Examples of such radicals include benzyl, diphenylmethyl and phenylethyl. The aryl in said aralkyl may be additionally substituted with halo, alkyl, alkoxy, haloalkyl and haloalkoxy.

The term"alkylthio"embraces radicals containing a linear or branched alkyl radical, of one to ten carbon atoms, attached to a divalent sulfur atom. Even more preferred are lower alkylthio radicals having one to three carbon atoms. An example of"alkylthio"is methylthio, (CH3S-).

The term"haloalkylthio"embraces radicals containing a haloalkyl radical, of one to ten carbon atoms, attached to a divalent sulfur atom. Even more preferred are lower haloalkylthio radicals having one to three carbon atoms. An example of"haloalkylthio"is trifluoromethylthio.

The term"alkylamino"embraces"N-alkylamino"and"N, N-dialkylamino" where amino groups are independently substituted with one alkyl radical and with two alkyl radicals, respectively. More preferred alkylamino radicals are"lower alkylamino"radicals having one or two alkyl radicals of one to six carbon atoms, attached to a nitrogen atom. Even more preferred are lower alkylamino radicals having one to three carbon atoms. Suitable alkylamino radicals may be mono or dialkylamino such as N- methylamino, N-ethylamino, N, N-dimethylamino, N, N-diethylamino and the like.

The term"arylamino"denotes amino groups which have been substituted with one or two aryl radicals, such as N-phenylamino. The arylamino radicals may be further substituted on the aryl ring portion of the radical.

The term"heteroarylamino"denotes amino groups which have been substituted with one or two heteroaryl radicals, such as N-thienylamino. The"heteroarylamino"radicals may be further substituted on the heteroaryl ring portion of the radical.

The term"aralkylamino"denotes amino groups which have been substituted with one or two aralkyl radicals. More preferred are phenyl-C,-C3-alkylamino radicals, such as N-benzylamino. The aralkylamino radicals may be further substituted on the aryl ring portion.

The terms"N-alkyl-N-arylamino"and"N-aralkyl-N-alkylamino"denote amino groups which have been independently substituted with one aralkyl and one alkyl radical, or one aryl and one alkyl radical, respectively, to an amino group.

The term"aminoalkyl"embraces linear or branched alkyl radicals having one to about ten carbon atoms any one of which may be substituted with one or more amino radicals. More preferred aminoalkyl radicals are"lower aminoalkyl"radicals having one to six carbon atoms and one or more amino radicals.

Examples of such radicals include aminomethyl, aminoethyl, aminopropyl, aminobutyl and aminohexyl.

Even more preferred are lower aminoalkyl radicals having one to three carbon atoms.

The term"alkylaminoalkyl"embraces alkyl radicals substituted with alkylamino radicals. More preferred alkylaminoalkyl radicals are"lower alkylaminoalkyl"radicals having alkyl radicals of one to six carbon atoms. Even more preferred are lower alkylaminoalkyl radicals having alkyl radicals of one to three carbon atoms. Suitable alkylaminoalkyl radicals may be mono or dialkyl substituted, such as N- methylaminomethyl, N, N-dimethyl-aminoethyl, N, N-diethylaminomethyl and the like.

The term"alkylaminoalkoxy"embraces alkoxy radicals substituted with alkylamino radicals.

More preferred alkylaminoalkoxy radicals are"lower alkylaminoalkoxy"radicals having alkoxy radicals of one to six carbon atoms. Even more preferred are lower alkylaminoalkoxy radicals having alkyl radicals of one to three carbon atoms. Suitable alkylaminoalkoxy radicals may be mono or dialkyl substituted, such as N-methylaminoethoxy, N, N-dimethylaminoethoxy, N, N-diethylaminoethoxy and the like.

The term"alkylaminoalkoxyalkoxy"embraces alkoxy radicals substituted with alkylaminoalkoxy radicals. More preferred alkylaminoalkoxyalkoxy radicals are"lower alkylaminoalkoxyalkoxy"radicals having alkoxy radicals of one to six carbon atoms. Even more preferred are lower alkylaminoalkoxyalkoxy radicals having alkyl radicals of one to three carbon atoms. Suitable alkylaminoalkoxyalkoxy radicals may be mono or dialkyl substituted, such as N- methylaminomethoxyethoxy, N-methylaminoethoxyethoxy, N, N-dimethylaminoethoxyethoxy, N, N- diethylaminomethoxymethoxy and the like.

The term"carboxyalkyl"embraces linear or branched alkyl radicals having one to about ten carbon atoms any one of which may be substituted with one or more carboxy radicals. More preferred carboxyalkyl radicals are"lower carboxyalkyl"radicals having one to six carbon atoms and one carboxy radical. Examples of such radicals include carboxymethyl, carboxypropyl, and the like. Even more preferred are lower carboxyalkyl radicals having one to three CH2 groups.

The term"halosulfonyl"embraces sulfonyl radicals substituted with a halogen radical. Examples of such halosulfonyl radicals include chlorosulfonyl and fluorosulfonyl.

The term"arylthio"embraces aryl radicals of six to ten carbon atoms, attached to a divalent sulfur atom. An example of"arylthio"is phenylthio.

The term"aralkylthio"embraces aralkyl radicals as described above, attached to a divalent sulfur atom. More preferred are phenyl-C,-C3-alkylthio radicals. An example of"aralkylthio"is benzylthio.

The term"aryloxy"embraces optionally substituted aryl radicals, as defined above, attached to an oxygen atom. Examples of such radicals include phenoxy.

The term"aralkoxy"embraces oxy-containing aralkyl radicals attached through an oxygen atom to other radicals. More preferred aralkoxy radicals are"lower aralkoxy"radicals having optionally substituted phenyl radicals attached to lower alkoxy radical as described above.

The term"heteroaryloxy"embraces optionally substituted heteroaryl radicals, as defined above, attached to an oxygen atom.

The term"heteroarylalkoxy"embraces oxy-containing heteroarylalkyl radicals attached through an oxygen atom to other radicals. More preferred heteroarylalkoxy radicals are"lower heteroarylalkoxy" radicals having optionally substituted heteroaryl radicals attached to lower alkoxy radical as described above.

The term"cycloalkyl"includes saturated carbocyclic groups. Preferred cycloalkyl groups include C3-C6 rings. More preferred compounds include, cyclopentyl, cyclopropyl, and cyclohexyl.

The term"cycloalkylalkyl"embraces cycloalkyl-substituted alkyl radicals. Preferable cycloalkylalkyl radicals are"lower cycloalkylalkyl"radicals having cycloalkyl radicals attached to alkyl radicals having one to six carbon atoms. Even more preferred are"5-6-membered cycloalkylalkyl" attached to alkyl portions having one to three carbon atoms. Examples of such radicals include cyclohexylmethyl. The cycloalkyl in said radicals may be additionally substituted with halo, alkyl, alkoxy and hydroxy.

The term"cycloalkenyl"includes carbocyclic groups having one or more carbon-carbon double bonds including"cycloalkyldienyl"compounds. Preferred cycloalkenyl groups include C3-C6 rings.

More preferred compounds include, for example, cyclopentenyl, cyclopentadienyl, cyclohexenyl and cycloheptadienyl.

The term"comprising"is meant to be open ended, including the indicated component but not excluding other elements.

The term"Formulas I-VII"includes any sub formulas.

The compounds of the invention are endowed with kinase inhibitory activity, such as Lck, KDR and/or c-Met inhibitory activity.

The present invention also comprises the use of a compound of the invention, or pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment either acutely or chronically of an angiogenesis mediated disease state, including those described previously. The compounds of the present invention are useful in the manufacture of an anti-cancer medicament. The compounds of the present invention are also useful in the manufacture of a medicament to attenuate or prevent disorders through inhibition of Lck, KDR and/or c-Met.

The present invention comprises a pharmaceutical composition comprising a therapeutically- effective amount of a compound of Formulas I-VII in association with a least one pharmaceutically- acceptable carrier, adjuvant or diluent.

The present invention also comprises a method of treating angiogenesis related disorders in a subject having or susceptible to such disorder, the method comprising treating the subject with a therapeutically-effective amount of a compound of Formula I-VII.

COMBINATIONS While the compounds of the invention can be administered as the sole active pharmaceutical agent, they can also be used in combination with one or more compounds of the invention or other agents.

When administered as a combination, the therapeutic agents can be formulated as separate compositions that are administered at the same time or sequentially at different times, or the therapeutic agents can be given as a single composition.

The phrase"co-therapy" (or"combination-therapy"), in defining use of a compound of the present invention and another pharmaceutical agent, is intended to embrace administration of each agent in a sequential manner in a regimen that will provide beneficial effects of the drug combination, and is intended as well to embrace co-administration of these agents in a substantially simultaneous manner, such as in a single capsule having a fixed ratio of these active agents or in multiple, separate capsules for each agent.

Specifically, the administration of compounds of the present invention may be in conjunction with additional therapies known to those skilled in the art in the prevention or treatment of neoplasia, such as with radiation therapy or with cytostatic or cytotoxic agents.

If formulated as a fixed dose, such combination products employ the compounds of this invention within the accepted dosage ranges. Compounds of Formula I may also be administered sequentially with known anticancer or cytotoxic agents when a combination formulation is inappropriate. The invention is not limited in the sequence of administration; compounds of the invention may be administered either prior to, simultaneous with or after administration of the known anticancer or cytotoxic agent.

Currently, standard treatment of primary tumors consists of surgical excision followed by either radiation or IV administered chemotherapy. The typical chemotherapy regime consists of either DNA alkylating agents, DNA intercalating agents, CDK inhibitors, or microtubule poisons. The chemotherapy doses used are just below the maximal tolerated dose and therefore dose limiting toxicities typically include, nausea, vomiting, diarrhea, hair loss, neutropenia and the like.

There are large numbers of antineoplastic agents available in commercial use, in clinical evaluation and in pre-clinical development, which would be selected for treatment of neoplasia by combination drug chemotherapy. Such antineoplastic agents fall into several major categories, namely, antibiotic-type agents, alkylating agents, antimetabolite agents, hormonal agents, immunological agents, interferon-type agents and a category of miscellaneous agents.

A first family of antineoplastic agents which may be used in combination with compounds of the present invention consists of antimetabolite-type/thymidilate synthase inhibitor antineoplastic agents.

Suitable antimetabolite antineoplastic agents may be selected from but not limited to the group consisting of 5-FU-fibrinogen, acanthifolic acid, aminothiadiazole, brequinar sodium, carmofur, Ciba-Geigy CGP- 30694, cyclopentyl cytosine, cytarabine phosphate stearate, cytarabine conjugates, Lilly DATHF, Merrel Dow DDFC, dezaguanine, dideoxycytidine, dideoxyguanosine, didox, Yoshitomi DMDC, doxifluridine, Wellcome EHNA, Merck & Co. EX-015, fazarabine, floxuridine, fludarabine phosphate, 5-fluorouracil, N- (2'-furanidyl)-5-fluorouracil, Daiichi Seiyaku FO-152, isopropyl pyrrolizine, Lilly LY-188011, Lilly LY-264618, methobenzaprim, methotrexate, Wellcome MZPES, norspermidine, NCI NSC-127716, NCI NSC-264880, NCI NSC-39661, NCI NSC-612567, Warner-Lambert PALA, pentostatin, piritrexim, plicamycin, Asahi Chemical PL-AC, Takeda TAC-788, thioguanine, tiazofurin, Erbamont TIF, trimetrexate, tyrosine kinase inhibitors, Taiho UFT and uricytin.

A second family of antineoplastic agents which may be used in combination with compounds of the present invention consists of alkylating-type antineoplastic agents. Suitable alkylating-type antineoplastic agents may be selected from but not limited to the group consisting of Shionogi 254-S, aldo-phosphamide analogues, altretamine, anaxirone, Boehringer Mannheim BBR-2207, bestrabucil, budotitane, Wakunaga CA-102, carboplatin, carmustine, Chinoin-139, Chinoin-153, chlorambucil, cisplatin, cyclophosphamide, American Cyanamid CL-286558, Sanofi CY-233, cyplatate, Degussu D-19- 384, Sumimoto DACHP (Myr) 2, diphenylspiromustine, diplatinum cytostatic, Erba distamycin derivatives, Chugai DWA-2114R, ITI E09, elmustine, Erbamont FCE-24517, estramustine phosphate sodium, fotemustine, Unimed G-6-M, Chinoin GYKI-17230, hepsul-fam, ifosfamide, iproplatin, lomustine, mafosfamide, mitolactol, Nippon Kayaku NK-121, NCI NSC-264395, NCI NSC-342215, oxaliplatin, Upjohn PCNU, prednimustine, Proter PTT-119, ranimustine, semustine, SmithKline SK&F-

101772, Yakult Honsha SN-22, spiromus-tine, Tanabe Seiyaku TA-077, tauromustine, temozolomide, teroxirone, tetraplatin and trimelamol.

A third family of antineoplastic agents which may be used in combination with compounds of the present invention consists of antibiotic-type antineoplastic agents. Suitable antibiotic-type antineoplastic agents may be selected from but not limited to the group consisting of Taiho 4181-A, aclarubicin, actinomycin D, actinoplanone, Erbamont ADR-456, aeroplysinin derivative, Ajinomoto AN-201-II, Ajinomoto AN-3, Nippon Soda anisomycins, anthracycline, azino-mycin-A, bisucaberin, Bristol-Myers BL-6859, Bristol-Myers BMY-25067, Bristol-Myers BMY-25551, Bristol-Myers BMY-26605, Bristol- Myers BMY-27557, Bristol-Myers BMY-28438, bleomycin sulfate, bryostatin-1, Taiho C-1027, calichemycin, chromoximycin, dactinomycin, daunorubicin, Kyowa Hakko DC-102, Kyowa Hakko DC- 79, Kyowa Hakko DC-88A, Kyowa Hakko DC89-A1, Kyowa Hakko DC92-B, ditrisarubicin B, Shionogi DOB-41, doxorubicin, doxorubicin-fibrinogen, elsamicin-A, epirubicin, erbstatin, esorubicin, esperamicin-Al, esperamicin-Alb, Erbamont FCE-21954, Fujisawa FK-973, fostriecin, Fujisawa FR- 900482, glidobactin, gregatin-A, grincamycin, herbimycin, idarubicin, illudins, kazusamycin, kesarirhodins, Kyowa Hakko KM-5539, Kirin Brewery KRN-8602, Kyowa Hakko KT-5432, Kyowa Hakko KT-5594, Kyowa Hakko KT-6149, American Cyanamid LL-D49194, Meiji Seika ME 2303, menogaril, mitomycin, mitoxantrone, SmithKline M-TAG, neoenactin, Nippon Kayaku NK-313, Nippon Kayaku NKT-01, SRI International NSC-357704, oxalysine, oxaunomycin, peplomycin, pilatin, pirarubicin, porothramycin, pyrindanycin A, Tobishi RA-I, rapamycin, rhizoxin, rodorubicin, sibanomicin, siwenmycin, Sumitomo SM-5887, Snow Brand SN-706, Snow Brand SN-07, sorangicin-A, sparsomycin, SS Pharmaceutical SS-21020, SS Pharmaceutical SS-7313B, SS Pharmaceutical SS-9816B, steffimycin B, Taiho 4181-2, talisomycin, Takeda TAN-868A, terpentecin, thrazine, tricrozarin A, Upjohn U-73975, Kyowa Hakko UCN-10028A, Fujisawa WF-3405, Yoshitomi Y-25024 and zorubicin.

A fourth family of antineoplastic agents which may be used in combination with compounds of the present invention consists of a miscellaneous family of antineoplastic agents, including tubulin interacting agents, topoisomerase II inhibitors, topoisomerase I inhibitors and hormonal agents, selected from but not limited to the group consisting of a-carotene, a-difluoromethyl-arginine, acitretin, Biotec AD-5, Kyorin AHC-52, alstonine, amonafide, amphethinile, amsacrine, Angiostat, ankinomycin, anti- neoplaston A10, antineoplaston A2, antineoplaston A3, antineoplaston A5, antineoplaston AS2-1, Henkel APD, aphidicolin glycinate, asparaginase, Avarol, baccharin, batracylin, benfluron, benzotript, Ipsen- Beaufour BIM-23015, bisantrene, Bristol-Myers BMY-40481, Vestar boron-10, bromofosfamide, Wellcome BW-502, Wellcome BW-773, caracemide, carmethizole hydrochloride, Ajinomoto CDAF, chlorsulfaquinoxalone, Chemes CHX-2053, Chemex CHX-100, Warner-Lambert CI-921, Warner- Lambert CI-937, Warner-Lambert CI-941, Warner-Lambert CI-958, clanfenur, claviridenone, ICN compound 1259, ICN compound 4711, Contracan, Yakult Honsha CPT-11, crisnatol, curaderm, cytochalasin B, cytarabine, cytocytin, Merz D-609, DABIS maleate, dacarbazine, datelliptinium, didemnin-B, dihaematoporphyrin ether, dihydrolenperone, dinaline, distamycin, Toyo Pharmar DM-341, Toyo Pharmar DM-75, Daiichi Seiyaku DN-9693, docetaxel elliprabin, elliptinium acetate, Tsumura

EPMTC, the epothilones, ergotamine, etoposide, etretinate, fenretinide, Fujisawa FR-57704, gallium nitrate, genkwadaphnin, Chugai GLA-43, Glaxo GR-63178, grifolan NMF-5N, hexadecylphosphocholine, Green Cross HO-221, homoharringtonine, hydroxyurea, BTG ICRF-187, ilmofosine, isoglutamine, isotretinoin, Otsuka JI-36, Ramot K-477, Otsuak K-76COONa, Kureha Chemical K-AM, MECT Corp KI-8110, American Cyanamid L-623, leukoregulin, lonidamine, Lundbeck LU-23-112, Lilly LY-186641, NCI (US) MAP, marycin, Merrel Dow MDL-27048, Medco MEDR-340, merbarone, merocyanlne derivatives, methylanilinoacridine, Molecular Genetics MGI-136, minactivin, mitonafide, mitoquidone mopidamol, motretinide, Zenyaku Kogyo MST-16, N- (retinoyl) amino acids, Nisshin Flour Milling N- 021, N-acylated-dehydroalanines, nafazatrom, Taisho NCU-190, nocodazole derivative, Normosang, NCI NSC-145813, NCI NSC-361456, NCI NSC-604782, NCI NSC-95580, ocreotide, Ono ONO-112, oquizanocine, Akzo Org-10172, paclitaxel, pancratistatin, pazelliptine, Warner-Lambert PD-111707, Warner-Lambert PD-115934, Warner-Lambert PD-131141, Pierre Fabre PE-1001, ICRT peptide D, piroxantrone, polyhaematoporphyrin, polypreic acid, Efamol porphyrin, probimane, procarbazine, proglumide, Invitron protease nexin I, Tobishi RA-700, razoxane, Sapporo Breweries RBS, restrictin-P, retelliptine, retinoic acid, Rhone-Poulenc RP-49532, Rhone-Poulenc RP-56976, SmithKline SK&F- 104864, Sumitomo SM-108, Kuraray SMANCS, SeaPharm SP-10094, spatol, spirocyclopropane derivatives, spirogermanium, Unimed, SS Pharmaceutical SS-554, strypoldinone, Stypoldione, Suntory SUN 0237, Suntory SUN 2071, superoxide dismutase, Toyama T-506, Toyama T-680, taxol, Teijin TEI- 0303, teniposide, thaliblastine, Eastman Kodak TJB-29, tocotrienol, topotecan, Topostin, Teijin TT-82, Kyowa Hakko UCN-01, Kyowa Hakko UCN-1028, ukrain, Eastman Kodak USB-006, vinblastine sulfate, vincristine, vindesine, vinestramide, vinorelbine, vintriptol, vinzolidine, withanolides and Yamanouchi YM-534.

Alternatively, the present compounds may also be used in co-therapies with other anti-neoplastic agents, such as acemannan, aclarubicin, aldesleukin, alemtuzumab, alitretinoin, altretamine, amifostine, aminolevulinic acid, amrubicin, amsacrine, anagrelide, anastrozole, ANCER, ancestim, ARGLABIN, arsenic trioxide, BAM 002 (Novelos), bexarotene, bicalutamide, broxuridine, capecitabine, celmoleukin, cetrorelix, cladribine, clotrimazole, cytarabine ocfosfate, DA 3030 (Dong-A), daclizumab, denileukin diftitox, deslorelin, dexrazoxane, dilazep, docetaxel, docosanol, doxercalciferol, doxifluridine, doxorubicin, bromocriptine, carmustine, cytarabine, fluorouracil, HIT diclofenac, interferon alfa, daunorubicin, doxorubicin, tretinoin, edelfosine, edrecolomab, eflornithine, emitefur, epirubicin, epoetin beta, etoposide phosphate, exemestane, exisulind, fadrozole, filgrastim, finasteride, fludarabine phosphate, formestane, fotemustine, gallium nitrate, gemcitabine, gemtuzumab zogamicin, gimeracil/oteracil/tegafur combination, glycopine, goserelin, heptaplatin, human chorionic gonadotropin, human fetal alpha fetoprotein, ibandronic acid, idarubicin, (imiquimod, interferon alfa, interferon alfa, natural, interferon alfa-2, interferon alfa-2a, interferon alfa-2b, interferon alfa-N1, interferon alfa-n3, interferon alfacon-1, interferon alpha, natural, interferon beta, interferon beta-la, interferon beta-lb, interferon gamma, natural interferon gamma-la, interferon gamma-lb, interleukin-1 beta, iobenguane, irinotecan, irsogladine, lanreotide, LC 9018 (Yakult), leflunomide, lenograstim, lentinan sulfate, letrozole,

leukocyte alpha interferon, leuprorelin, levamisole + fluorouracil, liarozole, lobaplatin, lonidamine, lovastatin, masoprocol, melarsoprol, metoclopramide, mifepristone, miltefosine, mirimostim, mismatched double stranded RNA, mitoguazone, mitolactol, mitoxantrone, molgramostim, nafarelin, naloxone + pentazocine, nartograstim, nedaplatin, nilutamide, noscapine, novel erythropoiesis stimulating protein, NSC 631570 octreotide, oprelvekin, osaterone, oxaliplatin, paclitaxel, pamidronic acid, pegaspargase, peginterferon alfa-2b, pentosan polysulfate sodium, pentostatin, picibanil, pirarubicin, rabbit antithymocyte polyclonal antibody, polyethylene glycol interferon alfa-2a, porfimer sodium, raloxifene, raltitrexed, rasburicase, rhenium Re 186 etidronate, RII retinamide, rituximab, romurtide, samarium (153 Sm) lexidronam, sargramostim, sizofiran, sobuzoxane, sonermin, strontium-89 chloride, suramin, tasonermin, tazarotene, tegafur, temoporfin, temozolomide, teniposide, tetrachlorodecaoxide, thalidomide, thymalfasin, thyrotropin alfa, topotecan, toremifene, tositumomab-iodine 131, trastuzumab, treosulfan, tretinoin, trilostane, trimetrexate, triptorelin, tumor necrosis factor alpha, natural, ubenimex, bladder cancer vaccine, Maruyama vaccine, melanoma lysate vaccine, valrubicin, verteporfin, vinorelbine, VIRULIZIN, zinostatin stimalamer, or zoledronic acid; abarelix; AE 941 (Aeterna), ambamustine, antisense oligonucleotide, bcl-2 (Genta), APC 8015 (Dendreon), cetuximab, decitabine, dexaminoglutethimide, diaziquone, EL 532 (Elan), EM 800 (Endorecherche), eniluracil, etanidazole, fenretinide, filgrastim SD01 (Amgen), fulvestrant, galocitabine, gastrin 17 immunogen, HLA-B7 gene therapy (Vical), granulocyte macrophage colony stimulating factor, histamine dihydrochloride, ibritumomab tiuxetan, ilomastat, IM 862 (Cytran), interleukin-2, iproxifene, LDI 200 (Milkhaus), leridistim, lintuzumab, CA 125 MAb (Biomira), cancer MAb (Japan Pharmaceutical Development), HER- 2 and Fc MAb (Medarex), idiotypic 105AD7 MAb (CRC Technology), idiotypic CEA MAb (Trilex), LYM-1-iodine 131 MAb (Techniclone), polymorphic epithelial mucin-yttrium 90 MAb (Antisoma), marimastat, menogaril, mitumomab, motexafin gadolinium, MX 6 (Galderma), nelarabine, nolatrexed, P 30 protein, pegvisomant, pemetrexed, porfiromycin, prinomastat, RL 0903 (Shire), rubitecan, satraplatin, sodium phenylacetate, sparfosic acid, SRL 172 (SR Pharma), SU 5416 (SUGEN), TA 077 (Tanabe), tetrathiomolybdate, thaliblastine, thrombopoietin, tin ethyl etiopurpurin, tirapazamine, cancer vaccine (Biomira), melanoma vaccine (New York University), melanoma vaccine (Sloan Kettering Institute), melanoma oncolysate vaccine (New York Medical College), viral melanoma cell lysates vaccine (Royal Newcastle Hospital), or valspodar.

Alternatively, the present compounds may also be used in co-therapies with other agents, such as other kinase inhibitors including p38 inhibitors and CDK inhibitors, TNF inhibitors, metallomatrix proteases inhibitors (MMP), COX-2 inhibitors including celecoxib, rofecoxib, parecoxib, valdecoxib, and etoricoxib, NSAID's, SOD mimics or avß3 inhibitors, and anti-inflamatories.

The present invention comprises processes for the preparation of a compound of Formula I-VII.

Also included in the family of compounds of Formula I-VII are the pharmaceutically-acceptable salts thereof. The term"pharmaceutically-acceptable salts"embraces salts commonly used to form alkali metal salts and to form addition salts of free acids or free bases. The nature of the salt is not critical, provided that it is pharmaceutically-acceptable. Suitable pharmaceutically-acceptable acid addition salts

of compounds of Formula I-VII may be prepared from an inorganic acid or from an organic acid.

Examples of such inorganic acids are hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric and phosphoric acid. Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, arylaliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids, example of which are formic, acetic, adipic, butyric, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, mesylic, 4-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, ethanedisulfonic, benzenesulfonic, pantothenic, 2-hydroxyethanesulfonic, toluenesulfonic, sulfanilic, cyclohexylaminosulfonic, camphoric, camphorsulfonic, digluconic, cyclopentanepropionic, dodecylsulfonic, glucoheptanoic, glycerophosphonic, heptanoic, hexanoic, 2-hydroxy-ethanesulfonic, nicotinic, 2-naphthalenesulfonic, oxalic, palmoic, pectinic, persulfuric, 2-phenylpropionic, picric, pivalic propionic, succinic, tartaric, thiocyanic, mesylic, undecanoic, stearic, algenic, (3-hydroxybutyric, salicylic, galactaric and galacturonic acid. Suitable pharmaceutically-acceptable base addition salts of compounds of Formula I-VII include metallic salts, such as salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc, or salts made from organic bases including primary, secondary and tertiary amines, substituted amines including cyclic amines, such as caffeine, arginine, diethylamine, N-ethyl piperidine, aistidine, glucamine, isopropylamine, lysine, morpholine, N-ethyl morpholine, piperazine, piperidine, triethylamine, trimethylamine. All of these salts may be prepared by conventional means from the corresponding compound of the invention by reacting, for example, the appropriate acid or base with the compound of Formula I-VII. When a basic group and an acid group are present in the same molecule, a compound of Formula I-VII may also form internal salts.

GENERAL SYNTHETIC PROCEDURES The compounds of the invention can be synthesized according to the following procedures of Schemes 1-16, wherein the substituents are as defined for Formulas I-VII, above, except where further noted.

The following abbreviations are used throughout the specification: AcOH-acetic acid BINAP-2,2'-bis (diphenylphosphino)-1, 1'-binapthyl BBr3-boron tribromide BH3-THF-borane-tetrahydrofuran complex BOC-t-butoxycarbonyl BSA-bovine serum albumin n-BuLi-n-butyl lithium CO-carbon monoxide C202CI2 or (COCI) 2-oxalyl chloride Cs2C03-cesium carbonate

CHC13-chloroform EtxO - diethyl ether DCM, CH2Cl2 - methylene chloride DIBAL-diisobutylaluminum hydride DIEA, DIPEA, Hunig's base-diisopropylethylamine DMF-dimethylformamide dppa-diphenylphosphoryl azide DPPP-1,3-diphenylphosphino propane DMAP-4-dimethylaminopyridine EtOAc, EA-ethyl acetate EtOH-ethanol Et2O-diethyl ether EDC, EDCI-1- (3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride EtNH2-ethyl amine FBS-fetal bovine serum g-gram h-hour HCI-hydrochloric acid HOAt-1-hydroxy-7-azabenzotriazole HOBt-1-hydroxybenzotriazole hydrate <BR> <BR> <BR> <BR> H2-hydrogen<BR> <BR> <BR> <BR> <BR> <BR> H20-water H202-hydrogen peroxide HATU-0- (7-azabenzotriazol-1-yl-) N, N, N', N', tetramethyluronium hexafluorophosphate KOH-potassium hydroxide K2CO3 - potassium carbonate K3PO4 potassium phosphate KMn04-potassium permanganate LAH-lithium aluminum hydride LiHMDS-lithium bis (trimethylsilyl)-amide LiOH-lithium hydroxide MgS04-magnesium sulfate MCPBA-meta-chloroperbenzoic acid MeOH, CH30H-methanol MeNH2-methyl amine NH4CI-ammonium chloride

NH40H-ammonium hydroxide NMP-N-methylpyrrolidinone NaHC03-sodium bicarbonate NaN3-sodium azide Na2SO-sodium sulfate NaOH-sodium hydroxide NaH-sodium hydride Na2S04-sodium sulfate NaOt-Bu-sodium tert-butoxide NaHB (OAc) 3-sodium triacetoxyborohydride N2-nitrogen O/N-overnight POCI3-phosphorus oxychloride Pd/C-palladium on carbon Pd2 (dba) 3-bis (dibenzylideneacetone) palladium Pd (OAC) 2-palladium (II) acetate P (t-bu) 3-tri (tert-butyl) phosphine PBS-phospate buffered saline <BR> <BR> <BR> <BR> PyBop-Benzotriazol-1-yl-oxy-tripyrrolidino-phosphonium<BR > <BR> <BR> <BR> <BR> hexafluorophosphate RT-room temperature SOC12-thionyl chloride TBTU - O-benzotriazol-l-yl-N, N, N', N'-tetramethyluronium tetrafluoroborate TBAI-tetrabutylammonium iodide TFA-trifluoroacetic acid THF-tetrahydrofuran TEA, Et3N-triethylamine Scheme 1 OH R8 0 R8 NH. p HX R9 Curtius HX Reaction R9 1 LG p R10 Z 3 3 3 Rlo R'rt ? R10 R8 NH2 DeprotectionIIxR8 \ I NH P 9 R 5 4 Coupling RY"-LG / N X \ rus R9 N"j 6

Substituted bicyclic compounds 6 [where Y is substituted amines or amides] can be prepared by the process outlined in Scheme 1. Disubstituted naphthyl compounds 1, e. g. 6-hydroxy-2-naphthoic acid, is protected, such as with benzyl alcohol in the presence of dppa and a base, such as Et3N at a temperature above RT, preferably at a temperature at about reflux, provide carbamates 2. The protected amine 2 [where X is O] is coupled with a quinoline derivative 3 [where LG is halo, and the like] such as in the presence of DMAP in a solvent such as toluene at a temperature above RT, preferably above about 100 °C, more preferably at a temperature of about 180 °C, to form the protected linked compound 4. Such heating is preferably heated by microwave. After deprotection, e. g. with H2 in the presence of a catalyst such as Pd/C, amine 5 is formed. Alternatively, the deprotection can be achieved by treatment with K2CO3 and copper, at a temperature above RT, preferably above about 100 °C, more preferably at about

120 °C. The amine 5 can be coupled with compounds having an active acyl moiety, such as acid chlorides and carboxylic acids, to form naphthyl amides 6 of the present invention.

Alternatively, protected amine 2 can be deprotected and coupled to nitrogen containing heterocyclic compounds such as quinolines and quinzaolines 3 can be achieved by treatment with K2CO3 and copper, at a temperature above RT, preferably above about 100 °C, more preferably at about 120 °C.

Scheme 2 R10 R8 , amination LG I i ZvN X Ro R R N 5 ZY 7 JL. J

Alternatively, naphthyl amines 5 can be prepared via amination of a bromo-derivative 7 e. g. a halo derivative more preferably a bromo-derivative such as in the presence of Pd and a strong base, e. g.

LiHMDS. Preferably Pd2 (dba) 3 in the presence of P (t-Bu) 3 is used. Preferably the reaction is kept at about RT.

Scheme 3

R8 i w o JLJLJ Ro R x" . R Rto X R10 XZ 6 R-Y 3 3 Alternatively, compounds where Y is-C02-6 can be prepared as described in Scheme 3. A substituted naphthalene-2-carboxylic acid ester 8 is treated with strong base, such as NaH, preferably in a solvent such as DMF, to form the anion. Preferably the reaction temperature is at about RT. Substituted nitrogen containing heteroaryl compounds 3, such as substituted quinazolines or quinolines, are coupled to the anion to form the compounds of the present invention 6. The reaction temperature is above RT, preferably above about 50 °C, more preferably at about 60 °C.

Scheme 4 OH s 11 ive I RNH2 N HX--H H HX coupling | R1oX Lu R R 3 R'o \ R HERZ \ _ Rs 6

Alternatively, compounds where Y is-C (=O) NH- 6 can be prepared as described in Scheme 4. A substituted naphthalene-2-carboxylic acid 1 can be coupled with an amine under standard coupling chemistry, such as with EDC in the presence of a solvent like DMF, to form amides 9. The reaction temperature is preferably kept at about RT. Coupling the amides 9 with nitrogen-containing heterocyclic compounds, such as quinolines and quinzaolines 3, by the method described above in Scheme 1 provides compounds of the present invention 6 [where Y is-C (=O) NH-].

Scheme 5

Alternatively, compounds where Y is-C (=O) NH- 6 can be prepared as described in Scheme 5. A substituted naphthylamine 10 can be coupled with an active carbonyl compound (Y"-R) as described in Scheme 1, to form amides 11. Coupling the amides 11 with nitrogen containing heterocyclic compounds, such as quinolines and quinzaolines 3 by the method described in Scheme 4, provides compounds of the present invention 6 [where Y is-NHC (=O)-].

Scheme 6

Bromonaphthyl intermediates 13 can be provided by the method described in Scheme 6. A mixture of substituted quinoline 3 [where LG is chloro], 6-bromo-naphthyl compound 12 and DMAP, in a solvent such as toluene, at a temperature above RT, preferably above about 100 °C, more preferably at a temperature of about 180 °C, to form the intermediates 13.

Scheme 7 Substituted bicyclic compounds can be prepared by the process outlined in Scheme 7. Coupling of bicyclic compounds (where R is not H) 15 with intermediates 14 (where Y'is a portion of Y, such as NH, C (=O), etc. ) yields compounds 16.

Scheme 8

Br H Grognard Br Coupling Ruz Ri 18 17 dehydroxylation I NH2. ! Br y R w 22 ru 20 R Ri

Substituted bicyclic compounds 22 [where Y is an amide] can be prepared by the process outlined in Scheme 8. 6-Bromo-2-hydroxymethylnaphthalenes 19 are prepared such as by the coupling of 6- bromonaphthyl-2-carbaldehydes 18 and activated R'containing compounds 17, such as phenylsulfinyl substituted compounds. Preferably the coupling occurs in the presence of a Grignard reagent, such as phenylmagnesium bromide, in an appropriate protic solvent such as THF. The temperature is preferably maintained at about RT. Preferably the Grignard is first added to the R'containing compound 17 prior to the addition of the carbaldehyde 18. The resulting hydroxymethyl compound 19 is dehydroxylated, such

as in the presence of Zn and formic acid. The dehydroxylation preferably occurs at a temperature above RT, more preferably above about 50 °C, and most preferably at about reflux temperature. The resulting 6- bromonaphtyl compound 20 is animated similar to that described in Scheme 2 to form naphthyl amine 21 and the amides 22 are consequently formed similar to that described in Scheme 1.

Scheme 9 oxidation Basa T ! 23 thiophenol 24 1 17 R Activated R'containing compounds 17 can be prepared such as by the method identified in Scheme 9. Halosubstituted compounds 23 are dehalogenated, such as with aqueous base, e. g. KOH, then treated with a thiol compound, such as thiophenol, at a temperature above RT, preferably above 75 °C, more preferably at about 100 °C. The thio compound 24 is oxidized, such as with mCPBA, at a temperature below RT, preferably below-23 °C, more preferably at about-78 °C, to form the sulfinyl compounds 17.

Scheme 10 'o" Weinreb reagent 0 B DIBAL 18 25 26 - I B 26 6-Bromonaphthyl-2-carbaldehydes 18 are prepared from the carboxylic acid 25 via reduction of the amide intermediate 26. The amide 26 is formed via peptide type coupling, such as in the presence of EDC, HOBt and base, of a substituted hydroxylamine, at a temperature preferably at about RT. Reduction of the amide 26, such as with DIBAL, in a solvent such as THF, at a temperature between-78 °C and RT, preferably at about RT, provides the desired 6-bromonaphthalene-2-carbaldehyde 18.

Scheme 11 R>4<yNH2. < R' base 27 28 27 28 27 28 Ureas of the present invention 28 are prepared by the method outlined in Scheme 11.

Naphthylamines 27 are treated with isocyantates, preferably an excess of isocyanate, in the presence of base, preferably an excess of base, in a solvent such as DMF to form the ureas 28. Preferably the reaction temperature is maintained at around RT.

Scheme 12 COzH C02H Ra R8 Base I base I LG 0-0 // HO R9 T Z T J R9 31 N 29 Rio 30 Rio 1) SO2CI, A 2) base 3) RNH2 cl R8\g4, Az R9 o AN ; 32 32 R10

Naphthyl amides of the present invention 32 are prepared by the method outlined in Scheme 12.

6-Hydroxynaphtoic acid 29, is treated with base, such as t-BuOK in an appropriate solvent such as DMSO. The ring 30 (where LG is a leaving group such as chloro) is added and the resulting mixture is heated to at a temperature above RT, preferably above about 50 °C, more preferably at a temperature of about 90 °C, to form ether 31. The ether is aminated, such as by treatment with SOC12 and DMF, in an appropriate solvent such as toluene, at a temperature above RT, preferably above about 50 °C, more preferably at a temperature of about 100 °C. The mixture is treated with base and the appropriate amine to form the desired amides 32.

Scheme 13

2,3-Dihydrobenzo [b] [1, 4] oxazine amides 38 of the present invention are prepared by the method outlined in Scheme 13. The 2-chloro-N- (2, 4-dihydroxyphenyl) acetamide 34 is formed by treatment of 4- aminoresorcinol hydrochloride 33 with chloroacetyl chloride in a solvent such as CH2CI2, in the presence of base, e. g. TEA at a temperature of about RT. The hydroxyl 2H-benzo [b] [1, 4] oxazin-3 (4H) -one 35 is formed from treatment of the acetamide 34 with base, e. g. NaH, in a suitable solvent such as CH2CI2 at a temperature of about RT. Reduction of the 2H-benzo [b] [1, 4] oxazin-3 (4H) -one 35, such as with treatment with BH3-THF in a solvent such as THF, at a temperature above RT, preferably above 50 °C, and more preferably at about 60 °C, provides the 3,4-dihydro-2H-benzo [b] [1, 4] oxazin-7-ol 36. Coupling of the alcohol 36 with the halide, such as in the presence of cesium carbonate, at a temperature above RT, preferably above 50 °C, and more preferably at about 80 °C, provides the substituted 3,4-dihydro-2H- benzo [b] [1, 4] oxazine 37. Treatment with an isocyante or carbamate, yields the desired amides 38.

Scheme 14 R NH base o>HNJJsR 39 Rl 40 I D'0 N R 39 o p) 'j, 40 R Cl

Formation of the desired 3,6-disubstituted naphthalenes 40 using a procedure described above but starting with the 3-amino-naphthalene 39 is shown in Scheme 14.

Scheme 15

Substituted 5-flouro-1-carboxy-naphthalenes 42 can be prepared such as by the method described in Scheme 15. Reaction of the alcohol 41, such as with the appropriate halide, in the presence of cesium carbonate, provides the desired ether.

Scheme 16

Dimethoxy-quinolines 45 can be prepared from the corresponding nitro 43 compounds via the method described in Scheme 16. Reduction of the nitro compound 43 to the amine 44, such as with H2 in the presence of a catalyst, such as Pd, e. g. Pd/C, followed by treatment with base and dimethyl ether, yields the desired quinolines 45.

Various substituted quinolines and quinazolines can be prepared by the methods described in WO 98/13350.

The starting compounds defined in Schemes 1-16 may also be present with functional groups in protected form if necessary and/or in the form of salts, provided a salt-forming group is present and the reaction in salt form is possible. If so desired, one compound of Formula I can be converted into another compound of Formula I, e. g. an N-oxide thereof; a compound of Formula I can be converted into a salt; a salt of a compound of Formula I can be converted into the free compound or another salt; and/or a mixture of isomeric compounds of Formula I can be separated into the individual isomers.

N-Oxides can be obtained in a known matter by reacting a compound of Formula I with hydrogen peroxide, oxone, or a peracid, e. g. mCPBA, in an inert solvent, e. g. CH2CI2, or a mixture of water and an alcohol such as MeOH or EtOH, at a temperature between about-10-35 °C, such as about 0 °C-RT.

If one or more other functional groups, for example carboxy, hydroxy, amino, or mercapto, are or need to be protected in a compound of Formula I or in the preparation of compounds of Formula I, because they should not take part in the reaction, these are such groups as are usually used in the synthesis of peptide compounds, and also of cephalosporins and penicillins, as well as nucleic acid derivatives and sugars.

The protecting groups may already be present in precursors and should protect the functional groups concerned against unwanted secondary reactions, such as acylations, etherifications, esterifications, oxidations, solvolysis, and similar reactions. It is a characteristic of protecting groups that they lend themselves readily, i. e. without undesired secondary reactions, to removal, typically by solvolysis, reduction, photolysis or also by enzyme activity, for example under conditions analogous to physiological conditions, and that they are not present in the end-products. The specialist knows, or can easily establish, which protecting groups are suitable with the reactions mentioned above and hereinafter.

The protection of such functional groups by such protecting groups, the protecting groups themselves, and their removal reactions are described for example in standard reference works, such as J. F. W. McOmie, "Protective Groups in Organic Chemistry", Plenum Press, London and New York (1973), in T. W. Greene, "Protective Groups in Organic Synthesis", Wiley, New York (1981), in"The Peptides", Volume 3, E. Gross and J. Meienhofer editors, Academic Press, London and New York (1981), in"Methoden der organischen Chemie" (Methods of Organic Chemistry), Houben Weyl, 4th edition, Volume 15/1, Georg Thieme Verlag, Stuttgart (1974), in H. -D. Jakubke and H. Jescheit,"Aminosauren, Peptide, Proteine" (Amino Acids, Peptides, Proteins), Verlag Chemie, Weinheim, Deerfield Beach, and Basel (1982), and in Jochen Lehmann, "Chemie der Kohlenhydrate: Monosaccharide und Derivate" (Chemistry of carbohydrates: monosaccharides and derivatives), Georg Thieme Verlag, Stuttgart (1974).

In the additional process steps, carried out as desired, functional groups of the starting compounds which should not take part in the reaction may be present in unprotected form or may be protected for example by one or more of the protecting groups mentioned above under"protecting groups". The protecting groups are then wholly or partly removed according to one of the methods described there.

Salts of a compound of Formula I with a salt-forming group may be prepared in a manner known per se. Acid addition salts of compounds of Formula I may thus be obtained by treatment with an acid or

with a suitable anion exchange reagent. A salt with two acid molecules (for example a dihalogenide of a compound of Formula I) may also be converted into a salt with one acid molecule per compound (for example a monohalogenide); this may be done by heating to a melt, or for example by heating as a solid under a high vacuum at elevated temperature, for example from 130 to 170 °C, one molecule of the acid being expelled per molecule of a compound of Formula I.

Salts can usually be converted to free compounds, e. g. by treating with suitable basic agents, for example with alkali metal carbonates, alkali metal hydrogen carbonates, or alkali metal hydroxides, typically potassium carbonate or sodium hydroxide.

All process steps described here can be carried out under known reaction conditions, preferably under those specifically mentioned, in the absence of or usually in the presence of solvents or diluents, preferably such as are inert to the reagents used and able to dissolve these, in the absence or presence of catalysts, condensing agents or neutralizing agents, for example ion exchangers, typically cation exchangers, for example in the Fi+ form, depending on the type of reaction and/or reactants at reduced, normal, or elevated temperature, for example in the range from about-100 °C to about 190 °C, preferably from about-80 °C to about 150 °C, for example at about-80 to about 60 °C, at room temperature, at about-20 to about 40 °C or at the boiling point of the solvent used, under atmospheric pressure or in a closed vessel, where appropriate under pressure, and/or in an inert atmosphere, for example under argon or nitrogen.

Salts may be present in all starting compounds and transients, if these contain salt-forming groups. Salts may also be present during the reaction of such compounds, provided the reaction is not thereby disturbed.

In certain cases, typically in hydrogenation processes, it is possible to achieve stereoselective reactions, allowing for example easier recovery of individual isomers.

The solvents from which those can be selected which are suitable for the reaction in question include for example water, esters, typically lower alkyl-lower alkanoates, e. g. , EtOAc, ethers, typically aliphatic ethers, e. g., Et2O, or cyclic ethers, e. g. , THF, liquid aromatic hydrocarbons, typically benzene or toluene, alcohols, typically MeOH, EtOH or 1-propanol, IPOH, nitriles, typically CH3CN, halogenated hydrocarbons, typically CH2CI2, acid amides, typically DMF, bases, typically heterocyclic nitrogen bases, e. g. pyridine, carboxylic acids, typically lower alkanecarboxylic acids, e. g., AcOH, carboxylic acid anhydrides, typically lower alkane acid anhydrides, e. g. , acetic anhydride, cyclic, linear, or branched hydrocarbons, typically cyclohexane, hexane, or isopentane, or mixtures of these solvents, e. g. , aqueous solutions, unless otherwise stated in the description of the process. Such solvent mixtures may also be used in processing, for example in chromatography.

The invention relates also to those forms of the process in which one starts from a compound obtainable at any stage as a transient and carries out the missing steps, or breaks off the process at any stage, or forms a starting material under the reaction conditions, or uses said starting material in the form of a reactive derivative or salt, or produces a compound obtainable by means of the process according to

the invention and processes the said compound in situ. In the preferred embodiment, one starts from those starting materials which lead to the compounds described above as preferred.

The compounds of Formula I, including their salts, are also obtainable in the form of hydrates, or their crystals can include for example the solvent used for crystallization (present as solvates).

New starting materials and/or intermediates, as well as processes for the preparation thereof, are likewise the subject of this invention. In the preferred embodiment, such starting materials are used and reaction conditions so selected as to enable the preferred compounds to be obtained.

Starting materials of the invention, are known, are commercially available, or can be synthesized in analogy to or according to methods that are known in the art.

In the preparation of starting materials, existing functional groups which do not participate in the reaction should, if necessary, be protected. Preferred protecting groups, their introduction and their removal are described above or in the examples.

All remaining starting materials are known, capable of being prepared according to known processes, or commercially obtainable; in particular, they can be prepared using processes as described in the examples.

Compounds of the present invention can possess, in general, one or more asymmetric carbon atoms and are thus capable of existing in the form of optical isomers as well as in the form of racemic or non-racemic mixtures thereof. The optical isomers can be obtained by resolution of the racemic mixtures according to conventional processes, e. g. , by formation of diastereoisomeric salts, by treatment with an optically active acid or base. Examples of appropriate acids are tartaric, diacetyltartaric, dibenzoyltartaric, ditoluoyltartaric, and camphorsulfonic acid and then separation of the mixture of diastereoisomers by crystallization followed by liberation of the optically active bases from these salts. A. different process for separation of optical isomers involves the use of a chiral chromatography column optimally chosen to maximize the separation of the enantiomers. Still another available method involves synthesis of covalent diastereoisomeric molecules by reacting compounds of the invention with an optically pure acid in an activated form or an optically pure isocyanate. The synthesized diastereoisomers can be separated by conventional means such as chromatography, distillation, crystallization or sublimation, and then hydrolyzed to deliver the enantiomerically pure compound. The optically active compounds of the invention can likewise be obtained by using optically active starting materials. These isomers may be in the form of a free acid, a free base, an ester or a salt.

The compounds of this invention may contain one or more asymmetric centers and thus occur as racemates and racemic mixtures, scalemic mixtures, single enantiomers, individual diastereomers and diastereomeric mixtures. All such isomeric forms of these compounds are expressly included in the present invention.

The compounds of this invention may also be represented in multiple tautomeric forms, for example, as illustrated below:

The invention expressly includes all tautomeric forms of the compounds described herein.

The compounds may also occur in cis-or trans-or E-or Z-double bond isomeric forms. All such isomeric forms of such compounds are expressly included in the present invention. All crystal forms of the compounds described herein are expressly included in the present invention.

Substituents on ring moieties (e. g. , phenyl, thienyl, etc. ) may be attached to specific atoms, whereby they are intended to be fixed to that atom, or they may be drawn unattached to a specific atom, whereby they are intended to be attached at any available atom that is not already substituted by an atom other than H (hydrogen).

The compounds of this invention may contain heterocyclic ring systems attached to another ring system. Such heterocyclic ring systems may be attached through a carbon atom or a heteroatom in the ring system.

Alternatively, a compound of any of the formulas delineated herein may be synthesized according to any of the processes delineated herein. In the processes delineated herein, the steps may be performed in an alternate order and may be preceded, or followed, by additional protection/deprotection steps as necessary. The processes may further comprise use of appropriate reaction conditions, including inert solvents, additional reagents, such as bases (e. g. , LDA, DIEA, pyridine, K2CO3, and the like), catalysts, and salt forms of the above. The intermediates may be isolated or carried on in situ, with or without purification. Purification methods are known in the art and include, for example, crystallization, chromatography (liquid and gas phase, and the like), extraction, distillation, trituration, reverse phase HPLC and the like. Reactions conditions such as temperature, duration, pressure, and atmosphere (inert gas, ambient) are known in the art and may be adjusted as appropriate for the reaction.

As can be appreciated by the skilled artisan, the above synthetic schemes are not intended to comprise a comprehensive list of all means by which the compounds described and claimed in this application may be synthesized. Further methods will be evident to those of ordinary skill in the art.

Additionally, the various synthetic steps described above may be performed in an alternate sequence or order to give the desired compounds. Synthetic chemistry transformations and protecting group methodologies (protection and deprotection) useful in synthesizing the inhibitor compounds described herein are known in the art and include, for example, those such as described in R. Larock, "Comprehensive Organic Transformations", VCH Publishers (1989); T. W. Greene and P. G. M. Wuts, "Protective Groups in Organic Synthesis", 3td edition, John Wiley and Sons (1999); L. Fieser. and M.

Fieser, "Fieser and Fieser's Reagents for Organic Synthesis", John Wiley and Sons (1994); A. Katritzky and A. Pozharski, "Handbook of Heterocyclic Chemistry", 2nd edition (2001); M. Bodanszky, A.

Bodanszky, "The Practice of Peptide Synthesis", Springer-Verlag, Berlin Heidelberg (1984); J. Seyden-

Penne, "Reductions by the Alumino-and Borohydrides in Organic Synthesis", 2"''edition, Wiley-VCH, (1997); and L. Paquette, editor, "Encyclopedia of Reagents for Organic Synthesis", John Wiley and Sons (1995).

The compounds of this invention may be modified by appending appropriate functionalities to enhance selective biological properties. Such modifications are known in the art and include those which increase biological penetration into a given biological compartment (e. g. , blood, lymphatic system, central nervous system), increase oral availability, increase solubility to allow administration by injection, alter metabolism and alter rate of excretion.

These detailed descriptions fall within the scope, and serve to exemplify, the above-described General Synthetic Procedures which form part of the invention. These detailed descriptions are presented for illustrative purposes only and are not intended as a restriction on the scope of the invention.

Unless otherwise noted, all materials were obtained from commercial suppliers and used without further purification. Anhydrous solvents such as DMF, THF, CH2CI2 and toluene were obtained from the Aldrich Chemical Company. Example 1 t N-(6-((6, 7-bis (Methoxy)-4- quinolinyl) oxy)-2-naphthalenyl)-2- (methoxy) benzamide 0+ 1 1--lo IN O) aN' 0' N Step (a) Preparation of N- (6-hydroxy- (2-naphthyl)) (benzyloxy) carboxamide 6-Hydroxy-2-naphthoic acid (30 g, 160 mmol, Aldrich), dppa (48.4 g, 176 mmol, Aldrich), benzyl alcohol (51.8 g, 480 mmol, Aldrich) and Et3N (32.3 g, 320 mmol, Aldrich) were heated at reflux with toluene (500 mL, Aldrich) for 16 h. After cooling to RT, the volatile portion was removed in vacuo. The resulting brown residue was purified by silica gel column chromatography (40% EtOAc/hexane) to give crude compound, which was further purified by crystallization from 50% EtOAc/Hexane to give the title compound as an off-white solid. MS (ESI, pos. ion) m/z : 294.2 (M+1). Mass Calc'd for C, 8H, 5NO3 : 293.11.

Step (b) Preparation of N- [6- (6, 7-dimethoxy (4-quinolyloxy)) (2-naphthyl)] (phenylmethoxy) carboxamide 4-Chloro-6, 7-dimethoxyquinoline (prepared by the method described in WO 03/33472) (223 mg, 1.0 mmol), N- (6-hydroxy- (2-naphthyl)) (benzyloxy) carboxamide (Step a, 293 mg, 1.0 mmol) and DMAP (122 mg, 1.0 mmol, Aldrich) in toluene (5 mL, Aldrich) were microwaved (Personal Chemistry,

Emrys Optimizer) at 180 °C for 2 h. After cooling to RT, the white precipitate was collected and purified by silica gel column chromatography (80% EtOAc/hexane) to give title compound as a white solid. MS (ESI, pos. ion) m/z : 481.3 (M+1). Mass Calc'd for C29H24N205 : 480.17.

Step (c) Preparation of 6-(6, 7-dimethoxy-4-quinolyloxy)-2-naphthylamine A mixture ofN-[6-(6, 7-dimethoxy (4-quinolyloxy)) (2-naphthyl)] (phenylmethoxy) carboxamide (Step b, 170 mg, 0. 35 mmol) and Pd/C (17 mg, 10%, Aldrich) in 60 mL of EtOAc was stirred at RT under H2 balloon for 16 h. The mixture was filtered through a Celite# pad. The filtrate was concentrated in vacuo to give the title compound as an off-white solid. MS (ESI, pos. ion) mlz : 347.0 (M+1). Mass Calc'd for C2, H, 8N203 : 346.13.

Step (d) Preparation of N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2-naphthalenyl)-2- (methoxy) benzamide To a mixture of6-(6, 7-dimethoxy-4-quinolyloxy)-2-naphthylamine (Step c, 34.6 mg, 0.1 mmol) and K2CO3 in dry CH2CI2 (10 mL, Aldrich) was added 2-methoxybenzoyl chloride (25.5 mg, 0.15 mmol, Aldrich). The reaction was stirred at RT for 3 h. The volatile portion was removed in vacuo. To the residue was added 15 mL of MeOH and the mixture was stirred at RT for 30 min. The MeOH was removed in vacuo. The resulting residue was diluted in EtOAc (50 mL) and washed with water and brine.

The organic phase was dried over MgS04 and concentrated. The resulting brown residue was purified by silica gel column chromatography (EtOAc) to give the title compound as a white solid. MS (ESI, pos. ion) m/z : 481.4 (M+1). Mass Calc'd for C29H24N2Os : 480. 17. Example 2, N-(6-((6, 7-bis (Methoxy)-4- 'quinolinyl) oxy)-2-naphthalenyl)-2- / N N ( (2- (dimethylamino) ethyl) oxy)-3- 1--lo O pyridinecarboxamide r o w wl 1. XN sO4N Step (a) Preparation of N- [6- ( (6, 7-dimethoxy-4-quinolyl) oxy) (2-naphthyl) l (2-fluoro-3- pyridyl) carboxamide 6- (6, 7-Dimethoxy-4-quinolyloxy) -2-naphthylamine (69.2 mg, 0.2 mmol, Example 1c), 2- fluoropyridine-3-carboxylic acid (33.8 mg, 0.24 mmol, Maybridge), DIEA (31 mg, 0.24 mmol, Aldrich) and TBTU (91.2 mg, 0.24 mmol, Advanced ChemTech) were stirred in 6 mL of dry DMF at RT for 24 h.

The solution was diluted with 50 mL of EtOAc and washed with saturated aqueous NaHC03 and brine.

The organic layer was dried over MgS04 and concentrated. The residue was purified by silica gel column chromatography (EtOAc) to give title compound as a white solid. MS (ESI, pos. ion) m/z : 470.0 (M+1).

Mass Calc'd for C27H2oFN304 469. 14.

Step (b) Preparation of N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2-naphthalenyl)-2-((2- (dimethylamino) ethyl) oxy) -3-pyridinecarboxamide To a mixture of N- [6- (6, 7-dimethoxy- (4-quinolyloxy)) (2-naphthyl)] (2-fluoro- (3- pyridyl) ) carboxamide (Step a, 62 mg, 0.13 mmol) and K2CO3 (166 mg, 1.3 mmol) in dry NMP (5 mL, Aldrich) was added N, N-dimethylethanolamine (35 mg, 0.36 mmol, Aldrich) at RT. The reaction was stirred at 110 °C for 16 h. The mixture was cooled and diluted with 60 mL of EtOAc, then washed with water and brine. The organic phase was dried over MgS04 and concentrated. The residue was purified by prep-HPLC to give title compound as a white solid. MS (ESI, pos. ion) m/z : 539 (M+1). Mass Calc'd for C3, H3oN40s : 538. 22. Example 3 H SA N-(6-((6, 7-bis (Methoxy)-4-quinolinyl) 11"N oxy)-5-fluoro-2-naphthalenyl)-2- thiophenecarboxamide zOX F 0-pa 0 1-10 F Step (a) Preparation of 6-bromo-1-fluoro-naphthalen-2-ol To a solution of 6-bromo-naphthalen-2-ol (5 g, 22.4 mmol, Aldrich) in dry DMF (50 mL, Aldrich) was added N-fluorobenzene sulfonimide (21.9 g, 67.2 mmol, Aldrich). The reaction was stirred at RT for 48 h. The volatile portion was removed in vacuo and the residue was purified by silica gel chromatography (CHC13) to give title compound as a yellow solid. MS (ESI, neg. ion) m/z : 240.0 (M-1).

Mass Calc'd for C, OH6BrFO : 239.96.

Step (b) Preparation of 2-(6, 7-dimethoxy-4-quinolyloxy)-6-bromo-1-fluoronaphthalene A mixture of 4-chloro-6, 7-dimethoxy-quinoline (prepared as in Example 1, Step b) (371 mg, 1.66 mmol), 6-bromo-1-fluoro-naphthalen-2-ol (Step a, 400 mg, 1.66 mmol) and DMAP (203 mg, 1.66 Aldrich) in toluene (in a microwave tube) was heated in a microwave oven (Personal Chemistry, Emrys Optimizer) at 180 °C for 2 h. The mixture was cooled to RT and diluted with 30 mL of EtOAc. The solution was washed with 10 mL of brine twice, dried over Na2SO4 and concentrated in vacuo. The residue was further purified with silica gel column chromatography (40-100% EtOAc in hexanes) to give title compound as a white solid. MS (ESI, pos. ion) y : 428.0 (M+l). Mass Calc'd for C2, H, 5BrFNO3 : 427.02.

Step (c) Preparation of 6- (6, 7-dimethoxy-4-quinolyloxy)-5-fluoro-2-naphthylamine A mixture of 2-(6, 7-dimethoxy-4-quinolyloxy)-6-bromo-1-fluoronaphthalene (Step b, 1.7 g, 4.0 mmol), Pd2 (dba) 3 (183 mg, 0.2 mmol, Aldrich) and P (t-Bu) 3 (40 mg, 0.2 mmol, Aldrich) in a two-necked round-bottom flask was degassed under vacuum and refilled with N2. Under N2, dry toluene and LiHMDS (5 mL, IM in THF, 5. 0 mmol, Aldrich) was added to the mixture via syringe. The reaction was stirred at RT under N2 for 16 h. To the reaction was added IN aqueous HCl (10 mL) and a yellow precipitate was collected by filtration. The solid was washed with 10 mL of water and dried in vacuo at 50 °C for 24 h to give title compound as HCl salt in the form of yellow solid. MS (ESI, pos. ion) m/z : 365 (M+l). Mass Calc'd for C2, l7FN203 : 364.12.

Step (d) Preparation of N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-5-fluoro-2-naphthalenyl)-2- thiophenecarboxamide To a solution of 6- (6, 7-dimethoxy-4-quinolyloxy) -5-fluoro-2-naphthylamine 2HC1 (Step c, 200 mg, 0.46 mmol), thiophene-2-carboxylic acid (120 mg, 0.91 mmol, Aldrich) and DIEA (353 mg, 2.74 mmol, Aldrich) in dry DMF was added PyBOP (476 mg, 0.91 mmol, Fluka) at RT. The reaction was stirred for 16 h. It was diluted with 40 mL of EtOAc and washed with saturated aqueous NaHC03, followed by brine. The organic phase was dried over Na2SO4 and concentrated in vacuo. The residue was purified by silica gel column chromatography (EtOAc) to give the title compound as a yellow solid. MS (ESI, pos. ion) m/z : 475.0 (M+1). Mass Calc'd for C2H19FN204S : 474.10. Example 4 0 Methyl 6-((6, 7-bis (methoxy)- pi 4-quinazolinyl) oxy)-2- r IT I naphthalenecarboxylate 0iX Ou+N 1-10- Step (a) Preparation of 6-hydroxy-naphthalene-2-carboxylic acid methyl ester Through a solution of 6-hydroxynaphthalene-2-carboxylic acid (4.87 g, 26 mmol, Aldrich) in MeOH (100 mL, Aldrich) was bubbled HCl gas for 1 h. The resulting mixture was stirred for 10 h at RT.

The solution was concentrated in vacuo to give the title compound as a pink powder. MS (ESI, pos. ion) m/z : 203 (M+1). Mass Calc'd for C12H, 003 : 202. 06.

Step (b) Preparation of methyl 6- ( (6, 7-bis (methoxy)-4-quinazolinyl) oxy)-2-naphthalenecarboxylate To a stirred mixture of NaH (200 mg, 60% in mineral oil, 5.0 mmol, Aldrich) in 10 mL of DMF at RT was added 6-hydroxy-naphthalene-2-carboxylic acid methyl ester (Step a, 675 mg, 3.34 mmol). After 20 min, 4-chloro-6,7-dimethoxy-quinazoline (750 mg, 3.34 mmol, Oakwood) was added and the reaction was heated to 60 °C for 20 min. The reaction was cooled to RT, quenched with saturated aqueous NH4CI

solution (30 mL) and extracted with CHCl3 (30 mL). The organic solution was washed with brine, dried over Na2SO4 and concentrated in vacuo. The residue was purified by column chromatography (30% EtOAc/hexane) to give the title compound as a white solid. MS (ESI, pos. ion) m/z : 390.9 (M+1). Mass Calc'd for CZZH, 8N205 : 390.12. Example5 H n Phenylmethyl 6-((6, 7-bis (methoxy)-4- N o/4zJ quinazolinyl) oxy) 2 naphthalenylcarbamate OJ'0 o,, Oa 0 N sO4N 0"N

N- (6-Hydroxy-2-naphthyl) (phenylmethoxy) carboxamide (180 mg, 0.61 mmol, Example la) was reacted with 4-chloro-6,7-dimethoxy-quinazoline (140 mg, 0.61 mmol, Oakwood) under the conditions of Example 4b to give the title compound as a white solid. MS (ESI, pos. ion) m/z : 482.5 (M+1). Mass Calc'd for C28H23N3Os : 481.16. Example 6-((6, 7-bis (Methoxy)-4- , N quinazolinyl) oxy)-N- (phenylmethyl)- 19 H U 2-naphthalenecarboxamide 0< wOu+N 0 N

Step (a) Preparation of (6-hydroxy (2-naphthyl))-N-benzylcarboxamide A solution of 6-hydroxy-naphthalene-2-carboxylic acid (2.0 g, 10.6 mmol, Aldrich) and benzylamine (1.7 g, 15.9 mmol, Aldrich) in DMF (40 mL, Aldrich) at 0 °C was added EDC (3.05 g, 15.9 mmol, Aldrich). The reaction was warmed to RT and stirred for 16 h. The volatile portion was removed in vacuo. The residue was diluted with 100 mL of EtOAc and washed with saturated aqueous NaHC03 and brine. The organic layer was dried over Na2SO4 and concentrated in vacuo. The residue was dissolved in EtOAc and passed through a short silica gel column and the filtrate was concentrated in vacuo. Recrystallization with 50% EtOAc/hexane provided the title compound as a white solid.

Step (b) Preparation of 6- ( (6, 7-bis (methoxy)-4-quinazolinyl) oxy)-N- (phenylmethyl)-2- naphthalenecarboxamide 6-Hydroxy (2-naphthyl))-N-benzylcarboxamide (Step a, 500 mg, 1.8 mmol) was reacted with 4- chloro-6,7-dimethoxy-quinazoline (400 mg, 1.8 mmol, Oakwood) under the conditions of Example 4b to give the title compound as a white solid. MS (ESI, pos. ion) m/z : 466.2 (M+1). Mass Calc'd for C28H23N304 : 465.17. Example H N- (6- ( (6, 7-bis (Methoxy)-4- 7 (N) quinazolinyl) oxy)-2-naphthalenyl)-2- , phenylacetamide 0. 1 -I N i0 N O4N

Step (a) Preparation of 6-aminonaphthalen-2-ol N- (6-Hydroxy-2-naphthyl) (phenylmethoxy) carboxamide (600 mg, 2.0 mmol) was reacted under conditions of Example lc to give the title compound as a light yellow solid. MS (ESI, pos. ion) m/z : 160.3 (M+1). Mass Calc'd for CloHgNO : 159.07.

Step (b) Preparation of N- (6-hydroxy-2-naphthyl)-2-phenylacetamide The 6-aminonaphthalen-2-ol from Step (a) above (320 mg, 2.0 mmol) reacted with phenylacetyl chloride (683 mg, 4.4 mmol, Aldrich) under the conditions of Example ld to give the title compound as a white solid. MS (ESI, pos. ion) m/z : 278.3 (M+1). Mass Calc'd for CX8HIsNO2 277.11.

Step (c) Preparation of N- (6- ( (6, 7-bis (methoxy)-4-quinazolinyl) oxy)-2-naphthalenyl)-2- phenylacetamide N- (6-Hydroxy-2-naphthyl)-2-phenylacetamide from step (b) above (260 mg, 0.9 mmol) reacted with 4-chloro-6,7-dimethoxy-quinazoline (210 mg, 0.9 mmol, Oakwood) under the conditions of Example 4b to give the title compound as a white solid. MS (ESI, pos. ion) m/z : 466.2 (M+1). Mass Calc'd for C28H23N3O4: 465. 17. Example 8 N- [6- (6, 7-Dimethoxy-quinolin-4- yloxy)-5-methyl-naphthalen-2-yl]- benzamide O \/O /O/ 1-1.

Step (a) Preparation of (6-hydroxy-5-methyl-naphthalen-2-yl)-carbamic acid benzyl ester To a mixture containing 6-hydroxy-5-methyl-naphthalene-2-carboxylic acid (3.42 g, 12.7 mmol), was added dppa (3 mL, 14.0 mmol) and Et3N (3.5 mL, 25.4 mmol) in 50 mL of toluene. After stirring for 10 min, benzyl alcohol (3.9 mL, 38.1 mmol) was added to the mixture and heated at reflux for 4 h. The crude was purified by silica-gel column chromatography in EtOAc/Hexanes to give the titled compound as brown solid. MS (ESI neg. ion) m/z : 306 (M-H). Mass Calc'd for Cl9Hl7NO3 : 307.12.

Step (b) Preparation of 6- (6, 7-dimethoxy-quinolin-4-yloxy)-5-methyl-naphthalen-2-ylamine (6-Hydroxy-5-methyl-naphthalen-2-yl)-carbamic acid benzyl ester (Step a, 0.300 g, 0.9 mmol), 4- chloro-6, 7-dimethoxy-quinoline (0.218 g, 0.9 mmol), K2CO3 (0.124 g, 0.9 mmol), and copper (4% by wt.) were added to a vial, then microwaved for 30 min at 120 °C with 150 watts of power (Powermax, CEM).

The mixture was diluted with CH2CI2 and 40 mL of IN NaOH, then extracted the organics 3 times with CH2CI2. The organics were combined, dried over Na2SO4, filtered, and concentrated in vacuo. The crude was crystallized from CH2C12/Hexanes to give a light brown solid, which was the titled compound. MS (ESI, pos. ion) m/z : 361 (M+1). Mass Calc'd for C22H2oN203 : 360.15.

Step (c) Preparation of N- [6- (6, 7-dimethoxy-quinolin-4-yloxy)-5-methyl-naphthalen-2-yl]- benzamide 6- (6, 7-Dimethoxy-quinolin-4-yloxy)-5-methyl-naphthalen-2-ylamine (Step b, 0.100 g, 0.2 mmol), benzoyl chloride (0.04 mL, 0.3 mmol) and K2CO3 (0.116 g, 0.6 mmol) in CH2CI2 were stirred overnight under inert atmosphere. The reaction was quenched with water and diluted with CH2CI2. The aqueous layer was extracted 3 times with CH2CI2. The organics were collected, dried over Na2SO4, filtered, and concentrated in vacuo. The crude was purified by silica-gel column chromatography in EtOAc/Hexanes to give the titled compound as a rust colored film. MS (ESI, pos. ion) m/z : 465 (M+l). Mass Calc'd for C29H24N204 : 464. 17. Example 9 n N-{5-Fluoro-6-[6-methoxy-7-(3- m Nt morpholin-4-yl-propoxy)-quinolin-4- I YP yloxyl-naphthalen-2-yll-2-methoxy- benzamide o I JNO N 0 oJ Step (a) Preparation of 4-(6-bromo-1-fluoro-naphthalen-2-yloxy)-6-methoxy-7-(3-morph olin-4-yl- propoxy)-quinoline.

A mixture of 4-chloro-6-methoxy-7- (3-morpholin-4-yl-propoxy)-quinoline (prepared as described in WO 03/33472) (0.465 mg, 1.93 mmol), 6-bromo-1-fluoro-naphthalen-2-ol (Example 3a) (0.65 mg, 1.93 mmol) and DMAP (0.235 mg, 1.93 mmol, Aldrich) in toluene (in a microwave tube) was heated in a microwave oven (Personal Chemistry, Emrys Optimizer) at 180 °C for 2 h. The mixture was cooled to RT and diluted with 30 mL of EtOAc. The solution was washed with brine (2x10 mL), dried over Na2SO4 and concentrated in vacuo. The residue was further purified with silica gel column chromatography (40% to 100% EtOAc in hexanes) to give the title compound as an orange foam. MS (ESI, pos. ion) m/z : 541.1 (M+1). Mass Calc'd for C27H26BrFN204 : 540.11.

Step (b) Preparation of 5-fluoro-6-[6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinolin- 4-yloxy]- naphthalen-2-ylamine HCl 4- (6-Bromo-1-fluoro-naphthalen-2-yloxy)-6-methoxy-7- (3-morpholin-4-yl-propoxy)-quinoline (Step a, 0.64 g, 1.17 mmol) was reacted under the conditions of Example 3c to afford a red solid. MS (ESI, pos. ion) m/z : 478.2 (M+l). Mass Calc'd for C27H28FN304 : 477.21.

Step (c) Preparation of N-{5-fluoro-6- [6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinolin-4-yloxyl- naphthalen-2-yl}-2-methoxy-benzamide 5-Fluoro-6- [6-methoxy-7- (3-morpholin-4-yl-propoxy)-quinolin-4-yloxy]-naphthalen-2-yl amine (Step b, 0.2 g, 0.34 mmol) was reacted under the conditions of Example 3d to afford a yellow solid. MS (ESI, pos. ion) m/z : 611.7 (M+1). Mass Calc'd for C35H34FN306 : 611.24. Example N-(6-((6, 7-bis (Methoxy)-4-quinolinyl) methyl)-2-naphthalenyl)-3- thiophenecarboxamide w I r o 1 o Step (a) Preparation of 6, 7-dimethoxy-4-phenylsulfanyl-quinoline To a solution of 4-chloro-6, 7-dimethoxy-quinoline (214 mg, 0.96 mmol) in EtOH (10 mL) and H2O (10 mL), was added KOH (107 mg, 1.44 mmol). The solution was stirred in a 100 °C bath. Then thiophenol (148 gL, 1.44 mmol) was added. The reaction was stirred at 100 °C for 1 h. The solvent was removed by rotary evaporation. The resulting residue was worked up with water and extracted with EtOAc 3x. The combined organic layer was washed with water and brine, dried over Na2SO4, filtered, and concentrated in vacuo. The crude material was purified by silica gel prep-TLC with 100% EtOAc to give the titled compound. MS (ESI, pos. ion) m/z : 298.1 (M+1).

Step (b) Preparation of 4-benzenesulfinyl-6, 7-dimethoxy-quinoline To a solution of 6, 7-dimethoxy-4-phenylsulfanyl-quinoline (Step a, 1.0 g, 3.4 mmol) in CH2CI2 (30 mL) at-78 °C, 3-chloroperoxybenzoic acid (0.64 g, 3.7 mmol) was added in CH2CI2 dropwise slowly.

The reaction was stirred at-78 °C for 2 h. The solution was poured into saturated NaHC03 and extracted with CH2CI2 3x. The combined organic layer was washed with saturated NaHC03, water and brine, dried over NazS04, filtered and concentrated in vacuo. The crude material was purified by silica gel column chromatography with (70-100% EtOAc/Hexane) to give the titled compound as a white solid. MS (ESI, pos. ion) m/z : 314.4 (M+1).

Step (c) Preparation of 6-bromo-naphthalene-2-carboxylic acid methoxy-methyl-amide To a suspension of 6-bromo-naphthalene-2-carboxylic acid (0.6 g, 2.4 mmol) and O, N-dimethyl- hydroxylamine (0.28 g, 2.87 mmol) in CH2CI2 (20 mL), was added EDC (0.55 g, 2.87 mmol), HOBt (0.39 g, 2.87 mmol) and TEA (0.66 mL, 4.8 mmol). The reaction was stirred at RT overnight. The solvent was removed in vacuo and the crude material was purified by silica gel column chromatography with (20-40% EtOAc/hexane) to give the titled compound as a white solid. MS (ESI, pos. ion) m/z : 294.0 (M+1).

Step (d) Preparation of 6-bromo-naphthalene-2-carbaldehyde To a solution of 6-bromo-naphthalene-2-carboxylic acid methoxy-methyl-amide (Step c, 6.3 g, 21.4 mmol) in THF (200 mL) at-78 °C, DIBAL (1M in THF, 25.7 mL, 25.7 mmol) was added. The mixture was stirred at-78 °C for 10 min, warmed to RT and stirred for 2 h. The reaction was poured into IN HCI and extracted with EtOAc 3x. The combined organic layer was washed with water and brine, dried over Na2SO4, filtered and concentrated in vacuo. The crude was purified by silica gel column chromatography with (5-20% EtOAc/hexane) to give the titled compound as a white solid. MS (ESI, pos. ion) m/z : 236.0 (M+1).

Step (e) Preparation of (6-bromo-naphthalen-2-yl)-(6, 7-dimethoxy-quinolin-4-yl)-methanol To a solution of 4-benzenesulfinyl-6, 7-dimethoxy-quinoline (step b, 1 g, 3.2 mmol) in THF (15 mL) at-10 °C, was added phenylmagnesium bromide (1M in THF, 3.5 mL, 3.5 mmol). The reaction was warmed to RT and stirred for 20 min. 6-Bromo-naphthalene-2-carbaldehyde (Step d, 0.75 g, 3.2 mmol) was added in THF. The resulting mixture was stirred at RT for 2 h, then poured into saturated NH4CI solution and extracted with ethyl acetate 3X. The combined organic layer was washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The crude was purified by silica gel column chromatography (15-35% acetone/CH2CI2) to give the titled compound. MS (ESI, pos. ion) m/z : 424.1 (M+1).

Step (f) Preparation of 4-(6-bromo-naphthalen-2-ylmethyl)-6, 7-dimethoxy-quinoline To a solution of (6-bromo-naphthalen-2-yl)- (6, 7-dimethoxy-quinolin-4-yl)-methanol (Step e, 0.55 g, 1.3 mmol) in formic acid (10 mL), was added Zn dust (500 mg, 7.6 mmol). The suspension was heated at reflux for 6 h and the solvent was removed in vacuo. The resulting residue was worked up with IN NaOH and extracted with CH2CI2 3x. The combined organic layer was washed with water and brine, dried over Na2SO4, filtered and concentrated in vacuo. The crude was purified with silica gel column chromatography (40-65% EtOAc/Hexane) to give the titled compound. MS (ESI, pos. ion) m/z : 408.1 (M+1).

Step (g) Preparation of 6- (6, 7-dimethoxy-quinolin-4-ylmethyl)-naphthalen-2-ylamine To a sealed tube, 4- (6-bromo-naphthalen-2-ylmethyl)-6, 7-dimethoxy-quinoline (Step f, 100 mg, 0.11 mmol), Pd2 (dba) 3 (5 mg, 0.0055 mmol), P (t-Bu) 3 (1.1 mg, 0.0055 mmol), toluene (1 mL) was combined under nitrogen, followed by addition of LiHMDS (1M in THF, 0.137 mL, 0,137 mmol). The reaction was stirred at RT overnight. The suspension was diluted with Et2O and HCI (IM, 1 mL) was added. The crude material was poured into 1N NaOH and extracted with Et20 3x. The combined organic layer was washed with water and brine, dried on Na2SO4, filtered, concentrated and purified by prep-TLC with 100% EtOAc to give the desired compound. MS (ESI, pos. ion) m/z : 345.1 (M+1).

Step (h) Preparation of N- (6- ( (6, 7-bis (Methoxy)-4-quinolinyl) methyl)-2-naphthalenyl)-3- thiophenecarboxamide To a solution of 6- (6, 7-dimethoxy-quinolin-4-ylmethyl)-naphthalen-2-ylamine (Step g, 36 mg, 0.10 mmol) and 3-thiophenecarboxylic acid (15 mg, 0.115 mmol) in CH2CI2 (1 mL), was added PyBop (163 mg, 0.314 mmol) and Et3N (44 p1L, 0.314 mmol). The mixture was stirred at RT overnight. The solvent was evaporated and the crude material was purified by Prep-TLC with EtOAc/CH2Cl2 (3: 2) to give the desired product. MS (ESI, pos. ion) m/z : 455.1 (M+1). Calc'd for C27H22N203S : 454.14.

The following Examples were prepared similar to the procedures described in either Example 1 or Example 2. Ex. Structure & Name Mol Mass M+H Proc. No. Formula No. 11 C36H34N404 586. 26 587. 8 1 CHs CH3 /CHs Non N /N CH3 0 N \N CHg I CH3 N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- naphthalenyl)-3-(1, 1-dimethylethyl)-I- (phenylmethyl)-1H-pyrazole-5-carboxamide 12 C30H30N404 510. 23 511. 6 1 CH3 N N/N CHg CH3 0 CH3 0 N O/ L ; tl3 CHs CH3 N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- naphthalenyl)-1- (1, 1-dimethylethyl)-3-methyl- 1 H-verazole-5-carboxamide 13 C3oH23FN206 526. 15 527. 3 1 F N Y40, 0 0 0 O/ CH3 0 0 N N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- naphthalenyl)-7-fluoro-2, 3-dihydro-1, 4- benzodioxine-5-carboxamide 14 n C28H21N306 495. 14 496. 6 1 N N-1-10- à /O O CH3 O O/ Zon CHs C H3 N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- naphthalenyl)-3-nitrobenzamide 15 C28H2oF2N204 486. 14 487. 6 1 F . or Cl3 0 CH3 p F 0 N CHUS ( ; H3 N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- naphthalenyl)-2, 5-difluorobenzamide 16/I Cz9H22N206 494. 15 495. 3 / N \ I / o- C3 O O/ °'Y I CHg N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- naphthalenyl)-1, 3-benzodioxole4-carboxamide 17 C24H2oN204 400. 14 401. 2 1 /\NCH /o c3 O ° R CHs I CH3 N- (6- ( (6, 7-bis (methoxy) 4-quinolinyl) oxy)-2- naphthalenyl)-2-propenamide 18 I C3HZgNzO4 492. 20 493. 6 1 CH3/CH3 ri CH3 0 CH3 i H3 O O/ CHg I CH3 N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- naphthalenyl)-2, 4, 6-trimethylbenzamide 19 C28H2, N306 495. 14 496. 6 1 fT° N*o N ya /\ CH3 °jD ° O/ ON'- CHs N- (6- ( (6, 7-bis (methoxy) 4-quinolinyl) oxy)-2- na hthalen 1-4-nitrobenzamide 20 \ Cz7HZgN3O4 453. 17 454. 6 1 N N --run 0 O \ N N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- naphthalenyl)-1-methyl-1 H-pyrrole-2- carboxamide 21 C27H28N204 444. 20 445. 4 1 (nui+1) 0 o o/ o rr N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- naphthaleny1-3, 3-dimethylbutanamide 22 r C30H26N206 S 10. 18 511 1 i w N i o o I o O N N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- naphthalenyl)-2, 4-bis (methoxy) benzamide 23 C3oH26N206 510. 18 511 1 N i w N 0 °Y 0 N O N N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- naphthalenyl)-2, 6-bis (methoxy) benzamide 24 C29H23F2N205 499 1 F F \ \ I 0, 0 u O/ 0 \ N I N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- naphthalenyl)-5-fluoro-2-(methoxy) benzamide 25 C27H26N204 442. 19 443. 5 NYIZI (M+I) oo 0 N Y N O N N-(6-((6, 7-bis (methoxy) 4-quinolinyl) oxy)-2- naphthalenyl) cyclopentanecarboxamide 26 141 C29H2lN304 475. 15 476. 5 N (M+I) 0 0 W 0. O, N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- naphthalenyl)-3-cyanobenzamide 27 F C28H2oF2N204 486. 14 487. 2 i (M+1) N Y- ( : bF 0 1e O) ICN I N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- na hthalen 1-3, 5-difluorobenzamide 28 C28HIsF3N204 504. 13 505. 7 1 F (M+ 1) SoN) \/O F N 0 0 F N- (6- ( (6, 7-bis (methoxy) 4-quinolinyl) oxy)-2- naphthalenyl)-2, 4, 6-trifluorobenzamide 29 C2sHzoC) 2N204 518. 08 520. 1 Cil, (M+2) Natl Xi ON N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- naphthalenyl)-2, 6-dichlorobenzamide 30 C28H2oFzN204 486. 14 487. 5 N (M+1) fTT g 0 F o O \ N I N-(6-((6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- naphthalenyl)-2, 6-difluorobenzamide 31 C29H21F3N204 518. 15 519. 4 1 _7F (M+I) O, J :, F 0 F /O F 0 o 0 N N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- naphthalenyl)-3- (trifluoromethyl) benzamide 32 C28H20C, 2N204 518. 08 520. 5 gCl Ny, aC, oloa 0 o i o I o 0 \ N N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- naphthalenyl)-3, 4-dichlorobenzamide 33 n C29H30N204 470. 22 471. 6 / N (M+1) ouzo 0 t O N I N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- naphthaleny1-3-cyclopen lpropanamide 34 oNyC C26H24N204 428. 17 429. 5 1 (M+ 1) o \/o o 0 O \ N N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- naphthalenyl) cyclobutanecarboxamide 35 j C29H24N20s 480. 17 481. 5 1 i w Np (M+1) 0 06- O1 Yl I N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- naphthalenyl)-2- (phenyloxy) acetamide 36 C28H2oC, 2N204 518. 08 520. 3 1 I c 1 N CN ci old 'YY ON I N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- naphthalenyl)-2, 4-dichlorobenzamide 37 C27H22N204S 470. 13 471. 6 1 SNm (M+1) i o / I o o>4 ozon N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- naphthalenyl)-2- (2-thienyl) acetamide 38 C29H2oF4N204 536. 14 537. 5 1 YrYS " N F (M+l) f ? F O 0 \ N 0 N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- naphthalenyl)-2-fluoro-3- (trifluoromethyl) benzamide 39 C27H, 9C, 2N304 519. 08 521. 4 1 Cl (M+2) ri) N N i O CI I O O N I N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- naphthalenyl)-2, 5-dichloro-3- pyridinecarboxamide 40 n C28H20F2N204 486. 14 487. 5 1 Nyl : ?- F (M+I) O ° F O) cb, TvS i 0 N N-(6-((6, 7-bis (methoxy) 4-quinolinyl) oxy)-2- naphthalenyl)-2, 3-difluorobenzamide 41 C29H2, F3N20s 534. 14 535. 5 1 w N Q 0 F 00, F F 0 N Ozon i N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- naphthalenyl)-2- ( (trifluoromethyl) oxy) benzamide 42 C30H26N20s 494. 18 495. 6 1 Nyp (M+I) a o . o o, 0 N I N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- naphthalenyl)-2- (ethyloxy) benzamide 43 C27H23N304S 485. 14 486 1 N >I, N) + 1°> 0/ O N N-(6-((6, 7-bis (methoxy) 4-quinolinyl) oxy)-2- naphthalenyl)-2, 4-dimethyl-1, 3-thiazole-5- carboxamide Cz6HzN3aS 471. 13 472 1 N I N 0 10, X 1° N N- (6- ( (6, 7-bis (methoxy) 4-quinolinyl) oxy)-2- naphthalenyl)-2-methyl-1, 3-thiazole4- carboxamide 45 C2sHI7Cl2N304S 525. 03 527 1 N-S ru cl 01e p C1 0/ Ozon I N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- naphthalenyl)-4, 5-dichloro-3- isothiazolecarboxamide 46 0 C27H22N205S 486. 12 487 1 0 N0 s O I O O N I N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- naphthalenyl)-4- (methoxy)-3- thiophenecarboxamide 47 1 C28H23N304 465. 17 466 1 //N \ N \ I O ( 09 O) CCH I N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- naphthalenyl)-6-methyl-3-pyridinecarboxamide 48 < N C27H20C, N304 485. 11 487 i N CI (M+1) , O 0 N O N N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- naphthalenyl)-2-chloro-4-pyridinecarboxamide 49 ni C27H2, N304 451. 15 452 1 , S, N, N zu po O N N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- naphthalenyl)-3-pyridinecarboxamide 50 s C27H22N204S 470. 13 471 1 , S, N@ Sf zozo N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- naphthalenyl)-5-methyl-2-thiophenecarboxamide 51 C27H22N204S 470. 13 471. 4 1 N J , SNp3 N O N N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- naphthalenyl)-3-methyl-2-thiophenecarboxamide 52 C28H24N205S 500. 14 501 1 S , S N 3 '0 1 \ NJ N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- naphthalenyl)-3- (ethyloxy)-2- thiophenecarboxamide 53 C26H2ON205 440. 14 441 1 oU o zozo Nu ON N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- naphthalenyl)-2-furancarboxamide 54 fg C26H2oN204S 456. 11 457tu zon oloa 0 , O O N N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- naphthalenyl)-3-thiophenecarboxamide SS CZgHz3C, NZOS 514. 13 515. 2 1 ce 0 zu go4NJ 0 N O, O N I N-(6-((6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- naphthalenyl)-4-chloro-2- (methoxy) benzamide YTY) 0 O O I 0 gO4N I N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- naphthalenyl) 4-chloro-2-(methoxy) benzamide 57 C29H23CIN205 514. 13 515. 1 1 ci /) .. CO po I O O N I N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- naphthalenyl)-5-chloro-2- (methoxy) benzamide 58 ) C3, H3oN405 538. 22 539. 4 2 NY"4z)-N i O O I i ON 0 N N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- naphthalenyl)-2- ( (2- (dimethylamino) ethyl) oxy)- 3-pyridinecarboxamide 59 o o C28H22N204 450. 16 451 1 N 0 N IY - ON 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- phenyl-2-naphthalenecarboxamide 60 C27H22N205S 486. 12 487. 3 1 ou 04 0 ozon I ON N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- naphthalenyl) benzenesulfonamide 61 C28H23N305 481. 16 482. 1 1 N N OU 0"0 O, ON I N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- naphthalenyl)-2- (methoxy)-3- pyridinecarboxamide 62 C28H2oF2N204 486. 14 487. 3 1 F (M+1) N 0 0 F 0 O, O N N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- naphthalenyl)-2, 4-difluorobenzamide 63 C26H2oN204S 456. 11 457. 1 1 N , N 0 (A N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- naphthalenyl)-2-thiophenecarboxamide 64 N n C28H2, BrN204 528. 07 531. 2 1 , N w Br (M+3) ,, o zoo O N N- (6- ( (6, 7-bis (methoxy) 4-quinolinyl) oxy)-2- naphthalenyl)-3-bromobenzamide 65 C3oH26N204 478. 19 479. 2 1 i w w o i O N 0 N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- na hthalen 1-4-eth tbenzamide 66 C C28H28N204 456. 20 457. 4 1 , X1, N zu PO O N N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- naphthalenyl) cyclohexanecarboxamide 67 C28H2lFN204 468. 15 469. 2 1 F sN@ zu N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- na hthalen 1-4-fluorobenzamide 68 C29H24N205 480. 17 481. 6 1 N 0 (M+I) JUU A' 0 0 1. 10 O) aN N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- naphthalenyl)-3- (methoxy) benzamide 69 C27ff2lN304 451. 15 454. 2 1 0 ffi N 0 0 N Ozon I N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- naphthalenyl)-pyridin_arboxamíde 70 \ 22204 454. 16 455. 2 1 N N 0 0 u O) ICN O N I N- (6- ( (6, 7-bis (methoxy) 4-quinolinyl) oxy)-2- naphthalenyl)-1-methyl-1 H-imidazole-5- carboxamide 7 ! [Y C29H24N20 480. 17 481. 2 1 Nu g N M N Ozon I N- (6- ( (6, 7-bis (methoxy) 4-quinolinyl) oxy)-2- naphthalenyl) 4-(methoxy) benzamide 72 C29H24N204 464. 17 465. 7 1 erNt (M+l) ou YY o Ozon N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- naphthalenyl)-2-methylbenzamide 73 C28H21CIN204 484. 12 485. 3 1 r w N w 0 ci I o O N N-(6-((6, 7bis (methoxy) 4-quinolinyl) oxy)-2- naphthalenyl)-2-chlorobenzamide 74 N n C29H2, F3N204 518. 15 519. 4 1 N (M+l) 0) + own "dz ON I N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- naphthalenyl)-2-trifluoromethyl benzamide 75 C28H22N204 450. 16 451 r 0 0 so N N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- naphthalenyl) benzamide 76 C29H24N205 480. 17 481 1 Ny kt, oica 0 I O 0 O I N phenylmethyl 6- ( (6, 7-bis (methoxy)-4- quinolinyl oxy)-2-naphthalenylcarbamate 77 C29H24N204 464. 17 465 1 N o O i "0 O N N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- naphthalenyl)-2-phenylacetamide 78 C28H20CIFN204 502. 11 503 3 N yl 0 cri O I F O N N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-5- fluoro-2-naphthalenyl)-2-chlorobenzamide 79 WN45 C26HI9FN204S 474. 10 475 3 , 0 F oJ o 0, 10 0 N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-5- fluoro-2-naphthalenyl)-3-thiophenecarboxamide 80 C27H2, FN205S 504. 12 505 3 {mS N) 5 0t ° lof' w W O , 0wM F IN O N N- (6- ( (6, 7-bis (methoxy) 4-quinolinyl) oxy)-5- fluoro-2-naphthalenyl) 4-(methoxy)-3- thiophenecarboxamide 81 C29H22F2N205 516. 15 517 3 F //N \ O 0 , 0 F 0 I N 03 F N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-5- fluoro-2-naphthalenyl)-5-fluoro-2- (methoxy) benzamide 82 C29H23FN205 498. 16 499 3 1Nyp O O 0 I F 0e 0 Ou 0< F N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-5- fluoro-2-naphthalenyl)-2- (methoxy) benzamide 83 C27H20FN304 469. 14 470 3 1neo oY'o \ \ (O ol . o I NJ N- (6- ( (6, 7-bis (methoxy) 4-quinazolinyl) oxy)-5- fluoro-2-naphthalenyl) benzamide 84 ep C28H2, FN204 468. 15 469 3 NY-0 O OLF 0 0 N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-5- fluoro-2-naphthalenyl) benzamide 85 C28H, 9F3N204 504. 13 505 3 Nyq F oJW O F , o) F soUNd N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-5- fluoro-2-naphthalenyl)-2, 3-difluorobenzamide 86 SA C32H30FN30sS 587. 19 588. 2 9 N O F . over OU 0 N- (5-fluoro-6- ( (6- (methoxy)-7- ( (3- (4- morpholinyl) propyl) oxy)-4-quinolinyl) oxy)-2- naphthalenyl)-2-thiophenecarboxamide 87 C32H30FN30sS 587. 19 588 9 N-rl : S // YS i0 \ \ F 0,,) 0 N- (5-fluoro-6- ( (6- (methoxy)-7- ( (3- (4- morpholinyl) propyl) oxy)-4-quinolinyl) oxy)-2- naphthalenyl)-3-thiophenecarboxamide 88 C3oH25N305 507. 18 508 3 N 0 I 0 ZON I 3- (acetylamino)-N- (6- ( (6, 7-bis (methoxy)-4- quinolinyl) oxy)-2-naphthalenyl) benzamide 89 sH22FN3s 499. 15 500 3 //N \ N O/0 /O I \ \ F i 0 N N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-5- fluoro-2-naphthalenyl)-2- (methoxy)-3- pyridinecarboxamide 90 C32H3, N305S 569. 20 570 9 s r w o i o o S » Q SN+ 0>4 01"i oJ N- (6- ( (6- (methoxy)-7- ( (3- (4- morpholinyl) propyl) oxy)-4-quinolinyl) oxy)-2- naphthalenyl)-2-thiophenecarboxamide 91 « C27H2oFN304 469. 14 470 3 ici , N °33t i 0 N N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- naphthalenyl)-2-fluoro-3-pyridinecarboxamide 92 .. CNOs 495. 18 496 3 / N N 0 \/O'O 0 ro , O O N N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- naphthalenyl)-2- (ethyloxy)-3- pyridinecarboxamide 93 C3H23N304 501. 17 502 3 N o (o N 0 N 0 N6 J'k 0' N N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- naphthalenyl)-8-quinolinecarboxamide 94 n C29H24N206S 528. 14 529 3 / N \ O i Nya 1 0 °l I O N N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- naphthalenyl)-3- (methylsulfonyl) benzamide 95 C30H27N304 493. 20 494 3 /\ N nj O N I o 0 N N- (6- ( (6, 7-bis (methoxy) 4-quinolinyl) oxy)-2- naphthalenyl)-3- (dimethylamino) benzamide 96 C30H26N204 478. 19 479 fit"" zozo r X O Ou soX N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) methyl)-2- naphthalenyl)-2- (methoxy) benzamide 97 C29H24N203 448. 18 449 0 N i O \ N N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) methyl)-2- naphthalenyl) benzamide 98'IN, C27H22N203S 454. 14 455 0 0 N ° r 0 N N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) methyl)-2- naphthalenyl)-3-thiophenecarboxamide 99 o fh C29H24N204 464. 17 456 Zt*l N10 razz , out 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-5- methyl-N-phenyl-2-naphthalenecarboxamide 100 0 C3oH26N205 494. 18 495 N Ots/Ou /09 0 \ Ni' ON 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-5- methyl-N- (2- (methoxy) phenyl)-2- naphthalenecarboxamide 101 C3oH26N205 494. 18 495 , N)) 2 o i o NY-01 O4N 0 N- (6- ( (6, 7-bis (methoxy) 4-quinolinyl) oxy)-5- methyl-2-naphthalenyl)-4- (methoxy) benzamide 102 N204 464. 17 465 o N 0 0 oN) N ON N- ( (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- naphthalenyl) methyl) benzamide 103 C3oH26N205 494. 18 495 0 N 0 zon y \ NJ 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-5- methyl-N- (4- (methoxy) phenyl)-2- naphthalenecarboxamide 104 C30H29N304S 527. 19 528 S N N oX lolo W N- (6- ( (7- ( (3- (dimethylamino) propyl) oxy)-6- (methoxy)-4-quinolinyl) oxy)-2-naphthalenyl)-3- thiophenecarboxamide 105 C3oH2gFN304S 545. 18 546 S I oll 0 : 1, o I w w F Over N- (6- ( (7- ( (3- (dimethylamino) propyl) oxy)-6- (methoxy)-4-quinolinyl) oxy)-5-fluoro-2- naphthalenyl)-3-thiophenecarboxamide 106 C30H28FN304S 545. 18 546 s N 0 r0 I \ \ F NO N N- (6- ( (7- ( (3- (dimethylamino) propyl) oxy)-6- (methoxy)-4-quinolinyl) oxy)-5-fluoro-2- naphthalenyl)-2-thiophenecarboxamide 107 C32H31N30sS 569. 67 570 rr N Y-O/ YYS . o 0 0 N- (6- ( (6- (methoxy)-7- ( (3- (4- morpholinyl) propyl) oxy)-4-quinolinyl) oxy)-2- naphthalenyl)-3-thiophenecarboxamide 108 i I C33HgN3Oq 533. 23 534 gS Nf ç o, ca 0 N N N- (6- ( (6- (methoxy)-7- ( (2- ( 1- pyrrolidinyl) ethyl) oxy)-4-quinolinyl) oxy)-2- naphthalenyl) benzamide 109 C3, H29N304 507. 22 508 N YO Nt 0< /NO \ N N- (6- ( (7- ( (2- (dimethylamino) ethyl) oxy)-6- (methoxy) 4-quinolinyl) oxy)-2- naphthalenyl) benzamide Example 110 N N (Ethylamino)-N- {6- [6- methoxy-7- (3-morpholin-4- Oww ca0 ylpropoxy) (4-quinolyloxy) (2-naphthyl)} carboxamide r NO \ \NJ 0,,)

To a solution of 6- [6-methoxy-7- (3-morpholin-4-ylpropoxy)-4-quinolyloxy]-2-naphthylamine (prepared similar to that described in Example 1, Step c) (46.0 mg, 0. 1 mmol) in anhydrous DMF (5 mL, Aldrich) was added Et3N (50.5 mg, 0.5 mmol, Aldrich) and ethyl isocyanate (35.5 mg, 0.5 mmol, Aldrich) at RT. The reaction was stirred at RT for 16 h, then was quenched with saturated aqueous solution of NaHC03 (20 mL) and extracted with EtOAc (2 x 30 mL). The combined organic extracts were dried over MgS04, filtered and concentrated in vacuo. The residue was purified by column chromatography (FPNH- 25S, Biotage, EtOAc) to give the title compound as white solid. MS (ESI, pos. ion) m/z : 531.3 (M+l) ; 529.3 (M-1). Calc'd for C30H33N405-530. 25. Example 111 H H (Ethylamino)-N-{5-fluoro-6- [6-methoxy-7- (3-morphoGn- r 0 4-ylpropoxy) (4-quinolyloxy) (2-naphthyl)} carboxamide F \ NAO+N 0,, J 0

5-Fluoro-6- [6-methoxy-7- (3-morpholin-4-ylpropoxy) (4-quinolyloxy)]-2-naphthylamine (Example 9, Step b, 47.7 mg, 0.1 mmol) was reacted with Et3N (55 mg, 0.5 mmol, Aldrich) and ethylisocyanate (35.5 mg, 0.5 mmol, Aldrich) under the conditions of Example 110 to give the title compound as a white solid. M. p. 193.5-196. 4 °C. MS (ESI, pos. ion) m/z : 549.6 (M+1), 547.4 (M-1). Calc'd for C3pH33F45- 548.24.

Example 112 was prepared similar to the procedure described in either Example 110. SzNbzN/ li, I o \/o ON 0 N Ex. 112) | N-(6-((6, 7-bis (methoxy)-4- quinolinyl) oxy)-2-naphthalenyl)-N'- (1-methylethyl) urea ; Mass calc'd for C2sH2sN3o4-431. 18. Example 113 H H N- [6- (6, 7-Dimethoxy (4- quinolyloxy)) (2-naphthyl)] 0< 0 tNs [(1-methyl (4-piperidyl)) amino] carboxamide sO4N JJ To a solution of 6- (6, 7-dimethoxy-4-quinolyloxy)-2-naphthylamine (Example 1, Step c, 52 mg, 0.15 mmol) in anhydrous DMF (5 mL, Aldrich) was added Et3N (30.3 mg, 0. 3 mmol, Aldrich) and N, N'- disuccunimidyl carbonate (46 mg, 0.18 mmol, Aldrich) at RT. After the reaction was stirred at RT for 16 h, it was treated with 1-methyl-4-piperidylamine (20.5 mg, 0.18 mmol, Aldrich) and stirred at RT for 16 h. The reaction was quenched with saturated aqueous solution of NaHC03 (20 mL) and extracted with EtOAc (2 x 30 mL). The combined organic extracts were dried over MgS04, filtered and concentrated in vacuo. The residue was purified by column chromatography (silica gel, EtOAc) to give the title compound as a white solid. MS (ESI, pos. ion) m/z : 487.5 (M+1) ; 485.5 (M-1). Calc'd for C28H3oN404- 486.23. Example 114 H Example 114 n H 6- (6, 7-Dimethoxy-quinoMn-4- yloxy)-naphthalene-1-carboxylic acid (4-chloro-phenyl)-amide CI °Y ! I u ( Ozon Step (a) Preparation of 6-Hydroxy-naphthalene-l-carboxylic acid (4-chloro-phenyl)-amide.

A slurry of 6-hydroxy-naphthalene-1-carboxylic acid (0.2 g, 1.06 mmol) in 10.6 mL of SOC12 and 1 drop of DMF was heated to 40 °C. After 4 h, the solution was concentrated to dryness and placed under high vacuum overnight. The crude residue was dissolved in 3.5 mL of CH2CI2. To the resulting solution was added DIEA (0.554 mL, 3.18 mmol), 4-chlorophenylamine (0.162 g, 1.27 mmol) and a catalytic amount of DMAP. The reaction was stirred under an argon atmosphere for 2 days. The reaction was

diluted with CH2CI2, washed with saturated aqueous NH4CI, saturated aqueous NaHC03, and brine. The organic layer was dried (Na2SO4), filtered and concentrated. The residue was passed through a medium- pressure silica gel column (solvent gradient: 94: 6 CH2CI2 : MeOH ; 95: 5 CH2CI2 : MeOH ; 90: 10 CH2CI2 : MeOH) to afford the desired crude compound. The fractions were concentrated to dryness to afford a solid residue. The residue was triturated with CHC13 to afford the desired compound as a pale yellow solid.

Step (b) 6-(6, 7-Dimethoxy-quinolin-4-yloxy)-naphthalene-1-carboxylic acid (4-chloro-phenyl)-amide The 6-hydroxy-naphthalene-1-carboxylic acid (4-chlorophenyl) -amide (Step a, 0.076 g, 0.254 mmol), Cs2C03 (0.248 g, 0.762 mmol), 4-chloro-6,7-dimethoxy-quinoline (0.114 g, 0.508 mmol) and DMF (0.250 mL) were combined in a screw-cap test tube under N2. The tube was sealed and heated to 100 °C. After 60 h at 100 °C, the reaction was cooled to RT. The solvent was removed in vacuo, dissolved in EtOAc and washed with saturated aqueous NaHCO3 and brine. The organic layer was dried (Na2SO4), filtered and concentrated. The residue remaining after concentration was dissolved in MeOH and purified by reverse-phase HPLC (pH 10 buffer solvent system). The fractions containing the desired product were concentrated, dissolved in EtOAc, and washed with brine. The organic layer was dried (Na2SO4), filtered and concentrated to afford the title compound as a tan solid. M+H-485.1. Calc'd for C28H3 N204-484. 12.

The following Examples were prepared similar to the procedures described in Example 114. Example Structure & Name Mol Formula Mass M+H No. 115 29304 518. 15 517. 0 O N (M-H) 1° CF3 fizz O oNJ 6- (6, 7-dimethoxy-quinolin-4-yloxy)-naphthalene- 1-carbox lix acid (4-trifluoromethyl-phenyl)-amide 116 C29H2, F3N204 518. 15 519. 0 H CF3 w w zizi I O ozon 1 6- (6, 7-dimethoxy-quinolin-4-yloxy)-naphthalene- 1-carboxylix acid (3-trifluoromethyl-phenyl)-amide 117 C29H20CIF3N204 552. 11 553. 0 H 91 CF3 kll cri JAZZ \ \ o NJ 6-(6, 7-dimethoxy-quinolin-4-yloxy)-naphthalene- 1-carboxylix acid (4-chloro-3-trifluoromethyl- phenyl)-amide 118 C32H3oN204 506. 22 507. 1 H O N/ o 0 I o NJ 6- (6, 7-dimethoxy-quinolin-4-yloxy)-naphthalene- 1-carboxylix acid (4-tert-butyl-phenyl)-amide Example 119 H 6-(6, 7-Dimethoxy-quinolin-4- yloxy)-naphthalene-l-carboxylic acid (4-chloro-phenyl)-amide CI 0e I I I O N

Step (a) Preparation of 6-(6, 7-Dimethoxy-quinolin-4-yloxy)-naphthalene-1-carboxylic acid hydrochloride A slurry of 6-hydroxy-naphthalene-1-carboxylic acid (0.100 g, 0.531 mmol), 4-chloro-6,7- dimethoxy-quinoline (0.143 g, 0.638 mmol) and Cs2C03 (0.519 g, 1.59 mmol) in 2.66 mL of DMSO under argon was stirred for 15 min at RT. The mixture was heated to 140 °C in a microwave. After 1 h, the reaction was diluted with ca. 2.7 mL of water. 6N HC1 was added dropwise until the solution was at pH 3-4. The resulting precipitate was filtered and washed with acetone to afford the titled compound as a tan solid.

Step (b) 6-(6, 7-Dimethoxy-quinolin-4-yloxy)-naphthalene-1-carboxylic acid (4-chloro-phenyl)-amide A slurry of 6- (6, 7-dimethoxy-quinolin-4-yloxy)-naphthalene-1-carboxylic acid hydrochloride (0.200 g, 0.532 mmol, step a), HATU (0.264 g, 0.692 mmol), and Et3N (0.296 mL, 2.12 mmol) in 1. 33 mL of DMF under argon was stirred at RT. After 1 h, 4-hydroxyaniline (0.116 g, 1.064 mmol) was added.

The solution was stirred at RT for 0.5 h then at 50 °C. After 2 h, the reaction was diluted with EtOAc and washed with saturated aqueous NaHC03, water, and brine. The organic layer was dried (Na2SO4), filtered and concentrated. The residue remaining after concentration was dissolved in acetone and purified by reverse-phase HPLC (pH 1 CH3CN/water solvent system). The fractions containing the desired product were concentrated, dissolved in CH2CI2, and washed with saturated aqueous NaHC03 and brine. The organic layer was dried (Na2SO4), filtered and concentrated to afford the titled compound as a pale yellow solid. M+H-467.1. Calc'd for C28H22N205-466. 49. Example 120 N- [6- (6, 7-Dimethoxy-quinolin-4- i F yloxy)-naphthalen-1-yll-2-fluoro- benzamide HN O O Meo Me0 N Step (a) Preparation of 6- (6, 7-Dimethoxy-quinolin-4-yloxy)-naphthalen-1-ylamine To a solution of 5-amino-2-naphthol (711 mg, 4.47 mmol) in NMP (3 ml), Cs2CO3 (4.37 g, 13.41 mmol) was added and the reaction was stirred at RT for 15 min. To the mixture, 4-chloro-6,7-dimethoxy- quinoline (500 mg, 2.23 mmol) was added and the vessel was sealed/clamped shut. The reaction was placed in the microwave and heated at 160 °C for 15 min, then 10 additional min with pre-stirring for 60 sec. The mixture was taken up into water and CH2C12, and filtered through Celite. The aqueous layer was extracted with CH2CI2. The combined organic layers were washed with water, IN NaOH, and brine, dried with Na2SO4, filtered and concentrated in vacuo. The 6- (6, 7-dimethoxy-quinolin-4-yloxy)-naphthalen-l- ylamine was purified by column chromatography using 0-10% MeOH in CH2CIz.

Step (b) Preparation of N-l6-(6, 7-dimethoxy-quinolin-4-yloxy)-naphthalen-1-yl]-2-fluoro-benz amide To a solution of 6-(6,7-dimethoxy-quinolin-4-yloxy)-naphthalen-1-ylamine (Step a, 50 mg, 0.14 mmol) and NaHC03 (38 mg, . 45 mmol) in CH2CI2 (1 mL), 2-fluorobenzoyl chloride (18 mL, 0.15 mmol) was added. The reaction was stirred at RT for 20 h. The mixture was taken up into CHC13 and water, washed with brine, dried with Na2SO4, filtered and concentrated in vacuo. The title compound was purified by column chromatography using 0-100% of a 90: 10: 1 (CH2CI2 : MeOH : NH40H) solution as the eluant. M+H 469.1, Calc'd for C28H21FN2O4-468. 49.

The following compounds were prepared similarly to the procedure outlined above: Example Structure & Name Mol Mass M+H Formula No. 121 ci C28H2, CIN204 484. 94 485. 1 NO HAN / o i Me0 ( Me0 NJ N-[6-(6, 7-Dimethoxy-quinolin4-yloxy)-naphthalen- 1-1-4-chloro-benzamide 122 2 C28H2lClN204 484. 12 485. 1 CI NO HN O \ I/ Mye0 I Met N-[6-(6, 7-dimethoxy-quinolin4-yloxy)-naphthalen- 1-yl]-2-fluoro-benzamide Example 123 N- (6- [7- (2-Dimethylamino- W ethoxy)-6-methoxy-quinolin- 4-yloxy]-naphthalen-1-yl}- HN ° benzamide fizz u 1--lo , N oX

Step (a) N- (6-Hydroxy-naphthalen-1-yl)-benzamide To a round bottom flask containing 1.00 g (6.3 mmol) 5-amino-naphthalene-2-ol in 10 mL CHzCl2, was added 2.61 g (0. 0189 mmol) K2CO3, followed by 1.46 mL (0. 0126 mmol) benzolyl chloride.

The solution mixture was stirred under inert atmosphere until completion. After stirring for 18 h, water was added into the mixture and diluted with CH2CI2. The organics were separated by sep. funnel, while extracting the organics 3X with CH2C12. The organic layers were combined, dried over Na2SO4, filtered and concentrated in-vacuo. The crude was purified by crystallization in CH2CI2/Hexanes. A gray colored powder was collected, which was titled compound. MS (ESI pos. ion) m/z : 264 (M+H) Step (b) N- {6- [7- (2-Dimethylamino-ethoxy)-6-methoxy-quinolin-4-yloxy]-naphtha len-1-yl}- benzamide To a microwaveable vial containing 0. 300 g (1. 1 mmol) of N- (6-hydroxy-naphthalen-1-yl)- benzamide in 1.5 mL DMF and 1.5 mL pyridine, was added 0.771 g (2.8 mmol) of [2- (4-chloro-6- methoxy-quinolin-7-yloxy) -ethyl] -dimethylamine. Then added (5 mmol %) copper grind into the mixture, along with 0. 158 g (2.5 mmol) KOH pellets. The vial was heated in a microwave for 18 min at 120 °C (60 Watts constant power, CEM powermax). The mixture was diluted with CH2CI2 and water, then transferred to seperatory funnel. The organics were extracted 3X with CH2C12. The organic layers were combined, dried over Na2SO4, filtered, and concentrated in-vacuo. The crude was purified by reverse-phase HPLC. A tan oil was collected, which was titled product. MS (ESI pos. ion) m/z : 508 (M+H). Calc'd for C31H29N3O4-507. 22. Example 124 N-16- [6-Methoxy-7- (2- pyrrolidin-1-yl-ethoxy)- w quinolin-4-y naphthalen-1-yl}- HAN 0 benzamide O ON ri O N

To a microwaveable vial containing 0.300 g (0.0011 mmol) of N- (6-hydroxy-naphthalen-1-yl)- benzamide in 1.5 mL DMF and 1.5 mL pyridine, was added 0.858 g (0.0028 mmol) of 4-chloro-6- methoxy-7- (2-pyrolidin-1-yl-ethoxy)-quinoline. Copper grind was added (5 mmol %) to the mixture, along with 0. 158 g (0.0025 mmol) KOH pellets. The vial was heated in a microwave for 18 min at 120 °C, (60 Watts of constant power, powermax, CEM). The mixture was diluted with CH2CI2 and water, then transferred to a seperatory funnel. The organics were extracted 3X with CH2CI2. Then combined all organics, dried over Na2SO4, filtered, and concentrated in-vacuo. The crude was purified by reverse- phase HPLC. A tan oil was collected, which was the titled product. MS (ESI pos. ion) m/z : 534 (M+H).

Calc'd for C33H3, N304-533. 23.

The following Example was prepared similar to the procedures described in either Example 123 or 124. N 0 N O /0/ 125) oOX N-(6-((6, 7-bis (methoxy) 4-quinolinyl) oxy)-1-

naphthalenyl) benzamide Mass Calc'd for C28H22N204-450. 16.

Other compounds included in this invention are set forth in Tables 1-2 below.

Table 1

&num R1 126. pyridin-4-yl 127.4-pyrimidinyl 128. quinazolin-4-yl 129.6, 7-dimethoxyquinazolin-4-yl Table 2

Table 2 cont.

The following Examples were prepared similar to the procedures described in either Example 114 or Example 123. Example Structure & Name Mol Formula Mass No. 140 l C28H22N204 450 50 v moo O mye0 w Mu0 6-(6, 7-Dimethoxy-quinolin-4-yloxy)-naphthalene-1-carboxylic acid phenylamide v 141 l C29H24N204 464. 53 9 zizi mye0 Me0 6-(6, 7-Dimethoxy-quinolin-4-yloxy)-naphthalene-1-carboxylic acid p-tolylamide 142 C2sH2, FN2Oq 468. 49 F ON O nu moto MOTO N N Me0 6-(6, 7-Dimethoxy-quinolin-4-yloxy)-naphthalene-1-carboxylic acid (4-fluoro-phenyl)-amide 143 Br C28H2, BrN204 529. 39 Br 0 NH 0 MENU O Me0 Me0 6- (6, 7-Dimethoxy-quinolin-4-yloxy)-naphthalene-I-carboxylic acid (4-bromo-phenyl)-amide 144 C29H2lF3N205 534. 50 F OF ON 0 NH O NH O ONH e N eo 6-(6, 7-Dimethoxy-quinolin4-yloxy)-naphthalene-1-carboxylic acid (4-trifluoromethoxyphenyl)-amide 145 C30H23N304S 521. 60 N 0 NU / O NH O XN N Me0 6-(6, 7-Dimethoxy-quinolin-4-yloxy)-naphthalene-1-carboxylic acid (2-methyl-benzothiazol-5-yl)-amide 146 Cz9H2, N305 497. 56 p N O NH M OX MeO Mu0 Me0 6-(6, 7-Dimethoxy-quinolin-4-yloxy)-naphthalene-1-carboxylic acid (5-tert-butyl-isoxazol-3-yl)-amide 147 C29H28N404 496. 57 han HN/ 0 NH met Mu0 moo N 6-(6, 7-Dimethoxy-quinolin-4-yloxy)-naphthalene-1-carboxylic acid (5-tert-butyl-2H-pyrazol-3-yl)-amide 148 C27H24F3N ; 02 507. 52 OFF F Fy HO O O N H IN z 6-(2-Amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid (2-piperidin-1-yl-5-trifluoromethyl-phenyl)-amide 149 C28H26F3N502 521. 55 OFF INS F N HN HN>jO 0 NU HAN N lu heinz HNNr 6-(2-Methylamino-pyrimidin4-yloxy)-naphthalene-1- carboxylic acid (2-piperidin-1-yl-5-trifluoromethyl-phenyl)- amide 150 C28H29F3N602 538. 58 F fi / F Han 0 Ok N lu H2N N 6-(2-Amino-pyrimidin4-yloxy)-naphthalene-1-carboxylic acid (2- [ (3-dimethylamino-propyl)-methyl-amino]-5- trifluoromethyl-phenyl}-amide 151 C29H3, F3N602 552. 60 F F F NAN N O t \ \ N N H H 6-(2-Methylamino-pyrimidin-4-yloxy)-naphthalene-1- carboxylic acid {2- [ (3-dimethylamino-propyl)-methyl-amino]- 5-trifluoromethyl-phenyl}-amide 152 C28H27F3N602 536. 56 FF F N Zon ho O N N O H2N N 6-(2-Amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid [2- (3-dimethylamino-pyrrolidin-1-yl)-5-trifluoromethyl- hen 1-amide 153 C29H29F3N602 550. 59 FI IF N N HN 0 0 N NIN'- H H H 6-(2-Methylamino-pyrimidin-4-yloxy)-naphthalene-1- carboxylic acid [2- (3-dimethylamino-pyrrolidin-1-yl)-5- trifluoromethyl-phenyl]-amide 154 C28H27F3N602 536. 56 OFF IF a N zu NU N H N N 6- (2-Amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid {2-[methyl-(1-methyl-pyrrolidin-3-yl)-amino]-5- trifluoromethyl-phenyl}-amide 155 \ F F C29H29F3N602 550. 59 IF N \ (NO o r N,, +F NU HN N 6-(2-Methylamino-pyrimidin4-yloxy)-naphthalene-1- carboxylic acid {2- [methyl- (I-methyl-pyrrolidin-3-yl)-amino]- 5-trifluoromethyl-phenyl}-amide 156 C24H, 7N302 379. 42 RIZ NMP N N N N H 6- (1 H-Pyrrolo [2, 3-b] pyridin-4-yloxy)-naphthalene-1- carboxylic acid phenylamide 157 C24Hl6FN302 397. 41 F O NH 0 N N H 6- (1 H-Pyrrolo [2, 3-b] pyridin4-yloxy)-naphthalene-1- carboxylic acid (4-fluoro-phenyl)-amide 158 CI C24H, 6C1N302 413. 87 OH 9 N N H 6- (1 H-Pyrrolo [2, 3-b] pyridin4-yloxy)-naphthalene-1- carboxylic acid (4-chloro-phenyl)-amide 159 Br C24HI6BrN302 458. 32 O NH p3 o i r N N H 6- (1 H-Pyrrolo [2, 3-b] pyridin-4-yloxy)-naphthalene-1- carboxylic acid (4-bromo-phenyl)-amide 160 C25H, 9N302 393. 45 OH 0 N N H 6- (1 H-Pyrrolo [2, 3-b] pyridin-4-yloxy)-naphthalene-1- carboxylic acid p-tolylamide 161 i FF C25H, 6F3N302 447. 42 F 0 nu O nu N N o N N H 6- (1 H-Pyrrolo [2, 3-b] pyridin4-yloxy)-naphthalene-1- carboxylic acid (4-trifluoromethyl-phenyl)-amide 162 CZSH, 6F3N303 463. 42 zu ON FIVS H N N NaN 6- (1 H-Pyrrolo [2, 3-b] pyridin-4-yloxy)-naphthalene-1- carboxylic acid (4-trifluoromethoxy-phenyl)-amide 163 CZSH, 6F3N30z 447. 42 Y O NH N N Y N N H 6- (1 H-Pyrrolo [2, 3-b] pyridin4-yloxy)-naphthalene-1- carboxylic acid (3-trifluoromethyl-phenyl)-amide 164 C26H, 8N402S 450. 52 N N ¢ (N NaN Na nu H 6- (1 H-Pyrrolo [2, 3-b] pyridin-4-yloxy)-naphthalene-1- carboxylic acid (2-methyl-benzothiazol-5-yl)-amide 165 CzsH23NsO2 425. 49 N- HN 0 NH ON zu NU N 6- (1 H-Pyrrolo [2, 3-b] pyridin4-yloxy)-naphthalene-1- carboxylic acid (5-tert-butyl-2H-pyrazol-3-1-amide 166 C25H22N403 426. 48 p N OH 0 c N ? H 6- (1 H-Pyrrolo [2, 3-b] pyridin4-yloxy)-naphthalene-1- carboxylic acid (5-tert-butyl-isoxazol-3-yl)-amide 167 C23H, 6N402 380. 41 OH 0 Zut N N H 6- (1 H-Pyrazolo [3, 4-b] pyridin4-yloxy)-naphthalene-1- carboxylic acid phenylamide 168 F NH C23H, 5FN02 398. 40 ON zers N N , N N H 6- (1 H-Pyrazolo [3, 4-b] pyridin-4-yloxy)-naphthalene-1- carboxylic acid (4-fluoro-phenyl)-amide 169 1ß1 C23HlsClN402 414. 85 O NU 0 N H H 6- (1 H-Pyrazolo [3, 4-b] pyridin4-yloxy)-naphthalene-1- carboxylic acid (4-chloro-phenyl)-amide 170 Br C23H, sBrN402 459. 31 RNH O NH zu zu , N N H 6- H-Pyrazolo [3, 4-b] pyridin-4-yloxy)-naphthalene-1- carboxylic acid (4-bromo-phenyl)-amide 171 Cz4H, sN402 394. 44 9 N Ilk N NAN N N 6- (1 H-Pyrazolo [3, 4-b] pyridin-4-yloxy)-naphthalene-I- carboxylic acid p-tolylamide 172 C24HlsF3N402 448. 41 r' O NH N N N N H 6- (I H-Pyrazolo [3, 4-b] pyridin-4-yloxy)-naphthalene-1- carboxylic acid (4-trifluoromethyl-phenyl)-amide 173 C24Hl5F3N403 464. 41 0'cl3 ON O nu 1 H'' 'J H 6- (1 H-Pyrazolo [3, 4-b] pyridin4-yloxy)-naphthalene-1- carboxylic acid (4-trifluoromethoxy-phenyl)-amide 174 C24HsF3N402 448. 41 fez ON 0 NH NJ , N N N N 6- (1 H-Pyrazolo [3, 4-b] pyridin4-yloxy)-naphthalene-1- carboxylic acid (3-trifluorometh l-nhen l4-amide v x Y r Y Z 175 7N : 02S 451. 51 N ON O nu N N N N Nr H 6- (1 H-Pyrazolo [3, 4-b] pyridin4-yloxy)-naphthalene-1- carboxylic acid (2-methyl-benzothiazol-5-yl)-amide 176 C24H22N602 426. 48 HN O NH ifs Zu , N N.. 'J H 6- (1 H-Pyrazolo [3, 4-b] pyridin4-yloxy)-naphthalene-1- carboxylic acid (5-tert-butyl-2H-pyrazol-3-yl)-amide 177 C24H2lN503 427. 47 , 0d N ON non Non , N N, H 6- (1 H-Pyrazolo [3, 4-b] pyridin4-yloxy)-naphthalene-1- carboxylic acid (5-tert-butyl-isoxazol-3-yl)-amide 178 C24Hl9N303 397. 44 Y 0 NH \ I N' NH 4- [5- (4-Fluoro-phenylcarbamoyl)-naphthalen-2-yloxy]- pyridine-2-carboxylic acid methylamide 179 F c24HIgFN303 415. 43 ON 0 ZU NH , NH 4- [5- (4-Fluoro-phenylcarbamoyl)-naphthalen-2-yloxy]- pyridine-2-carboxylic acid methylamide 180 C24H, sC ! N303 431. 88 ci ON Cl lo-INH 4- [5- (4-Chloro-phenylcarbamoyl)-naphthalen-2-yloxy]- pyridine-2-carboxylic acid methylamide 181 C24H, jiBrN303 476. 33 Br ON O nu NH N NH 4- [5- (4-Bromo-phenylcarbamoyl)-naphthalen-2-yloxy]- pyridine-2-carboxylic acid methylamide 182 ! C25HN303 411. 46 ON 0 Ol'-6N O N , NH 4- (5-p-Tolylcarbamoyl-naphthalen-2-yloxy)-pyridine-2- carboxylic acid methylamide toq _ 183 C25Hl8F3N303 465. 44 F F F 1¢ OH 0 O I N NH 4- [5- (4-Trifluoromethyl-phenylcarbamoyl)-naphthalen-2- yloxy]-pyridine-2-carboxylic acid methylamide 184 O4F C2sHl8F3N304 481. 44 F ON F 0 NH Q o , NH 4- [5- (4-Trifluoromethoxy-phenylcarbamoyl)-naphthalen-2- yloxy]-pyridine-2-carboxylic acid methylamide 185 C25HisF3N303 465. 44 F ON zu 0 RNH .-"NH NH 4- [5- (3-Trifluoromethyl-phenylcarbamoyl)-naphthalen-2- yloxy]-pyridine-2-carboxylic acid methylamide 186 C26H2ON403S 468. 54 N ON O NH QN ZINC , NH 4- [5- (2-Methyl-benzothiazol-5-ylcarbamoyl)-naphthalen-2- yloxy]-pyridine-2-carboxylic acid methylamide 187 \ C25HNs03 443. 51 HN HN/ O NH 0 .."NH , NH 4- [5- (5-tert-Butyl-2H-pyrazol-3-ylcarbamoyl)-naphthalen-2- yloxy]-pyndine-2-carboxylic acid methylamide 188 C25H24N404 444. 49 0 N O NH 0 NH RNH 4- [5- (5-tert-Butyl-isoxazol-3-ylcarbamoyl)-naphthalen-2- yloxy]-pyridine-2-carboxylic acid methylamide 189 C24Hl9N303 397. 44 HN N NH \ I N- NH 4- (5-Benzoylamino-naphthalen-2-yloxy)-pyridine-2-carboxylic acid methylamide 190 C24H, BFN303 415. 43 F han 0 NO I. ENH o r O I N NH 4- [5- (4-Fluoro-benzoylamino)-naphthalen-2-yloxy]-pyridine-2- carboxylic acid methylamide 191 C24Hl8CIN303 431. 88 ci HN 0 O Cl I N NH 4- [5- (4-Chloro-benzoylamino)-naphthalen-2-yloxy]-pyridine-2- carboxylic acid methylamide 192 C24H,, BrN303 476. 33 Br Han 0 0 N NH , NH 4- [5- (4-Bromo-benzoylamino)-naphthalen-2-yloxy]-pyridine-2- carboxylic acid methylamide 193 CZSHz, N303 411. 46 Han 0 NO O I-INH NH 4- [5- (4-Methyl-benzoylamino)-naphthalen-2-yloxy]-pyridine- 2-carboxylic acid methylamide 194 C25Hl8F3N303 465. 44 F F F NO NO O C NH 4- [5- (4-Trifluoromethyl-benzoylamino)-naphthalen-2-yloxy]- pyridine-2-carboxylic acid methylamide 195 C25Hl8F3N304 481. 44 F OUF zu HN 0 \ i r O N , NH 4- [5- (4-Trifluoromethoxy-benzoylamino)-naphthalen-2-yloxy]- pyridine-2-carboxylic acid methylamide 196 C2sH, sF3N303 465. 44 F F GOOF zu Zu // .."INH NH 4- [5- (3-Trifluoromethyl-benzoylamino)-naphthalen-2-yloxy]- pyridine-2-carboxylic acid methylamide 197 C24H, 7N302 379. 42 NO NAN N N H N-[6-(1 H-Pyrrolo [2, 3-b] pyridin-4-yloxy)-naphthalen-1-yl]- benzamide 198 C24Ht6FN302 397. 41 F Han-0 NEZ H o i r N N H 4-Fluoro-N- [6- (1 H-pyrrolo [2, 3-b] pyridin-4-yloxy)-naphthalen- 1-1-benzamide 199 C24H, 6CIN302 413. 87 ci HN-0 NON NEZ H" N N H 4-Chloro-N- [6- (1 H-pyrrolo [2, 3-b] pyridin-4-yloxy)-naphthalen- 1-yl]-benzamide 200 Br CMH, 6BrN302 458. 32 NO NON H H 4-bromo-N-[6-(1 H-pyrrolo [2, 3-b] pyridin-4-yloxy)-naphthalen- 1-1-benzamide 201 C2sHlgN302 393. 45 9 N N // N N H 4-methyl-N- [6- ( 1 H-pyrrolo [2, 3-b] pyridin-4-yloxy)-naphthalen- 1-1-benzamide 202 FyFF C2sHI6F3N302 447. 42 F NO NON c N"N H 4-trifluoromethyl-N-[6-(1 H-pyrrolo [2, 3-b] pyridin-4-yloxy)- naDhthalen-I-vll-benzamide 203 F C2sH, 6F3N303 463. 42 O-F F F HN ; O NAN H H 4-trifluoromethoxy-N-[6-(1 H-pyrrolo [2, 3-b] pyridin-4-yloxy)- naphthalen-1-y !]-benzamide 204 F C2sHl6F3N302 447. 42 F NO rF Ho O N N NJ H 3-trifluoromethyl-N-[6-(1 H-pyrrolo [2, 3-b] pyridin-4-yloxy)- naphthalen-I-yl]-benzamide 205 gJ C23H 6N402 380. 41 NO Han 0 , 'N N N N- [6- (IH-Pyrazolo [3, 4-b] pyridin-4-yloxy)-naphthalen-1-yl]- benzamide 06F C23H, sFN402 398. 40 Han 0 zu N H'' N N H 4-Fluoro-N- [6- (l H-pyrazolo [3, 4-b] pyridin-4-yloxy)- naphthalen-1-yl]-benzarnide 207 Cl C23HlsCIN402 414. 85 NO N O , N Nr N H 4-chloro-N-[6-(1 H-pyrazolo [3, 4-b] pyridin-4-yloxy)- naphthalen-1-yl]-benzamide 208 Br C23Hl5BrN402 459. 31 NO N N H J H 4-bromo-N- [6- ( 1 H-pyrazolo [3, 4-b] pyridin-4-yloxy)- naphthalen-I-yl]-benzamide 209 C24H, 8N402 394. 44 NO Ho O g N N H 4-methyl-N-[6-(1 H-pyrazolo [3, 4-b] pyridin-4-yloxy)- naphthalen-1-l]-benzamide 210 F F C24H, sF3N402 448. 41 F Han-0 ho O I t , N N H 4-trifluoromethyl-N-[6-(1 H-pyrazolo [3, 4-b] pyridin-4-yloxy)- naphthalen-I-yl]-benzamide 211 F C24H, sF3N403 464. 41 0-- F NO 0 i r po HAN N. v N N' H 4-trifluoromethoxy-N-[6-(1 H-pyrazolo [3, 4-b] pyridin4-yloxy)- naphthalen-1-yl]-benzamide 212 F C24HsF3N402 448. 41 F (F WJ F N zu H H 3-trifluoromethyl-N-[6-(1 H-pyrazolo [3, 4-b] pyridin-4-yloxy)- naphthalen-1-yl]-benzamide 213 C28H22N204 450 50 NO HO O \ I O I N N- [6- (6, 7-Dimethoxy-quinolin-4-yloxy)-naphthalen-1-yl]- benzamide 214 C28H21FN204 468. 49 F HN-0 HO O / I O I N N- [6- (6, 7-Dimethoxy-quinolin-4-yloxy)-naphthalen-1-yl]-4- fluoro-benzamide 215 ci C28H2, CIN204 484. 94 NO ho O °YY 4 p I N N- [6- (6, 7-Dimethoxy-quinolin-4-yloxy)-naphthalen-1-yl]-4- chloro-benzamide 216 C28H2, BrN204 529. 39 Br NO 0 O O o W N-[6-(6, 7-Dimethoxy-quinolin-4-yloxy)-naphthalen-1-yl] 4- bromo-benzamide 217 C29H24N204 464. 53 po han Ho O O I I o i N-[6-(6, 7-Dimethoxy-quinolin4-yloxy)-naphthalen-1-yl] 4- methyl-benzamide 218 F F C29H2, F3N204 518. 50 F F F NO ho O Han 0 I O o u N- [6- (6, 7-Dimethoxy-quinolin-4-yloxy)-naphthalen-1-yl]-4- trifluoromethyl-benzamide 219 C29H2lF3N20s 534. 50 F OF NO HN 0 oyez O zon N-[6-(6, 7-Dimethoxy-quinolin4-yloxy)-naphthalen-1-yl] 4- trifluoromethoxy-benzamide 220 Cz9H2) F3N204 518. 50 F NO I F HN 0 ho O // O O N N- [6- (6, 7-Dimethoxy-quinolin-4-yloxy)-naphthalen-1-yl]-3- trifluoromethyl-benzamide 221 C22H) sN402 370. 41 NO N NIEZ NN N- [6- (2-Methylamino-pyrimidin-4-yloxy)-naphthalen-1-yl]- benzamide 222 CZZH"FN402 388. 40 F Han-0 NINE Nez NN 4-Fluoro-N- [6- (2-methylamino-pyrimidin-4-yloxy)-naphthalen- I-yl]-benzamide 223 C) C22H, 7CIN402 404. 86 I N Nt NIN : NJ 4-chloro-N- [6- (2-methylamino-pyrimidin-4-yloxy)-naphthalen- 1-yl]-benzamide 224 Br C22HnBrN402 449. 31 NO NIEZ NAN 4-bromo-N-[6-(2-methylamino-pyrimidin4-yloxy)-naphthalen- 1-1-benzamide 225 C23H2oN402 384. 44 NO ho O N w 4-methyl-N- [6- (2-methylamino-pyrimidin-4-yloxy)- na hthalen-1-1-benzamide 226 FYFF C23H, 7F3N402 438. 41 F NO NIT N g 4-Trifluoromethyl-N- [6- (2-methylamino-pyrimidin-4-yloxy)- nwhthalen-I-yl]-benzamide _ 227 C23H"F3N403 454. 41 F Off h HN 0 o. r w NIN 4-Trifluoromethoxy-N- [6- (2-methylamino-pyrimidin-4-yloxy)- naphthalen-1-yl]-benzamide 228 C23Hl7F3N402 438. 41 F NO F Nu NAN \ \ o i i 3-trifluoromethyl-N-[6-(2-methylamino-pyrimidin4-yloxy)- na hthalen-1-1-benzamide 229C32H3oN204506. 22 0 W w I 0 I O 0o+l N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-1-naphthalenyl)-4- (1, 1-dimethylethyl) benzamide 230 0 C28H21FN204 468. 15 F , 0 O 41 O w N. N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-1-naphthalenyl)-3- fluorobenzamide 231 0 C28H2, CIN204 484. 12 NCI fYi 6 I 03ans 4 9 N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-1-naphthalenyl)-3- chlorobenzamide 232 0 C29H24N205 480. 17 N o, je I O, ON N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-1-naphthalenyl)-3- (methyloxy) benzamide 233 N + C28H20CI2N20 518. 08 NCI I O N r N-(6-((6, 7-bis (methoxy)-4-quinolinyl) oxy)-1-naphthalenyl)- 2, 3-dichlorobenzamide 234 C29H24N205 480. 17 0 N 0 0 I O 4 O N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-1-naphthalenyl)-4- (methyloxy) benzamide 235 C29H2lF3N204 518. 15 0 N F F 0 O Tl O WF N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-1-naphthalenyl)- 3- (trifluoromethyl) benzamide 236 C24Hl9N303 397. 14 N) t O N N 4 N 0 N-methyl-4- ( (5- ( (phenylcarbonyl) amino)-2-naphthalenyl) oxy)- 2-pyridinecarboxamide 237 C24H, sClN303 431. 10 0 NI fizz Or N N 0 4- ( (5- ( ( (3-chlorophenyl) carbonyl) amino)-2-naphthalenyl) oxy)- N-methyl-2-pyridinecarboxamide 238 C24H, 8FN303 415. 13 '. F N N oils zu ( 4- ( (5- ( ( (2-fluorophenyl) carbonyl) amino)-2-naphthalenyl) oxy)- N-methyl-2-pyridinecarboxamide 239 0 C24H, sFN303 415. 13 N i F (N-SNs O 0 4- ( (5- ( ( (3-fluorophenyl) carbonyl) amino)-2-naphthalenyl) oxy)- N-methyl-2-pyridinecarboxamide 240 o JA C28H27N303 453. 21 N O 0 Nu N N 4- ( (5- ( ( (4- ( 1, 1-dimethylethyl) phenyl) carbonyl) amino)-2- naphthalenyl) oxy)-N-methyl-2-pyridinecarboxamide 241 O N C26H, 8FSN303 515. 44 F F FEZ F / \ N N N 0 4-((5-(((4-(pentafluoro-ethyl) phenyl) carbonyl) amino)-2- na hthalen 1 ox-N-meth 1-2-idinecarboxamide 242 C29H24N203 448. 52 N 0 0 0 N N-(6-((6, 7-bis (methyloxy)-4-quinolinyl) methyl)-2- naphthalenyl) benzamide

The following Examples were prepared similar to that described above. Ex. Structure & Name Mol Formula Mass Mass No. I (M+I) 243 C32H3, N305S 569 570 H H S C NO4N Cil3 0 6 N'O N o,,,) 0 N- (6- ( (6- (methoxy)-7- ( (3- (4-morpholinyl) propyl) oxy)-4- quinolinyl) oxy)-2-naphthalenyl)-2-thiophenecarboxamide 244 C30H33FN405 548 549 H H , NNCH3 Cl 0 0 3 CNO) J NO""N" 0 N-ethyl-N'- (5-fluoro-6- ( (6- (methoxy)-7- ( (3- (4- morpholinyl) propyl) oxy)-4-quinolinyl) oxy)-2- naphthalenyl) urea 245 C35H33F2N306 629 630 F H fol i i CH p I O O, CH 3 3 O , F CH3 0_1aN 0 ol CH3 I 0,-,) 0 5-fluoro-N- (5-fluoro-6- ( (6- (methoxy)-7- ( (3- (4- morpholinyl) propyl) oxy)-4-quinolinyl) oxy)-2-naphthalenyl)- 2- (methoxy) benzamide 246 C3, H34FN30s 547 548 H °x+ <" tir Cl'3 I NO i NJ 01-li oa N- (5-fluoro-6- ( (6- (methoxy)-7- ( (3- (4- morpholinyl) propyl) oxy)-4-quinolinyl) oxy)-2- naphthalenyl) butanamide 247 C3oH3oF4N405 602 603 H H F F /\ 'w/ Il CH3 O 0 F NO \ N 0,,) N- (5-fluoro-6- ( (6- (methoxy)-7- ( (3- {4- morpholinyl) propyl) oxy)-4-quinolinyl) oxy)-2-naphthalenyl)- N'- (2, 2, 2-trifluoroethyl) urea 248 C32H37FN405 576 577 H H P H CH3 // Yy CH3 p I O NO NJ O N- (S-fluoro-6- ( (6- (methoxy)-7- ( (3- (4- morpholinyl) propyl) oxy)-4-quinolinyl) oxy)-2-naphthalenyl)- N'- (2-methylpropyl) urea 249 C28H28F4N404 560 561 F NIF NyNl-. Ik CH3 : N O F CHs i CH3 N- (6- ( (7- ( (3- (dimethylamino) propyl) oxy)-6- (methoxy)-4- quinolinyl) oxy)-5-fluoro-2-naphthalenyl)-N'- (2, 2, 2- trifluoroethyl) urea 250 C23H, gF4N20S 510 511 H N, ! -0 ) ! ! ! 6 F F F çç4 F 0 N 6H, N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-5-fluoro-2- naphthalenyl)-2, 2, 2-trifluoroethanesulfonamide 251 C25H24FN304 449 450 ÇH3 OXN) (N CH3 H H N y N--CH3 CH3 OF CHs 6H3 N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-5-fluoro-2- naphthalenyl)-N'-propylurea 252 C32H3, N306S 585 586 H s N l ° w "IY NON" 0 HO N- (6- ( (7- ( ( (2R)-2-hydroxy-3- (4-morpholinyl) propyl) oxy)-6- (methoxy)-4-quinolinyl) oxy)-2-naphthalenyl)-2- thiophenecarboxamide 253 C32H3iN306S 585 586 S i w N C3 O Cl3 0,,,) 0 H OJ OH N- (6- ( (7- ( ( (2S)-2-hydroxy-3- (4-morpholinyl) propyl) oxy)-6- (methoxy)-4-quinolinyl) oxy)-2-naphthalenyl)-2- thiophenecarboxamide 254 C2sHl7FN204S 460 461 rw CHs 0\ ° r F HON" HO NJ N- (5-fluoro-6- ( (7-hydroxy-6- (methoxy) 4-quinolinyl) oxy)-2- naphthalenyl)-3-thiophenecarboxamide 255 C32H30FN306S 603 604 NY-O/ CHs _ CH3 w w I O OH ; 5H 5H N- (5-fluoro-6- ( (7- ( ( (2R)-2-hydroxy-3- (4- morpholinyl) propyl) oxy)-6- 4-quinolinyl) oxy)-2- naphthalenyl)-3-thiophenecarboxamide 256 C32H3oFN306S 603 604 H CHs 0\ w NO NJ ou oh N- (5-fluoro-6- ( (7- ( ( (2S)-2-hydroxy-3- (4- morpholinyl) propyl) oxy)-6- 4-quinolinyl) oxy)-2- naphthalenyl)-3-thiophenecarboxamide Example 257 H 6-((6, 7-bis ((2-(methoxy) ethyl) oxy)-4-quinolinyl) oxy)-N- (4- /chlorophenyl)-1- CI naphthalenecarboxamide 0 0) aN so~°d ° o+N

Step (a) Preparation of 4-chloro-6, 7-dihydroxyquinoline.

In a tube with a stirring bar was introduced 4-chloro-6,7-dimethoxyquinoline (1.5 g, 6.71 mmol) and 15 g of pyridinium hydrochloride. The tube was sealed and the mixture stirred at 200 °C for 1 h. The reaction was cooled to RT and a saturated solution of NaHC03 was added followed by EtOAc. The EtOAc layer was washed with a saturated solution of NaHC03, and the aqueous solution was back extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4 and concentrated under vacuum. The crude mixture was used in the next step.

Step (b) Preparation of 4-chloro-6, 7-bis (2-methoxyethoxy) quinoline.

A portion of the crude obtained in the previous step was dissolved in acetone (9. 1 mL). Cs2C°3 (2.08 g, 6.37 mmol), 2-methoxyethylbromide (0.43 mL, 4.55 mmol) and TBAI (0.067 g, 0.182 mmol) were added to the reaction. The resulting slurry was heated to reflux for 24 h. The solvent was removed under vacuum and the resulting mixture partitioned between a saturated solution of NaHC03 and EtOAc.

The EtOAc layer was washed with a saturated solution of NaHC03 and brine. The crude was purified by chromatography using 100% EtOAc.

Step (c) Preparation of 6- (6, 7-bis (2-methoxyethoxy) quinolin-4-yloxy)-1-naphthoic acid The 6- (6, 7-bis (2-methoxyethoxy) quinolin-4-yloxy)-1-naphthoic acid was obtained starting from the 4-chloro-6, 7-bis (2-methoxyethoxy) quinoline (Step b) using the condition described in Example 801, Step d.

Step (d) Preparation of 6- ( (6, 7-bis ((2-(methoxy) ethyl) oxy)-4-quinolinyl) oxy)-N-(4-chlorophenyl)-1- naphthalenecarboxamide.

The title compound was obtained starting from 6- (6, 7-bis (2-methoxyethoxy) quinolin-4-yloxy)-1- naphthoic acid (step c) using the conditions described in Example 560. M+H 573.1, Calc'd for C32H29CIN206-573. 04. Example258 N 6-((6, 7-bis (methoxy)-4-quinolinyl) oxy)- N- ( ( (5R, S)-2-oxo-1, 3-oxazolidin-5- (o. yl) methyl)-1-naphthalenecarboxamide 0 NH 0@ I// /04 I Step (a) Preparation of (R, S)-5- (azidomethyl) oxazolidin-2-one.

5- (Chloromethyl) oxazolidin-2-one (1.36 g, 10 mmol) was dissolved in DMSO (20 mL). NaN3 (6.5 g, 100 mmol) and TBAI (0.37 g, 1.0 mmol) were added and the resulting mixture was stirred at 70 °C overnight. The mixture was cooled to RT and the resulting solid was diluted with DCM and water. In a separatory funnel, layers were separated, the aqueous layer was extracted several times with DCM, and the combined organic layers were washed with water and brine. After evaporation, the crude was dissolved in EtOAc, and this solution washed with IN HCI. The aqueous layer was neutralized with 6N NaOH and extracted several times with EtOAc to give the desired compound.

Step (b) Preparation of (R, S)-5- (aminomethyl) oxazolidin-2-one.

The crude 5- (azidomethyl) oxazolidin-2-one (0.28 g) was dissolved in EtOH (8 mL) and Pd/C 10% (0.05 g) was added under Argon. The Argon atmosphere was replaced by H2 and the mixture stirred under H2 atmosphere for three days. The catalyst was removed by filtration, and the solvent removed under vacuum to give crude material.

Step (c) 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N-(((5R, S)-2-oxo-1, 3-oxazolidin-5-yl) methyl)-1- naphthalenecarboxamide.

The title compound was obtained using the conditions described in Example 560 starting from 6- (6, 7-dimethoxyquinolin-4-yloxy)-1-naphthoyl chloride and the crude (R, S)-5-(aminomethyl)oxazolidin-2- one (step b). M+H 474.0, Calc'd for C26H23N306-473. 48. Example 259 p N 6- ( (6, 7-bis (methoxy)-4- quinolinyl) oxy)-N- (2- ( (3- (dimethylamino) propyl) (methyl) a mino)-5- (trifluoromethyl) phenyl)- 1-naphthalenecarboxamide O+N l l N F F \ I NNw F F Step (a) Preparation of N- (3- (dimethylamino) propyl)-N-methyl-2-nitro-4- (trifluoromethyl) benzenamine To 4-fluoro-3-nitrobenzotrifluoride (1.00 g, 4.78 mmol) in THF (25 mL) was added N', N', N3- trimethylpropane-1, 3-diamine (0.84 mL, 5.7 mmol) and NaHC03 (1. 1 g, 13 mmol). The resulting mixture was stirred for 1 h at RT, diluted with CH2CI2, and washed with H20. The organic layer was dried (MgSO4), filtered and concentrated to afford the title compound.

Step (b) Preparation of Nl- (3- (dimethylamino) propyl)-Nl-methyl-4- (trifluoromethyl) benzene-1, 2- diamine To N- (3- (dimethylamino) propyl)-N-methyl-2-nitro-4- (trifluoromethyl) benzenamine (Step a, 1.42 g, 4.65 mmol) in MeOH (47 mL) was added Pd/C (10%, 493 mg, 0.465 mmol). The mixture was stirred overnight under an atmosphere of H2. The mixture was filtered through a pad of Celite and concentrated to afford the title compound as a brown oil. M+H-276. Calc'd for C, 3H2oF3N3-275. 32.

Steps (c) Preparation of 6- ( (6, 7-bis (methoxy)-4-quinoHnyt) oxy)-N- (2- ( (3- (dimethylamino) propyl) (methyl) amino)-5-(trifluoromethyl) phenyl)-1-naphthalenecarboxamide Prepared according to Example 119, Step (b). M+H-633. Cal'd for C35H3sF3N404-632. 68. Example 260 6- ( (6, 7-bis (methoxy)-4-quinolinyl) gI | 1 oxy)-N-(2-(methyl ((R, S)-1- 0 methyl-3-pyrrolidinyl) amino)-5- p (trifluoromethyl) phenyl)-1- naphthalenecarboxamide own 0 N F N FF w I LN F F

Step (a) Preparation of (R, S) N, 1-dimethyl-N-(2-nitro-4-(trifluoromethyl) phenyl) pyrrolidin-3- amine To 4-fluoro-3-nitrobenzotrifluoride (5.00 g, 24.0 mmol) in THF (145 mL) was added (R, S) N, 1- dimethylpyrrolidin-3-amine (3.72 mL, 29. 0 mmol) and NaHC03 (5.52 g, 84.0 mmol). The resulting mixture was stirred overnight at RT, diluted with CH2CI2, and washed with H2O. The organic layer was dried (MgS04), filtered and concentrated to afford the title compound.

Step (b) Preparation of (R, S) Nl-methyl-Nl- (l-methylpyrrolidin-3-yl)-4- (trifluoromethyl) benzene- 1,2-diamine To (R, S) N, l-dimethyl-N-(2-nitro-4-(trifluoromethyl) phenyl) pyrrolidin-3-amine (7.25 g, 24.0 mmol) in MeOH (240 mL) was added Pd/C (10%, 1.3 g, 1.2 mmol). The mixture was stirred overnight under an atmosphere of H2 The mixture was filtered through a pad of Celite and concentrated to afford the title compound as a brown oil. M+H-274. Cal'd for C, 3H, 8F3N3-273. 30.

Step (c) Preparation of 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N-(2-(methyl ((R, S)-1-methyl-3- pyrrolidinyl) amino)-5-(trifluoromethyl) phenyl)-1-naphthalenecarboxamide The title compound was prepared according to Example 119, Step (b). M+H-631. Cal'd for C35H33F3N404-630. 66.

The following example was prepared similar to the procedures described in Example 114 Example No. Structure & Name Mol Formula Mass M+H 261 p C28H22N204 450. 49 451. 1 i O N. H I i i O N 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N-phenyl-1- naphthalenecarboxamide

The following Examples were prepared similar to the procedures described in Example 119 using either TEA or DIEA as the base. Example No. Structure & Name Mol Formula Mass M+H 262 H C29H24N204 464. 52 465. 1 NEZ ZON Nu Cl ? p 0 CH3 Cl3 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (4- methylphenyl)-1-naphthalenecarboxamide 263 C29H24N205 480. 52 481. 1 O-CHs zut O N. H \ oS5 0 O CH3 O N 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (4- (methoxy) phenyl)-1-naphthalenecarboxamide 264 C2sH24N204 416. 48 417. 2 CHs O NAH , c6 CH3 0 0 CH3 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N-propyl-1- naphthalenecarboxamide 265 CH3 C26H26N204 430. 5 431. 2 CHs cwr Oq/NH JOD CHAI CHAN 0 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (2- methylpropyl)-1-naphthalenecarboxamide 266 C27H2oCIN304 485. 93 486. 1 Ci N O NAH Cl3 0 0 O W CHO 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-14- (6-chloro- 3-pyridinyl)-1-naphthalenecarboxamide 267 C27H20ClN304 485. 93 486. 1 ci N N CH3 0 O Yin CL3 3 6- ( (6, 7-bis (methoxy) 4-quinolinyl) oxy)-N-(5-chloro- 2-pyridinyl)-1-naphthalenecarboxamide 268 Cl C28H20C12N204 519. 38 519 Ci ici Cl N, H cl 0 O CH3-0 O CH3,/ 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (2, 4- dichlorophenyl)-1-naphthalenecarboxamide 269 ! 2N204 519. 38 519 C'yC) O N. H ON Cl3 0 . 0 'O CH3-O N 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (3, 5- dichlorophenyl)-I-naphthalenecarboxamide 270 C25H22N204 414. 45 415. 2 HAN O o i r *'-0 N o 0'N o , N J 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- cyclopropyl-1-naphthalenecarboxamide Example 271 F 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)- N- ( (lS, 2R)-2-fluorocyclopropyl)-l- O N. H naphthalenecarboxamide 0 _04 Example 272 FN 6-((6, 7-bis (methoxy)-4-quinolinyl) oxy)- N- ( (lR, 2S)-2-fluorocyclopropyl)-1- H naphthalenecarboxamide 0 10 O N 0" N

6-(6, 7-Dimethoxyquinolin-4-yloxy)-1-naphthoyl chloride (200 mg, 0.50 mmol) was suspended in CH2CI2 and TEA (210 pL, 1.5 mmol) was added. The mixture was blanketed with nitrogen, cis-2- fluorocyclopropylamine (131 mg, 0.54 mmol) was added and the reaction was stirred at RT for 1 h. The mixture was washed with water, dried with Na2SO4, filtered and concentrated in-vacuo. The residue was purified by column chromatography to give the title compounds. MS (ESI pos. ion) m/z : 433.2 (M+H).

Calc'd for C25H2, FN2O4-432. 46. Example 273//H 7- ( (6, 7-bis (methoxy)-4- JL quinolinyt) oxy)-N- (3- /chlorophenyl)-2- naphthalenecarboxamide , oNJ I

Step (a) Preparation of 7- (6, 7-dimethoxyquinolin-4-yloxy) naphthalen-2-ol.

To a solution of naphthalene-2, 7-diol (8.95 g, 55.88 mmol) in NMP (50 mL) in a sealed tube, was added 4-chloro-6, 7-dimethoxyquinoline (5.0 g, 22.35 mmol). KOH (1.40 g, 24.58 mmol) was added, followed by copper powder (0.71 g, 11.18 mmol). The tube was sealed and the solution was stirred and heated to 150 °C for 24 h. The reaction was cooled to RT, diluted with water and extracted with EtOAc 3x. The combined organic layer was washed with brine, dried over MgS04, filtered, and concentrated in vacuo. The crude material was purified by silica gel chromatography with 50% to 100% (95: 5: 0.5 EtOAc/MeOH/NH40H) in Hexanes to give the titled compound. MS (ESI, pos. ion) m/z : 348.2 (M+l).

Step (b) Preparation of 7- (6, 7-dimethoxyquinolin-4-yloxy) naphthalen-2-yl trifluoromethanesulfonate.

To a solution of 7- (6, 7-dimethoxyquinolin-4-yloxy) naphthalen-2-ol (Step a, 1.0 g, 2.88 mmol) in CH2CI2 (40 mL) at 0 °C, Et3N (0.40 mL, 2.88 mmol) was added. The reaction was stirred at 0 °C for 5 min and N-phenyltrifluoromethanesulfonimide (1.23 g, 3.45 mmol) was added. The reaction was stirred at 0 °C and gradually warmed to RT for 16 h. The solution was concentrated in vacuo. The crude material was purified by silica gel column chromatography with 75% EtOAc/Hexane to give the titled compound as a white solid. MS (ESI, pos. ion) m/z : 480.1 (M+1).

Step (c) Preparation of methyl 7- (6, 7-dimethoxyquinolin-4-yloxy)-2-naphthoate.

To a solution of 7- (6, 7-dimethoxyquinolin-4-yloxy) naphthalen-2-yl trifluoromethanesulfonate (Step b, 1.0 g, 2.08 mmol) in DMF (10 mL) in a sealed tube, Pd (OAc) 2 (0.094, 0.416 mmol) was added, followed by DPPP (0.257 g, 0.624 mmol). CO (g) was bubbled through the mixture for 5 min, and MeOH (2 mL) and Et3N (0.58 mL, 4.16 mmol) was added. The tube was sealed and the mixture was stirred at 70 °C for 2 h. The reaction was diluted with water and extracted with EtOAc 3x. The combined organic layer was washed with water and brine, dried over MgS04, filtered and concentrated in vacuo. The crude material was taken on directly without purification. MS (ESI, pos. ion) n/z : 390.2 (M+l).

Step (d) Preparation of 7- (6, 7-dimethoxyquinolin-4-yloxy)-2-naphthoic acid.

To a solution of methyl 7- (6, 7-dimethoxyquinolin-4-yloxy)-2-naphthoate (Step c, 0.809 g, 2.08 mmol) in EtOH (10 mL), 1N NaOH (3 mL) was added. The solution was stirred at 70 °C for 2 h. The reaction was cooled to RT and concentrated in vacuo. The crude material was taken up in water (50 mL)

and acidified to pH=3 with IN HCI. The solid was filtered and dried in vacuo. MS (ESI, pos. ion) m/z : 376.1 (M+l).

Step (e) Preparation of 7- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (3-chlorophenyl)-2- naphthalenecarboxamide.

A slurry of 7- (6, 7-dimethoxyquinolin-4-yloxy) -2-naphthoic acid (0.54 g, 1.44 mmol) in 10 mL of C202CI2 and 2 drops of DMF was stirred at RT. After 2 h, the solution was concentrated to dryness and placed under high vacuum overnight. A portion of the crude residue (0.075 g, 0.191 mmol) was dissolved in 1 mL of CH2CI2. To the resulting solution was added DIPEA (0.133 mL, 0.764 mmol), 3-chloroaniline (0.024 mL, 0.229 mmol) and a catalytic amount of DMAP. The reaction was stirred under a N2 atmosphere for 16 h. The reaction was diluted with EtOAc, and washed with saturated aqueous NaHCO3.

The organic layer was dried (MgSO4), filtered and concentrated. The residue was passed through a medium-pressure silica gel column (solvent gradient: 95: 5 CH2CI2 : MeOH ; 90: 10 CH2CI2 : MeOH) to afford the desired crude compound. The fractions were concentrated to dryness to afford a solid residue.

The residue was triturated with Et2O/Hexanes to afford the desired compound as a pale yellow solid. MS (ESI, pos. ion) m/z : 485.0 (M+l). Mass Calc'd for C28H2lCIN204 : 484.937.

The following Examples were prepared similar to the procedures described in Example 273: Example No. Structure & Name Mol Formula Mass M+H 274 H C28H2oF2N204 486. 47 487. 3 CH3 0 N F O I F o NJ r 0 N I CH3 7- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (3, 4- difluorophenyl)-2-naphthalenecarboxamide 275 CH H F C28H2OF3N304 519. 48 520. 2 W W I N ( O O N CH3_oSNJ 0 7- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (4- (trifluoromethyl)-2-pyridinyl)-2-naphthalenecarboxamide 276 C23HMNz04 388. 42 389. 2 CH3 H cl3 CH3 O I// O// CH3 i CH3 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N-methyl-1- naphthalenecarboxamide Example 277 X, N 6-(6, 7-dimethoxyquinolin-4- OH yloxy) quinoline-3-carboxylic acid O I O 0 o , 04 0

Step (a) Preparation of diethyl 2- ( (4-methoxyphenylamino) methylene) malonate In a flask maintained under reduce pressure, p-methoxyaniline (35. 1 g, 280 mmol) and diethyl 2- (methoxymethylene) malonate (73.97 g, 340 mmol) were stirred at 100°C for two h. The crude mixture was used without further purification.

Step (b) Preparation of ethyl 4-chloro-6-methoxyquinoline-3-carboxylate The crude reaction mixture obtained above (74 g) was dissolved in toluene (300 mL). POCI3 (46.6 ml, 500 mmol) was added followed by PCIs (26 g, 125 mmol). The mixture was heated at reflux 6 h.

Toluene and excess of POCI3 were removed under vacuum. The residue was poured on a mixture of NaOH IN and ice. The resulting brown precipitate was filtered off and washed with water, then with methanol to give an off-white solid.

Step (c) Preparation of ethyl 6-methoxyquinoline-3-carboxylate To a solution of ethyl 4-chloro-6-methoxyquinoline-3-carboxylate (Step b, 18 g, 68 mmol) in EtOH (200 mL) stirred under N2 was introduced Pd/C 10% (2 g). The N2 atmosphere was replaced by H2 and the mixture was vigourously stirred at RT under H2 atmosphere (balloon) overnight. The mixture was diluted with DCM and filtered. The catalyst was washed several times with DCM. The solvents were removed under vacuum. The solid residue was suspended in EtOH and the filtered to give ethyl 6- methoxyquinoline-3-carboxylate.

Step (d) Preparation of 6-hydroxyquinoline-3-carboxylic acid hydrochloride salt A mixture of ethyl 6-methoxyquinoline-3-carboxylate (step e, 2.1 g, 9.1 mmol) and HBr 48% (in water) was heated at reflux for 72 h. The resulting solution was cooled at 0 °C. The crystalline solid was filtered off, washed with ice-cold water and rinsed with acetone to give a green-yellow solid.

Step (e) Preparation of 6-(6, 7-dimethoxyquinolin-4-yloxy) quinoline-3-carboxylic acid The title compound was prepared using a procedure similar to that described in Example 801, Step d.

The following examples were prepared similar to the procedure described in Example 273, Step e: Example No. Structure & Name Mol Formula Mass M+H 278 C27 2oCIN304 485. 93 486. 2 N CH3 O) 4NH<CI 064] 0 v H3Co4 N 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (3-chlorophenyl)- 3-quinolinecarboxamide 279 N C27H2oFN304 469. 47 470. 2 i CH3 p i N F H3C o) N H3C. I r NJ 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (3-fluorophenyl)- 3-quinolinecarboxamide 280 N Cz7H, gF2N3O4 487. 46 488. 2 , CH3 ° >f N>¢ F H 0 N F 3 H3C. I N 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (3, 4- difluorophenyl)-3-quinolinecarboxamide 281 H C2 ? H24N404 468. 51 469. 3 O N CH 3 S-N 0 H3C. I 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- ( 1-ethyl-1 H- pyrazol-5-yt)-1-naphthalenecarboxamide 282 H , C Cz6H2, N304S 471. 54 472 3 H NaN , CH3 O 1 U/ CH3 O O H3C. , 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (3-methyl-5- isothiazolyl)-l-naphthalenecarboxamide 283 H C32H24N204 500. 55 501. 1 OqzNA O N o Hck 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (2-naphthalenyl)- 1-naphthalenecarboxamide 284 C3lH23N304 501. 54 502. 2 N oJX3m N H3c, H. 4 H, CJ' 6-((6, 7 bis (methoxy) 4-quinolinyl) oxy)-N-(3-quinolinyl)-1- naphthalenecarboxamide 285 H C3lH22CIN304S 568. 05 568 0 s N /\ 0 ci H3C, ' OV 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (4- (4- chlorophenyl)-1, 3-thiazol-2-yl)-1-naphthalenecarboxamide 286 ; C,, H"N065 578. 6 579. 2 8 Nuls N Cl 0 C3 O ° i w w 0 N 0 0 i CH3 CHg 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (4- (4- nitrophenyl)-1, 3-thiazol-2-yl)-1-naphthalenecarboxamide 287 N C27H23N305 469. 5 470. 1 3 Nu ONH u NH cl3 0 H3C. I UT -0- N 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (3, 4-dimethyl-5- isoxazolyl)-1-naphthalenecarboxamide 288 C H3 C29H27N304S 513. 62 514. 1 3 N S Y 'NUS ON Hck N 0-k 6- ( (6, 7-bis (methoxy) 4-quinolinyl) oxy ?-N-(4-(1, 1- dimethylethyl)-1, 3-thiazol-2-yl)-1-naphthalenecarboxamide 289 HCH3 C26H2, N304S 471. 54 472 Ruz O nu NyS CH3 O ON H3C. 0 N cJ 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (5-methyl-1, 3- thiazol-2-yl)-I-naphthalenecarboxamide 290 H3c CH3 C27H23N304S 485. 56 486 H3C, 3 N, y S O NH CH3 0 C3 O r H3C. y 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (4, 5-dimethyl-1, 3- thiazol-2-yl)-1-naphthalenecarboxamide 291 8 C2sH, sBrN304S 536. 4 535. 9 s NyS O NU / c3 O cl3 0 H3c. o N 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (5-bromo-1, 3- thiazol-2-yl)-1-naphthalenecarboxamide 292 CH3 C26H22N404S 486. 55 487 3 N Nz O NH Cl3 0 CFi3 O \ Hck H3C. 0 N 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (5-ethyl-1, 3, 4- thiadiazol-2-yl)-1-naphthalenecarboxamide 293 X C25Hl, F3N404S 526. 49 527 OF N N S NUS ONH m NH cl 0 CN3 O o H3C. 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (5- (trifluoromethyl)-1, 3, 4-thiadiazol-2-yl)-1- naphthalenecarboxamide 294 C29H25N304 479. 53 480. 1 I W, CHs Nsjv NU ON CH3 O OL H3C. 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (4-ethyl-2- pyridinyl)-I-naphthalenecarboxamide 295 C25H2lN304S 459. 52 460 N- ON 0 nu CH3 0 i t H3c, 0 N 6- ( (6, 7-bis (mettioxy)-4-quinolinyl) oXy)-N- (4,.)-dihydro-1, 3- thiazol-2-vI)-I-naDhthalenecarboxamide 296 F Cz8HMF3N304 519. 48 520 N nu ON O nu CH3 O u H3C. 0 N 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (5- (trifluoromethyl)-2-pyridinyl)-1-naphthalenecarboxamide 297 C28H20F3N304 519. 48 520 N NU ON O NH CH3 0 O Hck 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (6- (trifluoromethyl)-3-pyridinyl)-I-naphthalenecarboxamide 298 0 NH C28H23N304 465. 51 466 NJ i OH ( C3 O I w H3C. w. O N 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (4-methyl-2- pyridinyl)-1-naphthalenecarboxamide 299 H3 C3 s C28H22N205S 498. 56 499. 2 /-\91 0 O NH CH. 0 OL Ljr) t 0 N- (2-acetyl-3-thienyl)-6- ( (6, 7-bis (methoxy)-4- quinolinyl oxy)-1-naphthalenecarboxamide 300 F C29H2oFN304S 525. 56 526. 1 0 NH CH 0 6b O H3 C. HsC. O NJ H3C-0-N" 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (6-fluoro-1, 3- benzothiazol-2-yl)-1-naphthalenecarboxamide 301 CH C3lH2sN30sS 551. 62 552. 1 0-' 0__/3 O NH I , 3 0 O i I HsC. O w N. O-TCN- 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (6- (ethoxy)-1, 3- benzothiazol-2-yl)-1-naphthalenecarboxamide 302 N C27H20CIN304 485. 93 486. 1 0 NH ON 6 CH3 O 3 C. 0 HsC. O w NJ 6- ( (6, 7-bis (methoxy) 4-quinolinyl) oxy)-N-(2-chloro4- pyridinyl)-1-naphthalenecarboxamide 303 C3oH23N304S 521. 6 522. 1 fi-cl 0 NH NtS O NH CH3 O O i I HsC. O w NJ LJ< 3 o " 6-((6, 7-bisfmethoxy) 4-quinolinyl) oxy)-N-(7-methyl-1, 3- benzothiazol-2-yl)-1-naphthalenecarboxamide 304 C25H, sN406S 502. 51 503. 1 O-N S N ON O H i, w c3 O ut* J N 6- ( (6, 7-bis (methoxy) 4-quinolinyl) oxy)-N- (5-nitro-1, 3- thiazol-2-yl)-1-naphthalenecarboxamide 305 C34H27N305 557. 6 558. 2 N--r'o NT O w Pu3 0 c3 O Ut H3 1nez 6-((6, 7-bisfmethoxy) 4-quinolinyl) oxy)-N-(3- ((phenylmethyl) oxy)-2-pyridinyl)-1-naphthalenecarboxamide 306 F C29H22F3N304 533. 5 534. 2 JF N OS, NH ON Cl3 0 r I HsC. O w NJ HsC-o-- 6- ( (6, 7-bis (methoxy) 4-quinolinyl) oxy)-N-((6- (tri fluoromethyl)-3-pyridinyl) methyl)-I- naphthalenecarboxamide 307 C2sH23N304 465. 51 466. 2 N ON roc 0 ni HsC. O w NJ 0 H3c. 0 N 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (4- pyridinylmethyl)-1-naphthalenecarboxamide 308 C3oH24N404 504. 54 505. 1 NYN-CH, ONH O NH Cl3 0 O i I Lez j 0 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- ( 1-methyl-1 H- benzimidazol-2-yl)-1-naphthalenecarboxamide 309 C, H2sN304S 535. 62 536. 2 HsCHg NS h O nu C3 O O i I Lu/** "sC-o- 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (5, 6-dimethyl-1, 3- benzothiazol-2-yl)-1-naphthalenecarboxamide 310 C3, H22CIN304S 568. 05 568. 1 0 SUN ON CIH3 0 CH3 O i t 0 N 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (5- (4- chlorophenyl)-1, 3-thiazol-2-yl)-1-naphthalenecarboxamide 311 CMH2oN404S 508. 56 509. 2 Sv Nr ZON O NU u C3 O i O, w N- (2, 1, 3-benzothiadiazol-4-yl)-6- ( (6, 7-bis (methoxy)-4- quinolinyl) oxy)-1-naphthalenecarboxamide 312 H Q C27H24N404 468. 51 469. 2 - N \. N %, NH ONH CHg 0 i, CH3 O 0 HaC. O w NJ 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- ( 1, 3-dimethyl-1 H- pyrazol-5-yl)-1-naphthalenecarboxamide 313 C35H38N406 610. 71 611. 3 O, CH3 N W CCH CH33 N \ \O \ \ H oi N H 0 N-(5-(1, 1-dimethylethyl)-3-isoxazolyl)-6-((6-(methoxy)-7- ( (3- (4-morpholinyl) propyl) oxy)-4-quinolinyl) oxy)-1- naphthalenecarboxamide 314 C35H32F3N305 631. 65 632. 2 CHs p 0 F c OICN F Nez 6- ( (6- (methoxy)-7- ( (3- (4-morpholinyl) propyl) oxy)-4- quinolinyl) oxy)-N- (3- (trifluoromethyl) phenyl)-1- naphthalenecarboxamide 315 C3sH4) N 619. 76 620. 3 OCH3 can t SCH, y 0--,) N J I'N H N-(4-(1, 1-dimethylethyl) phenyl)-6-((6-(methoxy)-7-((3-(4- morpholinyl) propyl) oxy) 4-quinolinyl) oxy)-1- naphthalenecarboxamide 316 C32H32N405S 584. 69 585. 2 O, CHg NO w N T ; H N 6- ( (6- (methoxy)-7- ( (3- (4-morpholinyl) propyl) oxy)-4- quinolinyl) oxy)-N- (5-methyl-1, 3-thiazol-2-yl)-1- naphthalenecarboxamide 317 C3, H33N30s 527. 62 528. 2 o. CH3 nN tOtN N \ ou N N-cyclopropyl-6- ( (6- (methoxy)-7- ( (3- (4- morpholinyl) propyl) oxy) 4-quinolinyl) oxy)-1- naphthalenecarboxamide 318 C3sH36N405 592. 69 593. 3 Ns¢S Nu OS, NH /\ 0-JL 0 (N) 0 0 N- (4-ethyl-2-pyridinyl)-6- ( (6- (methoxy)-7- ( (3- (4- morpholinyl) propyl) oxy)-4-quinolinyl) oxy)- 1-naDhthalenecarboxamide 319 C34H32CIN305 598. 1 598. 2 i O NU Cl 0 CH3 O wu 0 N C nez 0 N- (3-chlorophenyl)-6- ( (6- (methoxy)-7- ( (3- (4- morpholinyl) propyl) oxy)-4-quinolinyl) oxy)-1- naphthalenecarboxamide 320 _ C3sH3sN3Os 577. 68 578. 3 CH3 O m d CH3 N N 0- N/\ 6- ( (6- (methoxy)-7- ( (3- (4-morpholinyl) propyl) oxy)-4- quinolinyl) oxy)-N- (3-methylphenyl)-1- naphthalenecarboxamide 321 C3sH3lN305 573. 65 574. 2 "CH3 CH3 0 CH3 - p \- H CH3 0 \ 30 N- (5- ( 1, 1-dimethylethyl)-3-isoxazolyl)-6- ( (6- (methoxy)-7- ( (phenylmethyl) oxy)-4-quinolinyl) oxy)- I- naphthalenecarboxamide 322 C4, H39N306 669. 77 670. 3 C), CH3 w tU-. P zon CHU C H, 3 N- (4- (methoxy)-1, 1'-biphenyl-3-yl)-6- ( (6- (methoxy)-7- ( (3- (4-morpholinyl) propyl) oxy) 4-quinolinyl) oxy)-1- naphthalenecarboxamide 323 C36H34F3N30s 645. 67 646. 6 o. CH3 FwF N O. J O I I H CH3 6- ( (6- (methoxy)-7 ( (3- (4-morpholinyl) propyl) oxy)-4- quinolinyl) oxy)-N-(2-methyl-5-(trifluoromethyl) phenyl)-1- naphthalenecarboxamide 324 <1 C42H40N407 712. 8 713. 3 . CH3 HNzO 'O t wN9 CL3 CHg CH3 6- ( (6- (methoxy)-7- ( (3- (4-morpholinyl) propyl) oxy)-4- quinolinyl) oxy)-N- (2- (methoxy)-5- ((phenylamino) carbonyl) phenyl)-I-naphthalenecarboxamide 325 C3sH39Nss 609. 72 610. 2 CHg O H N. /' O °JLN. t XHSH3 CHs N-(5-(1, 1-dimethylethyl)-1 H-pyrazol-3-yl)-6-((6-(methoxy)- 7-((3-(4-morpholinyl) propyl) oxy) 4-quinolinyl) oxy)-1- naphthalenecarboxamide 326 0 C4oH42N406 674. 79 675. 3 N C) H _ 090 vCHW ° H3d0 < H3C CH3 N-(1-acetyl-3, 3-dimethyl-2, 3-dihydro-1 H-indol-6-yl)-6-((6- (methoxy)-7- ( (3- (4-morpholinyl) propyl) oxy)-4- quinolinyl) oxy)-1-naphthalenecarboxamide. 327-V F C36H34F3N305 645. 67 646. 2 --- F 0-/-/ zu / NJ 0 6- ( (6- (methoxy)-7- ( (3- (4-morpholinyl) propyl) oxy)-4- quinolinyl) oxy)-N-(2-methyl-3-(trifluoromethyl) phenyl)-1- naphthalenecarboxamide 328 F C35H3lF4N305 649. 64 650. 2 F C3 p N F --o / OC- N- (2-fluoro-3- (trifluoromethyl) phenyl)-6- ( (6- (methoxy)-7- ( (3- (4-morpholinyl) propyl) oxy)-4-quinolinyl) oxy)-1- naphthalenecarboxamide T F C35H3xF4N3Os 649. 64 650. 2 F CH3 O 0 N F - 0 H N N N O N-(2-fluoro-5-(trifluoromethyl) phenyl)-6-((6-(methoxy)-7- ( (3- (4-morpholinyl) propyl) oxy)-4-quinolinyl) oxy)-l- naphthalenecarboxamide 330 F F C4, H43F3N406 744. 81 745. 3 F CH3 O X XNH 0% N-CH3 ruz N= Nr-I 6- ( (6- (methoxy)-7- ( (3- (4-morpholinyl) propyl) oxy)-4- quinolinyl) oxy)-N- (2- ( (l-methyl-4-piperidinyl) oxy)-5- (trifluoromethyl) phenyl)-1-naphthalenecarboxamide 331 CH C36H4lN505 623. 75 624. 3 H3e, N'N dH3 PH3 0 CH 3 O H zozo N O-' N- (3- ( l, 1-dimethylethyl)-1-methyl-1 H-pyrazol-5-yl)-6- ( (6- (methoxy)-7- ( (3- (4-morpholinyl) propyl) oxy)-4- quinolinyl) oxy)-1-naphthalenecarboxamide 332 H. C rN C3sH39NsOs 609. 72 610. 2 zu O N 4 N0 /'-N N 0 3- (1, 1-dimethylethyl)-1- ( (6- ( (6- (methoxy)-7- ( (3- (4- morpholinyl) propyl) oxy) 4-quinolinyl) oxy)-1- naphthalenyl) carbonyl)-I H-pyrazol-5-amine 333 F F C35H31CIF3N305 666. 09 666. 5 Fuzz oCH3 O9N r < 9 0 N zu zozo -c6 N N- N- (4-chloro-3- (trifluoromethyl) phenyl)-6- ( (6- (methoxy)-7- ( (3- (4-morpholinyl) propyl) oxy) 4-quinolinyl) oxy)-1- naphthalenecarboxamide g g C3sH3lF2Ns07 643. 64 644. 5 Cl. 0 wop 0 off 0 0 H F 0'" Nez 0i O N- (2, 2-difluoro-1, 3-benzodioxol-4-yl)-6- ( (6- (methoxy)-7- ( (3- (4-morpholinyl) propyl) oxy)-4-quinolinyl) oxy)-1- naphthalenecarboxamide 335 C4lH39N507 713. 79 714. 6 NO N H PH3- CH3 O CH3 X O N N-Q- N N O 6- ( (6- (methoxy)-7- ( (3- (4-morpholinyl) propyl) oxy)-4- quinol inyl) oxy)-N-(2-(methoxy)-5-((2- . pyridinylamino) carbonyl) phenyl)-I-naphthalenecarboxamide 336 CH C39H4, Ns05 659. 78 660. 6 3CHg N Zu 0 N 0 0 H zu 0- N N-(2-(I, I-dimethylethyl) imidazo [1, 2-a] pyridin-6-yl)-6-((6- (methoxy)-7- ( (3- (4-morpholinyl) propyl) oxy)-4- quinolinyl oxy)-1-naphthalenecarboxamide 337 F F C37H35F3N406 688. 7 689. 5 F CHs 0 y= 0 CH3 0 0 N 0 N4 /-O \/ CH N N O N- (2- (acetylamino)-5- (trifluoromethyl) phenyl)-6- ( (6- (methoxy)-7- ( (3- (4-morpholinyl) propyl) oxy)-4- quinolinyl) oxy)-l-naphthalenecarboxamide 338 F F C39H37F3N406 714. 74 715. 5 F 0 0 N) CH3 O \J O N ruz \ N N'_ O 6- ( (6- (methoxy)-7- ( (3- (4-morpholinyl) propyl) oxy)-4- quinolinyl) oxy)-N- (3- (2-oxo-1-pyrrolidinyl)-5- trifluorometh 1 hen I-1-na hthalenecarboxamide 339 H C4lH44IF3N505 743. 82 744. 6 F F ZON F N , CH3 0e O N H Zozo NJ 0i 6- ( (6- (methoxy)-7- ( (3- (4-morpholinyl) propyl) oxy)-4- quinolinyl) oxy)-N-(3-((4-methyl-1-piperazinyl) methyl)-5- (trifluoromethyl) phenyl)-1-naphthalenecarboxamide 340 F C40H39F3N406 728. 76 729. 6 F PH3 0 N N H O O / O'/_CHs FisC CN} N O-' N- (2- (3, 3-dimethyl-2-oxo-1-azetidinyl)-5- (trifluoromethyl) phenyl)-6- ( (6- (methoxy)-7- ( (3- (4- morpholinyl) propyl) oxy) 4-quinolinyl) oxy)-1- naphthalenecarboxamide 341 F F C36H34F3N306 661. 67 662. 5 F ) CH3 0 $ H O-CH3 N lb\O O 6- ( (6- (methoxy)-7- ( (3- (4-morpholinyl) propyl) oxy)-4- quinolinyl) oxy)-N- (2- (methoxy)-5- (trifluoromethyl) phenyl)- 1-naphthalenecarboxamide 342 H3C CH3 C39H43N306 649. 78 650. 5 3 H3C CH3 0 O-H O-CH3 CS N O N- (5- ( 1, 1-dimethylethyl)-2- (methoxy) phenyl)-6- ( (6- (methoxy)-7- ( (3- (4-morpholinyl) propyl) oxy)-4- quinolin l oxy)-1-naphthalenecarboxamide 343 ci C34H3iCl2N30s 632. 54 632. 4 PH3 0- 0 N ci H O N NJ OJ N- (2, 5-dichlorophenyl)-6- ( (6- (methoxy)-7- ( (3- (4- morpholinyl) propyl) oxy) 4-quinolinyl) oxy)-1- naphthalenecarboxamide 344 H C CH3 C40H45N305 647. 81 648. 6 hic HsC PH3 0 < H O-CH3 N/b\O N- (5- (1, 1-dimethylethyl)-2- (methoxy) phenyl)-6- ( (6- (methoxy)-7- ( (3- ( 1-piperidinyl) propyl) oxy)-4- quinolinyl) oxy)-1-naphthalenecarboxamide 345 C3 (, H33F2N306 641. 67 642. 5 cf" H F / 0 N- (2, 2-difluoro-1, 3-benzodioxol-4-yl)-6- ( (6- (methoxy)-7- ( (3- (I-piperidinyl) propyl) oxy)-4-quinolinyl) oxy)-1- naphthalenecarboxamide 346 F F C37H36F3N305 659. 7 660. 6 F CH3 O t) N zizi 0 6- ( (6- (methoxy)-7- ( (3- ( 1-piperidinyl) propyl) oxy)-4- quinolinyl) oxy)-N- (2- (methoxy)-5- (trifluoromethyl) phenyl)- 1-naphthalenecarboxamide ~ 347 F F C36H34F3N305 645. 67 646. 5 F , CH3 o t N O-CH3 H 0 C 6- ( (6- (methoxy)-7- ( (3- ( 1-pyrrolidinyl) propyl) oxy)-4- quinolinyl) oxy)-N- (2- (methoxy)-5- (trifluoromethyl) phenyl)- I-naphthalenecarboxamide CH3 C39H43N35 633. 78 634. 6 H3C C3 O 0 H O-CH3 r X X c N- (5- ( 1, 1-dimethylethyl)-2- (methoxy) phenyl)-6- ( (6- (methoxy)-7- ( (3- (I-pyrrolidinyl) propyl) oxy)-4- quinolin l oxy)-1-naphthalenecarboxamide 349.-. C3H3, F2N306 627. 64 628. 5 0 3 zu H F / N lb\o C' - (2, 2-difluoro-1, 3-benzodioxol-4-yl)-6- ( (6- (methoxy)-7- ( (3- (1-pyrrolidinyl) propyl) oxy) 4-quinolinyl) oxy)-1- naphthalenecarboxamide 350 C38H37N50s 643. 74 644. 3 ov-0 ICH3 0 o<O H N _J N-/N N 6- ( (6- (methoxy)-7- ( (3- ( 1-piperidinyl) propyl) oxy)-4- quinazolinyl) oxy)-N- (4-methyl-3-phenyl-5-isoxazolyl)-l- naphthalenecarboxamide 351 r H3C | C44HszN407 748. 92 749. 4 hic , CH3 0 CH3 O 0 N 0 0 0 H tub\ ( ,-N N.- N N-0 N- (5- (1, 1-dimethylethyl)-2- ( (2- (4- morpholinyl) ethyl) oxy) phenyl)-6- ( (6- (methoxy)-7- ( (3- (4- morpholinyl) propyl) oxy) 4-quinolinyl) oxy)-1- naphthalenecarboxamide 352 N9 C4, H48N604 688. 87 689. 3 )-CH, N NU C3 O 0 N zu zozo /v 0 ZON N- (4- (4- ( 1-methylethyl)-1-piperazinyl) phenyl)-6- ( (6- (methoxy)-7- ( (3- ( 1-piperidinyl) propyl) oxy)-4- quinazolinyl oxy)-1-naphthalenecarboxamide FF j C3sH32F4No4 648. 65 649. 5 F ICH3 N=/ N F H /\ NaN 0 N N- (2-fluoro-5- (trifluoromethyl) phenyl)-6- ( (6- (methoxy)-7- ((3-(1-piperidinyl) propyl) oxy) 4-quinazolinyl) oxy)-1- naphthalenecarboxamide 354, F C36H3sF3N404 644. 69 645. 7 Pu 0 F 0 3 P F N CH3 O , \N N non 6- ( (6- (methoxy)-7- ( (3- (1-piperidinyl) propyl) oxy)-4- quinazolinyl) oxy)-N- (2-methyl-3- (trifluoromethyl) phenyl)-1- naphthalenecarboxamide T H3Ct C39H43N3Os ; 633. 78 634. 6 hic HsC CH3 O o N O-CH3 0 0 H zizi cri N- (5- ( 1, 1-dimethylethyl)-2- (methoxy) phenyl)-6- ( (6- (methoxy)-7- ( (3- (1-pyrrolidinyl) propyl) oxy)-4- quinolin l) oxy)-1-naphthalenecarboxamide 356 F F gC33H CIF3N304 650 09 650. 5 r X 4 P j k F ci Ici3 0 c3 O - 0 H -cul 0' N- (4-chloro-3- (trifluoromethyl) phenyl)-6- ( (6- (methoxy)-7- ((3-(I-pyrrolidinyl) propyl) oxy)-4-quinolinyl) oxy)-1- naphthalenecarboxamide Example 357 O N 6-((6, 7-bis (methoxy)-4- quinolinyl) oxy)-N- (2- , s | (dimethylamino) ethyl)-l- naphthalenecarboxamide oW I , o NJ

6-(6, 7-Dimethoxyquinolin-4-yloxy)-1-naphthoic acid (80 mg, 0.213 mmol), 1- (3- dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (61 mg, 0.32 mmol) and HOAT (29 mg, 0.213 mmol) were added to a reaction tube, then dissolved in DMF (0.6 mL). A solution of N, N- dimethylethylenediamine (23 mg, 0.256 mmol) in DMF (0.6 mL) was added to the reaction, followed by Hunig's base (75 mg, 0.581 mmol). The mixture became yellow and clear within 15 min and was stirred at RT for 16 h. The mixture was concentrated under vacuum. The remaining yellow oil was purified by silica gel chromatography (2% to 3% 7N NH3 in MeOH in CH2CI2) to afford 6- ( (6, 7-bis (methoxy)-4- quinolinyl) oxy)-N-(2-(dimethylamino)ethyl)-1-naphthalenecarboxamide as a white solid. MS (ESI, pos. ion) m/z : 446.1 (M+l). Calc'd for C226H27N304-445. 52.

The following Examples were prepared similar to the procedures described in Example 357. Example No. Structure & Name Mol Formula Mass M+H 358 H C2sH29N304 471. 55 472. 1 A D form C3 o,, 0 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (2- (1- pyrrolidinyl) ethyl)-I-naphthalenecarboxamide 359 ZSHz, FN204 432. 45 433 O NU 0 H3C. 0 F H, O) OCN'T H, CA N-cyclopropyl-6-((3-fluoro-6, 7-bis (methoxy)-4- quinolinyl) oxy)- I-naphthalenecarboxamide 360 F C29H2oF4N204 536. 48 537 ON 0 O NH 0 H C I F H3c, 0 N 6- ( (3-fluoro-6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (3- (trifluoromethyl) phenyl)-1-naphthalenecarboxamide 361 Cl C28H20CiFN204 502. 93 503 i O NH 0 H3C. 0 I F H3c, 0 N N- (4-chlorophenyl)-6- ( (3-fluoro-6, 7-bis (methoxy)-4- quinolinyl oxy)-1-naphthalenecarboxamide 362 0 N F C25H2iF3N204 470. 44 471. 1 F F o ~1 °. i i O N 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (3, 3, 3- trifluoropropyl)-1-naphthalenecarboxamide Example 363 F 6- (2-Methylamino-pyrimidin-4-yloxy)- o N naphthalene-l-carboxylic acid (4-chloro- 3-trifluoromethyl-phenyl)-amide zu //I CI \ \ I N tN/1Nz

Step (a) Preparation of 6-(2-fluoropyrimidin-4-yloxy)-1-naphthoic acid To a solution of 6-hydroxy-1-napthoic acid (3.23 g, 17.2 mmol) in DMSO (8 mL), Cs2C03 (16.8 g, 57. 6 mmol) was added and stirred at RT 10 min. 2,4-Difluoropyrimidine (2 g, 17.2 mmol) was added and the reaction was stirred at RT for 12 h. The mixture was diluted with water and made pH 7 using 1 N HCI, at which point it is a foamy emulsion. The mixture sat without stirring 2 days and the resulting solid was filtered and rinsed with water and Et20 to yield the title compound as a pink solid.

Step (b) Preparation of 6- (2- (methylamino) pyrimidin-4-yloxy)-1-naphthoic acid 6-(2-Fluoropyrimidin-4-yloxy)-1-naphthoic acid (step a, 1 g, 3.53 mmol) was suspended in THF (10 mL) and warmed to partially dissolve. The mixture was cooled to RT and N-methylamine (2 M in THF, 8.9 mL, 17.7 mmol) was added. After 2 h, the solvent was concentrated in-vacuo. The residue was diluted with H20 and made pH 7 using 1 N HCI. The solid was filtered and rinsed with water and Et2O to yield the title compound as a pink solid.

Step (c) Preparation of N- (4-chloro-3- (trifluoromethyl) phenyl)-6- ( (2- (methylamino)-4- pyrimidinyl) oxy)-1-naphthalenecarboxamide This compound was prepared similar to the procedure described in Example 357. MS (ESI pos. ion) m/z: 473.0 (M+H). Calc'd for C23H, 6CIF3N402-472. 85.

The following Examples were prepared similar to the procedures described in Example 357 and purified by column chromatography and/or crystallization. Example Structure & Name Mol Formula Mass M+H No. 364 t < C23H20N402 384. 43 385. 1 N ZON NaN 6- ( (2- (methylamino)-4-pyrimidinyl) oxy)-N- (3- methylphenyl)-I-naphthalenecarboxamide 365 o>N<*+ C23H20N402 384. 43 385. 1 0 ZON N 6- ( (2- (methylamino)-4-pyrimidinyl) oxy)-N- (4- methylphenyl)-I-naphthalenecarboxamide 366 0 NNO C22H24N402 376. 45 377. 2 fi N ZON N-cyclohexyl-6- ( (2- (methylamino)-4- pyrimidinyl) oxy)-1-naphthalenecarboxamide 367 C2sH24N402 412. 49 413. 1 0 N zizi 0 N N N 6- ( (2- (methylamino)-4-pyrimidinyl) oxy)-N- (3- (I- methylethyl) phenyl)-1-naphthalenecarboxamide 368 o N> C20H20N402 348. 40 349. 1 oJ N Non N-cyclobutyl-6- ( (2- (methylamino)-4- pyrimidinyl) oxy)-1-naphthalenecarboxamide 369 C24H22N402 398. 46 399. 1 141 N zizi ZON N- (3-ethylphenyl)-6- ( (2- (methylamino)-4- pyrimidinyl oxy)-1-naphthalenecarboxamide 370 JN>¢DzF C22H, 7FN402 388. 39 389. 1 okj fuzz N oW N- (3-fluorophenyl)-6- ( (2- (methylamino)-4- pyrimidinyl oxy)-1-naphthalenecarboxamide 371 O N F C22H, 6F2N402 406. 38 407. 1 lez zon N N_ _nez N- (3, 4-difluorophenyl)-6- ( (2- (methylamino)-4- pyrimidinyl) oxy)-I-naphthalenecarboxamide 372 Cl C22H, 7CIN402 404. 85 405. 1 oJ ZON NAN N- (3-chlorophenyl)-6- ( (2- (methylamino)-4- pyrimidinyl) oxy)-1-naphthalenecarboxamide 373 0 Na C24H22N402 398. 46 399. 1 0 fit-N N N- (3, 4-dimethylphenyl)-6- ( (2- (methylamino)-4- pyrimidinyl oxy)-1-naphthalenecarboxamide 374 C22HnFN402 388. 39 389. 1 0 ZON o N 14 uF N- (4-fluorophenyl)-6- ( (2- (methylamino)-4- pyrimidin l oxy)-1-naphthalenecarboxamide 375 O N CZZH, 8N402 370. 41 371. 1 run N N N N 6- ( (2- (methylamino)-4-pyrimidinyl) oxy)-N-phenyl-1- naphthalenecarboxamide r 376 C23H, 9CIN402 418. 88 419. 1 CL 0 P4 o N zon NaN N- (3-chloro-4-methylphenyl)-6- ( (2- (methylamino)-4- pyrimidinyl oxy)-1-naphthalenecarboxamide 377 C27H27N502 453. 55 _<N C (O) Ot-Bu 0 N N ZON NN tert-butyl 3, 3-dimethyl-6- (2- (2- (methylamino) pyrimidin-4-yloxy)-1- naphthamido) indoline-I-carboxylate Example 378 N- (3, 3-dimethyl-2, 3-dihydro-lH-indol-6- eN yl)-6-((2-(methylamino)-4-pyrimidinyl) oxy)-l-naphthalenecarboxamide O N 0@ N N Non

To a cooled (ice bath) solution of tert-butyl 3, 3-dimethyl-6-(2-(2-(methylamino) pyrimidin-4- yloxy)-1-naphthamido) indoline-1-carboxylate (theor. 76 mg, 0.17 mmol) in CH2C12 (1.5 mL), TFA (200 u. L) was added, the reaction stirred and warmed to RT overnight. The mixture was concentrated in-vacuo and the residue dissolved in CH2CI2, washed with 1 N NaOH, then brine and dried with Na2SO4. The mixture was filtered and evaporated. The residue was triturated with hexanes and the solid filtered to give the title compound as a white solid. MS (ESI pos. ion) m/z : 440.2 (M+H). Calc'd for C26H2sNsO2- 439.51. Example 379 O OH 5-fluoro-6- (2- (methylamino) pyrimidin- 4-yloxy)-l-naphthoic acid I N' O (N/1Nz N Nu

The title compound was prepared similar to Example 363, steps a and b.

The following examples were prepared similar to the procedures described in Example 357 and purified by column chromatography and/or crystallization. Example No. Structure & Name Mol Formula Mass M+H 380 C22H16CIFN402 422. 85 423. 1 cl 0 Q- N 0 H N F N z H-CH3 5-fluoro-6- ( (2- (methylamino)-4-pyrimidinyl) oxy)-N- (3- chlorophenyl)-1-naphthalenecarboxamide 381 F F C23Hl6F4N403 472. 4 473. 1 0z< F 0 H N H N F Nu N-CHU H 5-fluoro-6- ( (2- (methylamino)-4-pyrimidinyl) oxy)-N- (4- ( (trifluoromethyl) oxy) phenyl)-1-naphthalenecarboxamide 382 CHH, 9FN402 402. 43 403. 1 O 0 Q- N \N F N = NH-CH3 H 5-fluoro-6- ( (2- (methylamino)-4-pyrimidinyl) oxy)-N- (3- methylphenyl)-I-naphthalenecarboxamide 383 CH3 C23H, 8CIFN402 436. 87 437. 1 ci cl N Nu H \N F N z H-CH3 N-(3-chloro4-methylphenyl)-5-fluoro-6-((2-(methylarnino)- 4-pyrimidinyl) oxy)-1-naphthalenecarboxamide 384 F C22Hl5CIF2N402 440. 84 441 ci 0 0- N 'o H \N F Nu H-CH3 N- (3-chloro-4-fluorophenyl)-5-fluoro-6- ( (2- (methylamino)-4- pyrimidinyl) oxy)-I-naphthalenecarboxamide 385 H C CxaHznN402 416. 45 417. 2 3 H HYN O \/HsC F N H F NU N-, XF hIH 0'N 0- N N- (3, 4-dimethylphenyl)-S-fluoro-6- ( (2- (methylamino)-4- pyrimidinyl) oxy)-1-naphthalenecarboxamide 386 C C23H, SC1F4N402 490. 84 491. 1 F fi N 0 H F N= H-CH3 N-(4-chloro-3-(trifluoromethyl) phenyl)-5-fluoro-6-((2- (methylamino)-4-pyrimidinyl) oxy)-1- naphthalenecarboxamide Example 387 F N- (3- (trifluoromethyl) phenyl)-6- ( (2- ( (1- methylethyl) amino)-4-pyrimidinyl) oxy)- F 1-naphthalenecarboxamide F F 0 N own 0X M, (N/lNl N zon

Step (a) Preparation of 6-(2-(isopropylamino)pyrimidin-4-yloxy)-1-naphthoic acid The title compound was prepared similar to the procedure described in Example 363 (b).

Step (b) Preparation of N-(3-(trifluoromethyl) phenyl)-6-((2-((1-methylethyl) amino)-s pyrimidinyl) oxy)-1-naphthalenecarboxamide This compound was prepared similar to the procedure described in Example 357. MS (ESI pos. ion) m/z: 467.1 (M+H). Calc'd for C25H21F3N4O2-466. 46. The following examples were prepared similar to the procedures described in Example 387 and purified by column chromatography and/or crystallization. Example Structure & Name Mol Formula Mass M+H No. 388 ci C24H2lCIN402 432. 90 433. 0 0 N 0 N . N I N-'N N- (4-chlorophenyl)-6- ( (2- ( ( 1-methylethyl) amino)-4- pyrimidinyl oxy)-1-naphthalenecarboxamide 389 F C2sH21F3N403 482. 45 483. 1 F F N zap ru i N 6-((2-((l-methylethyl) amino)-4-pyrimidinyl) oxy)-N- (4-((trifluoromethyl) oxy) phenyl)-1- naphthalenecarboxamide 390 C25H24N402 412. 49 413. 2 ON // N ZU N 6- ( (2- ( ( 1-methylethyl) amino)-4-pyrimidinyl) oxy)- N- (3-methylphenyl)-1-naphthalenecarboxamide 391. ' C24H2iClN402 432. 90 433. 0 0 N 0 w w A N NN N- (3-chlorophenyl)-6- ( (2- ( ( 1-methylethyl) amino)-4- pyrimidinyl) oxy)-1-naphthalenecarboxamide 392 C25H23CIN402 446. 93 447. 1 cri I OJ ZON N_ _N- N- (3-chloro-4-methylphenyl)-6- ( (2- ( ( 1- methylethyl) amino)-4-pyrimidinyl) oxy)-1- naphthalenecarboxamide 393 ICI F C25H20CIF3N402 500. 90 501. 1 if F o O N N N O N i N-(4-chloro-3-(trifluoromethyl) phenyl)-6-((2-((1- methylethyl) amino)-4-pyrimidinyl) oxy)-l- naphthalenecarboxamide T O N C24H20ClFN402 450. 89 451. 0 ci own O N ION NNI \ N-(3-chloro-4-fluorophenyl)-6-((2-((1- methylethyl) amino)-4-pyrimidinyl) oxy)-1- naphthalenecarboxamide 395 C26H26N402 426. 51 427. 2 ON ZU Ion N-1 N N-(3, 4-dimethylphenyl)-6-((2-((1- methylethyl) amino)-4-pyrimidinyl) oxy)-1- naphthalenecarboxamide Example 396 O H 6-((2-amino-4-pyrimidinyl) oxy)-N- N I CI (3-chlorophenyl)-1- via naphthalenecarboxamide N 0 QNH. \NNHZ

Step (a) Preparation of 6-(2-aminopyrimidin-4-yloxy)-1-naphthoic acid 6-(2-Fluoropyrimidin-4-yloxy)-1-naphthoic acid (1.2 g, 4.2 mmol) was dissolved in NH40H (37 % water, 20 mL) and stirred at RT for 3h. Solvent was evaporated. A little bit of MeOH was added to the slurry followed by ether until the compound crashed out. Solid was filtered.

Step (b) Preparation of 6-(2-aminopyrimidin-4-yloxy)-N-4-chloro-1-naphthamide 6- (2-Aminopyrimidin-4-yloxy)-l-naphthoic acid (Step a, 82 mg, 0.29 mmol), 3-chloroaniline (0.046 mL, 0.43 mmol), HATU (166 mg, 0.43 mmol) and DIPEA (0.07 mL, 0.43 mmol) were stirred overnight in CHC13 (3 mL) at RT. The mixture was filtered and the solid was rinsed with CHCI3, ether and MeOH. The title compound was obtained as an off-with solid. MS (ESI pos. ion) m/z : 391 (M+H).

Calc'd for C2, H, 5CIN404-390. 82.

The following compounds were prepared similar to the procedures described in Example 396, step b. Example Mol No. Structure & Name Formula Mass M+H 397 H H z5H, 9FN404 458. 45 459. 1 ONN. g H C' 3 H C' i I F H3C. w 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-5-fluoro-N- ( 1 H- pyrazol-5-yl)-I-naphthalenecarboxamide 398 C23H20N402 384. 44 385. 1 O N I CH3 C H 3 0 Zon N nez N NH2 6- ( (2-amino-4-pyrimidinyl) oxy)-N- (3, 4-dimethylphenyl)-1- naphthalenecarboxamide 3 99 H C22H j 7CIN402 404. 86 405 p N CI / CH3 O \ zon N N NH- 6-((2-amino4-pyrimidinyl) oxy)-N-(3-chloro4-methylphenyl)- 1-naphthalenecarboxamide 400 O H ZZH, 8N402 370. 41 371. 1 fTj w fN N I N nez 6-((2-amino4-pyrimidinyl) oxy)-N-(3-(methyl) phenyl)-1- naphthalenecarboxamide 401 H F C22Hl5F3N402 424. 38 425 O N NK, 0 eNkNH2 6- ( (2-amino-4-pyrimidinyl) oxy)-N- (3- (Mfluoromethyl) phenyl)- 1-naphthalenecarboxamide 402 H C22H, sF3N403 440. 38 441. 1 O F lao4F OUT ZON (NINTH 2 N NNHZ 6-((2-amino4-pyrimidinyl) oxy)-N-(4- (irifluoromethyl) oxy) phenyl)-1-naphthalenecarboxamide 403 H C2, H, 6N402 356. 38 357. 1 N 0 ZON N NH- 6-((2-amino-4-pyrimidinyl) oxy)-N-phenyl-I- naphthalenecarboxamide 404 C26H2, FN404 472. 47 473 N O N, N 04 zu F O) ans 1- ( (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-5-fluoro-1- naphthalenyl) carbonyl)-3-methyl-1 H-pyrazol-5-amine Example 405 Q, N- (6- ( (6, 7-bis (methoxy)-4- A, ls J quinolinyl) oxy)-1-naphthalenyl)-N'- HN N T (2-fluorophenyl) urea F I O 0son O4N

6-(6,7-Dimethoxyquinolin-4-yloxy)naphthalen-1-amine (50 mg, 0.144 mmol) and 2- fluorophenylisocyanate (20 mg, 0.144 mmol) were dissolved in THF (1 mL) then stirred at RT for 16 h.

A precipitate formed in the mixture and was collected on a glass frit, washing with minimal THF then CH2CI2 to give N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-1-naphthalenyl)-N'-(2-fluorophenyl) urea as an off-white solid. MS (ESI, pos. ion) m/z : 484.2 (M+l). Mass Calc'd for C2sH22FN304 : 483.50 The following examples were prepared similar to the procedures described in Example 405.

Example No. Structure & Name Mol Formula Mass M+H 406 C28H22FN304 483. 5 484. 1 'fl, I Hi i CH3 O H H F H---I H3C. N- (7- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2-naphthalenyl)- N'-3-fluorophenyl) urea 407 C28H22CIN304 499. 95 500. 1 , CH3 O 0 O/ N N -u--/< \ CI CH3 \ / N N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-1-naphthalenyl)- N'- (4-chlorophenyl) urea 408 C29H22F3N304 533. 5 534. 2 , CH3 0 /0 HN CF3 -on- CH3 m/0 N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-1-naphthalenyl)- N'- (4- (trifluoromethyl) phenyl) urea 409C3tH29N304507. 59 508. 2 CHs 10 cl3 NAN H CH3 p (i i O I Chus CH3 N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-1-naphthalenyl)- N'- (4-l-methylethyl) phenyl) urea 410 O n C28H22ClN304 499. 95 500. 1 HN N CI H c3 O O CHUS L ; H3 CH3 N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-1- naphthalenyl)-N'-(3-chlorophenyl) urea 411 C28H2lCl2N304 534. 4 534. 1 cl HN) N ci H PH3 0 0°, > o . NJ CH3 CH3 N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-1- naphthalenyl)-N'- (3, 4-dichlorophenyl) urea 412 C2gH25N304 479. 53 480. 1 0 HN'A, N H PU3 6 zon CHg N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-1- naphthalenyl)-N'-(phenylmethyl) urea Ex. Calc No. Name & Structure Mol Formula MW M+ + M- 413 C24H, gFN403 430. 43 429. 2 HN) 4N F ive' H N. CH3 o 0 4- ( (5- ( ( ( (2-fluorophenyl) amino) carbonyl) amino)-2- naphthalenyt oxy)-N-methy1-2-'dinecarboxamide 414 24H, 9C1N. 4O3 446. 89 445. 1 e H S H HAN N H H H Õ CH3 0 4- ( (5- ( ( ( (4-chlorophenyl) amino) carbonyl) amino)-2- naphthalenyl) oxy)-N-methyl-2-pyridinecarboxamide 415 CzSH, 9F3N403 480. 444 479. 1 p Jl w HN N ok I w w O H 9 H o N-methyl-4- ( (S- ( ( ( (4- (trifluoromethyl) phenyl) amino) carbonyl) amino)-2-naphthalenyl) oxy)-2- pyridinecarboxamide 416 C H 6N4O3 454. 52 453. 2 0 NAN H H ich 0 O N-methyl-4- ( (5- ( ( ( (4- (1-methylethyl) phenyl) amino) carbonyl) amino)-2-naphthalenyl) oxy)-2- pyridinecarboxamide Example 417 0 N- (6- ( (6, 7-bis (methoxy)-4- HN N quinolinyl) oxy)-1-naphthalenyl)-N'- cyclopropylurea oJX O4N I O// o . NJ

6-(6, 7-Dimethoxyquinolin-4-yloxy) naphthalen-1-amine (80 mg, 0.231 mmol) was suspended in THF (1 mL), then added Hunig's base (33 mg, 0.254 mmol) and a solution of phenylchloroformate (36 mg, 0. 231 mmol) in THF (0.5 mL). The reaction was stirred at RT for 16 h. A solution of cyclopropylamine (26 mg, 0.462 mmol) in THF (0.6 mL) was added to the mixture and the reaction was heated at 50 °C for 4 h. A precipitate formed and was collected on a glass frit, washed with THF then CH2CI2. The tan solid was purified by preparative thin layer chromatography (8% MeOH in CH2CI2) to give N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-1-naphthalenyl)-N'-cyclopropylurea as a white solid. MS (ESI, pos. ion) mlz : 430.2 (M+l). Mass Calc'd for C25H23N304 : 429.47 The following examples were prepared similar to the procedures described in Example 417. Example No. Structure & Name Mol Formula Mass M+H 418 C26H25N304 443. 5 444. 1 0 NAN H CH3 O YY ON CHs N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-1-naphthalenyl)- N'- (cyclopropylmethyl) urea 419 ZSHZON404S 472. 52 473. 1 0 HNNS rire CH3 O i i I 0 N I L ; H3 N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-1-naphthalenyl)- N'-l, 3-thiazol-2-yl) urea 420-25H2sN304 431. 49 432. 1 O H3 O qH3 N- ( 0 N N N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-1-naphthalenyl)- N'-propylurea Example 421 H 4- ( (5- ( ( (4-chloro-3- (trifluoromethyl) phenyl) O N I CFg amino) carbonyl)-2-naphthalenyl) oxy)-N- /methyl-2-pyridinecarboxamide -aci CI N N N 0

Step (a) Preparation of 6-(2-(methylcarbamoyl)pyridine-4-yloxy)-1-napthoic acid.

Cs2CO3 (52.0 g, 160 mmol) was added to a solution of 6-hydroxy-1-naphthoic acid (10 g, 53. 0 mmol) in DMSO (140 mL). After stirring vigorously for 15 min N-methyl-4-chloropicolinamide (10. 8 g,

61.0 mmol) was introduced and the mixture was heated at 100 °C for 10 h. After cooling to RT, the mixture was filtered through a plug of silica gel (10: 1: 0.5 ; CH2C12 CH30H, AcOH). The filtrate was concentrated and triturated with EtOAc to provide the title compound as a slightly pink solid. MS (ESI, pos. ion) m/z : 323.3 (M+l). Mass Calc'd for Cl8H, 2N204 : 322. 31.

Step (b) Preparation of 6-(2-(methylcarbamoyl)pyridine-4-yloxy)-1-napthoyl chloride.

To a suspension of 6-(2-methylcarbamoyl)pyridin-4-yloxy)-1-napthoic acid (Step a, 6.00 g, 18.6 mmol) in CH2CI2 (100 mL) were added oxalyl chloride (5.2 mL, 60.5 mmol) and DMF (143 IlL, 1.86 mmol). Stirring was continued 2 h at which point the resulting slurry was concentrated and azeotroped with benzene (3 x 25 mL) to provide the title compounds as a yellow powder. MS (methyl ester) (ESI, pos. ion) m/z : 337.3 (M+l). Mass Calc'd for Cl9Hl6N204 : 336.34.

Step (c) Preparation of 4- ( (5- ( ( (4-chloro-3- (trifluoromethyl) phenyl) amino) carbonyl)-2- naphthalenyl) oxy)-N-methyl-2-pyridinecarboxamide.

To a solution of 6-(2-methylcarbamoyl)pyridin-4-yloxy)-1-napthoyl chloride (Step b, 50 mg, 0.13 mmol) and 5-amino-2-chlorobenzotrifluoride (26 mg, 0.13 mmol) in 2 mL of CH2CI2 was added TEA (93 I1L, 0.66 mmol). The reaction was maintained at RT for 1 h before being concentrated and purified by silica gel column chromatography (50% acetone in hexanes) to give the title compound as a yellow solid.

MS (ESI, pos. ion) m/z : 500.4 (M+l). Mass Calc'd for C25Hl7CIF3N303 : 499.87.

The following examples were prepared similar to the procedures described in Example 421. Example No. Structure & Name Mol Formula Mass M+H 422 C24Hl8CIN303 431. 87 432. 4 H N i CI cri N NCH3 N 4- ( (5- ( ( (4-chlorophenyl) amino) carbonyl)-2- naphthalenyl) oxy)-N-methyl-2-pyridinecarboxamide 423 C28H27N303 453. 54 454. 5 H O N i i CH3 CHCH3 H N N. CHs 0 CHpHs H O 0 4-((5-(((4-(1, I-dimethylethyl) phenyl) amino) carbonyl)-2- naphthalenyl) oxy)-N-methyl-2-pyridinecarboxamide 424 _ _ C24Hl9N303 397. 43 398. 3 H O N i i H N-CH3 0 N-methyl-4- ( (5- ( (phenylamino) carbonyl)-2- naphthalenyl) oxy)-2-pyridinecarboxamide 425 C25HIgF3N303 465. 42 466. 4 H O N if O I F F ( I NN'CH 0 rN o N-methyl-4- ( (5- ( ( (4- (trifluoromethyl) phenyl) amino) carbonyl)-2-naphthalenyl) oxy)- 2-pyridinecarboxamide 426 H C25Hl 8F3N304 481. 43 482. 4 H O N zizi 0 F+F F H INCH3 N N. CHs 0 N-methyl-4- ( (5- ( ( (4- ( (trifluoromethyl) oxy) phenyl) amino) carbonyl)-2-naphthalenyl) oxy)- 2-pyridinecarboxamide 427 C2sH2lN3o4 427. 45 428. 1 H O N zizi O CH3 0 bu3 N N. CHs N CH3 N-methyl-4- ( (5- ( ( (4- (methoxy) phenyl) amino) carbonyl)- 2-naphthalenyl) oxy)-2-pyridinecarboxamide 428 CzSH2 N303 411. 46 412. 1 H O N I CH3 0 H 0" N N. CHs O N-methyl-4- ( (5- ( ( (4-methylphenyl) amino) carbonyl)-2- naDhthalenvl) oxv)-2-Dvridinecarboxamide 429 C24Hl8CIN303 431. 88 432. 4 H 0 ci i w w i i NU H -eN"r C H 3 0 0 4-((5-(((3-chlorophenyl) amino) carbonyl)-2- naphthalenyl) oxy)-N-methyl-2-pyridinecarboxamide 430 C26H, gFsN303 515. 43 516. 1 H O N F F w w FF O F H N N. CHs ¢NCH3 N-methyl-4- ( (5- ( ( (4- (pentafluoroethyl) phenyl) amino) carbonyl)-2-naphthalenyl) oxy)-2- pyridinecarboxamide 431 CZ, Hl9N303 361. 4 362. 3 H ON 0 H N. O 0 4- ( (5- ( (cyclopropylamino) carbonyl)-2- naphthalenyl) oxy)-N-methyl-2-pyridinecarboxamide 432 C25H2oCIN303 445. 9 446. 4 H CRI wN CH3 0 H N. CH3 o 4- ( (5- ( ( (3-chloro-4-methylphenyl) amino) carbonyl)-2- naphthalenyl) oxy)-N-methyl-2-pyridinecarboxamide 433 C2sH21N304 427. 46 428. 4 i O_CH3 ON H r H O 0 N-methyl-4- ( (5- ( ( (2- (methoxy) phenyl) amino) carbonyl)- 2-naphthalenyl) oxy)-2-pyridinecarboxamide 434 pzOcH C2sH2lN3o4 427. 46 428. 4 O nu ON H ri) H O NH 0 N-methyl-4- ( (5- ( ( (3- (methoxy) phenyl) amino) carbonyl)- 2-naphthalenyl) oxy)-2-pyridinecarboxamide 435 n C2sH2, N303 411. 46 412. 4 CH3 O nu ON H r H O 0 N-methyl-4- ( (5- ( ( (2-methylphenyl) amino) carbonyl)-2- naphthalenyl) oxy)-2-pyridinecarboxamide 436 C25H2lN303 411. 46 412. 4 1 CH3 ON O NU H N. Nt H O 0 N-methyl-4- ( (5- ( ( (3-methylphenyl) amino) carbonyl)-2- naphthalenyl) oxy)-2-pyridinecarboxamide 437 C2sH, sF3N303 465. 43 466. 4 Cl F i F 0 NH H N. CH3 0 N-methyl-4- ( (5- ( ( (3- (trifluoromethyl) phenyl) amino) carbonyl)-2-naphthalenyl) oxy)-2-pyridinecarboxamide 438 C24Hl7F2N303 433. 41 434. 2 F F zizi p nu H 0 N N'CH3 O 4- ( (5- ( ( (3, 4-difluorophenyl) amino) carbonyl)-2- naphthalenyl) oxy)-N-methyl-2-pyridinecarboxamide 439 C26H, 9N303 421. 45 422. 2 CH 0 NH ON O N. 0 0 4- ( (5- ( ( (3-ethynylphenyl) amino) carbonyl)-2- naphthalenyl) oxy)-N-methyl-2-pyridinecarboxamide 440 (r H3 C26H23N303 425. 49 426. 2 ON p nu H N. 0 0 4- ( (5- ( ( (3-ethylphenyl) amino) carbonyl)-2- naphthalenyl oxy)-N-methyl-2-pyridinecarboxamide 441 C24H, sBrN303 476. 33 477. 1 1 ber ON p nu I N 0 N. CH3 O 4- ( (S- ( ( (3-bromophenyl) amino) carbonyl)-2- naphthalenyl) oxy)-N-methyl-2-pyridinecarboxamide 442 C26H23N303 425. 49 426. 2 CH CH3 ON OH O N. 0 0 4-((5-(((3, 5-dimethylphenyl) amino) carbonyl)-2- naphthalenyl) oxy)-N-methyl-2-pyridinecarboxamide 443 C26H23N305 457. 48 458. 2 CHYs ON p nu H H CH3 t 0 4- ( (5- ( ( (3, 5-bis (methoxy) phenyl) amino) carbonyl)-2- naphthalenyl) oxy)-N-methyl-2-pyridinecarboxamide 444 C24Hl7F2N303 433. 41 434. 2 F F ON p nu H H N'CH3 0 4-((5-(((3, 5-difluorophenyl) amino) carbonyl)-2- naphthalenyl) oxy)-N-methyl-2-pyridinecarboxamide 445 C23Hl7CIN403 432. 87 433. 1 N. CI zizi ON w w N H 0 O 4- ( (5- ( ( (2-chloro-4-pyridinyl) amino) carbonyl)-2- naphthalenyl) oxy)-N-methyl-2-pyridinecarboxamide 446 CZZHz, N303 375. 43 376. 1 Og, NH rus H H 0 O 4- ( (5- ( ( (cyclopropylmethyl) amino) carbonyl)-2- naphthalenyl) oxy)-N-methyl-2-pyridinecarboxamide 447 09 C26H2lN30s 455. 47 456. 1 tu ON zu H N. CH3 0 4- ( (5- ( (2, 3-dihydro-1, 4-benzodioxin-6-ylamino) carbonyl)-2-naphthalenyl) oxy)-N-methyl- 2-pyridinecarboxamide 448 C2 H, 6N403S 404. 45 405. 1 SN O NH 0 NH O H 0 0 N-methyl-4- ( (5- ( (1, 3-thiazol-2-ylamino) carbonyl)-2- naphthalenyl) oxy)-2-pyridinecarboxamide 449 C25H, sF3N304 481. 43 482. 1 0 F zu ON 0 NH Fi H H 0 O N-methyl-4- ( (5- ( ( (3- ( (trifluoromethyl) oxy) phenyl) amino) carbonyl)-2-naphthalenyl) oxy)- 2-pyridinecarboxamide 450) C26H24N403 440. 5 441. 1 try OH O 0g X N. CH3 0 4-((5-(((3-(dimethylamino) phenyl) amino) carbonyl)-2- naphthalenyl) oxy)-N-meth 1-2-pyridinecarboxamide 451 N, Boc C34H36N4Os 580. 68 581. 1 OH ZU fl H t g o 1, 1-dimethylethyl 4, 4-dimethyl-7-(((6-((2- ((methylamino) carbonyl)-4-pyridinyl) oxy)-1- naphthalenyl) carbonyl) amino)-3, 4-dihydro- 2 (1 H)-isoquinolinecarboxylate 452 10 C26Hl9N305S 485. 52 485. 9 (je ZOZO O NU I b H 0 I 4- ( (5- ( ( (1, 1-dioxido-1-benzothien-6-yl) amino) carbonyl)- 2-naphthalenyl) oxy)-N-methyl-2-pyridinecarboxamide The following examples were prepared similar to the procedure described in Example 421, step c omiting the base and using THF as the solvent.

Example No. Structure & Name Mol Formula Mass M+H 453 C3, H32F3N03 579. 62 580. 2 0 HN zu CHg I zu CH3 3 ho O C4N Nt F UF FF 4-((5-(((2-((3-(dimethylamino) propyl) (methyl) amino)-5- (trifluoromethyl) phenyl) amino) carbonyl)-2- naphthalenyl) oxy)-N-methyl-2-pyridinecarboxamide 454 C3oH27F3N403 548. 56 549. 2 0 HO Chus lu O TUS F F F F N-methyl-4- ( (5- ( ( (2- ( 1-piperidinyl)-5- (trifluoromethyl) phenyl) amino) carbonyl)-2-naphthalenyl) oxy)- 2-pyridinecarboxamide 455 C32H32F3N503 591. 63 592. 2 0 HAN I CH3 Y CI-13 Y CH3 HN O NDr N F CH3 F F CH3 F F N-methyl4-((5-(((2-(methyl (l-methyl4-piperidinyl) amino)-5- (trifluoromethyl) phenyl) amino) carbonyl)-2- naphthalenyl oxy)-2-pyridinecarboxamide 456 C3lH3oF3N503 577. 6 578. 2 0 l CHs T OY HN JX i i W Zon / Cl3 F F F 4-((5-(((2-((3R)-3-(dimethylamino)-1-pyrrolidinyl)-5- (trifluoromethyl) phenyl) amino) carbonyl)-2- naphthalenyl) oxy)-N-methyl-2-pyridinecarboxamide 457 C28H22F3N303 505. 49 506. 1 0 HO CH3 i 0 0 ZOZO IF OFF N-methyl-4- ( (5- ( (7- (trifluoromethyl)-3, 4-dihydro- 1 (2H)-quinolinyl) carbonyl)-2-naphthalenyl) oxy)-2- pyridinecarboxamide Example 458 CHn 4- ( (5- ( ( (4, 4-dimethyl-1, 2, 3, 4-tetrahydro-7- CH3 NH isoquinolinyl) amino) carbonyl)-2- naphthalenyl) oxy)-N-methyl-2- pyridinecarboxamide O NH 0 0X eNy CH3 0

The title compound was prepared similar to the procedure described in Example 378 from 1, 1- dimethylethyl 4, 4-dimethyl-7- ( ( (6- ( (2- ( (methylamino) carbonyl)-4-pyridinyl) oxy) -1- naphthalenyl) carbonyl) amino) -3, 4-dihydro-2 (1H)-isoquinolinecarboxylate. MS (ESI pos. ion) m/z : 481.1 (M+H). Calc'd for C29H28N403-480. 57.

The following examples were prepared similar to the procedures described in Example 421, Step c using either TEA or DIEA as the base. Example Mol No. Structure & Name Formula Mass M+H 459 H C24H2ON404 428. 45 429. 0 nit ou N O CH3 p Nd NH CH3 N-methyl-4- ( (5- ( ( 1-methyl-6-oxo-1, 6-dihydro-3-pyridinyl) amino) carbonyl)-2-naphthalenyl) oxy)-2-pyridinecarboxamide 460 H C2sH23N503 441. 49 442. 0 Non in-po O N N 3 bH3 Nu CHUG cl3 CH3 4- ( (S- ( ( (6- (dimethylamino)-3-pyridinyl) amino) carbonyl)-2- naphthalenyl) oxy)-N-methyl-2-pyridinecarboxamide 461 EZCH3 C26H24N204 428. 49 429. 2 rcHs ON. H i Cl13 0 O o CH3 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N-(1- methylcyclopropyl)-I-naphmal enecarboxamide 462 C24Hl8F4N204 474. 41 475 H F 0 F F i \H3 oSW 0 0 F CHs I 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-5-fluoro-N- (2, 2, 2- trifluoroethyl)-1-naphthalenecarboxamide 463C24H2oFN30s 449. 44 450. 1 H 0 OtN=NH2 jazz PH3 0 6b N-F ON chus CH3 N- (2-amino-2-oxoethyl)-6- (6, 7-dimethoxyquinolin4-yloxy)- 5-fluoro-1-naphthamide 464 C27H27N502 553. 67 NA CH3 CH3 N N O O O d/ t O v H H tert-butyl 4, 4-dimethyl-7- (2- (2- (methylamino) pyrimidin-4- yloxy)-1-naphthamido)-3, 4-dihydroquinoline-1 (2H)- carboxylate 465 C24H22N205 418. 44 419. 2 0 / N o O/ 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (2-hydroxyethyl)-1- naphthalenecarboxamide 466 C29H23FN204 482. 51 483 C 3 ON O NU zu CH3 O O F O NH 0 CHg 6- ( (3-fluoro-6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (3- methylphenyl)-I-naphthalenecarboxamide 467 C29H26FN305 515. 53 516. 2 I nhJf T"y N_ I 0 F j6 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (5- (I, I- dimethylethyl)-3-isoxazolyl)-5-fluoro-1- naphthalenecarboxamide The following example was prepared according to Example 421, Step C, but using chloroform as the solvent. Example Mol No. Structure & Name Formula Mass M+H 468 C26H24N3Os 47i. 4S 478. 1 0 N NH 0 \ \ F o NJ 6- (6, 7-dimethoxyquinolin-4-yloxy)-N- (2- (dimethylamino)- 2-oxoethyl)-5-fluoro-1-naphthamide

The following example was prepared according to Example 421, step C, but using chloroform as the solvent, omitting the base. Example Mol No. # Structure & Name Formula Mass M+H 469 C24H, 8FN304 431. 42 432. 1 H O N =N C3 O OF 0 N CHg 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (cyanomethyl)-5- fluoro-1-naphthalenecarboxamide The following example was prepared similar to Example 421, Step c, omitting the base. Example No. Structure & Name Mol Formula Mass M+H 470 C2sH23FN204 434. 46 435. 1 H 0 N y CH3 Cl. 3 CHg O O, F O NJ CHs CH3 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-5-fluoro-N-(1- methylethyl)-1-naphthalenecarboxamide Example 471 CH3 CH3 N-(4, 4-dimethyl-1, 2, 3, 4- tetrahydro-7-quinolinyl)-6- ( (2- (methylamino)-4- N pyrimidinyl) oxy)-1- NH H naphthalenecarboxamide 04 O N N N 3 H

The title compound was prepared similar to Example 378 using tert-butyl 4, 4-dimethyl-7- (2- (2- (methylamino) pyrimidin-4-yloxy)-1-naphthamido)-3, 4-dihydroquinoline-1 (2H) -carboxylate as the starting material. MS (ESI pos. ion) m/z: 454.1 (M+H). Calc'd for C27H27N5O2-453. 54. Example 472 N w/6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)- N-ethyl-S-fluoro-l- naphthalenecarboxamide O 1-110 F y NJ ON

6-(6,7-Dimethoxyquinolin-4-yloxy)-5-fluoro-1-naphthoyl chloride (70 mg) was stirred in a solution of 2M EtNH2 in THF (3 mL) at RT for 4 days. Solvent was evaporated and residue purified by prep plate using 5% MeOH in CH2CI2 as the eluent. The solid obtained was rinsed with ether and dried to afford the title compound. MS (ESI pos. ion) m/z : 421. 1 (M+H). Calc'd for C24H2, FN204-420. 43.

The following examples were prepared similar to the procedures described in Example 421, step c, omitting the base and using THF as the solvent. Example No. Structure & Name Mol Formula Mass M+H 473 C27H23N304S 485. 56 486. 1 CHs CH3 I CH3 N han"0 razz CL3 HN 0 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (l- (1, 3-thiazol-2- yl) ethyl)-1-naphthalenecarboxamide 474 C33H2sF3N304S 619. 66 620 CHs qH3 0 N CH3 0 I w w HAN O VS ON OFF 6- ( (6, 7-bis (methoxy) 4-quinolinyl) oxy)-N-(2-(4- thiomorpholinyl)-5- (trifluoromethyl) phenyl)-l- naphthalenecarboxamide 475 C33H28F3N3OsS 635. 66 636 CHs H3 0 N Cl3 0 cl3 0 C LJt. t' S 1 HN 0 ZON \ I F FF 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N-(2-(1-oxido-4- thiomorpholinyl)-5-(trifluoromethyl) phenyl)-1- naphthalenecarboxamide 476 C33H28F3N306S 651. 66 652. 1 CH3 O N O CH3 0 I w w CH3 0 0 H N20 ON F OFF 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N-(2-(1, 1-dioxido-4- thiomorpholinyl)-5- (trifluoromethyl) phenyl)-1- naphthalenecarboxamide Example 477 0 N-methyl-4- ( (5- ( ( (3- chlorophenyl) carbonyl) amino)-2- naphthalenyl) oxy)-2-pyridinecarboxamide 04 N 0

Step (a) Prepration of 4- (5-aminonaphthalen-2-yloxy)-N-methylpicolinamide To a solution of 5-amino-2-napthol (2.8 g, 17. 6 mmol) in DMF (20 mL), NaH (60% in oil, 843 mg, 21. 1 mmol) was added and stirred until the bubbling stopped. To the mixture 4-chloro-N-

methylpicolinamide (Org. Proc. Res. & Dev. , 2002,6, 777-781) (1 g, 5.86 mmol) was added and the reaction heated to 90 °C for 22 h. The mixture was cooled to RT and diluted with CHC13 and washed with water. The emulsion was filtered thru a pad of Celite and the layers separated. The water was washed with CHC13 and the organic portions combined and washed with 1N NaOH and brine, dried with Na2SO4, filtered and evaporated. The residue was purified by column chromatography using hexanes and EtOAc as the eluent to give the title compound as a rose-colored solid.

Step (b) Preparation of N-methyl-4-((5-(((3-chlorophenyl) carbonyl) amino)-2-naphthalenyl) oxy) -2- pyridinecarboxamide To a suspension of 4- (5-aminonaphthalen-2-yloxy)-N-methylpicolinamide (40 mg, 0.14 mmol) and NaHC03 (33 mg, 0.44 mmol) in CH2C12, 3-chlorobenzoyl chloride (17 OL, 0.14 mmol) was added.

The reaction was stirred at RT for 12 h then taken up into CHC13 and washed with water and brine, dried over Na2SO4, and filtered. The title compound was isolated after purification by column chromatography. MS (ESI pos. ion) frizz : 432.4 (M+H). Calc'd for C24H, 8CIN303-431. 87.

The following examples were prepared similar to the procedures described in Example 477 and purified by column chromatography and/or crystallization. Example Structure & Name Formula Calc MW M+H 478 0 C24Hl8CIN303 431. 88 432. 4 NY Cri 0 NY 0 4- ( (S- ( ( (4-chlorophenyl) carbonyl) amino)-2- naphthalenyl) oxy)-N-methyl-2-pyridinecarboxamide 479 CMH, 9N303 397. 43 398. 4 0 N 0 u Y 0 N-methyl-4- ( (5- ( (phenylcarbonyl) amino)-2- naphthalenyl) oxy)-2-pyridinecarboxamide 480 C25Hl8F3N303 465. 43 466. 4 0 N cl3 N (N y N N 0 N-methyl-4- ( (5- ( ( (4- (trifluoromethyl) phenyl) carbonyl) amino)-2- naphthalenyl) oxy)-2-pyridinecarboxamide 481 C24Hl8FN303 415. 42 416. 4 141 zu 0 O 4- ( (5- ( ( (2-fluorophenyl) carbonyl) amino)-2- naphthalenyl) oxy)-N-methyl-2-pyridinecarboxamide 482 sFN303 415. 42 416. 4 0 F N 4ì 0 4- ( (5- ( ( (3-fluorophenyl) carbonyl) amino)-2- naphthalenyl) oxy)-N-methyl-2-pyridinecarboxamide 483 C24H, 8FN303 415. 42 416. 4 0 N Zu N 4- ( (5- ( ( (4-fluorophenyl) carbonyl) amino)-2- naphthalenyl) oxy)-N-methyl-2-pyridinecarboxamide 484 0 C28H27N303 453. 54 454. 5 r fuzz O r o 4-((5-(((4-(1, 1-dimethylethyl) phenyl) carbonyl) amino)-2- naphthalenyl) oxy)-N-methyl-2-pyridinecarboxamide 485 0 C25H2, N304 427. 46 428. 1 N 0,, 0 U ('N-Y N N-methyl-4- ( (S- ( ( (3- (methoxy) phenyl) carbonyl) amino)-2- naphthalenyl) oxy)-2-pyridinecarboxamide 486 Cz5H2, N304 427. 46 428. 1 O w i i 4 O bzw 0 0 N-methyl 4-((5-(((4-(methoxy) phenyl) carbonyl) amino)-2- naphthalenyl) oxy)-2-pyridinecarboxamide 4870 C23H, sN403 398. 42 399. 1 NAN N ion oils 0 N-methyl-4- ( (5- ( (2-pyridinylcarbonyl) amino)-2- naphthalenyl) oxy)-2-pyridinecarboxamide 488 0 C23H, 8N403 398. 42 399. 1 N N 0 O 4W 0 N-methyl-4- ( (5- ( (3-pyridinylcarbonyl) amino)-2- naphthalenyl) oxy)-2-pyridinecarboxamide 489 0 C23H, 8N403 398. 42 399. 1 N N O < N u BZW 0 N-methyl-4- ( (5- ( (4-pyridinylcarbonyl) amino)-2- naphthalenyl) oxy)-2-pyridinecarboxamide 490 0 F C2sHgF3N303 465. 43 466. 1 N F F 0 ('N y N 0 N N O N-methyl-4- ( (S- ( ( (3- (trifluoromethyl) phenyl) carbonyl) amino)-2-naphthalenyl) oxy)- 2-pyridinecarboxamide 491 0 C25H, 7C1F3N303 499. 87 500 CF3 / CRI O N N 04 0 4- ( (5- ( ( (4-chloro-3- (trifluoromethyl) phenyl) carbonyl) amino)-2-naphthalenyl) oxy)-N-methyl-2- pyridinecarboxamide 492 C25H20CIN303 445. 9 446. 1 0 N fizz O N N 0 4- ( (5- ( ( (4-chlorophenyl) acetyl) amino)-2- naphthalenyl) oxy)-N-methyl-2-nyridinecarboxamide 493 C2sHN303411. 46412. 1 N zu O 0 0 N-methyl-4- ( (5- ( (phenylacetyl) amino)-2- naphthalenyl oxy)-2-pyridinecarboxamide 494 C26H, 7F6N303 533. 43 534. 1 N F F IF F zu 0 0 - ( (5- ( ( (3, 5-bis (trifluoromethyl) phenyl) carbonyl) amino)-2 naphthalenyl oxy)-N-methyl-2-pyridinecarboxamide 495 C22H23N303 377 44 378. 2 Ni-1 nutz 0 nu O 4- ( (5- ( (2, 2-dimethylpropanoyl) amino)-2- naphthalenyl) oxy)-N-methyl-2-pyridinecarboxamide 496 C24H25N303 403. 48 404. 2 N N / O N) t1 0 4- ( (5- ( (cyclohexylcarbonyl) amino)-2-naphthalenyl) oxy)- N-methyl-2-pyridinecarboxamide 497 CSHZ, N303 411. 46 412. 1 0 N\ 0 (N y u 0 0 N-methyl-4- ( (5- ( ( (4-methylphenyl) carbonyl) amino)-2- naphthalenyl) oxy)-2-pyridinecarboxamide 498 0 C25H2lN303 411. 46 412. 1 N 0 Nu 0 N-methyl-4- ( (5- ( ( (3-methylphenyl) carbonyl) amino)-2- naphthalenyl) oxy)-2-pyridinecarboxamide gObXo 1 N i oll, ('nay '\.. N N 0 4- ( (5- ( ( (3, 4-bis (methoxy) phenyl) carbonyl) amino)-2- naphthalenyl) oxy)-N-methyl-2-pyridinecarboxamide 500 0 C26H23N303 425. 49 426. 1 NY oia \ nu o 4- ( (5- ( ( (3, 4-dimethylphenyl) carbonyl) amino)-2- naphthalenyl) oxy)-N-methyl-2-pyridinecarboxamide 'O C26H23N303 425. 49 426. 1 N zu 0 (N y 4- ( (5- ( ( (3, 5-dimethylphenyl) carbonyl) amino)-2- naphthalenyl) oxy)-N-methyl-2-pyridinecarboxamide 502 T 3 C26H2 N303 447. 49 448. 1 N /w 0 N N O N-methyl-4- ( (5- ( ( 1-naphthalenylcarbonyl) amino)-2- naphthalenyl) oxy)-2-pyridinecarboxamide Example 503 F\F 6-« 2-(methylamino)-4-pyrimidinyl) oxy)- N- (3- (tritluoromethyl) phenyl)-1- naphthalenecarboxamide HN O 0 NIN-- H NH N

Step (a) Preparation of 6-(2-chloropyrimidin-4-yloxy)-1-naphthoic acid To a solution of 6-hydroxy-1-naphthoic acid (10.0 g, 53.1 mmol) in DMSO (60 mL) was added Cs2C03 (51.9 g, 159.4 mmol). Bubbling was evident. The mixture was stirred at RT for 5 min, at which time 2, 4-dichloropyrimidine (15. 8 g, 16.3 mmol) was added. The reaction was stirred at RT and monitored by LCMS for the disappearance of starting material. EtOAc (1.0 L) was added, and the reaction was filtered to remove solid Cs2CO3. The mixture was extracted with 2N aqueous NaOH. The aqueous layer was washed with EtOAc, then acidified with 6N aqueous HCI to provide a white suspension. Filtration yielded a white solid.

Step (b) Preparation of 6-(2-chloropyrimidin-4-yloxy)-1-naphthoyl chloride To a suspension of 6- (2-chloropyrimidin-4-yloxy)-1-naphthoic acid (Step a, 2.30 g, 7.65 mmol) in CH2CI2 (50 mL) was added DMF (5 drops), followed by oxalyl chloride (0.734 mL, 8.41 mmol) dropwise.

The mixture bubbled and was stirred at RT overnight. The reaction was filtered through a frit to remove any remaining solid and concentrated to afford the desired light-tan solid as its hydrochloride salt.

Step (c) Preparation of 6- (2-chloropyrimidin-4-yloxy)-N- (3- (trifluoromethyl) phenyl)-l-naphthamide To a suspension of the hydrochloride salt of 6- (2-chloropyrimidin-4-yloxy)-1-naphthoyl chloride (step b, 0.122 g, 0.34 mmol) in THF (3 mL) was added 3- (trifluoromethyl) benzenamine (0.047 mL, 0. 38 mmol). The reaction was stirred at RT overnight. The mixture was concentrated and partitioned between EtOAc and 2N aqueous NaOH. Extraction with several portions of EtOAc was followed by washing of the organic layer with brine and drying with MgS04. The solution was filtered and concentrated to afford the desired compound.

Step (d) Preparation of 6-(2-chloropyrimidin-4-yloxy)-N-(3-(trifluoromethyl) phenyl)-1- naphthamide 6-(2-Chloropynmidin-4-yloxy)-N-(3-(trifluoromethyl) phenyl)-1-naphthamide (0.075 g, 0.17 mmol) was stirred overnight at RT in a sealed tube with 2.0 M methylamine (3.0 mL) in THF. The reaction was concentrated, taken up in EtOAc, and washed with 2N aqueous NaOH. The mixture was washed with brine, dried with MgS04 and filtered. The concentrated mixture was purified by chromatography on silica gel to afford the desired product. MS (ESI, pos. ion) m/z : 439.0 (M+1). Mass Calc'd for C23H, 7F3N402 : 438.07.

The following examples were prepared similar to the procedures described in Example 503. Example Structure & Example Mol Formula Mass M+H No. 504 C26H26N402 426. 52 427. 2 H x I N, p NO CHUT HN 0 CH3 CH3 CH3 N- (4- ( 1, 1-dimethylethyl) phenyl)-6- ( (2- (methylamino)-4- pyrimidinyl) oxy)-1-naphthalenecarboxamide 505 C23H, 7F3N402 438. 41 439. 0 H ZU CH3 0 HN'0 IF F F F F F 6- ( (2- (methylamino)-4-pyrimidinyl) oxy)-N- (4- (trifluoromethyl) phenyl)-1-naphthalenecarboxamide 506 C29H3, F3N602 552. 598 553. 6 NaN Nu N 0 zu I N O F F F N- (2- ( (3- (dimethylamino) propyl) methyl) amino)-5- (trifluoromethyl) phenyl)-6- ( (2- (methylamino)-4- pyrimidin l oxy)-1-naphthalenecarboxamide 507 C2sH26F3N502 521. 54 522 nez NU N/ O ON v" N, kJF 6- ( (2- (methylamino)-4-pyrimidinyl) oxy)-N- (2- (1- piperidinyl)-5- (trifluoromethyl) phenyl)-1- naphthalenecarboxamide The following examples were prepared similar to the procedures described in Example 503, with heating to 60 C in Step d.

Example Mol No. Structure & Name Formula Mass M+H 508 C23H23NsO3 417. 47 418. 1 ZON NU N NEO N N- (5- ( 1, 1-dimethylethyl)-3-isoxazolyl)-6- ( (2- (methylamino)- 4-pyrimidinyl) oxy)-1-naphthalenecarboxamide 509 CZqH, 9N502S 441. 51 442. 1 N (j OOH NU fun C 4 H H 6- ( (2- (methylamino)-4-pyrimidinyl) oxy)-N- (2-methyl-1, 3- benzothiazol-5-yl)-1-naphthalenecarboxamide 510 C23H2ON403 400. 44 401. 1 H O N /w u 0 6H3 N NN. CH3 H 6- ( (2- (methylamino)-4-pyrimidinyl) oxy)-N- (4- (methoxy) phenyl)-1-naphthalenecarboxamide 511 H C22H, 7CIN402 404. 86 405. 1 N 1 ci NN. CH3 H N-(4-chlorophenyl)-6- ( (2- (methylamino)-4-pyrimidinyl) oxy)- 1-naphthalenecarboxamide 512 CH3 CH3 C28H27N503 481. 55 482. 1 fez O o-JL zon I N NH CHs N- (1-acetyl-3, 3-dimethyl-2, 3-dihydro-I H-indol-6-yl)-6-((2- (methylamino)-4-pyrimidinyl) oxy)-1- naphthalenecarboxamide 513 CH3 C26H26N402 426. 52 427. 2 eCH3 0 HN CH3 0 ZON I H H 6- ( (2- (methylamino)-4-pyrimidinyl) oxy)-N- (3-methyl-4- ( 1- methylethyl) phenyl)-1-naphthalenecarboxamide 514 Cz3H, F3N403 454. 41 455. 1 , off zu jan 0 N I OH H 6- ( (2- (methylamino)-4-pyrimidinyl) oxy)-N- (4- (trifluoromethyl oxy) phenyl)-1-naphthalenecarboxamide 515 p N O-CH C23H20N43 400. 44 401. 1 0 N zon ZON H NN. CH3 0 6- ( (2- (methylamino)-4-pyrimidinyl) oxy)-N- (3- (methoxy) phenyl)-1-naphthalenecarboxamide Example 516 6-(pyrimidin-4yloxy)-1-naphthoic acid

To a solution of 6- (2-chloropyrimidin-4-yloxy)-1-naphthoic acid (1.3 g, 4.3 mmol) in a CH2CI2/EtOAc/MeOH mixture were added ammonium formate (2.74 g, 43 mmol) and wet Pd/C. The mixture was stirred at RT overnight, filtered through a pad of Celite and evaporated to give the title compound as a brown solid.

The following examples were prepared similar to the procedures described in Example 357 and purified by column chromatography and/or crystallization. Example No. Structure & Name Mol Formula Mass M+H 517 H C2, H, 4CIN302 375. 81 376. 1 H O N w w ci jan N ZON J -nit N- (4-chlorophenyl)-6- (4-pyrimidinyloxy)- I- naphthalenecarboxamide 518 C2, Hi4CIN302 375. 81 376. 1 H 0 c I N zu 0 ice . nu N- (3-chlorophenyl)-6- (4-pyrimidinyloxy)-1- naphthalenecarboxamide 519 C22H, 3CIF3N302 443. 81 444. 1 H F O N Cul 0 N '¢NsXF Nt N N- (4-chloro-3- (Mfluoromethyl) phenyl)-6- (4-pyrimidinyloxy)- 1-naphthalenecarboxamide 520 C22H"N302 355. 39 356. 2 H N 0 cl3 J zon C55 0 N- (3-methylphenyl)-6- (4-pyrimidinyloxy)-1- naphthalenecarboxamide 521 C22H, 6CIN302 389. 84 390. 1 H 0 CRI w w N O AN N N- (3-chloro-4-methylphenyl)-6- (4-pyrimidinyloxy)-1- naphthalenecarboxamide 522 C23Hl9N302 369. 42 370. 1 H O N CH3 zu . 40 0 ZON . J N N- (3, 4-dimethylphenyl)-6- (4-pyrimidinyloxy)-1- naphthalenecarboxamide Example 523 6- (pyrimidin-4-yloxy)-N- (3- (trifluoromethyl) phenyl)-l-naphthamide 0 F

To a solution of 6- (2-chloropyrimidin-4-yloxy)-N- (3- (trifluoromethyl) phenyl)-l-naphthamide (0.075 g, 0.17 mmol) in EtOAc (3 mL) and methanol (0.5 mL) was added 10% Pd/C (20 mg). The flask was capped with a septum, and H2 gas was introduced through a balloon/needle. Positive H2 pressure was continued as the reaction was stirred vigorously overnight at RT. The reaction was filtered through Celite, concentrated, and purified by chromatography on silica to afford the desired product as a white solid. MS (ESI, pos. ion) m/z : 410.1 (M+1). Mass Calc'd for C22H, 4F3N302 : 409. 36.

The following examples were prepared similar to the procedures described in Example 523: Example Mol No. Structure & Name Formula Mass M+H 524 I C28H28F3N502 523. 56 524. 3 N HNCFa zou Han N oy, N- (2- ( (3- (dimethylamino) propyl) (methyl) amino)-5- (trifluoromethyl) phenyl)-6- (4-pyrimidinyloxy)-l- naphthalenecarboxamide l 6- ( (6- (methylamino)-4- pyrimidinyl) oxy)-N- (3-methylphenyl)- 1-naphthalenecarboxamide O N sN 1NS ZON tN.'y

Step (a) Preparation of 6-chloro-N-methylpyrimidin-4-amine To an ice-bath cooled solution of 4, 6-dichloropyrimidine (3 g, 20 mmol) in THF (5 mL), NEt3 (5.6 mL, 40 mmol) was added followed by slow addition of N-methylamine (2 M in THF, 10 mL, 20 mmol). The mixture was warmed to RT and stirred overnight. The mixture was concentrated in-vacuo, the residue suspended in Et2O and solid collected to give the title compound as a white solid.

Step (b) Preparation of 6- (6- (methylamino) pyrimidin-4-yloxy)-1-naphthoic acid The title compound was prepared similar to the procedure described in Example 783, Step (a), with the temperature of 70-100 °C (until the starting material is consumed).

Step (c) Preparation of 6-((6-(methylamino)-4-pyrimidinyl) oxy)-N-(3-methylphenyl)-1- naphthalenecarboxamide The title compound was prepared similar to the procedure described in Example 357. MS (ESI pos. ion) m/z : 385.2 (M+H). Calc'd for C23H2oN402-384. 43.

The following examples were prepared similar to the procedures described in Example 525 and purified by column chromatography and/or crystallization. Example Structure & Name Mol Formula Mass. M+H No. 526 C22Hl7CIN402 404. 85 405. 1 O N ZON CL O ZON N N N- (4-chlorophenyl)-6- ( (6- (methylamino)-4- pyrimidinyl) oxy)-I-naphthalenecarboxamide 527 C24H22N402 398. 46 399. 2 O N O ZON N NJ N- (3, 4-dimethylphenyl)-6- ( (6- (methylamino)-4- pyrimidinyl) oxy)-1-naphthalenecarboxamide 528 C23HzoN402 384. 43 385. 2 O N zon --N O N N NJ 6- ( (6- (methylamino)-4-pyrimidinyl) oxy)-N- (4- methylphenyl)-1-naphthalenecarboxamide 529 C25HMN402 412. 49 413. 2 O N N u fun N 6-((6-(methylamino) 4-pynmidinyl) oxy)-N-(3-(I- methylethyl) phenyl)-1-naphthalenecarboxamide 530 C23H2oN403 400. 43 401. 2 0 Zon 10 zon ( N NJ 6- ( (6- (methylamino)-4-pyrimidinyl) oxy)-N- (3- (methoxy) phenyl)-1-naphthalenecarboxamide 531 C22Hl8N402 370. 41 371. 2 O N 0 N NNJ 6-((6-(methylamino) 4-pyrimidinyl) oxy)-N- phenyl-I-naphthalenecarboxamide 5 3 2 C22H, 7CIN402 404. 85 405. 1 0 N ci fi ZON ZON N- (3-chlorophenyl)-6- ( (6- (methylamino)-4- pyrimidinyl) oxy)-I-naphthalenecarboxamide 533 C22HI7FN402 388. 39 389. 1 O N F O ZON N lN)- N- (4-fluorophenyl)-6- ( (6- (methylamino)-4- pyrimidinyl) oxy)-I-naphthalenecarboxamide 534 C23H23NsO3 417. 46 418. 2 O, N FOL)" /neo zon , c6 zon N tN-)- N- (5- ( 1, 1-dimethylethyl)-3-isoxazolyl)-6- ( (6- (methylamino)-4-pyrimidinyl) oxy)-1- naphthalenecarboxamide 535 C22H, 7FN402 388. 39 389. 1 O N F i : 6 ZON N N- (3-fluorophenyl)-6- ( (6- (methylamino)-4- pyrimidinyl) oxy)-1-naphthalenecarboxamide 536 C26H26N402 426. 51 427. 2 O N fizz N N N tN-)- N- (4- (1, 1-dimethylethyl) phenyl)-6- ( (6- (methylamino)-4-pyrimidinyl) oxy)-1- naphthalenecarboxamide 537 C, 9H2ON403 352. 39 353. 2 O N i O N N NJ 6-((6-(methylamino)-4-pyrimidinyl) oxy)-N-(2- (methoxy) ethyl)-1-naphthalenecarboxamide Example 538/N-(5-(1, 1-dimethylethyl)-3-isoxazolyl)-6-((3- fluoro-6, 7-bis (methoxy)-4-quinolinyl) oxy)-1- naphthalenecarboxamide N O NH 0 F 0

Step (a) Preparation of 6- (3-fluoro-6, 7-dimethoxyquinolin-4-yloxy)-1-naphthoic acid A resealable tube was charged with 4-chloro-3-fluoro-6, 7-dimethoxyquinoline (prepared by the method described in WO 98/13350) (0.610 g, 2.52 mmol), 6-hydroxy-1-naphthoic acid (0.474 g, 2.52 mmol), palladium acetate (0.023 g, 0. 101 mmol), 2-di-t-butylphosphino-2', 4', 6'-tri-i-propyl-l, l'-biphenyl (0.086 g, 0.202 mmol), potassium phosphate (2.14 g, 10.08 mmol), and DMF (12.6 mL, Aldrich). The system was flushed with argon and the tube was sealed. The mixture was stirred at 100 °C for 19 h then cooled to RT. Water (13 mL) was added, and the pH was adjusted to 6-7 with aqueous 6 N HCl solution.

The resulting precipitate was filtered, washed with water, and purified by column chromatography on silica gel (eluting with 0-100% (50: 50: 2, EtOAc: hexane: AcOH) ) to afford 6- (3-fluoro-6, 7- dimethoxyquinolin-4-yloxy)-1-naphthoic acid as an off-white solid. MS (ESI, pos. ion) m/z : 394. 0 (M+H). Mass Calc'd for C22Hl6FNOs : 393.1 Step (b) Preparation of N- (5- (1, 1-dimethylethyl)-3-isoxazolyl)-6- ( (3-fluoro-6, 7-bis (methoxy)- 4-quinolinyl) oxy)-1-naphthalenecarboxamide Pyridine (1.0 mL) was added to a mixture of 6- (3-fluoro-6, 7-dimethoxyquinolin-4-yloxy)-1- naphthoyl chloride (prepared from 6- (3-fluoro-6, 7-dimethoxyquinolin-4-yloxy)-1-naphthoic acid and oxalyl chloride by the procedure described in Example 273) (0.044 g, 0.107 mmol) and 3-amino-5-t- butylisoxazole (0.075 g, 0.535 mmol). The mixture stirred at 80 °C for 10 h and was then cooled to RT.

The mixture was concentrated and the residue was purified by preparative thin layer chromatography on silica gel plates (eluting with 5% MeOH-CH2CI2). Further purification via preparative thin layer chromatography on silica gel plates (eluting with 90: 10: 1 CH2CI2 : MeOHl : NH4OH) afforded N- (5- (1, 1- dimethylethyl)-3-isoxazolyl)-6- ( (3-fluoro-6, 7-bis (methoxy)-4-quinolinyl) oxy)-1-naphthalenecarboxamide as an off-white solid. MS (ESI, pos. ion) m/z : 516. 0 (M+H). Mass Calc'd for C29H26FN305 : 515. 5 The following examples were prepared similar to the procedures described in Example 538, Step b. Example Structure & Name Mol Formula Mass M+H No. 539 z$HZN504 497. 55 498 0 N N O NH O 0 o I NJ 6- ( (6, 7-bis (methoxy)-4-quinazolinyl) amino)-N- (5- ( 1, 1- dimethylethyl)-3-isoxazolyl)-1-naphthalenecarboxamide 540 C3oH26N405 522. 56 523 'yo VN NH O Con 0 N 6- ( (3-cyano-6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (5- (1, 1- dimethylethyl)-3-isoxazolyl)-1-naphthalenecarboxamide 541 C3oH29N305 511. 57 512. 3 'po N 0 NH 0 0/ 0 N 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (5- (1, 1- dimethylethyl)-3-isoxazolyl)-4-methyl-1- naphthalenecarboxamide 542 C29H28N405 512. 56 513. 1 Te ÇN OH 0 , O <NH2 '-0 N 6- ( (3-amino-6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (5- (1, 1- dimethylethyl)-3-isoxazolyl)-1-naphthalenecarboxamide 543 C30H N406 540. 573 541 0 N N 0 N i \ \ p . o N J 4- ( (5- ( ( (5- (1, 1-dimethylethyl)-3-isoxazolyl) amino) carbonyl)-2- naphthalenyl) oxy)-6, 7-bis (methoxy)-3-quinolinecarboxamide 544'7C2sHMN40s 496. 52 497. 1 NU N NON H 0 O N 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (4-methyl-6- (methoxy)-2-pyrimidinyl)-1-naphthalenecarboxamide 545 C27H21CIN404S 533. 01 533 SyN C, NU ON O NU / o tV 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (6-chloro-2- (methylsulfanyl)-4-pyrimidinyl)-1-naphthalenecarboxamide 546 C3lH24F3N305 575. 54 576. 5 4 HJk I N O NH F3C NH \ - N- N-(2-(acetylamino)-5-(trifluoromethyl) phenyl)-6-((6, 7- bis (methox-4-quinolin l oxy)-1-naphthalenecarboxamide 547 Nt C2gH2íN305 491. 5 492. 1 10 o N I -0 N H 0 \ \ N=-J N- (1, 2-benzisoxazol-3-yl)-6- ( (6, 7-bis (methoxy)-4- quinolinyl) oxy)-1-naphthalenecarboxamide 548 C3oH23N306 521. 53 522. 4 ! XNH - O NH Y po O N- 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (4- (methoxy)-1, 2- benzisoxazol-3-yl)-l-naphthalenecarboxamide 549 C26H2oBNO, 534. 36 534. 3 N 0 CH3 0 - nu Nu 0-ce N= 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (4-bromo-5- methyl-3-isoxazolyl)-1-naphthalenecarboxamide 550 C37H28N404 592. 65 593. 5 N N - O-NH \ O N=- 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (1, 3-diphenyl-lH- pyrazol-5-y-naphthalenecarboxamide 551 C32H3ON205S 554. 66 555. 5 fus Z -0 NH CH3 O O \ N= N- (2-acetyl-5- (1, 1-dimethylethyl)-3-thienyl)-6- ( (6, 7- bis (methoxy)-4-quinolinyl) oxy)-1-naphthalenecarboxamide 552 C28H2oCIN304 497. 93 498. 4 N cri CRI 0 0 4-((5-(((4-chlorophenyl) amino) carbonyl)-2-naphthalenyl) oxy)- 7-methox-6-uinolinecarboxamide 553 C27H20N404 464. 47 465. 4 ON N 0 0 N I - kk ON 7- (methoxy)-4- ( (5- ( (2-pyridinylamino) carbonyl)-2- na hthalen 1 ox-6-uinolinecarboxamide 554 zSH, gN404S 470. 50 471. 3 0 N y S N O O N I 0 N 7- (methoxy)-4- ( (5- ( (1, 3-thiazol-2-ylamino) carbonyl)-2- na hthalen 1 ox-6-uinolinecarboxamide 555 CZSH, $N405 454. 4 455. ON Tri /NO N I N I \ o 4- ( (5- ( (3-isoxazolylamino) carbonyl)-2-naphthalenyl) oxy)-7- methox-6-uinolinecarboxamide Example 556 O OH 6- (3-cyano-6, 7-dimethoxyquinolin- 4-yloxy)-1-naphthoic acid 04 0 N ON o NJ

Step (a) Preparation of 4-chloro-3-cyano-6, 7-dimethoxyquinoline Copper (I) cyanide (0.301 g, 3.36 mmol) was added to a solution of 4-chloro-3-diazonium-6, 7- dimethoxy quinoline tetrafluoroborate (prepared by the method described in WO 98/13350) (1.03 g, 3.05 mmol) in acetonitrile (30 mL). The reaction mixture stirred at RT for 2.5 h, then filtered. The filtrate was concentrated to afford 4-chloro-3-cyano-6,7-dimethoxyquinoline as a brown solid. MS (ESI, pos. ion) m/z : 249.0 (M+H). Mass Calc'd for Cz2HsCIN202 : 248.

Step (b) Preparation of 6- (3-cyano-6, 7-dimethoxyquinolin-4-yloxy)-1-naphthoic acid A resealable tube was charged with 6-hydroxy-1-naphthoic acid (0. 596 g, 3.17 mmol), cesium carbonate (3.10 g, 9.51 mmol), and N, N-dimethylformamide (15 mL, Aldrich). The system was flushed with argon, the tube was sealed, and the mixture stirred at RT for 15 min. A solution of 4-chloro-3-cyano- 6,7-dimethoxyquinoline (0.788 g, 3.17 mmol) in N, N-dimethylformamide (10 mL) was added (along with a 5 mL DMF rinse), and the system was again flushed with argon. The tube was sealed and the mixture stirred at 60 °C for 2 h. The mixture was diluted with water (30 mL) and 6 N HCI (aq) was added dropwise with stirring until the pH of the solution was 6-7. The resulting precipitate was filtered and washed with water. The filter cake was dried under vacuum to afford 6- (3-cyano-6, 7-dimethoxyquinolin- 4-yloxy)-1-naphthoic acid as a light brown solid. MS (ESI, pos. ion) m/z : 401.0 (M+H). Mass Calc'd for C23Hs6N205 : 400. Example 557 6- (3-amino-6, 7-dimethoxyquinolin- 0 CI 4-yloxy)-1-naphthoyl chloride I OU , O » NH2 /nua Step (a) Preparation of 6-(6, 7-dimethoxy-3-nitroquinolin-4-yloxy)-1-naphthoic acid A resealable tube was charged with 6-hydroxy-1-naphthoic acid (0.070 g, 0.37 mmol), cesium carbonate (0. 364 g, 1.12 mmol), and DMF (2 mL, Aldrich). The system was flushed with argon, the tube was sealed, and the mixture stirred at RT for 15 min. 4-Chloro-6, 7-dimethoxy-3-nitroquinoline (prepared by the method described in WO 98/13350) (0.100 g, 0.373 mmol) was added, and the system was again flushed with argon. The tube was sealed and the mixture stirred at RT for 4.5 h. The mixture was diluted with water (2 mL) and 6 N HCl (aq) was added dropwise with stirring until the pH of the solution was 5- 6. The resulting precipitate was filtered and washed with water. The filter cake was dried under vacuum to afford 6-(6, 7-dimethoxy-3-nitroquinolin-4-yloxy)-1-naphthoic acid as a yellow solid. MS (ESI, pos. ion) m/z : 421.1 (M+H). Mass Calc'd for C22H, 6N207 : 420.

Step (b) Preparation of 6- (3-amino-6, 7-dimethoxyquinolin-4-yloxy)-1-naphthoic acid Pd on carbon (5 wt%, 0. 015 g) was added to a solution of 6- (6, 7-dimethoxy-3-nitroquinolin-4- yloxy)-l-naphthoic acid (0.149 g, 0. 354 mmol) in MeOH (30 mL). The system was purged with H2 (g) and stirred under a H2 atmosphere at RT for 21 h to afford a thick suspension. The pH of the reaction was adjusted to 6-7 with 2N NaOH (aq), and Pd on carbon (5 wt%, 0.025 g) was added to the resulting solution. The mixture was purged with H2 then stirred under a H2 atmosphere at RT for 3 days (additional

Pd on carbon (5 wt%, 0.025 g) was added after the first and second days). The mixture was filtered through a pad of Celite and the filtrate was concentrated to afford 6- (3-amino-6, 7-dimethoxyquinolin-4- yloxy)-l-naphthoic acid as a brown solid. MS (ESI, pos. ion) m/z : 391.1 (M+H). Mass Calc'd for C22H, 8N205 : 390.

Step (c) Preparation of 6- (3-amino-6, 7-dimethoxyquinolin-4-yloxy)-l-naphthoyl chloride The title compound was prepared similar to the procedure described in Example 801, Step e. Example 558 6- (6, 7-dimethoxyquinolin-4-yloxy)- 0 OH 4-methyl-1-naphthoic acid 04 /°sv ON NJ Step (a) Preparation of 6-(benzyloxy)-4-(dibenzylamino)-1-naphthoic acid A freshly prepared solution of sodium chlorite (16.8 g, 186 mmol) in a 20% aqueous solution of sodium dihydrogen phosphate (155 mL) was added to a solution of 6- (benzyloxy)-4- (dibenzylamino)-1- naphthaldehyde (prepared by the method described in WO 03/014064) (8.50 g, 18.6 mmol) and 2-methyl- 2-butene (27.2 g, 41 mL, 387 mmol) in t-butanol (186 mL). The mixture was stirred vigorously at RT for 1 h. The reaction mixture was diluted with a saturated aqueous solution of sodium sulfite (150 mL) and stirred for 15 min. The mixture was concentrated and then partitioned between CH2CI2 and water. The aqueous phase was separated and extracted with CH2CI2. The combined organic phases were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated to afford a tan solid. This material was purified via column chromatography on silica gel (eluting with 0-50% EtOAc-hexane) to afford 6- (benzyloxy)-4- (dibenzylamino)-l-naphthoic acid as an orange brown solid. MS (ESI, pos. ion) m/z : 474.1 (M+H). Mass Calc'd for C32H27NO3 : 473.

Step (b) Preparation of Methyl 6-(benzyloxy)-4-(dibenzylamino)-1-naphthoate Oxalyl chloride (2.60 g, 1.79 mL, 20.5 mmol) was added dropwise to a solution of 6- (benzyloxy)- 4- (dibenzylamino)-l-naphthoic acid (3.236 g, 6.834 mmol) in dichloromethane (70 mL) and DMF (1 drop). The mixture stirred at RT for 1 h and was concentrated to afford a yellow solid. CH2CI2 (60 mL) was added followed by the dropwise addition of MeOH (10 mL), and the mixture stirred at RT for 45 min.

The mixture was concentrated to afford methyl 6- (benzyloxy)-4- (dibenzylamino)-1-naphthoate as a light brown solid. MS (ESI, pos. ion) m/z : 488.2 (M+H). Mass Calc'd for C33H29NO3 : 487.

Step (c) Preparation of Methyl 4-amino-6-hydroxy-l-naphthoate Pd on carbon (5 wt%, 0.350 g) was added to a solution of methyl 6- (benzyloxy)-4- (dibenzylamino)-l-naphthoate (3.409 g, 6.834 mmol) in MeOH (70 mL). The system was evacuated and purged with argon and then stirred under a H2 (g) atmosphere for 20 h. The mixture was filtered through a pad of Celite and concentrated to afford methyl 4-amino-6-hydroxy-1-naphthoate as a light brown solid.

MS (ESI, pos. ion) mlz : 218.1 (M+H). Mass Calc'd for C, ZH"N03 : 217.

Step (d) Preparation of Methyl 6-hydroxy-4-iodo-1-naphthoate A solution of methyl 4-amino-6-hydroxy-1-naphthoate (0.500 g, 2.30 mmol) in THF (2.5 mL) was cooled to 0 °C and 3 N HCI (5.0 mL) was added. A solution of sodium nitrite (0.175 g, 2.53 mmol) in water (1.2 mL) was added and the mixture stirred at 0 °C for 15 min. A solution of potassium iodide (0.764 g, 4.60 mmol) in water (1.2 ml) was added and the mixture was stirred at 0 °C for 1 h. EtOAc was added and the solution was poured into water. The aqueous phase was separated and extracted with EtOAc. The combined organic phases were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated to afford a red-brown oil. This material was purified via column chromatography on silica gel (eluting with 0-50% EtOAc-hexane) to afford methyl 6-hydroxy-4-iodo-1- naphthoate as a tan solid. MS (ESI, pos. ion) m/z : 328.8 (M+H). Mass Calc'd for Cs2HgIO3 : 328.

Step (e) Preparation of Methyl 6-hydroxy-4-methyl-1-naphthoate A resealable tube was charged with methyl 6-hydroxy-4-iodo-1-naphthoate (0.302 g, 0.920 mmol), toluene (5.0 ml), tetramethyltin (0.40 g, 0.30 mL, 2.2 mmol), and tetrakis (triphenylphosphine) palladium (0) (0.042 g, 0. 036 mmol). The system was purged with argon and the tube was sealed. The mixture stirred at 90 °C for 24 h and was cooled to RT. The mixture was partitioned between EtOAc and water. The aqueous phase was separated and extracted with EtOAc. The combined organic phases were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated to afford an orange solid. This material was purified via column chromatography on silica gel (eluting with 0-50% ethyl acetate-hexane) to afford methyl 6-hydroxy-4-methyl-1-naphthoate as an orange brown solid. MS (ESI, pos. ion) m/z : 217.1 (M+H). Mass Calc'd for C, 3H, ZO3 : 216.

Step (f) Preparation of 6-(6, 7-dimethoxyquinolin-4-yloxy)-4-methyl-1-naphthoic acid A resealable tube was charged with methyl 6-hydroxy-4-methyl-1-naphthoate (0.087 g, 0.402 mmol), cesium carbonate (0.393 g, 1.21 mmol), and DMF (2 mL). The system was flushed with argon, the tube was sealed, and the mixture stirred at RT for 15 min. 4-Chloro-6, 7-dimethoxyquinoline (0.090 g, 0.40 mmol) was added, and the system was again flushed with argon. The tube was sealed and the mixture stirred at 100 °C for 18 h. Additional cesium carbonate (0.393 g, 1.21 mmol) was added and the system was again flushed with argon. The tube was sealed and the mixture stirred at 100 °C for 16 h. The mixture was partitioned between CH2Cl2 and water. The aqueous phase was separated and extracted with CH2CI2. The aqueous phase was acidified to pH 5-6 with 6 N HCI (aq). The resulting precipitate was filtered and washed with water. The filter cake was dried under vacuum to afford 6- (6, 7- dimethoxyquinolin-4-yloxy)-4-methyl-1-naphthoic acid as a light brown solid. MS (ESI, pos. ion) m/z : 390.1 (M+H). Mass Calc'd for C23H, 9NOs : 389.

Example559 C (O) CI 6-(3-carbamoyl-6, 7-dimethoxyquinolin- o, 4-yloxy)-1-naphthoyl chloride 0 0 MeO I NH2 MeO N MeO'N Step (a) Preparation of 3-iodo-6, 7-dimethoxyquinolin-4 (lH)-one A solution of iodine (14.84 g, 58.48 mmol) in KI (20% aq, 100 mL) was added to a solution of 6, 7-dimethoxyquinolin-4 (1H)-one (10.00 g, 48.73 mmol) in 2 N NaOH (aq, 100 mL), and the solution stirred at RT for 17 h. The mixture was acidified with AcOH and the resulting dark purple mixture was filtered and washed with water. The dark purple filter cake was recrystallized from water to afford an off- white suspension. This material was filtered and dried to afford 3-iodo-6,7-dimethoxyquinolin-4 (1H)-one as an off-white solid. MS (ESI, pos. ion) m/z : 332.1 (M+H). Mass Calc'd for C"H, oIN03 : 331.

Step (b) Preparation of 4-chloro-3-iodo-6, 7-dimethoxyquinoline Phosphorus oxychloride (6.743 g, 4.100 mL, 43.98 mmol) was added to a solution of 3-iodo-6, 7- dimethoxyquinolin-4 (1H)-one (13. 237 g, 39. 98 mmol) in DMF (100 mL). The mixture was stirred at 100 °C for 2 h then cooled to RT. The mixture was poured into ice water and the resulting precipitate was filtered and dried to afford 4-chloro-3-iodo-6,7-dimethoxyquinoline as a light brown solid. MS (ESI, pos. ion) m/z : 349.9 (M+H). Mass Calc'd for CuH. ClINOz : 349.

Step (c) Preparation of 4-chloro-6, 7-dimethoxyquinoline-3-carboxamide A stainless steel cylinder was charged with 4-chloro-3-iodo-6,7-dimethoxyquinoline (0.200 g, 0.572 mmol), palladium (II) acetate (0. 013 g, 0.057 mmol), 1, 3-bis (diphenylphosphino) propane (0.047 g, 0.11 mmol), DMF (2 mL), and 1,1, 1,3, 3,3-hexamethyldisilazane S (0.37 g, 0.48 mL, 2.3 mmol). The cylinder was sealed and pressurized with CO gas at 30 psi. The system was heated at 100 °C for 1.5 h and then cooled to RT. The mixture was concentrated to afford an orange solid. This material was triturated with dichloromethane and the resulting precipitate was filtered and dried to afford 4-chloro-6,7- dimethoxyquinoline-3-carboxamide as an off-white solid. MS (ESI, pos. ion) m/z : 267.0 (M+H). Mass Calc'd for C, 2Ho, CIN203 : 266.

Step (d) Preparation of 6- (3-carbamoyl-6, 7-dimethoxyquinolin-4-yloxy)-1-naphthoic acid A resealable tube was charged with 6-hydroxy-1-naphthoic acid (0.035 g, 0.187 mmol), cesium carbonate (0.183 g, 0.561 mmol), and DMF (1.0 mL). The system was flushed with argon, the tube was sealed, and the mixture stirred at RT for 15 min. 4-Chloro-6, 7-dimethoxyquinoline-3-carboxamide (0.050 g, 0.187 mmol) mL) was added (along with a 1 mL DMF rinse), and the system was again flushed with argon. The tube was sealed and the mixture stirred at 60 °C for 26 h. The reaction mixture was diluted with water (2.5 mL) and 6 N HCl (aq) was added dropwise with stirring until the pH of the solution was 5-6. The resulting precipitate was filtered and washed with water. The filter cake was dried under vacuum to afford 6- (3-carbamoyl-6, 7-dimethoxyquinolin-4-yloxy)-1-naphthoic acid as a tan solid. MS (ESI, pos. ion) m/z : 419.0 (M+H). Mass Calc'd for C23H, 8N206 : 418.

Step (e) Preparation of 6- (3-carbamoyl-6, 7-dimethoxyquinolin-4-yloxy)-1-naphthoyl chloride The title compound was prepared similar to the procedure described in Example 682, Step b. Example 560 < H 7-((6, 7-bis (methoxy)-4- quinolinyl) oxy)-N- (4-chlorophenyl)- 2-naphthalenecarboxamide 0 0 ci soin ON A slurry of 7- (6, 7-dimethoxyquinolin-4-yloxy) -2-naphthoic acid (0.54 g, 1.44 mmol) in 10 mL of C202CI2 and 2 drops of DMF was stirred at RT. After 2 h, the solution was concentrated to dryness and placed under high vacuum overnight. A portion of the crude residue (0.075 g, 0.191 mmol) was dissolved in 1 mL of CH2CI2. To the resulting solution was added Et3N (0.106 mL, 0.76 mmol), 4-chloroaniline (0.036 g, 0.286 mmol) and a catalytic amount of DMAP. The reaction was stirred under a nitrogen atmosphere for 16 h. The reaction was diluted with CH2CI2, washed with saturated aqueous NaHCO3, and brine. The organic layer was dried (MgSO4), filtered and concentrated. The residue was passed through a medium- pressure silica gel column (solvent gradient: 95: 5 CH2CI2 : MeOH ; 90: 10 CH2CI2 : MeOH) to afford the desired crude compound. The fractions were concentrated to dryness to afford a solid residue. The residue was triturated with Et20/Hexanes to afford the desired compound as a pale yellow solid. MS (ESI, pos. ion) m/z : 485.0 (M+1). Mass Calc'd for C28H2, CIN204 : 484.937.

The following examples were prepared using that described for Example 560. Example No. Structure & Name Mol Formula Mass M+H 561 C32H3ON204 506. 60 507. 1 dCH3 CH3 0 3/\ \- N-NH 0 H3 CH3 CH3 7- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (4- ( 1, 1- dimethylethyl) phenyl)-2-naphthalenecarboxamide 562 ICH3 oX N ow C2sH22N204 414. 46 415. 1 Cl3 0 N O nu 04 CH3 7- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N-cyclopropyl- 2-naphthalenecarboxamide 563 H C2sH24N205 432. 47 433. 1 CH3 O) 9+N o CH3 6 0 o I \ \ o O NJ I Utl3 7- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (2- (methoxy) ethyl)- 2-naphthalenecarboxamide 564 H C32H3ON204 506. 6 507. 1 FH n\Y3 CH3 O+fNnArCH3 0) e 0 %, CH3 0 N CH3 I CH3 7- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (3-methyl-4- (l- methylethyl) phenyl)-2-naphthalenecarboxamide 565 H C29H2lF3N205 534. 49 535. 0 CH3 0 N-I ,, OF 00) ° wo F I CH3 7- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (4- ((trifluoromethyl) oxy) phenyl)-2-naphthalenecarboxamide 566 H C29H24N205 480. 52 481. 1 CH3 O I N 'CH3 O w w O O N CH3 CHg 7- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (3- (methoxy) Dhenvl)-2-naDhthalenecarboxamide .-. Oll 567 H C25Hl9N305 441. 44 442. 0 PH3 0 N N 6 L ; H3 CHs 7- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (3-isoxazolyl)-2- naphthalenecarboxamide 568 < H C28H2, FN204 468. 48 469. 1 CeJ <r N s F 3 0 \ \ I/ I CH CHs 7- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (3-fluorophenyl)- 2-naphthalenecarboxamide 569 < H C27H2, N304 451. 48 452. 1 CH3 p w N I N o CH3 PF13 0 7- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (3-pyridinyl)-2- naphthalenecarboxamide 570 H C25Hl9N304S 457. 51 458. 0 cH oYs °YS PH 0 N S CHs CH3 7- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (1, 3-thiazol-2-yl)- 2-naphthalenecarboxamide 571 H F C29H2lF3N20s 534. 49 535. 0 , C+b-N) O,, 09 F 3w w I i F O N CH3 7- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (3- trifluorometh I ox hen I-2-na hthalenecarboxamide 572 < H F C29H2, F3N204 518. 4 519. 0 Cl3 N F O O i F O 0 9 0 CHUG 7- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (3- (trifluoromethyl) phenyl)-2-naphthalenecarboxamide 573 H C28H2OCl2N204 519. 38 520. 9 PH 0 N ci 6 0 ci o 0gt ° oCI CH3 CHs 7- ( (6, 7-bi s (methoxy)-4-quinolinyl) oxy)-N- (3, 4- dichlorophenyl)-2-naphthalenecarboxamide 574 H CH3 C3lH28N204 492. 57 493. 1 CH3 p w N I C 0 0-N I CHg 7- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (3- ( 1- methyl) phenyl)-2-naphthalenecarboxamide 575 H C29H23CIN204 498. 96 499. 0 CH p I N CI 0 CIH3 0 N ci 0 CH3 0 UN3 7- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (3-chloro-4- methylphenyl)-2-naphthalenecarboxamide 576 < H C29H27N230s 497. 55 498. 1 CH p I N CH3 3 w w N'O CHCH3 L ; tel3 o CH3 CHg 7-((6, 7-bis (methoxy) 4-quinolinyl) oxy)-N-(5-(1, I- dimethylethyl)-3-isoxazolyl)-2-naphthalenecarboxamide 577/N H CH3 30H27N34 493. 56 494. 2 CH3 p w N I C 0S 0 C 6) 0 CH3 CH3 OLN" CHg 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (3- (l- methylethyl) phenyl)-3-quinolinecarboxamide 578 C27H20ClN304 485. 93 486. 1 N CH3 0 N 6) 0 ci 3 O N I CH3 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (4-chlorophenyl)- 3-quinolinecarboxamide 579 C28H23N305 481. 51 482. 2 N H 0 0 k Iso ( o 0 CH3 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (3- (methoxy) phenyl)-3-quinolinecarboxamide 580-27HlgCI2N304 520. 37 521. 2 ZON CH p I N CI , ci \ \ I/ I o'N' CH3 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (3, 4- dichlorophenyl)-3-quinolinecarboxamide 581-28H20F3N30s 535. 48 536. 2 rTn H F N CH p I N OF O) w i F N CH3 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (3- ( (trifluoromethyl oxy) phenyl)-3-quinolinecarboxamide 582 C3oH2lF6N304 601. 50 602. 1 I H CH3, F CH3 O O N I j FF CIH3 0 N F O N F F 6 0 CHUG 6- ( (6, 7-bis (methoxy) 4-quinolinyl) oxy)-N-(2-methyl-3, 5- bis (trifluoromethyl) phenyl)-3-quinolinecarboxamide 583 Cz9HzN305 497. 55 498. CH H3 OI _CH3 T4 I C3 O Nu nul CH 0 H 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N-(5-(1, I- dimethylethyl)-3-isoxazolyl)-l-naphthalenecarboxamide 584 84 C27H2, N304 451. 48 452. 1 0-N. CH3 o 0 O CHUG CH3 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (4-pyridinyl)-1- naphthalenecarboxamide 585 , N304 451. 48 452. 1 ZON 0 N. H 0. K) 1 i Hs w w BD o ON CHg 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (3-pyridinyl)-1- naphthalenecarboxamide 586 C2sH24N20s 432. 47 433. 1 yCHs O N. H PH3 0 CH3 O O I UN3 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (2- (methoxy) ethyl)- 1-naphthalenecarboxamide 587 C27H26Nz0s 458. 51 459. 1 0 0 N O N. H C3 O O o . NJ 6H3 CHs 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N-tetrahydro-2H- pyran-4-yl-1-naphthalenecarboxamide 588 CMNOs 481. 51 482. 1 N. CH3 ON CH H c3 O O o . NJ 6H3 CHg 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- ( 1-methyl-6-oxo- 1, 6-dihydro-3-pyridinyl)-I-naphthalenecarboxamide 589 C29H28N404 496. 56 497. 2 c 3 H3 H HN- {" N ON I jazz 1 0 o . NJ CHs 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (5- ( 1, 1- dimethylethyl)-I H-pyrazol-3-yl)-I-naphthalenecarboxamide 590 N C29H26N404 494. 55 495. 1 CH3 3 eN 9 i O NH CHEZ 0 0 I UN3 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (6- (dimethylamino)-3-pyridinyl)-1-naphthalenecarboxamide 591 li C25Hl9N304 S 457. 51 458 SUN NH CH3 i i 'H ON chug 1 0 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (1, 3-thiazol-2-yl)- 1-naphthalenecarboxamide 592 C26H26N205 446. 5 477. 1 CHs 0 NH OH 3 C3 O/ ON CHg Ci-13 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (3- (methoxy) propyl)-I-naphthalenecarboxamide 593 C2sH22N206 446. 46 447. 1 OCHs H0 ot, NH LJ 0 o . NJ I L ; tl3 CHs methyl N-((6-((6, 7-bis (methoxy)-4-quinolinyl) oxy)-1- naphthalenyl) carbonyl) glycinate 594 C25H24N206S 480. 54 481. 1 Q CHs 0% OH 'Hs i i 1 0 o . NJ C3 I 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (2- meth lsulfon 1 eth 1-1-na hthalenecarboxamide S,,,,, CH YCH3 N CH3 0 J11 : 6 O CHUS L ; H3 6- ( (6, 7-bis (methoxy) 4-quinolinyl) oxy)-N-(I-(I- methylethyl) 4-piperidinyl)-1-naphthalenecarboxamide 596 C2sHlgN3os 441. 44 442. 1 0 0-H 05 p N'H 0 (0) o . NJ 1 CH3 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (3-isoxazolyl)-1- naphthalenecarboxamide 597 C27H23N3O5 469. 5 470. 1 CH3 O Nr. H N OH Joys 0 O i i I I CHs CH3 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- ( (5-methyl-3- isoxazolyl) methyl)-1-naphthalenecarboxamide 598 C28H21FN204 468. 48 469. 1 F 0 N. H O N. H C3 O O 0 N CHg CH3 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (4-fluorophenyl)- 1-naphthalenecarboxamide 599 C2sH23N304 465. 51 466. 2 N O N. H CH3 1 0 O i i I Chug 1 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (2- pyridinylmethyl)-I-naphthalenecarboxamide 600 N204 464. 52 465. 2 0 N I N. H CH3 1 0 !" o u CHs 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N-(phenylmethyl)-I- naphthalenecarboxamide 601 ¢ ;) C29H24N204 464. 52 465. 2 0-cl3 O NAH 0 0 CH3 O ( O ON CHs 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N-methyl-N-phenyl- 1-naphthalenecarboxamide 602 C29H24N205 480. 52 481. 1 S5N'H H /*LJ O i i I ) I oCQ I 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (2- (methoxy) phenyl)- 1-naphthalenecarboxamide 603 C2sH2, C ! N204 484. 94 485. 1 q ci O N. H 1'' O 0 CH3 CHs 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (3-chlorophenyl)- 1-naphthalenecarboxamide 604 C2sH2) FN204 468. 48 469. 1 q F 0 N. H Cl3 0 0 1 CHs 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (3-fluorophenyl)- 1-naphthalenecarboxamide 605 C26H24N204 428. 49 429. 1 0 N. H Cl3 o 0 0 N I L ; H3 CHs 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N-cyclobutyl- I- naphthalenecarboxamide 606 X C28H2lFN204 468. 48 469 IF Zon CH3 0 i i O 09X 1° N CH3 ON CHg 6-((6, 7-bis (methoxy)-4-quinolinyl) oxy)-N-(2-fluorophenyl)- 1-naphthalenecarboxamide 607 C27H26N204 442. 51 443. 1 O N. H CH3 O O ON CHs 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N-cyclopentyl-I- naphthalenecarboxamide 608 C26H26N2Os 446. 5 447. 1 CH3Nf o-CH3 ; ° ; Y3 0 O// OZON CHg CHs 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- ( (R, S)-l-methyl- 2-(methoxy) ethyl)-1-naphthalenecarboxamide 609 C28H3ON204 458. 56 459. 2 CHs CH3 zizi 0 N O i 0 |C 3 og CHs 6- ( (6, 7-bis (methoxy) 4-quinolinyl) oxy)-N, N-dipropyl-1- naphthalenecarboxamide 610 1 C27H2, N304 451. 48 452. 1 ZON ON... cl3 0 C3 O O) tr-N) o . NJ CH3 CHs 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N-(2-pyridinyl)-1- naphthalenecarboxamide

The following Examples were prepared similar to the procedures described in Example 560 and purified by column chromatography and/or crystallization. Example Mol Calc No. Structure & Name Formula MW M+H 611 C35H37FN406 628. 69 629. 2 0 ÇN O N RU) N---'oN Jazz 61-li 0 N- (5- ( 1, 1-dimethylethyl)-3-isoxazolyl)-5-fluoro-6- ( (6- (methoxy)-7- ( (3- (4-morpholinyl) propyl) oxy)-4- quinolin l oxy)-1-naphthalenecarboxamide Example//0 N- (7- ( (6, 7-bis (methoxy)-4- quinolinyl) oxy)-2-naphthalenyl)- O+H m 4-chlorobenzamide (H cri 0 N O<\N

Step (a) Preparation of 7- (6, 7-dimethoxyquinolin-4-yloxy) naphthalen-2-amine.

To a solution of 7- (6, 7-dimethoxyquinolin-4-yloxy) naphthalen-2-yl trifluoromethanesulfonate (0.825 g, 1.72 mmol) in THF (30 mL), was added Pd (OAc) 2 (0.039, 0.17 mmol), followed by BINAP (0. 1187 g, 0.19 mmol) and Cs2C03 (0. 784 g, 2.41 mmol). Diphenylmethanimine was added and the mixture was stirred at 65 °C for 16 h. The reaction was cooled to RT, treated with IN HCl (12 mL) and stirred for 4 h. The mixture was diluted with water and extracted with EtOAc 3x. The aqueous extract was treated with NH40H until pH=12. This was extracted with EtOAc 3x. The combined organic layers were washed with water and brine, dried over MgSO4, filtered and concentrated in vacuo. The crude material was taken on directly without purification. MS (ESI, pos. ion) m/z : 347.4 (M+l).

Step (b) Preparation of N- (7- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2-naphthalenyl)-4- chlorobenzamide.

To a solution of 7- (6, 7-dimethoxyquinolin-4-yloxy) naphthalen-2-amine (0.110 g, 0.31 mmol) in 10 mL of CH2CI2 was added K2CO3 (0.086 g, 0.62 mmol). The mixture was cooled to 0 °C and 4- chlorobenzoyl chloride (44 mL, 0. 34 mmol) was added. The solution was stirred for 16 h and allowed to gradually warm up to RT. The reaction was diluted with water and extracted with EtOAc 3x. The organic

layer was dried (Na2SO4), filtered and concentrated. The residue was purified using a Gilson Prep HPLC system. The fractions were collected, combined, and extracted with EtOAc 3x. The organic layer was dried (Na2S04), filtered and concentrated to afford the desired compound. MS (ESI, pos. ion) m/z : 485.0 (M+l). Mass Calc'd for C28H2, CIN204 : 484.937.

The following examples were prepared similar to the procedures described in Example 612. Example Structure & Name Mol Formula Mass M+H No. 613 0 F C29H2iF3N204 518. 49 519. 1 PH3 O) N) <F 0 H 1S1 F 0 CH3 UH3 N- (7- ( (6, 7-bis (methoxy) 4-quinolinyl) oxy)-2-naphthalenyl)-3- (trifluoromethyl) benzamide 614 7kN, 0 29H24N205 480. 52 481. 1 leo"0 0o H v o . N J cl3 CH3 N- (7- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2-naphthalenyl)-3- (methoxy) benzamide 615 fr 0 C3zH3oN204 506. 6 507. 2 CH3 O) N) +, X VXCH CH3 0-N"CH3 CHs CHs N- (7- ( (6, 7-bis (methoxy) 4-quinolinyl) oxy)-2-naphthalenyl) 4- (1, 1-dimethylethyl) benzamide 616 M O 30H22N20s 490. 51 491. 1 Po cl-13 0I) aN o . NJ Url3 O N CH3 N- (7- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2-naphthalenyl)-l- benzofuran-2-carboxamide 617 0 F C29H2oF4N204 536. 48 537. 1 cl 0 N F I OXN H F O N i CH3 N- (7- ( (6, 7-bis (methoxy) 4-quinolinyl) oxy)-2-naphthalenyl)-3- fluoro-5- (trifluoromethyl) benzamide 618 » O C27H20CIN304 485. 93 486. 1 J= ci O PH3 ») N O N CH3 N- (7- ( (6, 7-bis (methoxy) 4-quinolinyl) oxy)-2-naphthalenyl)-5- chloro-3-pyridinecarboxamide 619 0 CH3 C27H23N304 453. 5 454. 1 Cl3 0 N 0 H O L ; H3 CHs CH3 N- (7- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2-naphthalenyl)-1- methyl-1H-pyrrole-2-carboxamide 620 » O C3lH26N204 490. 56 491. 2 CH O' N' 6) N CH3 ON CHs (1 S, 2S)-N- (7- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- naphthalenyl)-2-phenylc clopropanecarboxamide 621 PH3 N0 C3oH26N204 478. 55 479. 1 0 O i i H i l 0 N 6H3 CHs N- (7- ( (6, 7-bis (methoxy) 4-quinolinyl) oxy)-2-naphthalenyl)-3- phenylpropanamide 622 1 0 C25H24N205 432. 47 433. 1 CH3 p i i N. CH3 c HJk owCH3 O N I CHs N- (7- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2-naphthalenyl)-3- (methoxy) propanamide 623 0 C27H2lN304 451. 48 452. 1 CH3 p I i i N N --Iy Nl PH3 (D' I CH3 N- (7- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2-naphthalenyl)-2- pyridinecarboxamide 624 » O C28H2lFN204 468. 48 469. 1 CH3 p I, N F O i i H i L ; H3 CH3 ON CHs N- (7- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2-naphthalenyl)-3- fluorobenzamide 625 91 0 C3OH27N3o4 493. 56 494. 2 0-'H IL-19 OJ 0-N C N-CH3 CH3 N- (7- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2-naphthalenyl)-3- (dimethylamino) benzamide 626 91 0 C26H20N205 440. 45 441. 1 CH3 p I i i N O O i i H I/ (Da PH, 0- N CH3 CHs N- (7- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2-naphthalenyl)-2- furancarboxamide 627 C25HlgN305 441. 44 442. 1 CH3 O>@NH 0 0 CH3 N- (7- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2-naphthalenyl)-5- isoxazolecarboxamide 628 1<1 C2gH24N204 464. 52 465. 3 CH3 O<NH ! CH3 S Ot (N- Ou N- (7- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2-naphthalenyl)-2- phenylacetamide 629 C26H2ON204S 456. 52 457. 4 CH3 O>NH O i O IS bb-IS 0 JI 6H, CHg N- (7- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2-naphthalenyl)-2- thiophenecarboxamide 630Y0CMH22N204414. 46 415. 0 ClH3 OwNJ4V N ODE CHUS 1 N- (7- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2-naphthalenyl) cyclopropanecarboxamide 631 CH 0 C27H26N204 442. 51 443. 2 3 N O i w H O) OCN I N- (7- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2-naphthalenyl) cyclopentanecarboxamide 632 oll 0 C29H24N205 480. 52 481. 0 PH3 0"CaN 6 H ob O N CH3 0""N"CHs CHUG N- (7- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2-naphthalenyl)-2- (methoxy) benzamide 633 fT) 0 C28H2, C1N204 484. 94 486. 0 C, JXHX N Cl CH3 CH3 I N- (7- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2-naphthalenyl)-3- chlorobenzamide 634 \ 0 C29H2, F3N204 518. 49 520. 0 CH3 o@N) + O H i F O w NJ F F n CHg N-(7-((6, 7-bis (methoxy) 4-quinolinyl) oxy)-2-naphthalenyl) 4- (trifluoromethyl) benzamide 635 < O C29H2, F3N205 534. 48 535. 4 I O 4N °e Y ° N OyF FT N- (7- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2-naphthalenyl)-3- (trifluoromethoxy) benzamide Example 636 m ° F F N-(7-((6, 7-bis (methoxy)-4- 04 N Jw F quinolinyl) oxy)-2-naphthalenyl)-4- u H ci chloro-3- (trifluoromethyl) benzamide Cl ON"

To a solution of 7- (6, 7-dimethoxyquinolin-4-yloxy) naphthalen-2-amine (0. 137 g, 0. 40 mmol) in 10 mL of DMF was added EDCI (0.077 g, 0.40 mmol), HOBt (0.054 g, 0.40 mmol), and 4-chloro-3- (trifluoromethyl) benzoic acid (0.099 g, 0.44 mmol). DIPEA (0.140 mL, 0.80 mmol) was added and the solution was stirred for 16 h at RT under an atmosphere of nitrogen. The reaction was diluted with water

and extracted with EtOAc 3x. The organic layer was washed with brine, dried (Na2SO4), filtered and concentrated. The residue was purified using a Gilson Prep HPLC system. The fractions were collected, combined, treated with NaHC03 (aq) and extracted with EtOAc 3x. The organic layer was dried (Na2SO4), filtered and concentrated to afford the desired compound. MS (ESI, pos. ion) m/z : 553.0 (M+1). Mass Calc'd for C29H20CIF3N204 : 552.934.

The following examples were prepared similar to the procedures described in Example 636. Example Structure & Name Mol Mass M+H No. Formula 637, CH3 OJXN w C30H26N204 478. 55 479. 2 OJ H 1 T M CHg H z O N CH3 CH3 (2S)-N- (7- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- naphthalenyl)-2-phenylpropanamide 638 C3, H28N205 508. 57 509. 2 0 OrCH3 CN3 p I i i H CHs 3OHX , N i CH3 N- (7- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2-naphthalenyl)-3- (2-methoxy) phenyl) propanamide 639 » O C26H2ON4O4 452. 47 453. 1 CH3 O) >N aN PH3 0 N I) 6 H N O N CH3 N- (7- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2-naphthalenyl)-2- pyrazinecarboxamide 640 ) 0 N C28Hz3N304 465. 51 466. 1 CH3 O//H w PH3 6 1 H CHs I N- (7- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2-naphthalenyl)- 2- (4-pyridinyl) acetamide Example < 9, O N- (7- ( (6, 7-bis (methoxy)-4- 641 1 ON gi/quinolinyl) oxy)-2-naphthalenyl)-3- methylbenzenesulfonamide r -kk., 0 N

To a solution of 7- (6, 7-dimethoxyquinolin-4-yloxy) naphthalen-2-amine (0.168 g, 0.48 mmol) in 20 mL of CH2CI2 was added K2CO3 (0.134 g, 0.96 mmol), and pyridine (1 mL). The mixture was cooled to 0 °C and m-toluenesulfonyl chloride (0.110 g, 0. 58 mmol) was added and the solution was stirred for 16 h at RT under an atmosphere of nitrogen. The reaction was diluted with water and extracted with CH2CI2 3x. The organic layer was washed with brine, dried (Na2SO4), filtered and concentrated. The residue was purified using a Gilson Prep HPLC system. The fractions were collected, combined, treated with NaHC03 (aq) and extracted with EtOAc 3x. The organic layer was dried (Na2SO4), filtered and concentrated to afford the desired compound. MS (ESI, pos. ion) m/z : 501. 0 (M+1). Mass Calc'd for C28H24N205S : 500.573.

The following examples were prepared similar to the procedures described in Example 641. Example No. Structure & Name Mol Formula Mass M+H 642 00 F C28H2lF3N205S 554. 54 555. 1 ,., Vu 6) H 0"N I CHs N- (7- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-2- naphthalenyl)-3- (trifluoromethyl benzenesulfonamide Example 643 6- ( (6, 7-bis (methoxy)-4-quinofinyl) oxy)-N- t N (5-methyl-3-isoxazolyl)-1- naphthalenecarboxamide O NH oJL 0 O) aN- ON

A 16 x 100 mm resealable vial with stir-bar was charged with 1,2-dichloroethane (3.0 mL), 6- (6, 7-dimethoxyquinolin-4-yloxy)-1-naphthoyl chloride (0.15 g, 0.38 mmol), and 5-amino-3-

methylisoxazole (0.045 g, 0.46 mmol). To the suspension was added triethylamine (0.13 mL, 0.95 mmol) and N, N-dimethylaminopyridine (0.005 g, 0.04 mmol). The mixture stirred at 80 °C for 15 h and was then cooled to RT. The reaction mixture was concentrated and the residue was purified by column chromatography on silica gel (eluting with 2% methanol in dichloromethane) to afford 6- ( (6, 7- bis (methoxy)-4-quinolinyl) oxy)-N- (5-methyl-3-isoxazolyl)-1-naphthalenecarboxamide as an off-white solid. MS (ESI, pos. ion) m/z : 456.1 (M+H). Mass Calc'd for C29H26FN3Os : 455.468 The following examples were prepared similar to the procedures described in Example 643. Example Mol No. Structure & Name Formula Mass M+H 644 C26H2lN305 455. 47 456. 1 H -CHi t nCH3 , e, O-N Cl3 0 "lys o 6H3 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (3-methyl-5- isoxazolyl)-I-naphthalenecarboxamide 645 C28H26N404S 514. 6 515. 1 CH3 CH3 N=CH3 NUS ON 0 nu cl3 O o CHs 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (5- (l, 1- dimethylethyl)-1, 3, 4-thiadiazol-2-yl)-1- naphthalenecarboxamide 646 C29H20F2N20 530. 48 531. 2 F HGF O N 0 NI (y CH3 O O chug 0 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (2, 2-difluoro-1, 3- benzodioxol-4-yl)-1-naphthalenecarboxamide _ 647 C33H23N305 541. 56 542. 1 N H mu 0 I CH O 3 O N CH3 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (2-cyano-5-phenyl- 3-furanyl)-l-naphthalenecarboxamide 648 C3oH26N404S 538. 62 539. 1 H O N N -N CL CH3 CH3 c 6 H3 O-N H3 CH3 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (5-cyano4- (1, 1- dimeth leth I-1, 3-thiazol-2- 1-1-na hthalenecarboxamide 649 3, H29N305S 555. 65 556. 2 NU2 H NH2 O 09rNH2 O9No/x HC O N "lys o CH3 3- ( ( (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-1-naphthalenyl) carbonyl) amino)-5-(1, 1-dimethylethyl)-2- thiophenecarboxamide The following example was prepared similar to the procedure described in Example 643, using 2- mercaptothiazoline in place of the amine.

Example No. Structure & Name Mol Formula Mass M+H 650 CsH2oN204S2 476. 57 477 N zozo O/ Su O SN S- (4, 5-dihydro-1, 3-thiazol-2-yl) 6- ( (6, 7-bis (methoxy)-4- quinolinyl) oxy)-1-naphthalenecarbothioate Example 651 SCF3 6-((6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (2-fluoro-5- (trifluoromethyl) phenyl)-l- F naphthalenecarboxamide HN 0 0@ 04N i i , o , NJ

Into a 16 x 100 mm vial was added 3-amino-4-fluorobenzotrifluoride (100 mg, 0. 563 mmol), and dichloromethane (1 mL). To this was added 1.5 mL of a stock solution that is both 0.25M 6- (6, 7- dimethoxyquinolin-4-yloxy)-1-naphthoyl chloride and 0. 5M DMAP in dichloromethane. Reactions was stirred 24 h at RT. The mixture loaded directly onto silica column. Purified using 0 to 100% EtOAc in hexane. Best fractions were pooled, concentrated under reduced pressure to afford the title compound as a yellow oil. MS (ESI, pos. ion) m/z : 537 (M+1). Mass Calc'd for C29H2oF4N204 : 536.47.

The following examples were prepared similar to that described in Example 651. Example No. Structure & Name Mol Formula Mass M+H M-H- 652 C3oH23F3N205 548. 51 549 N/A H C/3 CH3 n r 1 0 F F 0\ ON CHUG 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (2- (methoxy)-5- (trifluoromethyl) phenyl)-1- naphthalenecarboxamide 653 C30H23F3N204 532. 52 533 N/A H CHg ON I VIF CH3 O F F O o CHg 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (2-methyl- 5-trifluorometh 1 hen 1-1-na hthalenecarboxamide 654 C3sH36N404 576. 69 M/2 = 575 O N 289 0 N i N CH3 tN CYC3H3 CH ozon 0 N CH3 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (4- (4- ( 1- methylethyl)-I-piperazinyl) phenyl)-I- naphthalenecarboxamide 655 C3oH3oN404 510. 59 M/2 509 H PH3 =256 0 N N'N lN CH3 CHs 0 CHsCHs m o CHg 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N-(3-(I, I- dimethylethyl)-1-methyl-1 H-pyrazol-5-yl)-1- naphthalenecarboxamide 656 C36H38N405 606. 72 M/2 605 OX N CH3 =304 H CH3 g WCH3 bX CH3 CH3 YY O N i CH3 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (4- (1, 1- dimethylethyl)-3- ( (N, N- dimethylglycyl) amino) phenyl)-1- naphthalenecarboxamide 657 C28H2oF3N304 519. 48 520 N/A H OqzN N I i ( Chug CL3 o CH3 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (4- (trifluoromethyl)-2-pyridinyl)-1- naphthalenecarboxamide ap 658 C3oH2gN20s 496. 56 497 N/A H O NO i w I CH CH 3 I o 1 CHs 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (5, 5- dimethyl-3-oxo-1-cyclohexen-1-yl)-I- naphthalenecarboxamide 659 C35H32F3N304 615. 65 M/2 614 H N'CH3 =308 0 N CH3 F fi "IN Ozon CHUS 0 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (3- (1- methyl-4-piperidinyl)-5- (trifluoromethyl) phenyl)-1- naphthalenecarboxamide Example 660 O N CI N- (3-chloi-o-4-tluorophenyl)-6- ( (6- (methoxy)- §4 Ws 3-pyridinyl) oxy)-1-naphthalenecarboxamide F N N

Step (a) Preparation of 6-methoxypyridin-3-ylboronic acid.

To 5-bromo-2-methoxypyridine (8.25 g, 43.9 mmol) and triisopropylborate (10.3 g, 55.0 mmol) in THF (110 mL) at-80°C was dropwise added n-BuLi (1.6M in hexanes, 30.1 mL, 48.2 mmol). The reaction mixture was gradually warmed to RT over Ih and then stirred at RT for 16h. The reaction mixture was quenched by addition of IN aqueous HCI solution and stirred for lh. The aqueous layer was basified with 6N aqueous NaOH to pH=9, extracted with a mixture of EtOAc and Et2O. The aqueous layer was acidified to pH=7 and extracted with EtOAc. The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo. This material was used in the next step without further purification.

Step (b) Preparation of methyl 6-(6-methoxypyridin-3-yloxy)-1-naphthoate.

A solution/suspension of methyl 6-hydroxy-1-naphthoate (2.49 g, 12.3 mmol), 6-methoxypyridin- 3-ylboronic acid (2.26 g, 14.8 mmol), copper acetate (2.46 g, 13.6 mmol), triethylamine (6.24 g, 61.7 mmol) and 4A molecular sieves (2.00 g) in acetonitrile (120 mL) was stirred at RT for 16 h. The solids were filtered off. The filtrate was concentrated in vacuo. Water was added and extracted with EtOAc.

The organic layer was washed with IM aqueous NaOH solution, water, brine and dried over Na2SO4, filtered and concentrated in vacuo. Purification by silica gel chromatography afforded the title compound.

Step (c) Preparation of 6-(6-methoxypyridin-3-yloxy)-1-naphthoic acid To a solution of 6- (6-methoxypyridin-3-yloxy)-1-naphthoate (480 mg, 1.55 mmol) in THF (155 mL) at RT was added 1M aqueous LiOH (31 mL). The reaction was stirred until the reaction was completed. THF was removed in vacuo. The aqueous layer was acidified using 6M aqueous HCl to pH=6- 7 and extracted with EtOAc. The aqueous layer was further acidified to pH=5 and extracted with EtOAc.

The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo to give the title compound, which was used without further purification.

Step (d) Preparation of 6-(6-methoxypyridin-3-yloxy)-1-naphthoyl chloride hydrochloride salt The title compound was prepared according to Example 273, Step a using 6- (6-methoxypyridin-3- yloxy)-l-naphthoic acid as starting material.

Step (e) Preparation of N- (3-chloro-4-fluorophenyl)-6- ( (6- (methoxy)-3-pyridinyl) oxy)-1- naphthalenecarboxamide To a stirred solution of 6-(6-methoxypyridin-3-yloxy)-l-naphthoyl chloride hydrochloride salt (225 mg, 0.64 mmol) and DIPEA (0.22 mL, 1.285 mmol) in DCM (5 mL) at RT was added 3-chloro-4- fluoroaniline (93.5 mg, 0.64 mmol). After stirring for 16 h, the reaction mixture was directly purified by silica gel chromatography (elution hexanes/EtOAC: 85/15 to 35/65) to give the title compound as a tan solid. MS (ESI, pos. ion) m/z : 423.1 (M+1). Mass Calc'd for C23H, 6CIFN203 : 422.84. Example 661 H N- (l-acetyl-3, 3-dimethyl-2, 3-dihydro-lH- t < indol-6-yl)-6-((6-(methoxy)-3-pyridinyl) oxy)- 1-naphthalenecarboxamide zon ! rS 0 0 The title compound was prepared according to the experimental procedure described in example 660. MS (ESI, pos. ion) m/z : 482.2 (M+1). Mass Calc'd for C29H27N304 : 481. 55. t Example 662 H N- (3, 3-dimethyl-2, 3-dihydro-lH-indol-6-yl)- 6- ( (6- (methoxy)-3-pyridinyl) oxy)-1- /naphthalenecarboxamide N N zon

To a solution of N-(1-acetyl-3, 3-dimethyl-2, 3-dihydro-lH-indol-6-yl)-6-((6-(methoxy)-3- pyridinyl) oxy)-1-naphthalenecarboxamide (482 mg, 0.48 mmol) in EtOH (5.5 mL) was added concentrated aqueous HCl solution (3.3 mL). The reaction mixture was heated at 55-65 °C for 4 h, cooled to RT. EtOH was removed in vacuo. The aqueous layer was basified to pH=7-8 by adding 6M aqueous NaOH solution. The title compound was isolated by filtration and dried under high vacuum. MS (ESI, pos. ion) m/z : 440.1 (M+l). Mass Calc'd for C27H25N3O3 : 439. 51. Example 663 o H N- (3-chtoro-4-nuorophenyt)-6- ( (6-oxo-l, 6- dihydro-3-pyridinyl) oxy)-l- /F naphthalenecarboxamide HCI Into NH Nu 0

To a stirred solution/suspension of N- (3-chloro-4-fluorophenyl)-6- ( (6- (methoxy)-3- pyridinyl) oxy)-1-naphthalenecarboxamide (167 mg, 0.39 mmol) in chloroform (4.7 mL) was added trimethylsilyl iodide (Aldrich, 221 mg, 1.10 mmol). The reaction mixture was heated at 70 °C (oil bath) for 2.5 h, cooled to RT and MeOH (1 mL) was added. After stirring for 15 min, the dark yellow solution was concentrated in vacuo and treated with concentrated aqueous NH40H (3 mL). The title compound was isolated by filtration and dried under high vacuum. MS (ESI, pos. ion) m/z : 409.1 (M+1). Mass Calc'd for C22Hs4CIFN203 : 408.81. Example 664 H N- (3, 3-dimethyl-2, 3-dihydro-lH-indol-6-yl)- 6- ( (6-oxo-1, 6-dihydro-3-pyridinyl) oxy)-1- naphthalenecarboxamide HN nu 0

The compound was prepared similarly to the procedure outlined above by using N- (3, 3-dimethyl- 2, 3-dihydro-1H-indol-6-yl)-6-((6-(methoxy)-3-pyridinyl)oxy)-1- naphthalenecarboxamide as starting material: MS (ESI, pos. ion) m/z : 426.2 (M+1). Mass Calc'd for C26H23N3O3: 425.49. Example 665 H N-(3-methylphenyl)-6-((2-oxo-1, 2-dihydro-4- pyridinyl) oxy)-1-naphthalenecarboxamide "N0 0 N O H Step (a) Preparation of 6-(2-chloropyridin-4-yloxy)-1-napthoic acid.

6-hydroxy-1-napthoic acid (3.2 g, 17 mmol) was reacted with 2, 4-dichloropyridine (2.5 g, 17 mmol) and Cs2CO3 (16.6 g, 51 mmol) under the conditions of Example 421 step a to furnish the title compound as a brown solid. MS (ESI, pos. ion) m/z : 300.4 (M+1). Mass Calc'd for Cl6HloCINO3 299.708.

Step (b) Preparation of 6-(2-oxo-1, 2-dihydropyridi-4-yloxy)-1-napthoic acid.

A mixture of 6-(2-chloropyridin-4-yloxy)-1-napthoic acid (100 mg, 0.33 mmol) and p- toluenesulfonic acid (12 mg, 0.06 mmol) in AcOH (4 mL) were heated in a sealed tube at 130 °C for 72 h.

The resulting suspension was filtered to provide the title compound as a white solid. MS (ESI, pos. ion) m/z : 282.1 (M+1). Mass Calc'd for C, 6H"N04 : 281.263.

Step (c) Preparation ofN- (3-methyiphenyt)-6- ( (2-oxo-l, 2-dihydro-4-pyridinyt) oxy)-l- naphthalenecarboxamide.

To a solution of 6-(2-oxo-1,2-dihydropyridi-4-yloxy)-1-napthoic acid (step b, 125 mg, 0.44 mmol), m-toluidine (53 mL, 0.48 mmol) and TBTU (143 mg, 0.44 mmol) in DMF (4.5 mL) at at °C was

added DIPEA (195 IlL, 1.1 mmol). The mixture was maintained at 0 °C for 15 minutes and then allowed to warm to ambient temperature where it was maintained for 10 h. The reaction was diluted with EtOAc (50 mL) and poured into sat'd NaHC03 (50 mL). The layers were separated and the aqueous phase was extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with H2O (3 x 100 mL), sat'd NaHC03 (3 x 100 mL) and brine. Concentration under reduced pressure and purification by silica gel chromatography (2-8% MeOH in CH2CI2) provided the title compound as a white solid. MS (ESI, pos. ion) m/z : 371. 1 (M+1). Mass Calc'd for C23Hl8N203 : 370. 401. Example 666 O N, 6-((2-(methylamino)-4-pyridinyl) oxy)-N- t (4-(methoxy) phenyl)-1- w --1 naphthalenecarboxamide - 11 1 Step (a) Preparation of 6- (2-chloropyridin-4-yloxy)-1-naphthoic acid 6-Hydroxynaphtoic acid (10.0 g, 53.1 mmol), 2,4-dichloropyridine (9.44 g, 63.8 mmol) and cesium carbonate (51.9 g, 159 mmol) were combined in DMSO (266 mL) and the reaction mixture was heated at 90 °C for 16 h. After cooling to RT, water was added and the aqueous layer was acidified to pH=4-5. The title compound was isolated by filtration and dried under vacuum.

Step (b) Preparation of 6-(2-methylaminopyridin-4-yloxy)-1-naphthoic acid To melted methylamine hydrochloride (Aldrich, 73.7 g, 1090 mmol) at 235 °C (oil bath) was added 6-(2-chloropyridin4-yloxy)-1-naphthoic acid (6.54 g, 21.8 mmol). The reaction mixture was stirred for 3 min and cooled to RT. The brownish solid was treated with EtOAc and water and stirred until all residue was either in solution or suspended. The precipitate was filtered off, washed with EtOAC and purified by silica gel chromatography using 0-100% of a 85: 15: 0.5 mixture of DCM : MeOH: AcOH. The product obtained was washed with water, filtered and dried under vacuum to give the title compound.

Step (c) Preparation of 6-((2-(methylamino)-4-pyridinyl) oxy)-N-(4-(methoxy) phenyl)-1- naphthalenecarboxamide 6-(2-Methylaminopyridin4-yloxy)-1-naphthoic acid (170 mg, 0.58 mmol), p-anisidine (107 mg, 0.87 mmol), DIPEA (149 mg, 1.16 mmol) and TBTU (223 mg, 0.69 mmol) were combined in DMF (3.0 mL) and the reaction mixture was stirred at RT for 16 h, quenched by addition of a 6M aqueous NaOH solution. The precipitate was filtered off, treated with DCM, sonicated. The title compound was isolated by filtration. MS (ESI, pos. ion) m/z : 400.1 (M+1). Mass Calc'd for C24H2lN303 : 399. 45. The following compounds were prepared similarly to Example 665 isolated after purification by silica gel chromatography and/or crystallization: Example Structure & Name Mol Formula Mass M+H No. 667 0 H C26H25N302 411. 50 412. 1 N N"N'- 6- ( (2- (methylamino)-4-pyridinyl) oxy)-N- (4- ( 1- methylethyl) phenyl)-1-naphthalenecarboxamide 668 H C24H, sF3N303 453. 42 454. 4 N 0 F if NAN 6- ( (2- (methylamino)-4-pyridinyl) oxy)-N- (4- ( (trifluoromethyl) oxy) phenyl)-1- naphthalenecarboxamide 669 H CMHN302 383. 45 384. 4 N N N N N 6- ( (2- (methylamino)-4-pyridinyl) oxy)-N- (4- methylphenyl)-1-naphthalenecarboxamide 670 H C23H, 8ClN302 403. 87 404. 4 N cri N N N- (4-chlorophenyl)-6- ( (2- (methylamino)-4- pyridinyl) oxy)-1-naphthalenecarboxamide 671 H C24H2, N303 399. 45 400. 2 N NAN 6- ( (2- (methylamino)-4-pyridinyl) oxy)-N- (3- (methoxy) phenyl)-1-naphthalenecarboxamide 672 N CzgH2gN403 480. 56 481. 5 I i N 0 : N N N N-N N- (1-acetyl-3, 3-dimethyl-2, 3-dihydro-1 H-indol-6- yl)-6-((2-(methylamino)-4-pyridinyl) oxy)-1- naphthalenecarboxamide 673 H C24H2, N302 383. 45 384. 2 i N 6- ( (2- (methylamino)-4-pyridinyl) oxy)-N- (3- methylphenyl)-1-naphthalenecarboxamide 674 H C24Hl7CIF3N302 471. 86 472. 1 ci HCI NaN N- (4-chloro-3- (trifluoromethyl) phenyl)-6- ( (2- (methylamino)-4-pyridinyl) oxy)-1- naphthalenecarboxamide 675 H CN 425. 53 426. 5 i N N N N-(4-(1, 1-dimethylethyl) phenyl)-6-((2- (methylamino)-4-pyridinyl) oxy)-1- naphthalenecarboxamide 676 O N C23H, 8ClN302 403. 87 404. 1 r w Ci NAN N- (3-chlorophenyl)-6- ( (2- (methylamino)-4- pyridinyl oxy)-1-naphthalenecarboxamide 677 H C23H, 7C1FN302 421. 86 422. 2 F /cl oW Cl N- (3-chloro-4-fluorophenyl)-6- ( (2- (methylamino)-4- pyridinyl) oxy)-1-naphthalenecarboxamide 678 H C23H2oN403 400. 44 401. 2 N N Q N N N-N 6- ( (2- (methylamino)-4-pyridinyl) oxy)-N- (6- (methoxy)-3-pyridinyl)-1-naphthalenecarboxamide 679 C27H27N302 425. 53 426. 0 N i ZON N 6- ( (2- (methylamino)-4-pyridinyl) oxy)-N- (3-methyl- 4-1-methylethyl) phenyl)-1-naphthalenecarboxamide Example 680 0 N N-(3, 3-dimethyl-2, 3-dihydro-111-indol-6-yl)- 6- ( (2- (methylamino)-4-pyridinyl) oxy)-1- naphthalenecarboxamide 0 HN N N N

The title compound was prepared from N-(1-acetyl-3, 3-dimethyl-2, 3-dihydro-lH-indol-6-yl)-6- ((2-(methylamino)-4-pyridinyl) oxy)-1-naphthalenecarboxamide using the experimental procedure outlined in Example 662. MS (ESI, pos. ion) m/z : 439.2 (M+1). Mass Calc'd for C27H26N402 : 438.53. Example 681 o NH 6-((2-(methylamino)-4-pyridinyl) oxy)-N-(1- methyl-6-oxo-1, 6-dihydro-3-pyridinyl)-l- naphthalenecarboxamide N N I I w

Step (a) Preparation of tert-butyl 6-methoxypyridin-3-ylcarbamate To a stirring solution of 5-amino-2-methoxypyridine (8.00 g, 64.4 mmol) and triethylamine (11.7 mL, 83.8 mmol) in dioxane (32 mL) at 0 °C was added a solution of di-tert-butyl carbonate in dioxane (20 mL). The reaction mixture was allowed to warm to RT, stirred for 16 h. After concentration in vacuo, the residue was dissolved in 65 mL of EtOAc and 32 mL of a saturated aqueous NaHC03 solution and stirred at RT for 2 h. The layers were separated. The organic layer was washed with water and dried over Na2SO4, filtered and concentrated in vacuo to provide the title compound.

Step (b) Preparation of tert-butyl 1-methyl-6-oxo-1, 6-dihydropyridin-3-ylcarbamate To a stirred solution of tert-butyl 6-methoxypyridin-3-ylcarbamate (14.4 g, 64.2 mmol) in MeOH (95 mL) was added methyl iodide (14.6 g, 103 mmol). The reaction mixture was heated at reflux for 16 h, cooled to RT and concentrated down. The residue was purified by silica gel chromatography to give the title compound.

Step (c) Preparation of 5-amino-1-methylpyridin-2 (lH)-one hydrochloride To a stirred solution of tert-butyl 1-methyl-6-oxo-1, 6-dihydropyridin-3-ylcarbamate (1.20 g, 5.35 mmol) in dioxane (15 mL) at RT was added HCl (4M in dioxane, 5.35 mL, 21.4 mmol). The reaction mixture was heated at 70 °C for 9 h, cooled to RT and filtered to give the title compound.

Step (d) Preparation of 6-((2-(methylamino)-spyridinyl) oxy)-N-(1-methyl-6-oxo-1, 6-dihydro-3- pyridinyl)-1-naphthalenecarboxamide The title compound was prepared according to the procedure outlined in example 666. MS (ESI, pos. ion) m/z : 401. 0 (M+1). Mass Calc'd for C23H2oN403 : 400.44. Example 682 H 4-((5-(((3-(trifluoromethoxy)- phenyl) amino) carbonyl)-2-naphthalenyl) NI oxy)-2-pyridinecarboxamide XNH2 o 0 Step (a) Preparation of 6-(2-carbamoylpyridin-4-yloxy)-1-napthoic acid.

6-Hydroxy-1-napthoic acid (2.5 g, 13 mmol) was reacted with 4-chloropicolinamide (WO 02/085857) (2.6 g, 15 mmol) under the conditions of Example 421 Step a to give the title compound as a brown solid. MS (ESI, pos. ion) m/z : 309.2 (M+1). Mass Calc'd for C, 7H, 2N204 : 308.29.

Step (b) Preparation of 6-(2-carbamoylpyrdin-4yloxy)-1-napthoyl chloride.

A mixture of 6-(2-carbamoylpyridin-4-yloxy)-1-napthoic acid (Step a, 1.0 g, 3.2 mmol) and SOC12 (600 pL, 8.1 mmol) in toluene (25 mL, Aldrich) was heated at 110 °C for 7 h. The resulting solution was concentrated under reduced pressure and azeotroped from toluene (3 x 10 mL) to provide the title compounds as a yellow solid. MS (ESI, pos. ion) m/z : 327.5 (M+1). Mass Calc'd for Cl7H"CIN203 : 326.73.

Step (c) Preparation 4-((5-(((3-((trifluoromethyl)oxy)phenyl)amino)carbonyl)-2-na phthalenyl)oxy)- 2-pyridinecarboxamide.

6-(2-carbamoylpyridin-4-yloxy)-1-napthoyl chloride (step b, 150 mg g, 0.41 mmol) was reacted with 3-trifluoromethoxyaniline 56 pL, 0.41 mmol, Aldrich) under the conditions of Example 421 Step c to furnish the title compound as a yellow solid. MS (ESI, pos. ion) m/z : 468.1 (M+l). Mass Calc'd for C24H, 6F3N304 : 467.40.

The following compounds were prepared similarly to the procedure outlined in Example 421 step c using either TEA or DIEA as the base. Example No. Structure & Name Mol Formula Mass M+H 683 C23H, 6CIN303 417. 85 418. 1 0 0 1 N N ci ci 0 NH2 4- ( (5- ( ( (3-chlorophenyl) amino) carbonyl)-2- naphthalenyl) oxy)-2-pyridinecarboxamide 684 C24H, 9N304 413. 43 414. 1 (XNH X N N N/\ I'H CH3 nu2 4- ( (5- ( ( (3- (methoxy) phenyl) amino) carbonyl)-2- naphthalenyl) oxy)-2-pyridinecarboxamide 685 C24HlgN303 397. 43 398. 1 wu N N 3 H NH2 4- ( (5- ( ( (3-methylphenyl) amino) carbonyl)-2- naphthalenyl) oxy)-2-pyridinecarboxamide Example 686 N- (4- (1, 1-dimethylethyl) phenyl)-6- (7H- pyrrolo [2, 3-d] pyrimidin-4-yloxy)-1- naphthalenecarboxamide Y) J- N wu H

Step (a) Preparation of 6- (7H-pyrrolo [2, 3-d] pyrimidin-4-yloxy)-1-naphthoic acid.

Cs2CO3 (23.4 g, 71.9 mmol) was added in one portion to a solution of 6-hydroxy-1-naphthoic acid (5.41 g, 28.7 mmol) and 6-chloro-7-deazapurine (3.68 g, 24.0 mmol) in DMSO (47.9 ml) at RT. The resulting mixture was heated to 100 °C and stirred for 14 hours. The mixture was cooled to RT and neutralized to a pH of 7 with 6N HCI. Solid material proceeded to crash out of solution. The entire mixture was centrifuged and the liquid was decanted. To the solid was added saturated aqueous NaHC03 and the resulting mixture was agitated over night on a rotating plate. The mixture was centrifuged again and decanted into a 1 L flask. The solution was acidified to neutral pH, centrifuged again and decanted.

EtOAc was added to the solid material, the mixture centrifuged and the liquid was decanted to reveal the desired compound. MS (ESI, pos. ion) m/z : 306.1 (M+1). Mass Calc'd for C, 8HI5NO3 : 305.08.

Step (b) Preparation of 6- (7H-pyrrolo [2, 3-d] pyrimidin-4-yloxy)-1-naphthoyl chloride.

To a solution of 6- (7H-pyrrolo [2, 3-d] pyrimidin4-yloxy)-1-naphthoic acid (357 mg, 1.17 mmol) in DCM (11.7 mL) under an N2 atmosphere, was added DMF (2 drops) followed by (COCI) 2 (143 pL, 1.64 mmol) dropwise. After stirring at RT for 4 hours, the reaction mixture became a yellow slurry. An aliquot was removed and placed in a vial containing 500 u. l of 1M MeNH2. After 5 min, the resulting solution was analyzed by LCMS to indicate complete conversion to the methylamine and that no acid was present in the reaction mixture. The slurry was concentrated to a yellow stable solid, which was taken directly to the next step of the reaction sequence.

Step (c) Preparation of N- (4- (1, 1-dimethylethyl) phenyl)-6- (7H-pyrrolo [2, 3-d] pyrimidin-4-yloxy)-1- naphthalenecarboxamide.

THF (1.3 mL) was added to 6- (7H-pyrrolo [2,3-d] pyrimidin4-yloxy)-1-naphthoyl chloride (84.0 mg, 0.259 mmol) in a 10 mL round bottom flask, followed by 4-t-butyl aniline (62.4 pL, 0.389 mmol) and Hunig's base (45.1 pL, 0.259 mmol). The resulting solution was stirred for 14 h and then transferred to a 50 mL flask. To this solution was added-5 g of silica gel. The resulting slurry was concentrated by reduced pressure. The impregnated silica gel was loaded into a dry pack column cartridge and the crude mixture was purified through Biotage chromatography (Hex: EtOAc). The collected product was repurified through trituration with DCM. MS (ESI, pos. ion) m/z : 437.1 (M+1). Mass Calc'd for C, 8H, sNO3 : 436. 51.

The following compounds were prepared similarly to the procedure outlined in Example 686. Example Structure & Name Mol Formula Mass M+H No. 687 C24H, SF3N403 464. 465. 1 0 F IF F N NN H 6- (7H-pyrrolo [2, 3-d] pyrimidin-4-yloxy)-N- (4- ((trifluoromethyl) oxy) phenyl)- I-naphthalenecarboxamide 688 C23HlsClN402 414. 85 415. 0 /cl HN O/O I N 'ro WH H N- (4-chlorophenyl)-6- (7H-pyrrolo [2, 3-d] pyrimidin-4- yloxy)-l-naphthalenecarboxamide 689 O n C23H16N402 380. 4 381. i HN N N-,// N-phenyl-6- (7H-pyrrolo [2, 3-d] pynmidin4-yloxy)-1- naphthalenecarboxamide 690 24H, sN402 394. 43 395. 1 CHs 0 nu 0 N /INN H'' N N H N- (4-methylphenyl)-6- (7H-pyrrolo [2, 3-d] pyrimidin-4- yloxy)-1-naphthalenecarboxamide CzqH, gNqO3 410. 43 411. 1 CHg-o CH3-0 O NH 0 ZON NDN N N H N- (4- (methoxy) phenyl)-6- (7H-pyrrolo [2, 3-d] pyrimidin-4- yloxy)-1-naphthalenecarboxamide 692 CzsHNS 451. 51 452. 1 H3 S N 0 NH 0 zon J N N H N- (2-methyl-1, 3-benzothiazol-5-yl)-6- (7H-pyrrolo [2, 3- d] imidin-4-loxy)-1-naphthalenecarboxamide 693 C24Hl4CIF3N402 482. 85 483. 0 Cl F F if 0 NH N urn . J N"N" H N- (4-chloro-3- (trifluoromethyl) phenyl)-6- (7H-pyrrolo [2, 3- d] pyrimidin-4-yloxy)-1-naphthalenecarboxamide 694 C24HsN403 410. 43 411. 1 rycHs y NH 0 zon N ZON N N- (3- (methoxy) phenyl)-6- (7H-pyrrolo [2, 3-d] pyrimidin-4- yloxy)-1-naphthalenecarboxamide 695 C27H24N402 436. 51 437. 1 CHs CHs CH3 O NU 0 NH zon ZON N H N- (3-methyl-4- (l-methylethyl) phenyl)-6- (7H-pyrrolo [2, 3- d] pyrimidin-4-yloxy)-1-naphthalenecarboxamide 696 C29H25N503 491. 55 492. 2 3r-H \H3 CH3 H3 C < "Y H CHg N N- (l-acetyl-3, 3-dimethyl-2, 3-dihydro-1 H-indol-6-yl)-6- (7H- pyrrolo [2, 3-d] pyrimidin4-yloxy)-1- naphthalenecarboxamide 697C23H, sClN402 414. 85 415. 0 Cl G _\ O/ H HNf XH N N- (3-chlorophenyl)-6- (7H-pyrrolo [2, 3-d] pyrimidin-4- yloxy)-1-naphthalenecarboxamide 698 C24H) 7C1N402 428. 88 429. 1 CHs / 'CI HN . 1 N w I, H NEZ N- (3-chloro-4-methylphenyl)-6- (7H-pyrrolo [2, 3- d] pyrimidin4-yloxy)-1-naphthalenecarboxamide F 699 l L. F ! wHC I / F NN \ N \ I H 6- (7H-pyrrolo [2, 3-d] pyrimidin-4-yloxy)-N- (4- (trifluoromethyl) phenyl)-1-naphthalenecarboxamide 700/. F CzaHsFsNa4z 448. 449. 0 N F H N4 H Ksi NaN 6- (7H-pyrrolo [2, 3-d] pyrimidin4-yloxy)-N- (3- (trifluoromethyl) phenyl)-I-naphthalenecarboxamide 701CMH, sF3N403464. 4 465. 1 O I F ( Y F Y--F ZON 0 nu N N H 6- (7H-pyrrolo [2, 3-d] pyrimidin-4-yloxy)-N- (3- ((trifluoromethyl) oxy) phenyl)-1-naphthalenecarboxamide 702 C26H22N402 422. 49 423. 1 O NH 0 ZON H'' N kN N- (4- (l-methylethyl) phenyl)-6- (7H-pyrrolo [2, 3- d] imidin-4-lox-1-na hthalenecarboxamide 703 C26H22N403 438. 49 439. 1 my 0 NU 0 N N H N- (3- ( ( 1-methylethyl) oxy) phenyl)-6- (7H-pyrrolo [2, 3- d imidin-4-loxy)-1-naphthalenecarboxamide 704 C24H) 4F4N402 466. 39 467. 1 F F if F o XF 0 N N N N H N- (2-fluoro-3- (trifluoromethyl) phenyl)-6- (7H-pyrrolo [2, 3- d rimidin-4-yloxy)-1-naphthalenecarboxamide 705 C26H20N402 420. 47 421. 1 NH O nu zon O N zu N N H N- (2, 3-dihydro-1 H-inden-5-yl)-6- (7H-pyrrolo [2, 3- d] pyrimidin-4-yloxy)-1-naphthalenecarboxamide 706 Q NH, gHqN4O2 318. 33 319. 1 0 NU zon N N N H N-methyl-6- (7H-pyrrolo [2, 3-d] pyrimidin4-yloxy)-1- naphthalenecarboxamide 707 (CtgHl6N402 332. 36 333. 1 O NH OH ZON N N NAN H N-ethyl-6- (7H-pyrrolo [2, 3-d] pyrimidin4-yloxy)-1- naphthalenecarboxamide 708 CH3 C20H, 8N402 346. 39 347. 1 PH3 0. RNH O \ \ J) HN N N-propyl-6- (7H-pyrrolo [2, 3-d] pyrimidin4-yloxy)-1- naphthalenecarboxamide 709 C2oH, sN402 346. 39 347. 1 O NH o ZON N N H N- (1-methylethyl)-6- (7H-pyrrolo [2, 3-d] pyrimidin-4-yloxy)- 1-naphthalenecarboxamide 710 Y C20Hl6N402 344. 37 345. 1 O NH 0 ZON ' N N H N-cyclopropyl-6- (7H-pyrrolo [2, 3-d] pyrimidin4-yloxy)-1- naphthalenecarboxamide 711 C24H2lN503 427. 46 428. 1 0 N O NU 0 N zu H" H N- (5- (I, I-dimethylethyl)-3-isoxazolyl)-6- (7H-pyrrolo [2, 3- dlpyrimidin4-yloxy)-1-naphthalenecarboxamide 712 NtS C2oHs3N502S 387. 42 388. 0 N, S ON 0 NH zon ZU N N H 6- (7H-pyrrolo [2, 3-d] pyrimidin-4-yloxy)-N- (1, 3-thiazol-2- 1-I-naphthalenecarboxamide 713 ( ?- C24HigN402 394. 43 395. 1 ON O NU ZON ZON H N N H N- (2-methylphenyl)-6- (7H-pyrrolo [2, 3-d] pyrimidin-4- yloxy)-I-naphthalenecarboxamide 714 C24Hl8N403 410. 43 411. 1 TOP zizi O NH CH, zon NAN ZON J N N H N- (2- (methoxy) phenyl)-6- (7H-pyrrolo [2, 3-d] pyrimidin-4- yloxy)-1-naphthalenecarboxamide 715 C2sH2oN4o4 440. 46 441. 1 CH, HNZ 0 0 J : bol CH3 3 H N- (3, 5-bis (methoxy) phenyl)-6- (7H-pyrrolo [2, 3-d] pyrimidin- 4-yloxy)-1-naphthalenecarboxamide 7T6C25H2oN402408. 46 409. 1 CH CH3 O nu o i i non ZON H N- (3, 5-dimethylphenyl)-6- (7H-pyrrolo [2, 3-d] pyrimidin-4- yloxy)-I-naphthalenecarboxamide 717 C2sHl7F3N403 478. 43 479. 1 F FYCH, ON O NH O ? TN ZU H N- (3- (methoxy)-5- (trifluoromethyl) phenyl)-6- (7H- pyrrolo [2, 3-d] pyrimidin-4-yloxy)-l- naphthalenecarboxamide 718 C23Hj4F2N402 416. 39 417. 0 Zu OH O N N N NAN H N- (3, 5-difluorophenyl)-6- (7H-pyrrolo [2, 3-d] pyrimidin-4- yloxy)-1-naphthalenecarboxamide 719 O NH C22H, 5N502 381. 39 382. 0 y OH 0 N N N H H N- (3-pyridinyl)-6- (7H-pyrrolo [2, 3-d] pyrimidin-4-yloxy)-l- naphthalenecarboxamide 720 C2, H, gN402 358. 4 359. 0 OH O zon N N N H N-cyclobutyl-6- (7H-pyrrolo [2, 3-d] pyrimidin-4-yloxy)-l- naphthalenecarboxamide 721 22002 372. 43 373. 1 OH w w N ZON H N N H N-cyclopentyl-6- (7H-pyrrolo [2, 3-d] pyrimidin4-yloxy)-1- naphthalenecarboxamide 722 O Nu 8N403 362. 39 363. 0 OH I \ \ N ZON H N N H N- (2- (methoxy) ethyl)-6- (7H-pyrrolo [2, 3-d] pyrimidin-4- yloxy)-I-naphthalenecarboxamide 723 C24H2oN602 424. 46 425. 1 N, 0 0 N H NJ ZON HNrO N NN \ H N- (6- (dimethylamino)-3-pyridinyl)-6- (7H-pyrrolo [2, 3- d] pyrimidin4-yloxy)-1-naphthalenecarboxamide 724 Cy, H, gN402 358. 4 359. 0 OH ZON ZON N nu N N H N- (cyclopropylmethyl)-6- (7H-pyrrolo [2, 3-d] pyrimidin4- yloxy)-1-naphthalenecarboxamide 725 C23Hl7N504S 459. 48 460. 0 CNH2 su OvsssNH2 H H 0 neo N- (4- (aminosulfonyl) phenyl)-6- (7H-pyrrolo [2, 3- d] pyrimidin4-yloxy)-1-naphthalenecarboxamide 726 C28H25FN602 496. 54 497. 1 NICH3 NJ HN ° T"" NaN H N- (3-fluoro-4- (4-methyl-1-piperazinyl) phenyl)-6- (7H-pyrrolo [2, 3-d] pyrimidin4-yloxy)-1- naphthalenecarboxamide 727 ZgH26N6O3 494. 55 495. 1 CH, 0 CH, N C H, N H nu J N N N N- (3- ( ( (2- (dimethylamino) ethyl) amino) carbonyl) phenyl)- 6- (7H-pyrrolo [2, 3-d] pyrimidin4-yloxy)-1- naphthalenecarboxamide 728 N Cz7H25N5O2 451. 53 452. 1 H 1'4f 0 0 H N ( N NN YJ H N- (3- (2- (dimethylamino) ethyl) phenyl)-6- (7H-pyrrolo [2, 3- d] pyrimidin-4-loxy)-1-naphthalenecarboxamide 729 C3oH27F3N602 560. 58 561. 2 F F NEZ O NH N- O ¢<N N N ; I't N H N- (2- ( (3 S)-3- (dimethylamino)-1-pyrrolidinyl)-5- (trifluoromethyl) phenyl)-6- (7H-pyrrolo [2, 3-dlpyrimidin- 4-yloxy)-1-naphthalenecarboxamide 730 C3oH28CIF3N602 597. 04 597. 2 cl CI 0 NH CH, O NH CH3 CH3 / 0 O NJ N N N- (3-chloro-2- ( (3- (dimethylamino) propyl) (methyl) amino)- 5- (trifluoromethyl) phenyl)-6- (7H-pyrrolo [2, 3-d] pyrimidin- 4-yloxy)-1-naphthalenecarboxamide 731 0 C3oH25F3N603 574. 56 575. 1 Fi O F N N, O NU 0 nu ZON N H N N- (3- ( (4-methyl-I-piperazinyl) carbonyl)-5- (trifluoromethyl) phenyl)-6- (7H-pyrrolo [2, 3-d] pyrimidin- 4-yloxy)-1-naphthalenecarboxamide Example 732 N= (5- (1, 1-dimethylethyl)-3- isoxazolyl)-6- ( (6- (methoxy)-7- ( (3- (l- piperidinyl) propyl) oxy)-4- o sN H quinazolinyl) oxy)-l- naphthalenecarboxamide 0 "0 N O>NJ GN

Step (a) Preparation of (6-methoxy-4-oxo-7- (3-piperidin-1-yl) propoxy) quinazolin-3 (4I)-yl) methyl pivalate To a solution of (7-hydoxy-6-methoxy-4-oxoquinazolin-3 (4H)-yl) methyl pivalate (2.0 g, 6.52 mmol, see J. Med Chem. , 47: 871 (2004) ) and 1- (2-chloropropyl) piperidine hydrochloride (1.4 g, 8.85 mmol) in DMF (13 mL), was added potassium carbonate (2.7 g, 19. 59 mmol). The mixture was heated to 90 °C for 20 h. After cooling RT, the mixture was diluted with H20 (50 mL). The mixture was extracted with EtOAc (3 x 25 mL) and the organic extracts were washed with H20 and brine. The organic phase was dried over MgS04, filtered, and concentrated in vacuo to give the title compound as a light yellow solid. MS (ESI, pos. ion) m/z : 432 (M+1). Mass Calc'd for C23H33CN30s : 431. 2.

Step (b) Preparation of 6-methoxy-7- (3-piperidin-1-yl) propoxy) quinazoline-4 (3H)-one Dissolve (6-methoxy-4-oxo-7- (3-piperidin-1-yl) propoxy) quinazolin-3 (4H)-yl) methyl pivalate (1.9 g, 4.5 mmol) ) in a solution of ammonia in MeOH (2M, 45 mL). The solution was stirred at ambient temperature for 24 h, then diluted with CH2CI2 (20 mL). The mixture was filtered and the filtrate was concentrated in vacuo. The crude mixture was triturated with Et2O/CH2C12 (95: 5) and the precipitate

filtered and dried under vacuum to give title compound as a white solid. MS (ESI, pos. ion) m/z : 318 (M+1). Mass Calc'd for Cl, H23N303 : 317.1.

Step (c) Preparation of 4-chloro-6-methoxy-7- (3-piperidin-1-yl) propoxy) quinazoline To a solution of 6-methoxy-7- (3-piperidin-1-yl) propoxy) quinazoline-4 (3H) -one (1.53 g, 4.82 mmol) in thionyl chloride (11.3 mL), was added DMF (0.10 mL). The mixture was heated to 80 °C for 1.5 h. After cooling RT, the mixture was concentrated in vacuo then diluted with CH2Cl2. The solution was cooled to 0 °C in an ice bath followed by addition of H2O and aqueous saturated NaHC03 to adjust the pH of the mixture to 8. The mixture was extracted with CH2CI2 (3 x 25 mL) and the organic extracts were washed with H2O and brine. The organic phase was dried over MgS04, filtered, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (92: 8 CH2CI2/MeOH) to yield the title compound as a light yellow solid. MS (ESI, pos. ion) m/z : 336 (M+1). Mass Calc'd for C17H22CIN302 : 335. 1.

Step (d) Preparation of 6- (6-methoxy-7- (3- (piperidin-1-yl) propoxy) quinazolin-4-yloxy)-1-naphthoic acid To a solution of 6-hydroxy-1-naphthoic acid (0.26 g, 1.36 mmol, 1.05 equiv) in DMSO (2 mL), was added potassium tert-butoxide (0.44 g, 3.90 mmol, 3.0 equiv). The solution was stirred at ambient temperature for a period of 15 minutes. To this solution was added, 4-chloro-6-methoxy-7- (3-piperidin-1- yl) propoxy) quinazoline (0.44 g, 1.30 mmol) in DMSO (1 mL). The reaction mixture was heated to 90 °C for 15 h. After cooling RT, the mixture was diluted with H20 (10 mL) and acidified with 3N HCI to a pH of 5. The precipitate was isolated by filtration and vacuum dried to give the title compound as a light brown solid. MS (ESI, pos. ion) m/z : 488 (M+l). Mass Calc'd for C28H29N3O5 : 487.2.

Step (e) Preparation of N-(S-(l, l-dimethylethyl)-3-isoxazolyl)-6-((6-(methoxy)-7-((3-(1- piperidinyl) propyl) oxy)-4-quinazolinyl) oxy)-1-naphthalenecarboxamide The compound was prepared according to Example 273, step e to afford the title compound as a light yellow solid. MS (ESI, pos. ion) m/z : 610.3 (M+l). Mass Calc'd for C35H39N5O5 : 609. 3.

The following examples were prepared similar to the procedures described in Example 732. Example Structure & Name Mol Mass M+H No. Formula 733 7C35H4oN604 608. 73 609. 3 zon /-/0 N --\N N N N= - (3- (1, 1-dimethylethyl)-1-methyl-1 H-pyrazol-5-yl)-6- ( (6- (methoxy)-7- ( (2- ( 1-piperidinyl) ethyl) oxy)-4-quinazolinyl) oxy)-1-naphthalenecarboxamide Example 734, N- (3-chlorophenyl)-6- ( (6- (methoxy)-7- ( (3- (4- morpholinyl) propyl) oxy)- 4-quinolinyl) oxy)-l- naphthalenecarboxamide zizi

Step (a) Preparation of 4-chloro-6-methoxyquinolin-7-ol To a solution of 7-(benzyloxy)-4-chloro-6-methoxyquinoline (W098/13350A1) (2.0 g, 6.67 mmol) in TFA (13 mL), was added methansulfonic acid (0.95 mL, 13.3 mmol). The mixture was heated to reflux for 3 h. After cooling to RT, the mixture was concentrated in vacuo. The resulting residue was diluted with ice/H20 and neutralized with cold IN NaOH to a pH of 7. The resulting precipitate was stirred for 1 h at RT, filtered, and dried under high vacuum to give the title compound as a light yellow solid. MS (ESI, pos. ion) m/z : 210 (M+1). Mass Calc'd for CloH8CINO2 : 209.0.

Step (b) Preparation of 4- (3-chloropropyl) morpholine To a solution of l-bromo-3-chloropropane (3.4 mL, 34.5 mmol) in DMF (40 mL), was added potassium carbonate (6.4 g, 69 mmol) and morpholine (2.0 mL, 23.0 mmol). The solution was stirred at RT for 15 h, then diluted with H20 (150 mL). The mixture was extracted with EtOAc (3 x 25 mL) and the organic extracts were washed with H20 and brine. The organic phase was dried over MgS04, filtered, and concentrated in vacuo to give title compound as a colorless oil. MS (ESI, pos. ion) m/z : 164 (M+l).

Mass Calc'd for C7Hi4CINO : 163.08.

Step (c) Preparation of 4-chloro-6-methoxy-7- (3-morpholinopropoxy) quinoline To a solution of 4-chloro-6-methoxyquinolin-7-ol (1.0 g, 4.77 mmol) and 4- (3- chloropropyl) morpholine (0.86 g, 5.25 mmol) in DMF (9.5 mL), was added potassium carbonate (2.0 g, 14.3 mmol). The mixture was heated to 90 °C for 15 h. After cooling RT, the mixture was diluted with H20 (30 mL). The mixture was extracted with EtOAc (3 x 25 mL) and the organic extracts were washed

with H20 and brine. The organic phase was dried over MgS04, filtered, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (5% MeOH/CH2CI2) to yield the title compounds as a light yellow solid. MS (ESI, pos. ion) m/z : 337 (M+l). Mass Calc'd for C, 7H22CIN203 : 336.1.

Step (d) Preparation of 6-(6-methoxy-7-(3-morpholinopropoxy)quinolin-4-yloxy)-1-naph thoic acid The compound was prepared according to Example 732, step d to afford the title compound as a light brown solid. MS (ESI, pos. ion) m/z : 489 (M+l). Mass Calc'd for C28H28N206 : 488.2.

Step (e) Preparation of N- (3-chlorophenyl)-6- ( (6- (methyloxy)-7- ( (3- (4-morpholinyl) propyl) oxy) -4- quinolinyl) oxy)-l-naphthalenecarboxamide The compound was prepared according to Example 273, step e to afford the title compound as a light yellow solid. MS (ESI, pos. ion) m/z : 598.2 (M+1). Mass Calc'd for C34H32CIN305 : 597.2. Example735, gOMe N-(6-((6, 7-bis (methoxy)-4-quinolinyl) oxy)- 1-naphthalenyl)-N'- (4- (methoxy) HN phenyl) thiourea S'NH 0jol MeO Me0 NJ MeO-N Step (a) Preparation of 4- (5-isothiocyanatonaphthalen-2-yloxy)-6, 7-dimethoxyquinoline.

Thiocarbonyl diimidazole (108 mg, 0.606 mmol) was added to a solution of 6- (6, 7- dimethoxyquinolin-4-yloxy) naphthalen-1-amine (210,0. 606 mmol) and NEt3 (84.5 L, 0.606) in DCM (1.52 mL) in one portion at RT. After 15 minutes of stirring, LCMS and TLC indicated that the reaction was complete. The crude mixture was purified by silica gel chromatography (Hex: EtOAc). MS (ESI, pos. ion) m/z : 389.0 (M+l). Mass Calc'd for Cs8HlsNO3 : 388.45.

Step (b) Preparation of N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-1-naphthalenyl)-N'- (4- (methoxy) phenyl) thiourea.

To a solution of 4-(5-isothiocyanatonaphthalen-2-yloxy)-6, 7-dimethoxyquinoline (27 mg, 0.070 mmol) in DCM (348 lull) at RT was added 4-methoxyaniline (17.2 mg, 0.140 mmol) in one portion. After stirring for 14 h, the crude mixture was concentrated under reduced pressure and purified by silica gel chromatography. MS (ESI, pos. ion) m/z : 512.1. (M+1). Mass Calc'd forCl8HlsNO3 : 511.60.

The following examples were prepared similar to the procedures described in Example 735. Example Structure & Name Mol Formula Mass M+H No. 736 C32H3, N303S 537. 68 538. 2 CL eCH3 HAN HN SNH Cl, C3 O 0 cl, CL, N- (6- ( (6, 7-bis (methoxy) 4-quinolinyl) oxy)-1-naphthalenyl)- N'-(4-(1, 1-dimethylethyl) phenyl) thiourea 737/ z9H25N3O4S S 11. S 12. H N O' S. , NH S>NH O I I o . NJ N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-1-naphthalenyl)- N'- (3- (methoxy) phenyl) thiourea 738 C29H22F3N303S 549. 57 550. 1 F F NEF HO SNH HN4J O// ON N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-1-naphthalenyl)- N'- (4-trifluoromethyl) phenyl) thiourea Example 739 6- ( (6, 7-bis (methoxy)-4- quinolinyl) (methyl) amino)-N- (4- O N I chlorophenyl)-1-naphthalenecarboxamide HCI Zll _0e O \ N

Step (a) Preparation methyl-6-(trifluoromethylsulfonyloxy)-1-napthoate To a mixture of methyl-6-hydroxy-1-napthoate (1.5 g, 7.4 mmol) in dry CH2CI2 (100 mL) at-78 °C was added diisoproylethylamine (3.8 mL, 21 mmol, Aldrich) and trifluoromethanesulfonic anhydride (1.4 mL, 8.1 mmol). The reaction was maintained at this temperature for 1 h at which point it was quenched by the addition of sat'd NaHC03 (50 mL). The mixture was warmed to ambient temperature and the aqueous layer was extracted with CH2CI2 (3 x 50 mL). The combined organic layers were washed with brine, dried over Na2SO4 and concentrated in vacuo. The resulting brown residue was purified by silica gel column chromatography (10-30% acetone in hexanes) to give the title compound as a yellow solid. MS (ESI, pos. ion) m/z : 335.3 (M+1). Mass Calc'd for C, 3H9F305S : 334.27.

Step (b) Preparation methyl-6-amino-1-napthoate To a solution of methyl-6- (trifluoromethylsulfonyloxy-1-napthoate (2.0 g, 6.0 mmol) in dimethoxyethane (10 mL) was added Pd2 (dba) 3 (55 mg, 0.06 mmol), 2- (dicyclohexylphosphino) biphenyl (84 mg, 0.23 mmol), K3PO4 (1. 9 g, 8.9 mmol) and benzophenone imine (1.25 mL, 7.5 mmol). The mixture was heated at 90 °C for 10 h. After cooling to ambient temperature, 2N HCl (4 mL) was added the mixture was stirred vigorously for 1 h. EtOAc (5 mL) was added to the reaction and the mixture was basified to pH 14 with 6N NaOH. The aqueous layer was extracted with EtOAc (3 x 30 mL). The combined organic layers were washed with brine, dried over Na2SO4 and concentrated in vacuo. The resulting brown residue was purified by silica gel column chromatography (0-25% EtOAc in hexanes) to give the title compound as a orange oil. MS (ESI, pos. ion) m/z : 202.1 (M+l). Mass Calc'd for C, 2H"NO2 : 201.22.

Step (c) Preparation methyl-6-(6, 7-dimethoxyquinolin-4-ylamino)-1-napthoate To a mixture of methyl-6-amino-1-napthoate (300 mg, 1.5 mmol) and 4-chloro-6,7- dimethoxyquinoline (416 mg, 1.8 mmol) in a 20 mL sealed tube was added isopropyl alcohol (6 mL) and trifluoroacetic acid (287 pL, 3.7 mmol). The reaction vessel was sealed and heated at 90 °C for 1 h before being allowed to cool to ambient temperature. To the resulting thick yellow slurry was added isopropyl alcohol (6 mL). The reaction vessel was sealed and heated at 90 °C for 10 h. The mixture was then

cooled to 0 °C and filtered. The resulting solid was washed well with cold CH30H and dried in vacuo to provide the title compound as a yellow solid. MS (ESI, pos. ion) m/z : 389.3 (M+l). Mass Calc'd for C23H2oN204 : 388.42.

Step (d) Preparation methyl-6-(6, 7-dimethoxyquinolin-4-yl) (methyl) amino)-1-napthoate To a suspension of methyl-6-(6,7-dimethoxyquinolin-4-ylamino)-1-napthoate (125 mg, 0.32 mmol) in DMF (3 mL) at 0 °C was added NaH (40 mg, 0.96 mmol, Aldrich). The resulting slurry was allowed to warm to ambient temperature and stir 0.5 h before being cooled to 0 °C and exposed to iodomethane (60 u. L, 0.96 mmol). The mixture was allowed to warm to ambient temperature and stir for an additional 1 h before it was quenched with sat'd NH4C1 (10 mL) and extracted with CH2CI2 (5 x 50 mL). The organic layer was washed with H2O (3 x 50 mL) then brine and dried over Na2S04.

Concentration and purification by silica gel chromatography (0-10% CH30H in CH2CI2) provided the title compound as a white solid. MS (ESI, pos. ion) m/z : 403.3 (M+l). Mass Calc'd for C24H22N204 : 402.44.

Step (e) Preparation 6-(6,7-dimethoxyquinolin-4-yl)(methyl)amino)-1-napthoic acid To methyl-6- (6, 7-dimethoxyquinolin-4-yl) (methyl) amino)-1-napthoate (275 mg, 0.68 mmol) in CH30H (5 mL) was added 6 N NaOH (5 mL). The resulting mixture was maintained at RT for 10 h at which point the organics were removed in vacuo and the resulting mixture was diluted with H20 (5 mL) and acidified to pH 3 with 2N HCI. The resulting precipitate was collected by filtration and washed with Et2O (2 x 10 mL) to provide the title compound as a yellow solid. MS (ESI, pos. iion) m/z : 389.4 (M+1).

Mass Calc'd for C23H2oN204 : 388.42.

Step (f) Preparation 6-(6, 7-dimethoxyquinolin-4-yl) (methyl) amino)-1-napthoyl chloride.

6- (6, 7-dimethoxyquinolin-4-yl) (methyl) amino)-1-napthoic acid (60 mg g, 0.15 mmol) was reacted with oxalyl chloride (55 1L, 0.60 mmol) under the conditions of Example 421 Step b to give the title compound as a yellow solid. MS (ESI, pos. ion) m/z : 388.4 (M+MeOH). Mass Calc'd for C24H2, F3NO4 : 387. 43.

Step (g) Preparation 6- ( (6, 7-bis (methoxy)-4-quinolinyl) (methyl) amino)-N-(4-chlorophenyl)-1- naphthalenecarboxamide.

6- (6, 7-dimethoxyquinolin-4-yl) (methyl) amino)-1-napthoyl chloride (Step f, 63 mg, 0.15 mmol) was reacted with 4-chloroaniline (30 pL, 0.23 mmol) and TEA (85 u. L, 0.61 mmol) under the conditions of Example 421 Step c to give the title compound as a white solid. MS (ESI, pos. ion) m/z : 497.8 (M+H).

Mass Calc'd for C30H23CIN203 : 496.98. Example 740 6- ( (6, 7-bis (methoxy)-4-quinoUnyl) H amino)-N- (4-chlorophenyl)-l- 0 N I naphthalenecarboxamide CI I _0e o N_

Step (a) Preparation of 6- (6, 7-dimethoxynapthenlen-1-ylamino) l-napthoic acid.

Methyl-6- (6, 7-dimethoxyquinolin-4-yl) (methyl) amino)-1-napthoate (275 mg, 0.68 mmol) in CH30H (5 mL) was reacted with 6 N NaOH (5 mL) under the conditions of Example 739 Step e to give the title compound as a pale green powder. MS (ESI, pos. ion) m/z : 374.3 (M+l). Mass Calc'd for C23H, gNO4 : 373.40.

Step (b) Preparation of 6- ( (6, 7-bis (methoxy)-4-quinolinyl) amino)-N- (4-chlorophenyl)-l- naphthalenecarboxamide.

To a solution of 6- (6, 7-dimethoxynapthenlen-1-ylamino) l-napthoic acid (step a, 150 mg, 0.38 mmol), EDC (295 mg, 1.5 mmol), HOBt (208 mg, 1.5 mmol) and 4-chloroaniline (295 mg, 2.3 mmol) in DMF (8 mL, Aldrich) was added TEA (650 pL, 4.6 mmol). The reaction was maintained at RT for 10 h before being poured into H20 (20 mL). The aqueous layer was extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with H20 (3 x 100 mL) then concentrated under reduced pressure.

The resulting solid was triturated with CH2CI2 to give the title compound as an off-white powder. MS (ESI, pos. ion) m/z : 484.4 (M+1). Mass Calc'd for C28H22CIN303 : 483. 95.

The following examples were prepared similar to the procedures described in Example 740. Example No. Structure & Name Mol Formula Mass M+H 741 C32H3lN303 505. 62 506. 2 CHs CH3 CH3 CH3 O nu HN \ 0 CH3 , o NJ 6- ( (6, 7-bis (methoxy)-4-quinolinyl) amino)-N- (4- (l, I- dimethylethy1 henyl)-1-naphthalenecarboxamide 742 C26H25N303 427. 5 428. 1 O NH CL3 HAN 0 CH30 I/NJ 6- ( (6, 7-bis (methoxy)-4-quinolinyl) amino)-N- (cyclopro lmethy1-1-naphthalenecarboxamide Example 743 N- (6- ( (6, 7-bis (methoxy)-4- /quinolinyl) oxy)-l-naphthalenyl)-lH- HN H benzimidazol-2-amine O --o N

Thiocarbonyl diimidazole (113 mg, 0. 65 mmol) was added to a solution of 6- (6, 7- dimethoxyquinolin-4-yloxy) naphthalene-1-amine (150 mg, 0. 43 mmol), in HCI2 (5 mL). After stirring for 3 h, the mixture was concentrated and the derived residue was dissolved in MeCN (3 mL). A solution of 1, 2-diphenylamine (50 mg, 0. 46 mmol) in MeCN (1 mL, Aldrich) was added and the mixture was stirred for 10 min before the addition of EDC (75 mg, 0. 39 mmol). The reaction was heated at 80 °C for

0.5 h before being cooled to ambient temperature, concentrated under reduced pressure and purified by silica gel chromatography (0-10% MeOH in CH2CI2) to provide the title compound as a tan solid. MS (ESI, pos. ion) m/z : 463.2 (M+l). Mass Calc'd for C28H22N403 : 462.50. Example 744 N-(6-((6, 7-bis (methoxy)-4- quinolinyl) oxy)-1-naphthalenyl)-1, 3- HNlo benzoxazol-2-amine Ky9 0joli N Thiocarbonyl diimidazole (113 mg, 0.65 mmol) was added to a mixture of 6- (6, 7- dimethoxyquinolin-4-yloxy) naphthalene-1-amine (150 mg, 0.43 mmol), in CH2CI2 (5 mL) at ambient temperature. After stirring for 3 h, the mixture was concentrated and the derived isothiocyanate was dissolved in MeCN (2 mL). A solution of 2-aminophenol (50 mg, 0.45 mmol) in MeCN (2 mL) was added and the mixture was stirred for 48 h at which point EDC (125 mg, 0.65 mmol) was introduced. The reaction was heated at 80 °C for 2 h. After cooling to ambient temperature, the suspension was filtered and the resulting solid was washed well with MeOH to furnish the title as a tan solid. MS (ESI, pos. ion) m/z: 464. 1 (M+1). Mass Calc'd for C28H2lN304 : 463.48. Example 745 Nt N-(6-((6, 7-bis (methoxy)-4-quinolinyl) oxy)- 1-naphthalenyl)-2-pyridinamine 0e 04 O O . o NJ To a solution of 6- (6, 7-dimethoxyquinolin-4-yloxy) naphthalene-1-amine (150 mg, 0.43 mmol), 2- chloropyridine (45 tL, 0.47 mmol), and NaOtBu (52.0 g, 160 mmol) in dioxane (4 mL) were added Pd2 (dba) 3 (12 mg, 0.01 mmol) and 2- (dicyclohexylphosphino)-2'-4'-6'-tri-i-propyl-1, 1'-biphenyl (25 mg, 0.05 mmol). The resulting mixture was heated at 100 oC for 3 h. After cooling to ambient temperature, the mixture was diluted with EtOAc (25 mL) and poured into sat'd NaHC03 (50 mL). The phases were separated and the aqueous phase was extracted with EtOAc (2 x 25 mL). The organic layers were combined, washed with brine, dried over Na2SO4 and concentrated in vacuo. The derived residue was purified by silica gel chromatography (0-10% CH30H in CH2C12) to provide the title compound as a white solid. MS (ESI, pos. ion) m/z : 424.1 (M+l). Mass Calc'd for C26H2lN303 : 423. 46.

The following examples were prepared similar to the procedures described in Example 745. Example Structure & Name Mol Mass M+H No. Formula 7AE 746, j C27H22N203 422. 48 423. 2 HO CH'o CH3 t3 , ZO N CH3 CHg 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N-phenyl-1- naphthalenamine 747 C3lH24N403 500. 56 501. 2 N N N CIH3 0 0 CHUG , o NJ CH3 N- (6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-1-naphthalenyl)- _ N-(2-pyridiny1)-2-yridinamine 748 C28H24N204 452. 51 453. 2 O. CH3 HUB nu O// 0 N 0-N CH3 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (3- (methoxy) phenyl)-I-naphthalenaniine 749 C3, H3oN203 478. 59 479. 2 CHs IN HN C3 O Han 0"N chus 1 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (4- (1, 1- dimethylethyl) phenyl)-1-naphthalenamine Example 750 oll ol 0 N- (7- ( (6, 7-bis (methoxy)-4- NN N F quinolinyl) oxy)-2-naphthalenyl)-N'- H H (3-fluorophenyl) urea O I N

To a solution of 7- (6, 7-dimethoxyquinolin-4-yloxy) naphthalen-2-amine (0. 158 g, 0.45 mmol) in 20 mL of THF was added 3-fluorophenyl isocyanate (0.057 mL, 0.50 mmol). The solution was stirred for 16 h at RT under an atmosphere of nitrogen. The reaction was concentrated and the crude solid was treated with CH2CI2. The resulting solid was collected by vacuum filtration and dried in vacuo to afford the desired compound. MS (ESI, pos. ion) m/z : 484.0 (M+1). Mass Calc'd for C28H22FN304 : 483.497.

The following compounds were prepared in a manner similar to Example 421, step c, omitting the base and using excess ammonia (as either a 0.5 M solution in dioxane or a saturated solution on CH2CI2). Example Structure & Name Mol Mass M+H No. Formula 751 C21HI6N203 344. 37 345. 1 O NH2 I jazz 1 6-((7-(methoxy)-4-quinolinyl) oxy)-1- naphthalenecarboxamide 752 C2gH28FN305 505. 54 506. 2 0 NH2 C3 O O,, I F rDN"'-"Ott-Nl o 5-fluoro-6- ( (6- (methoxy)-7- ( (3- (4-morpholinyl) propyl) oxy)- 4-quinolinyl) oxy)-1-naphthalenecarboxamide 753 O NH2zoHl4N20z 314. 34 315. 1 0 N NAZI 6-(6-quinolinyloxy)-1-naphthalenecarboxamide 754 C22Hl8N206 374. 39 375. 1 O9r, NH2 0 0) 'N N' 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-1- naphthalenecarboxamide 755 C22Hl7FN204 392. 38 393. 1 N 0 0 / J 0 N 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-5-fluoro-l- naphthalenecarboxamide 756 ONH2 C2 ; H, 7N304 375. 38 376. 1 ( 0 Cl19 N CL NJ 6- ( (6, 7-bis (methoxy)-4-quinazolinyl) oxy)-1- naphthalenecarboxamide 757 Cz2H, N304 387. 39 388. 3 O NH2 0 O HN OZON I CHs 4- ( (5- (aminocarbonyl)-2-naphthalenyl) oxy)-7- (methoxy)-6- quinolinecarboxamide 758 22Hl6FN34 405. 38 406. 3 O NH2 jazz H2N \ \ F ON CH3 4- ( (5- (aminocarbonyl)-1-fluoro-2-naphthalenyl) oxy)-7- (methoxy)-6-quinolinecarboxamide Example 759 CF3 7- (6, 7-dimethoxyquinolin4-yloxy)-N- (3- (trifluoromethyl) phenyl)-2, 3- X dihydrobenzo [b] [l, 41oxazine-4- Oqz N H carboxamide 0203 w I J O O MeO MeO4N

Step (a) Preparation of 2-chloro-N- (2, 4-dihydroxyphenyl) acetamide To a solution of 4-aminoresorcinol hydrochloride (30 g, 0.1857 mol) in CH2CI2, (460 mL) TEA (77.6 mL, 0.557 mol) was added at 0 °C. To the resulting mixture, chloroacetyl chloride (14.78 mL,

0.1857 mol) was added drop wise and the solution was stirred for 60 h at RT. The crude product was washed through a plug of silica gel with CH2CI2 and purified through column chromatography using 100% CH2CI2-> 25% 4 50%--> 75% 90: 10: 1 CH2CI2 : MeOH : NH4OH. The solution was concentrated in vacuo to give the title compound. MS (ESI, pos. ion) m/z : 202 (M+l). Mass calc'd for C8H8ClNO3 : 201.02.

Step (b) Preparation of 7-hydroxy-2H-benzo [b] [1, 4] oxazin-3 (4H)-one To a solution of 2-chloro-N- (2, 4-dihydroxyphenyl) acetamide (20 g, 0.0995 mol) in CH2CI2 (250 mL) sodium hydride (7.164 g, 0.2985 mol) was slowly added at RT. The resulting mixture was stirred for 6 h before water (10 mL) was slowly added. The solution was concentrated in vacuo and purified with column chromatography using 100% CH2Cl2 # 25% # 40% 90: 10: 1 CH2Cl2: MeOH: NH40H to yield the title compound. MS (ESI, pos. ion) m/z : 166 (M+1). Mass cal'd for C8H7N03 : 165.04.

Step (c) Preparation of 3, 4-dihydro-2H-benzo [b] [1, 4] oxazin-7-ol To a solution of 7-hydroxy-2H-benzo [b] [1, 4] oxazin-3 (4H) -one (6 g, 36.36 mmol) in THF (50 mL) BH3-THF (150 mL, 254.54 mmol) was slowly added at RT. The resulting reaction was stirred for 4 h at 60°C before water (5 mL) was added. The solution was concentrated in vacuo and purified with column chromatography using 100% CH2Cl2 # 25% # 50% 90: 10: 1 CH2Cl2:MeOH:NH4OH to yield the title compound. MS (ESI, pos. ion) m/z: 152 (M+1). Mass calc'd for C8H9N02 : 151. 06.

Step (d) Preparation of 7- (6, 7-dimethoxyquinolin-4-yloxy)-3, 4-dihydro-2H-benzo [b) [1, 4] oxazine A solution of 3, 4-dihydro-2H-benzo [b] [1, 4] oxazin-7-ol (2.5 g, 16.54 mmol), cesium carbonate (16.167, 49.62 mmol), and 4-chloro-6,7-dimethoxyquinoline (5.534 g, 24.81 mmol) in DMF (30 mL) was stirred for 15 h at 80 °C. The solution was concentrated in vacuo and purified with column chromatography using 100% CH2CI2 e 10% 90: 10: 1 CH2CI2 : MeOH : NH4OH to yield the title compound.

MS (ESI, pos. ion) m/z : 339 (M+l). Mass calc'd for C19HX8N204 : 338.13.

Step (e) Preparation of 7-(6,7-dimethoxyquinolin-4-yloxy)-N-(3-(trifluoromethyl)phen yl)-2, 3- dihydrobenzo [b] [l, 4] oxazine-4-carboxamide To a solution of 7-(6,7-dimethoxyquinolin-4-yloxy)-3, 4-dihydro-2H-benzo [b] [1, 4] oxazine (50 mg, 0.1478 mmol) in CH2CI2 (1 mL) 1-isocyanato-3-(trifluoromethyl) benzene (31 iL, 0.2217 mmol) was added. The resulting mixture was stirred for 1 h at RT. The solution was concentrated in vacuo and purified with column chromatography using 100% CH2Cl2 # 15% 90: 10: 1 CH2CI2 : MeOH : NH4OH to yield the title compound. MS (ESI, pos. ion) m/z : 526 (M+1). Mass calc'd for C27H22F3N305 : 525.15.

The following Examples were prepared similar to the procedures described in Example 759. Example Structure & Name Mol. Mass M+H No. Formula 760 C3oH3lN305 513. 59 514. 1 O. NH N 0 0 O O 0 N o NJ 7- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N- (4- ( 1, 1- dimethylethyl) phenyl)-2, 3-dihydro-4H-1, 4-benzoxazine- 4-carboxamide 761 C26H22ClN30s 491. 93 492. 1 CI ONH N . CH3 O O O o NJ CHs 7- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N- (3- chlorophenyl)-2, 3-dihydro-4H-1, 4-benzoxazine- 4-carboxamide 762 C26H22CIN30s 491. 93 492. 1 CI 0y NH N zon CHg O O O ON CHs CH3 7- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N- (4- chlorophenyl)-2, 3-dihydro-4H-1, 4-benzoxazine-4- carboxamide 763 9 C26H23N305 457. 48 458. 1 0 y NH ONH , CH3 O O 0 CHs 6H3 7- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N-phenyl-2, 3- dihydro4H-1, 4-benzoxazine-4-carboxamide 764 C27H22F3N305 525. 48 526. 1 F F RNH fla I N CH3 oxo Fs, F CHs 7- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N- (4- (trifluoromethyl) phenyl)-2, 3-dihydro-4H-1, 4-benzoxazine- 4-carboxamide 765 C22H23N3Os 409. 44 410. 1 , CH3 ONH N C113 OC (O 0 N CH3 O O CHs o NJ CH3 7-((6, 7-bis (methyloxy) 4-quinolinyl) oxy)-N-ethyl-2, 3- dihydro-4H-1, 4-benzoxazine-4-carboxamide 766 C27H2sN3Os 471. 51 472. 1 0y NH ONH J CH3 O O 6H3 CHs CH3 7- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N- (2- methylphenyl)-2, 3-dihydro-4H-1, 4-benzoxazine-4- carboxamide 767 C27H25N30s 471. 51 472. 2 CH3 03e OH fY CH3 I N o NJ CHs 7- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N- (4- methylphenyl)-2, 3-dihydro-4H-1, 4-benzoxazine-4- carboxamide 768 C27H25N305 471. 51 472. 1 q CH3 ONH fl CH3 O O O CHs 7- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N- (3- methylphenyl)-2, 3-dihydro-4H-1, 4-benzoxazine-4- carboxamide 769 C26H22CIN3Os 491. 93 492. 1 Cl ONH je W CH3 O O CHUS o NJ CH3 7- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N- (2- chlorophenyl)-2, 3-dihydro-4H-1, 4-benzoxazine-4- carboxamide 770 C27H21CIF3N305559. 93 560. 1 H or I HCI O O F F N ci y i No 0) N 7- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N- (4-chloro-3- (trifluoromethyl) phenyl)-2, 3-dihydro-4H-1, 4-benzoxazine-4- carboxamide 771 C32H27N305 533. 58 534. 1 /04 N 0\ 0) N y N- (1, 1'-biphenyl-4-yl)-7- ( (6, 7-bis (methyloxy)-4- quinolinyl) oxy)-2, 3-dihydro-4H-1, 4-benzoxazine-4- carboxamide 772 C27H25N305-471. 51 472. 1 On, N ç jfl oo o. L XN 7- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N- (phenylmethyl) 2, 3-dihydro-4H-1, 4-benzoxazine-4-carboxamide 773 H C3sH37N305 p485. 54 486. 2 zizi oo" YT O N ZON o NJ 7- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N- ( (4- methylphenyl) methyl)-2, 3-dihydro-4H-1, 4-benzoxazine-4- carboxamide 774 C28H28N405 500. 55 501. 1 H H 0y N N N oiao 1. 10 y Nr 7- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N- (4- (dimethylamino) phenyl)-2, 3-dihydro-4H-1, 4-benzoxazine-4- carboxamide 775 H C28H27N305 485. 54 486. 1 OYN/ro N . CO O<NS rr O-N 7- ( (6, 7-bis (methyloxy) 4-quinolinyl) oxy)-N-((I S)-I- phenylethyl)-2, 3-dihydro-4H-1, 4-benzoxazine-4- carboxamide 776 O NSO C NjOs 485. 54 486. 1 0 y N zou zers ' w j O i N 7- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N- ( (IR)-l- phenylethyl)-2, 3-dihydro-4H-1, 4-benzoxazine-4- carboxamide 777 1 C2lH2lN305 395. 41 396. 1 0y NH N 0 0 ON" 7- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N-methyl-2, 3- dihydro-4H-1, 4-benzoxazine-4-carboxamide 778 N C25H24N4OsS 492. 55 493. I N O O O 0 0 0 7- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N- (l- (1, 3-thiazol- 2-yl) ethyl)-2, 3-dihydro-4H-1, 4-benzoxazine-4-carboxamide Example 779 Y 7-(6, 7-dimethoxyquinolin-4-yloxy)-N- isopropyl-2, 3-dihydrobenzo [b] [1, 4] OqzNH oxazine-4-carboxamide N oo o, ao MeO Me0 NJ

Step (a) Preparation of 4-nitrophenyl 7- (6, 7-dimethoxyquinolin-4-yloxy)-2, 3- dihydrobenzo [b] [1, 4]oxazine-4-carboxylate To a solution of 7-(6,7-dimethoxyquinolin-4-yloxy)-3, 4-dihydro-2H-benzo [b] [1, 4] oxazine (400 mg, 1.182 mmol) andp-nitrophenyl chloroformate (262 mg, 1.300 mmol) in THF (6 mL) DIPEA (245

L, 1.419 mmol) was added drop wise at RT. The solution was stirred for 1 h at RT before the resulting mixture was concentrated in vacuo and the title compound was used in the following reaction without purification. MS (ESI, pos. ion) m/z: 504 (M+l). Mass cal'd for C26H21N308 : 503.13.

Step (b) Preparation of 7-(6,7-dimethoxyquinolin-4-yloxy)-N-isopropyl-2,3-dihydroben zo[b] [1,4] oxazine-4-carboxamide To a solution of 4-nitrophenyl 7-(6,7-dimethoxyquinolin-4-yloxy)-2, 3-dihydrobenzo [b] [1, 4] oxazine-4-carboxylate (190 mg, 0. 3777 mmol) in THF (4 mL) isopropylamine (321 uL, 3.777 mmol) was added at RT. The reaction was stirred for 1 h at RT before the resulting mixture was concentrated in vacuo and purified by column chromatography using 100% CH2Cl2 # 10% # 20% 90: 10: 1 CH2CI2 : MeOH: NH40H to yield the title compound. MS (ESr, pos. ion) m/z: 424 (M+l). Mass cal'd for C23H2sN305 : 423. 18 Example 780 OqzNH2 7-(6, 7-dimethoxyquinolin-4-yloxy)-2, 3- dihydrobenzo [b] [1, 4] oxazine-4-carboxamide 0X03 MeO MeON" Preparation of 7- (6, 7-dimethoxyquinolin-4-yloxy)-2, 3-dihydrobenzo [b] [l, 4] oxazine-4-carboxamide To a solution of 7- (6, 7-dimethoxyquinolin-4-yloxy)-3, 4-dihydro-2H-benzo [b] [1, 4] oxazine (100 mg, 0.2955 mmol) in toluene (2 mL) trichloroacetyl isocyanate (39 ßL, 0.325 mmol) was added at RT.

The resulting reaction mixture was stirred for 2 h at 60°C. The solution was cooled to RT and 10% HCl/H2O (5 mL) was added. The solution was concentrated in vacuo and purified with column chromatography using 100% CH2Cl2 # 10% # 20% # 30% 90: 10: 1 CH2CI2 : MeOH : NH4OH to yield the title compound. MS (ESI, pos. ion) m/z : 382 (M+1). Mass cal'd for C20H19N3O5 : 381.13. Example 781 O 7-(6, 7-dimethoxyquinolin-4-yloxy)-N- (isoxazol-3-yl)-2, 3-dihydrobenzolb] [1, 4] oxazine-4-carboxamide ONH 0X0 0 ao) Mu0 MeON"

Step (a) Preparation of 4-nitrophenyl isoxazol-3-ylcarbamate A solution of 3-amino isoxazole (220 uL, 2.973 mmol) andp-nitrophenyl chloroformate (659 mg, 3.271 mmol) in THF (8 mL) was stirred for 15 min at RT before the solution was concentrated in vacuo.

The title compound was used immediately in the following reaction without further purification. MS (ESI, pos. ion) m/z : 250 (M+l). Mass calc'd for CloH7N305 : 249.18.

Step (b) Preparation of 7-(6,7-dimethoxyquinolin-4-yloxy)-N-(isoxazol-3-yl)-2, 3-dihydrobenzo [b] [1, 4] oxazine-4-carboxamide To a solution of 7- (6, 7-dimethoxyquinolin-4-yloxy) -3,4-dihydro-2H-benzo [b] [1, 4] oxazine (100 mg, 0. 2955 mmol) and 4-nitrophenyl isoxazol-3-ylcarbamate (294 mg, 1.182 mmol) in CH2CI2 (3 mL) D1PEA (269 p1L, 2.069 mmol) was added at RT. The reaction mixture was stirred at 35 °C for 15 h before the solution was concentrated in vacuo and purified with column chromatography using 100% EtOAc- 10% # 30% # 50% 19: 1 EtOAc: MeOH to yield the title compound. MS (ESI, pos. ion) m/z: 449 (M+1). Mass calc'd for C23H20N406 : 448.44.

The following compounds were prepared similar to the procedures described in Example 781. Example Name & Structure Mol Formula Mass M+H No. 782/==\ C23H2oN40sS 464. 5 465 YIN OH N OO" ., o 0-N 7- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N- (1, 3-thiazol-2-yl)- 2, 3-dihydro-4H-1, 4-benzoxazine-4-carboxamide Example 783 O N Cl N-(3-chlorophenyl)-6-(4-pyridinyloxy)-1- naphthalenecarboxamide / 6N

Step (a) Preparation of 6-(pyridin-4-yloxy)-1-naphthoic acid To a solution of 6-hydroxy-1-napthoic acid (2 g, 10.6 mmol) in DMSO (5 mL), Cs2CO3 (14 g, 42.4 mmol) was added and stirred at RT 10 min. 4-Chloropyridine hydrochloride (1.9 g, 12.7 mmol) was added in one portion and the reaction mixture heated to 140 °C for 12 h. The reaction mixture was cooled to RT, diluted with water and made pH 5 using 6 N HCI, at which point a brown precipitate crashed out.

The solid was filtered and rinsed with water and hexanes to yield the title compound.

Step (b) Preparation of 6-(pyridin-4-yloxy)-1-naphthoyl chloride This compound was prepared similar to the procedure described in Example 273 Step (a).

Step (c) Preparation of N- (3-chlorophenyl)-6- (4-pyridinyloxy)-l-naphthalenecarboxamide 6-(Pyridin4-yloxy)-1-naphthoyl chloride (50 mg, 0.18 mmol) was suspended in CH2CI2 and solid NaHC03 (excess) was added. The mixture was blanketed with nitrogen and 3-chloroaniline (18.6 ptL, 0.18 mmol) was added and the reaction mixture stirred at RT for 1 h. The reaction mixture was diluted with CHC13 and water (using heat to dissolve the solids) and the organic layer further washed with brine, dried with Na2S04, filtered and concentrated in-vacuo. The residue was crystallized from CH2CI2/hexanes to give the title compound as a brown solid. MS (ESI pos. ion) m/z : 375.1 (M+H). Calc'd for C22Hl5CIN202-374. 82.

The following compounds were prepared similar to the procedures described in Example 783 and purified by column chromatography and/or crystallization. Example Structure & Name Mol Formula Mass M+H No. 784 C22Hl5CIN202 374. 82 375. 1 p, ci W. N N- (4-chlorophenyl)-6- (4-pyridinyloxy)-1- naphthalenecarboxamide 785 C26H24N202 396. 48 397. 2 O O \ NS WNJr N4 N N- (4- ( 1, 1-dimethylethyl) phenyl)-6- (4-pyridinyloxy)-1- naphthalenecarboxamide 786 C23H, 8N202 354. 40 355. 1 own O N ? 6 N N- (3-methylphenyl)-6- (4-pyridinyloxy)- I- naphthalenecarboxamide 787 C22H, 6N202 340. 38 341. 1 O N 0 O y N-phenyl-6- (4-pyridinyloxy)-1- na hthalenecarboxamide 788 C23HnC ! N202 388. 85 389. 1 FUZZ O N 0 N6 y N- (3-chloro-4-methylphenyl)-6- (4-pyridinyloxy)-1- naphthalenecarboxamide 789 Cz3H, gN202 354. 40 355. 1 own 0 (N O y N- (4-methylphenyl)-6- (4-pyridinyloxy)-1- naphthalenecarboxamide 790 C25H22N202 3 82. 46 383. 1 O N / O y N- (3- ( 1-methylethyl) phenyl)-6- (4-pyridinyloxy)-1- naphthalenecarboxamide 791 C26H24N202 396. 48 397. 1 O N 6"' 1 N- (3-methyl-4- ( 1-methylethyl) phenyl)-6- (4- pyridinyloxy)-I-naphthalenecarboxamide 792 C24H20N202 368. 43 369. 1 N \ \ y N- (3, 4-dimethylphenyl)-6- (4-pyridinyloxy)-1- naphthalenecarboxamide 793 C23H, N202 408. 37 409. 1 43 WF /if O \ \ I FF ( 6- (4-pyridinyloxy)-N- (4- (trifluoromethyl) phenyl)-1- naphthalenecarboxamide 794 C23H, 4CIF3N202 442. 82 443. 1 F 0 N&F F g Cl I 6 ZON N- (4-chloro-3- (trifluoromethyl) phenyl)-6- (4- pyridinyloxy)-I-naphthalenecarboxamide The following examples were prepared similar to the procedures described in Example 783 step c.

Example Structure & Name Mol Formula Mass M+H No. 795 H C23Hl8N404 414. 42 415. 1 N 0 ICN 0 N 0 O N RNH N-methyl-4- ( (5- ( ( (6-oxo-1, 6-dihydro-3- pyridinyl) amino) carbonyl)-2-naphthalenyl) oxy)-2- pyridinecarboxamide The following examples were prepared similar to the procedures described in Example 783, Step c, using 1.5-1. 8 equiv amine. Example No. Structure & Name Mol Formula Mass M+H 796 C24H, 9F3N204 456. 42 457 F OH o O NH O y 6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N- (2, 2, 2- trifluoroethyl)-1-naphthalenecarboxamide 797 C26H24Nz04 428. 49 429. 1 O NH zu r , 0s+} 6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N- (cyclopropylmethyl)-I-naphthalenecarboxamide 798 r\ C27H26N20s 458. 51 459. 1 ro o<rzNH O NH OJ .."0 0 6- ( (6, 7-bis (methyloxy) 4-quinolinyl) oxy)-N-((2R)- tetrahydro-2-furanylmethyl)-1-naphthalenecarboxamide 799 O 27H26N205 458. 51 459. 1 O nu ON i0 I \ 1-10 0 6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N- ( (2S)- tetrahydro-2-furanylmethyl)-1-naphthalenecarboxamide 800 O NH C24H22N204 402. 45 403. 2 O NH f o ON 6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N-ethyl-l- naphthalenecarboxamide Example 801 2 6-((6, 7-bis (methyloxy)-4-quinolinyl) oxy)-5- ( ? fluoro-N-phenyl-l-naphthalenecarboxamide ON i O I O F, F

Step (a) Preparation of methyl 6-hydroxy-1-naphthoate To a cooled solution of 6-hydroxy-1-napthoic acid (TCI America) (50 g, 0.27 mmol) in methanol (500 mL), thionyl chloride (29 mL, 0.40 mmol) was added slowly. The temperature was maintained at 15 to 30 °C. The reaction mixture was allowed to warm to RT and stirred O/N. The solvent was concentrated in-vacuo and the residue azeotroped with benzene. The title compound was obtained as a pink solid.

Step (b) Preparation of methyl 5-fluoro-6-hydroxy-1-naphthoate To a stirred solution of methyl 6-hydroxy-1-naphthoate (25 g, 123.8 mmol) in anhydrous acetonitrile (130 mL), SelectFluor (45 g, 127.5 mmol) was added and the reaction vessel sealed (sealed

tube). The reaction mixture was heated to 85 °C for 3 d. The reaction mixture was allowed to cool to RT, diluted with ethyl acetate and washed with water, then brine, dried with Na2SO4, filtered and evaporated. The mixture was purified by column chromatography using methylene chloride as the eluent.

The title compound was obtained as a tan solid.

Step (c) Preparation of 5-fluoro-6-hydroxy-1-naphthoic acid Sodium hydroxide (116 g, 2.9 mol) was dissolved in 100 mL water and added to a solution of methyl 5-fluoro-6-hydroxy-1-naphthoate (8.56 g, 38.9 mmol) in methanol (200 mL). The mixture was refluxed at 80 °C for 2 h. The mixture was allowed to cool to RT, then poured into 6N HCI in ice. The pH was adjusted to 3 to give a fine purple/pink solid. The title compound was isolated by centrifuge (with some salts).

Step (d) Preparation of 6- (6, 7-dimethoxyquinolin-4-yloxy)-5-fluoro-l-naphthoic acid To a solution of 5-fluoro-6-hydroxy-1-naphthoic acid (1 g, 4.87 mmol) in DMSO (5 mL), Cs2CO3 (4.75 g, 14.61 mmol) was added in one portion. The mixture was stirred at RT 10 min. To the suspension, 4-chloro-6,7-dimethoxyquinoline (1.09 g, 4.87 mmol) was added and the mixture heated to 140 °C O/N. The mixture was allowed to cool to RT, pH adjusted to 7 and the resulting solid filtered and rinsed with water. The title compound was obtained as a tan solid.

Step (e) Preparation of 6-(6, 7-dimethoxyquinolin-4-yloxy)-5-fluoro-1-naphthoyl chloride A suspension of 6-(6, 7-dimethoxyquinolin-4-yloxy)-5-fluoro-1-naphthoic acid (1.23 g, 3.12 mmol) in thionyl chloride (3 mL, excess) was refluxed for 1.5 h. The reaction mixture was concentrated in-vacuo and azeotroped with toluene (x2) to give the title compound as a brown solid.

Step (f) Preparation of 6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-5-fluoro-N-phenyl-1- naphthalenecarboxamide The title compound was prepared similar to the procedure described in Example MHP-1 (c). The product was purified by column chromatography. MS (ESI pos. ion) m/z: 469.0 (M+H). Calc'd for C28H2, FN204- 468. 48.

The following examples were prepared similar to the procedures described in Example 801 and purified by column chromatography and/or crystallization. Example No. Structure & Name Mol Formula Mass M+H 802 C25H23FN205 450. 46 451. 0 O N i jazz 0 ON "0 N, o NJ 6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-5-fluoro- N- (2- (methyloxy) ethyl)-1-naphthalenecarboxamide 803 C25H2, FN204 432. 44 433. 0 OWN O 0 u F 0 N 6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N- cvoloDroDyl-5-fluoro-1-naDhthalenecarboxamide 804 F\ C25H, 8FN304S 475. 49 476. 0 NUS OWN 0 N 0 O F 0 N 6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-5-fluoro- N-(I, 3-thiazol-2-yl)-1-naphthalenecarboxamide 805 C28H9CI2FN204 537. 37 537. 0 CI ON ci r ci O ON 6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N- (3, 4- dichlorophenyl)-5-fluoro-1- naphthalenecarboxamide 806 C28H2oClFN204 502. 92 503. 1 CI N 0 0 O F 0 N 6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N- (3- chlorophenyl)-5-fluoro-I-naphthalenecarboxamide 807 C29H23FN204 482. 50 483. 2 own O N O F I 6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-5-fluoro- N- (4-methylphenyl)-1-naphthalenecarboxamide 808 C2sH2oF2N204 486. 47 487. 1 (/ ON O L) F ( N J 6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-5-fluoro- N-3-fluorophenyl)-1-naphthalenecarboxamide 809 F C28H20F2N204 486. 47 487. 1 F 0 N O N X O W O F , o NJ 6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-5-fluoro- N- (4-fluorophenyl)-1-naphthalenecarboxamide 810 C2sH, 9F3N204 504. 46 505. 1 F F N O N O y/NJ 6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N- (3, 4- di fluorophenyl)-5-fluoro-1- naphthalenecarboxamide 811 fY C29H23FN204 482. 50 483. 2 OWN L) F I crV 6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-5-fluoro- N- (3-methylphenyl)-1-naphthalenecarboxamide 812 C23H, gFN204 406. 41 407. 1 O>Ns O u -'0 ON 6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-5-fluoro- N-methyl-1-naphthalenecarboxamide 813 C25H, SFN305 459. 43 460. 1 F- ZON Own u F I i Na 6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-5-fluoro- N- (3-isoxazolyl)-1-naphthalenecarboxamide 814 \F0-C26H2oFN30s 473. 45 474. 2 Vh ZON O N 0 N O I 6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-5-fluoro- N- (5-methyl-3-isoxazolyl)-l- naphthalenecarboxamide 815 C28H20CIFN204 502. 92 503 ci 0 N Own I y Nr ON 6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N- (4- chlorophenyl)-5-fluoro-1-naphthalenecarboxamide Example 816 Cl N-(4chlorophenyl>5-fluoro-6-((6- w (methyloxy)-7- ( (3- (4-morpholinyl) 9 propyl) oxy)-4-quinolinyl) oxy)-1- O N naphthalenecarboxamide Ouf old ou CNOX oa

Step (a) Preparation of 5-fluoro-6-(6-methoxy-7-(3-morpholinopropoxy)quinolin-4-ylox y)-1- naphthoic acid In a microwave tube, 5-fluoro-6-hydroxy-1-naphthoic acid (300 mg, 1.48 mmol) and Cs2CO3 (1.45 g, 4.44 mmol) in DMSO (1.5 mL) were stirred for 3 min at RT. 4-Chloro-6-methoxy-7- (3- morpholinopropoxy) quinoline (500 mg, 1.48 mmol) was added and the vessel sealed. The mixture was subjected to the microwave (Personal Chemistry) at 160 °C for 15 min, then 30 min. The vessel was opened and the mixture stirred with a spatula, resealed and heated another 5 minutes. The reaction mixture made pH 7 with IN HCI and evaporated. The residual solid was taken up into MeOH and filtered and evaporated. The solid was then taken up into and CH2CI2/MeOH mixture and filtered. The filtrate was evaporated to dryness and triturated with ethyl acetate/hexanes and the title compound collected as a yellow solid.

Step (b) Preparation of N- (4-c6lorophenyl)-5-fluoro-6- ( (6- (methyloxy)-7- ( (3- (4-morpholinyl) propyl) oxy)-4-quinoUnyt) oxy)-1-naphthalenecarboxamide The title compound was prepared similar to Example 421, Steps b and c. MS (ESI pos. ion) m/z : 616. 1 (M+H). Calc'd for C34H3lClFN3Os-616. 08.

The following examples were prepared similar to the procedures described in Example 816 Example Structure & Name Mol Formula Mass M+H No. 817 C35H34FN305 595. 66 596. 2 own ON 0 O I NO NJ O 5-fluoro-6- ( (6- (methyloxy)-7- ( (3- (4- morpholinyl) propyl) oxy)-4-quinolinyl) oxy)-N- (3- methylphenyl)-1-naphthalenecarboxamide 818 C34H3, ClFN305 616. 08 616. 1 ' CI O N O F 6) (DN-)- Neo N- (3-chlorophenyl)-5-fluoro-6- ( (6- (methyloxy)-7- ( (3- (4-morpholinyl) propyl) oxy)-4-quinolinyl) oxy)-1- naphthalenecarboxamide Example 819 H 4-((5-((cyclopropylamino) carbonyl)-2- N naphthalenyl) oxy)-7- (methyloxy)-6- V quinolinecarboxamide O O O N

Step (a) Preparation of 4-chloro-7-methoxyquinoline-6-carboxamide.

The synthesis of this compound follows the procedure described in the following patent (patent No. WO 00/050405, Application No. WO 2000-GB579).

Step (b) Preparation of 6-(6-carbamoyl-7-methoxyquinolin-4-yloxy)-1-naphthoic acid.

The title compound was synthesized in a manner similar to that described in Example 801, Step d.

Step (c) Preparation of 6-(6-carbamoyl-7-methoxyquinolin-4-yloxy)-1-naphthoyl chloride The title compound was synthesized in a manner similar to that described in Example 801, Step e.

Step (d) Preparation of 4- ( (5- ( (cyclopropylamino) carbonyl)-2-naphthalenyl) oxy)-7- (methyloxy)-6- quinolinecarboxamide.

The title compound was synthesized in a manner similar to that described in Example 273, Step e.

MS (ESI pos. ion) m/z: 469.0 (M+H). Calc'd for C28H2, FN204-468. 48.

The following examples were prepared similar to the procedures described in Example 819, Step d. Example Structure & Name Mol Formula Mass M+H No. 820 C2SH2oFN304 445. 45 446. H ON 0 0 zu w y r 4- ( (5- ( (cyclopropylamino) carbonyl)-1-fluoro-2- naphthalenyl ox-7- (methyloxy)-6-uinolinecarboxamide Example 821 NH 4-((5-((cyclopropylamino) carbonyl)-2- naphthalenyl) oxy)-N-methyl-7- (methyloxy)-6-quinolinecarboxamide or-, H _o NJ Step (a) Preparation of 4-chloro-7-methoxy-N-methylquinoline-6-carboxamide.

The synthesis of this compound follows the procedure described in the following patent (patent No. WO 00/050405, Application No. WO 2000-GB579).

Step (b) 6- (7-methoxy-6- (methylcarbamoyl) quinolin-4-yloxy)-1-naphthoic acid.

The title compound was synthesized in a manner similar to that described in Example 801, Step d.

Step (c) Preparation of 4- ( (5- ( (cyclopropylamino) carbonyl)-2-naphthalenyl) oxy)-N-methyl-7- (methyloxy)-6-quinolinecarboxamide.

The title compound was synthesized in a manner similar to that described in Example 273, Step e.

The following examples were prepared similar to the procedures described in Example 821. Example Structure & Name Mol Formula Mass M+H No. 822 H C26H25N305 459. 5 460. 2 H OqzN o, CH3 0 otb nez H N-methyl-7- (methyloxy)-4- ( (5- ( ( (2- (methyloxy) ethyl) amino) carbonyl)-2-naphthalenyl) oxy)- 6-quinolinecarboxamide 823 C25H23N305 445. 47 446. 1 H OYN oz o 0 H2N ON- 7- (methyloxy)-4- ( (5- ( ( (2- (methyloxy) ethyl) amino) carbonyl)-2- naphthalenyl) oxy)-6-quinolinecarboxamide

The following examples were prepared similar to the procedures described in Example Ex 120 and purified by column chromatography and/or crystallization. Example Structure & Name Mol Formula Mass M+H No. 824 C2sHz, FN204 468. 48 469. 2 N Nyi u I Nr N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-1- naphthalenyl)-4-fluorobenzamide 825 X C28H2, FN204 468. 48 469. 2 0 F 141 O I -'0 y \ NJ N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-1- naphthalenyl)-3-fluorobenzamide 826 C2sH2jClN204 484. 93 485. 0 0 CI ci N Nr N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-1- naphthalenyl)-3-chlorobenzamide 827 , N304 451. 48 452. 0 0 c 41 NU -'0 JkJ N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-1- naphthalenyl)-2-pyridinecarboxamide 828 0 C27HziN304 451. 48 452. 0 N N 084 sO) 4N O/ \ N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-1-naphthalenyl)- 3-pyridinecarboxamide 829 t C27H2, N304 451. 48 452. 0 , 41 N 0 N ION / O I J N-(6-((6, 7-bis (methyloxy)-4-quinolinyl) oxy)-1-naphthalenyl)- 4-pyridinecarboxamide 830 C29H20CIF3N204 552. 93 553. 1 0 F N F F ci O I O nu N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-1-naphthalenyl)- 4-chloro-3-(trifluoromethyl) benzamide 831 C29H24N204 464. 51 465. 1 141 O 0 N . zoo ON N-(6-((6, 7-bis (methyloxy)-4-quinolinyl) oxy)-1-naphthalenyl)- 3-methylbenzamide 832 Cz9Hz4NZO4 464. 51 465. 1 0 / O N r) , o oY ON N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-1-naphthalenyl)- 4-methylbenzamide 833 C3oH2oF6N204 586. 48 587. 1 0 F NYyF if F F F -'0 . oiNJ N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-1-naphthalenyl)- 3, 5-bis (trifluoromethyl) benzamide 834 C2sHXgN3os 441. 44 442. 1 0 N N) % o r L O oiNJ N-(6-((6, 7-bis (methyloxy)-4-quinolinyl) oxy)-1-naphthalenyl)- 5-isoxazolecarboxamide 835 C28H28N204 456. 53 457. 2 N) + N O 4W o NJ N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-1- naphthalenyl) cyclohexanecarboxamide 836 C26H26N204 430. 50 431. 2 N nez / O O , o NJ N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-1-naphthalenyl)- 2, 2-dimeth I ro anamide 837 < C29H24N204 464. 51 465. 1 N O O N N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-1-naphthalenyl)- 2-phenylacetamide v 838 C29H23CIN204 498. 96 499. 1 N , J / O 4 NJ N-(6-((6, 7-bi s (methyloxy)-4-quinolinyl) oxy)-1-naphthalenyl)- 2-(4-chlorophenyl) acetamide 839 C30H26N206 510. 54 511. 1 0 N \ O N sO N -'0 nu zon y r N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-1-naphthalenyl)- 3, 4-bis (methyloxy) benzamide 840 C30H26N204 478. 54 479. 2 0 N o w i ! 0 0g N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-1- naphthalenyl)-3, 5-dimethylbenzamide 841 C28H2oF2N204 486. 47 487. 1 0 F N I O O/ 0 * N N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-1- naphthalenyl)-3, 4-difluorobenzamide 842 C28H20CIFN204 502. 92 503. 1 0 CI F "0 ! \ Jk 0"N N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-1- naphthalenyl)-3-chloro4-fluorobenzamide 843 C29H2, F3N205 534. 48 535. 1 NtS°TF N OUF /\ O 4 N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-1- naphthalenyl)-3-trifluoromethy1 oxy) benzamide 844 0 C26H2, N305 455. 46 456. 1 0 N I fez O N9_ ON N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-1- naphthalenyl)-5-methyl-3-isoxazolecarboxamide 845 C30H26N204 478. 54 479. 2 0 N O u , NJ 0 N N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-1- naphthalenyl)-3, 4-dimethylbenzamide 846 C29H24N20s 480. 51 481. 1 0 / Y 0 4 w "0 Phenylmethyl 6- ( (6, 7-bis (methyloxy) 4-quinolinyl) oxy)-1- naphthalenylcarbamate 847 C28H21CIN204 084. 94 485. 1 Ci HNO HN 0 job H3C. I N N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-1-naphthalenyl)- 4-chlorobenzamide 848 C28H2, C ! N204 484. 94 485. 1 V" HN 0 Hck Hck w H3C. (N N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-1-naphthalenyl)- 2-chlorobenzamide 849 t C28H2, FN204 468. 48 469. 1 HN ° HN / H, : OF cl H3 00) can N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-1-naphthalenyl)- 2-fluorobenzamide 850 0 C32H3oN204 506. 6 507. 4 HN H3CsoX CH3 p H3C CH3 O, H C, OL CJA N-(6-((6, 7-bis (methyloxy)-4-quinolinyl) oxy)-1-naphthalenyl)- 4- (1, 1-dimethylethyl) benzamide 851 CF3 C29H2, F3N204 518. 49 519. 3 CF3 I HO O O I O w0 N N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-1-naphthalenyl)- 4-(trifluoromethyl) benzamide 852 o C29H24N20s 480. 52 481. 3 , eJt CH3 C3 O 0 HsCJ N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-1-naphthalenyl)- 3- (methyloxy) benzamide 853 'C28HzoC1zNz04 519. 38 521. 4 ci Job Oh3 0 O, °Yfi 3 0 N.- N-(6-((6, 7-bis (methyloxy)-4-quinolinyl) oxy)-1-naphthalenyl)- 2, 3-dichlorobenzamide 854 0 C29H24N205 480. 52 481. 1 HN _O CH 0, C : : b 6H, 1 3 zu H3Cvo) N N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-1-naphthalenyl)- 4- (methyloxy) benzamide 855 Q p C29H2, F3Nz04 518. 49 519. 3 HN FF lu C3 O O, H3C. Q I N N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-1-naphthalenyl)- 3- (trifluoromethyl) benzamide Example 856 NH2 6- (pyridin-4-yloxy) naphthalen-1-amine 0

Preparation of 6-(pyridin-4-yloxy) naphthalen-1-amine The title compound was prepared in a manner similar to that described in Example 120 Step a.

The following compounds were prepared in a manner similar to that described in Example 120 Step b. Example Structure & Name Mol Formula Mass M+H nô. 857 C22Hl5CIN202 374. 82 375. 1 0 C O \ \ I I C 4-chloro-N-(6-(4-pyridinyloxy)-1-naphthalenyl) benzamide 858 Cz2H, sCINz02 374. 8 375. 0 0 N ci // u y 3-chloro-N- (6- (4-pyridinyloxy)-l-naphthalenyl) benzamide Example 859 6- ( (7- (methoxy)-4-quinolinyl) oxy)-N- phenyl-1-naphthalenecarboxamide ON vu O N. H 0m o '

Step (a) Preparation of 7-methoxyquinolin-4-ol To a solution of 1- (2-amino-4-methoxyphenyl) ethanone [J Med Chem, 32 (4): 807-826 (1989)] (7.32 g, 44.3 mmol) in dioxane (150 mL), NaOt-Bu (9.8 g, 102 mmol) was added and stirred at RT for 30 min. The color changed from lime green to dark green. Ethyl formate (23.64 mL, 292 mmol) was added with an additional 20 mL dioxane. The reaction mixture was stirred at RT 18 h after which the mixture was poured into water (20 mL) and the pH adjusted to 7 with 2N HCI. The solution was evaporated a little. The red solid was filtered and rinsed with water. The solid was triturated with 1: 1 EtOAc: hexanes and then filtered to give the title compound as a brown solid.

Step (b) Preparation of 4-chloro-7-methoxyquinoline To a solution of POC13 (11 mL, excess), 7-methoxyquinolin-4-ol (1.87 g, 10.67 mmol) was added and heated from RT to 90 °C. The mixture was allowed to cool to RT, concentrated in-vacuo and cooled in an ice bath during the slow adjustment to pH 7 by alternating ice and 1N NaOH. The solid was filtered and rinsed with water. The title compound was isolated as a tan solid.

Step (c) Preparation of 6- (7-methoxyquinolin-4-yloxy)-1-naphthoic acid The title compound was prepared similar to the procedure described in Example 760 step (d).

Workup: The reaction mixture was filtered through a pad of Celites using 95: 5: 0.5 (CH2CIz : MeOH: Acetic acid) as the eluent and concentrated in-vacuo before pH adjustment.

Step (d) Preparation of 6- (7-methoxyquinolin-4-yloxy)-1-naphthoyl chloride The title compound was prepared similar to the procedure described in Example 273.

Step (e) Preparation of 6-((7-(methyloxy)-4-quinolinyl) oxy)-N-phenyl-l-naphthalenecarboxamide The title compound was prepared similar to the procedure described in Example 783 Step (c).

MS (ESI pos. ion) m/z : 421.0 (M+H). Calc'd for C27H2oN203-420. 46.

The following examples were prepared similar to the procedures described in Example 859 and purified by column chromatography and/or crystallization. Example Structure & Name Mol Formula Mass M+H No. 860 ci ! Cz7HIgCINzO 454. 91 455. 0 0 N, H 0 O N- (4-chlorophenyl)-6- ( (7- (methyloxy)-4- quinolinyl oxy)-1-naphthalenecarboxamide 861 O C24H22N204 402. 44 403. 0 0 N, H 0 O i ruz O N N- (2- (methyloxy) ethyl)-6- ( (7- (methyloxy)-4- quinolinyl oxy)-1-naphthalenecarboxamide 862 C24H20N203 384. 43 385. 1 0 N, H 0 1 * - oy N-cyclopropyl-6- ( (7- (methyloxy)-4- quinolinyl) oxy)-1-naphthalenecarboxamide 863 C24Hl7N303S 427. 48 428. 0 N, S ON 0 N, H o ' 6- ( (7- (methyloxy)-4-quinolinyl) oxy)-N- (1, 3- thiazol-2-yl)-1-naphthalenecarboxamide Example 864 ON- 7- ( (6, 7-bis (methyloxy)-4- quinolinyl) oxy)-N- (4-chlorophenyl)-4- quinolinecarboxamide- 0 N zu "YY ON

Step (a) Preparation of methyl 7-methoxyquinoline-4-carboxylate The following reagents were placed in a glass jacket inside of a Parr bomb: 4-chloro-7- methoxyquinoline (2 g, 10.33 mmol), Pd (OAC) 2 (225 mg, 1.0 mmol), 1, 3-diphenylphosphino propane [DPPE] (618 mg, 1.55 mmol), DMF (15 mL), MeOH (3 mL) and TEA (2.87 mL, 20.66 mmol) and the vessel sealed. The vessel was pressurized to 50 psi CO and stirred at 70 °C (internal temperature) for 19 h. The vessel was allowed to cool to RT, carefully opened and the contents transferred to a round bottom flask and concentrated in-vacuo. A solution of 2: 1 EtOAc: hexanes was added to the residual solid and the solid filtered (and discarded). The filtrate was evaporated and the residue purified by column chromatography using a mixture of EtOAc/hexanes as the eluent. The title compound was obtained as a yellow solid.

Step (b) Preparation of 7-hydroxyquinoline-4-carboxylic acid To a cooled (0 °C) solution of methyl 7-methoxyquinoline-4-carboxylate (378 mg, 1.74 mmol) in CH2CI2, BBr3 (9 mL, excess) was added and the reaction mixture stirred and warmed to RT. After 4 days, the mixture was poured into ice and the yellow solid collected as the title compound.

Step (c) Preparation of 7- (6, 7-dimethoxyquinolin-4-yloxy) quinoline-4-carboxylic acid The title compound was prepared similar to the procedure described in Example 783 step (a) using 7-hydroxyquinoline-4-carboxylic acid as the reagent.

Step (d) Preparation of 7- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N- (4-chlorophenyl)-4- quinolinecarboxamide The title compound was prepared similar to the procedure described in Example 357. MS (ESI pos. ion) m/z : 486.1 (M+H). Calc'd for C27H20CIN304-485. 92.

The following examples were prepared similar to the procedures described in Example 864 and purified by column chromatography and/or crystallization. Example Structure & Name Mol Formula Mass M+H No. 865 ON CMH2iN304 415. 44 416. 2 i ruz zon O O I N 7- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N- cyclopropyl-4-quinolinecarboxamide 866 OqzN Ow C24H23N3Os 433. 46 434. 2 i vil I O W wN J O O I N 7- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-N- (2- (methyloxy) ethyl)-4-quinolinecarboxamide Example 867,, 6-((6, 7-bis (methoxy)-4-quinazolinyl) oxy)-N- phenyl-1-naphthalenecarboxamide O N N 0X N N 0 zon

Step (a) Preparation of 6-(6, 7-dimethoxyquinazolin-4-yloxy)-1-naphthoic acid The title compound was prepared similar to the procedure described in Example 477 Step (a) using 4-chloro-6,7-dimethoxyquinazoline as the reagent and K2CO3 as the base.

Step (b) Preparation of 6- ( (6, 7-bis (methyloxy)-4-quinazolinyl) oxy)-N-phenyl-1- naphthalenecarboxamide The title compound was prepared similar to the procedure described in Example 357. MS (ESI pos. ion) m/z : 452.1 (M+H). Calc'd for C27H2lN304-451. 48.

The following examples were prepared similar to the procedures described in 867 and purified by column chromatography and/or crystallization. Example Structure and Name Mol Mass M+H No. Formula 868ciC27HzoClN304 485. 92 486. 1 NU 0 nu On H3C. I 6- ( (6, 7-bis (methyloxy)-4-quinazolinyl) oxy)-N- (4- chlorophenyl)-I-naphthalenecarboxamide 869 C2sH23N304 465. 50 466. 2 Nu 0.' 3 Zon HsC. O I i NJ H, C. oA 6- ( (6, 7-bis (methyloxy)-4-quinazolinyl) oxy)-N- (3- methylphenyl)-1-naphthalenecarboxamide 870 H3C CH3 C3lH29N304 507. 58 508. 2 CH3 zou NH 1 N O wN -ON 6- ( (6, 7-bis (methyloxy) 4-quinazolinyl) oxy)-N-(4-(1, I- dimethylethyl) phenyl)-1-naphthalenecarboxamide 87lC24H2, N304 415. 44 416. 2 NH C3 O Cl 0 H3 C, 6- ( (6, 7-bis (methyloxy)-4-quinazolinyl) oxy)-N-cyclopropyl-l- naphthalenecarboxamide 872 H C24H23N30s 433. 46 434. 1 CH oJi3 HN O N. CH3 For) N H3. HsCJL 6- ( (6, 7-bis (methyloxy)-4-quinazolinyl) oxy)-N- (2- (methyloxy) ethyl)-1-naphthalenecarboxamide 873Cz2H, 9N304 389. 40 390. 1 , CH3 0 CH30 N Hck O \ wN H3Cso) &N 6- ( (6, 7-bis (methyloxy)-4-quinazolinyl) oxy)-N-methyl-1- naphthalenecarboxamide 874 0 C24Hl8N405 442. 42 443. 1 zizi N C3 O Cl3 0 Hck 6- ( (6, 7-bis (methyloxy)-4-quinazolinyl) oxy)-N- (3-isoxazolyl)- 1-naphthalenecarboxamide Example 875 6- ( (6, 7-bis (methyloxy)-4- quinazolinyl) amino)-N-phenyl-l- naphthalenecarboxamide 0 N \ \ I N N N N

Step (a) Preparation of Methyl 6- (6, 7-dimethoxyquinazolin-4-ylamino)-1-naphthoate The following reagents were combined in a flask and placed in a RT oil bath that was then heated to 90 °C : 4-Chloro-6, 7-dimethoxyquinazoline (954 mg, 4.24 mmol), methyl 6-amino-1-naphthoate (857 mg, 4.24 mmol), TFA (098 mL, 12.7 mmol), and isopropanol (12 mL). The reaction was done before the bath reached the desired temperature. The mixture was diluted with water and made pH basic with 6N NaOH. The solid was filtered and rinsed with water and EtzO. The title compound was obtained as a pink solid.

Step (b) Preparation of 6-(6, 7-dimethoxyquinazolin-4-ylamino)-1-naphthoic acid Methyl 6-(6, 7-dimethoxyquinazolin-4-ylamino)-1-naphthoate (500 mg, 1.28 mmol) was stirred with 6N NaOH (10 mL) and MeOH (10 mL) at 70 °C for 3 h. The mixture was poured into 6N HCI/ice and the pH adjusted to 7. The solid was collected and rinsed with water, stirred with MeOH (5 mL) and filtered again. The title compound was obtained (crude) as a yellow solid.

Step (c) Preparation of 6- ( (6, 7-bis (methyloxy)-4-quinazolinyl) amino)-N-phenyl-l- naphthalenecarboxamide The title compound was prepared similar to the procedure described in Example 357. MS (ESI pos. ion) m/z: 451. 1 (M+H). Calc'd for C27H22N403-450. 49. The following examples were prepared similar to the procedures described in Example 875 and purified by column chromatography and/or crystallization. Example Structure & Name Mol Formula Mass M+H No. 876 C27Hz, ClN403 484. 94 485. 1 asz N I N O \ \N o NJ 6- ( (6, 7-bis (methyloxy)-4-quinazolinyl) amino)-N- (3- chlorophenvI)-1-naPhthalenecarboxamide 877 O C27H7XFNOs 468. 49 469. 1 ON O nu CH3 HN \ ON H3C. 6- ( (6, 7-bis (methyloxy)-4-quinazolinyl) amino)-N- (4- fluorophenyl)-I-naphthalenecarboxamide 878., C24H22N403 414. 46 415. 2 n ZON ON 0 N H3c, 0 N H, C 6- ( (6, 7-bis (methyloxy)-4-quinazolinyl) amino)-N- cyclopropyl-I-naphthalenecarboxamide 879 C24H24N404 432. 48 433. 1 O N. CH3 CH H N ozon H3C. I/ 6- ( (6, 7-bis (methyloxy)-4-quinazolinyl) amino)-N- (2- (methyloxy) ethyl)-1-naphthalenecarboxamide Example 880 0 N- (4-chlorophenyl)-6- (4-quinolinyloxy)-l- naphthalenecarboxamide OJC6 ci C ( o zu N

Step (a) Preparation of 6- (quinolin-4-yloxyy-l-naphthoic acid The title compound was prepared similar to the procedure described in Example 801 Step (d).

Step (b) Preparation of 6-(quinolin-4-yloxy)-1-naphthoyl chloride The title compound was prepared similar to the procedure described in Example 273 Step (a).

Step (c) Preparation of N- (4-chlorophenyl)-6- (4-quinolinyloxy)-1-naphthalenecarboxamide The title compound was prepared similar to the procedure described in Example 783 Step (c).

MS (ESI pos. ion) m/z: 425.1 (M+H). Calc'd for C26H"CIN202-424. 88.

The following examples were prepared similar to the procedures described in Example 880 and purified by column chromatography and/or crystallization. Example Structure & Name Formula Calc MW M+H No. 881 H C26H, 8N202 390. 44 391. 1 0 nô O 0 N N-phenyl-6- (4-quinolinyloxy)-1-naphthalenecarboxamide 882 H Cz3HzoNzs 372. 42 373. 2 O N. CH3 0 ,. N N- (2- (methyloxy) ethyl)-6- (4-quinolinyloxy)-1- naphthalenecarboxamide 883 C23Hl8N202 354. 41 355. 2 H ON 0 N N-cyclopropyl-6- (4-quinolinyloxy)-1- naphthalenecarboxamide 884 H C2sHI 7N302 391. 43 392. 1 0 N N 0 O N N- (3-pyridinyl)-6- (4-quinolinyloxy)-l- naphthalenecarboxamide 885 C2 ; H) 7N302 391. 43 392. 1 H 0 0 N N N- (4-pyridinyl)-6- (4-quinolinyloxy)-1- naphthalenecarboxamide Example 886 0 N- (6- ( (6, 7-bis (methyloxy)-4- HN t> quinolinyl) oxy)-1- /naphthalenyl) benzenesulfonamide 1 0110 0 O / zon

6- (6, 7-Dimethoxyquinolin-4-yloxy) naphthalen-1-amine (50 mg, 0.144 mmol) and benzenesulfonylchloride (25 mg, 0.144 mmol) were dissolved in pyridine (0.6 mL) then stirred at RT for 3 days. The reaction mixture was concentrated under vacuum. The crude material was purified by silica gel chromatography (2% to 4% MeOH in DCM) to give N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-1- naphthalenyl) benzenesulfonamide as a tan solid. MS (ESI pos. ion) m/z : 487.1 (M+H). Calc'd for C27H22N2O5s-486. 55.

The following Examples were prepared similar to the procedures described in Example 890. Example Structure & Name Mol Formula Mass M+H No. 887 C27H2) FN205S 504. 54 505. 1 HN's H N O F CH3 O YH3 0 H3C. NJ - (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-1- naphthalenyl)-2-fluorobenzenesulfonamide 888 CHztClNS 520. 99 521. 4 11 BCH3 OW os CH, O o, J N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-1- na hthalen I-4-chlorobenzenesulfonamide 889 O C27H2lFN205S 504. 54 505. 2 xi Is han CH3 0 0) H3CovN N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-1- naphthalenyl) 4-fluorobenzenesulfonamide 890 0 C26H25N304S 475. 566 476. 2 11 S HN'1% 0 cl3 0 CH3 N. CH3 envy N-methyl-4- ( (5- ( ( (4- ( 1-methylethyl) phenyl) sulfonyl) amino)-2-naphthalenyl) oxy)-2- pyridinecarboxamide 891 0 C23Hl8CIN304S 467. 931 468. 1 ici s HCI cri I H eNy O 0 4- ( (5- ( ( (4-chlorophenyl) sulfonyl) amino)-2- _ naphthalenyl) oxy)-N-methyl-2-pyridinecarboxamide 892 892 C22H,8N404S 434. 474 435. 2 11 HN N zu razz 1 H 0 \N NCH3 O N-methyl-4- ( (5- ( (3-pyridinylsulfonyl) amino)-2- naphthalenyl) oxy)-2-pyridinecarboxamide Example 893 4-chloro-N-(6-(lH-pyrazolo [3, 4- 0 blpyridin-4-yloxy)-1- naphthalenyl) benzamide HAN ci o i i 0 NhlN

Step (a) Preparation of 4-iodo-lH-pyrazolo [3, 4-blpyridine.

AIM solution of hydrazine in tetrahydrofuran (150 mL) was added slowly to 2-fluoro-4- iodopyridine-3-carboxaldehyde (10 g, 39.84 mmol) to give a clear solution. The reaction mixture was stirred at RT for 16 h. The mixture was concentrated in vacuo and the remaining solid was triturated with DCM to give the title compound as a pale yellow solid (8 g). The DCM filtrate was also washed with saturated sodium bicarbonate and brine. The organic layer was dried over sodium sulfate and concentrated under vacuum. The crude material was purified by trituration with DCM to give additional 4-iodo-1H-pyrazolo [3, 4-b] pyridine as a yellow solid. MS (ESI, pos. ion) m/z : 245.9 (M+1).

Step (b) Preparation of 6- (lH-pyrazolo [3, 4-b] pyridin-4-yloxy) naphthalen-1-amine.

5-Aminonaphthalen-2-ol (356 mg, 2.24 mmol) was dissolved in DMF (2.5 mL) then cooled to 0 °C. Sodium hydride (94 mg) was added slowly and the stirring was continued for 15 min at 0 °C. 4-Iodo- 1H pyrazolo [3, 4-b] pyridine (274 mg, 1.12 mmol) was then added slowly and the reaction was heated at 100 °C for 16 h, followed by 4.5 h at 120 °C. The mixture was partitioned between water and EtOAc then washed with water, IN aqueous NaOH, and brine. The organic layer was dried over sodium sulfate and concentrated in vacuo to give 6- (1H pyrazolo [3, 4-b] pyridin-4-yloxy) naphthalen-1-amine as a brown solid . MS (ESI, pos. ion) m/z : 277.1 (M+1).

Step (c) Preparation of 4-chloro-N-(6-(1H-pyrazolo [3, 4-b]pyridin-4-yloxy)-1- naphthalenyl) benzamide.

6- (lH-Pyrazolo [3, 4-b] pyridin-4-yloxy) naphthalen-1-amine (25 mg, 0.09 mmol), 4-chlorobenzoic acid (16 mg, 0.10 mmol) and TBTU (35 mg, 0.108 mmol) were dissolved in DMF (0.75 mL). Hunig's base (18 mg, 0.14 mmol) was then added and the reaction mixture was stirred at RT for 16 h. Additional 4-chlorobenzoic acid (6 mg, 0.036 mmol) and TBTU (12 mg, 0. 036 mmol) were added to the reaction and stirring was continued for 3 days. The reaction mixture was concentrated in vacuo. The remaining dark brown residue was purified by silica gel chromatography (0% to 2% MeOH in DCM) to yield 4- chloro-N- (6- (1H-pyrazolo [3, 4-b] pyridin-4-yloxy)-1-naphthalenyl) benzamide as an off-white solid. MS (ESI, pos. ion) m/z : 415.0 (M+1). MS (ESI pos. ion) m/z: 415.0 (M+H). Calc'd for C23Hl5ClN402- 414.85.

The following example was prepared similar to the procedures described in Example 114.

Example No. Structure & Name Mol Formula Mass M+H 894 C28H22N204 450. 49 451. 1 ON 0 N. H O O, O N 6- ( (6, 7-bis (methoxy)-4-quinolinyl) oxy)-N-phenyl-1- naphthalenecarboxamide Example 895 6- (6-methoxy-7- (3- (piperidin-l- yl) propoxy) quinolin-4-yloxy)-1-naphthoic acid OJX , 04 N GON

Step (a) Preparation of 4-chloro-7- (3-chloropropoxy)-6-methoxyquinoline To a solution of 4-chloro-6-methoxyquinolin-7-ol (5.7 g, 0.027 mole) and 1-bromo-3- chloropropane (13.2 mL, 0.14 mole) in DMF (150 mL), was added potassium carbonate (30 g, 0.27 mole).

The mixture was stirred at RT for 20 h. The mixture was concentrated in vacuo then diluted with H2O (100 mL). The mixture was extracted with EtOAc (3 x 50 mL) and the organic extracts were washed with H20 and brine. The organic phase was dried over MgS04, filtered, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (5% MeOH/CH2CI2) to yield the title compounds as a light yellow solid. MS (ESI, pos. ion) m/z : 286 (M+l). Mass Calc'd for C, 3H, 3CI2NO2 : 285.0.

Step (b) Preparation of 4-chloro-6-methoxy-7- (3- (piperidin-1-yl) propoxy) quinoline To a solution of 4-chloro-7- (3-chloropropoxy)-6-methoxyquinoline (3. 1 g, 0.0108 mole) NaI (2.4 g, 0.0162 mole), and potassium carbonate (7.5 g, 0.054 mole in DMF (100 mL), was added piperidine (6.4 mL, 0.065 mole). The mixture was heated to 70 °C for 16 h. The mixture was concentrated in vacuo then diluted with H2O (100 mL). The mixture was extracted with EtOAc (3 x 50 mL) and the organic extracts were washed with H20 and brine. The organic phase was dried over MgS04, filtered, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (7.5% MeOH/CH2CI2) to yield the title compounds as a light yellow solid. MS (ESI, pos. ion) m/z : 335 (M+1). Mass Calc'd for C, 8H23CIN202 : 334.1.

Step (c) Preparation of 6- (6-methoxy-7- (3- (piperidin-1-yl) propoxy) quinolin-4-yloxy)-1-naphthoic acid The compound was prepared according to Example 732, step d to afford the title compound as a light brown solid. MS (ESI, pos. ion) m/z : 487 (M+1). Mass Calc'd for C29H30N2Os : 486.2.

900) 6- (6-methoxy-7- (3-pyrrolidinopropoxy) quinolin-4-yloxy)-1-naphthoic acid was prepared similar to Example 899.

901) 6- (7- (Benzyloxy)-6-methoxyquinolin-4-yloxy)-1-naphthoic acid was prepared using a procedure similar to that described in Example 732, Step d: The following compounds were prepared by methods previously described: Example No. Structure & Name Mol Formula Mass M+H C35H33'2N306 629 630 F F O O. \ r olpa CH3 0 ol CH3 F 5-fluoro-N- (5-fluoro-6- ( (6- (methoxy)-7- ( (3- (4- morpholinyl) propyl) oxy)-4-quinolinyl) oxy)-2- naphthalenyl)-2- (methoxy) benzamide 897 C3, H34FN30s 547 548 N CH3 II C O o,, J o I w w F 0 0 N- (5-fluoro-6- ( (6- (methoxy)-7- ( (3- (4- morpholinyl) propyl) oxy)-4-quinolinyl) oxy)-2- naphthalenyl) butanamide 898 C30H30F4N4Os 602 603 F F N y N F CH p /O i 3 OF r', N 0 N o,,) N- (5-fluoro-6- ( (6- (methoxy)-7- ( (3- (4- morpholinyl) propyl) oxy)-4-quinolinyl) oxy)-2- naphthalenyl)-N'-(2, 2, 2-trifluoroethyl) urea 899 C32H37FN4Os 576 577 CH3 mcNrN9ucH3 ÇH3 O o , F O, I F 0 s F O oJ N- (5-fluoro-6- ( (6- (methoxy)-7- ( (3- (4- morpholinyl) propyl) oxy)-4-quinolinyl) oxy)-2- naphthalenyl)-N'-(2-methylpropyl) urea 900 C28H28F4N404 560 561 F F CH3 O OP NO) 4N I N- (6- ( (7- ( (3- (dimethylamino) propyl) oxy)-6- (methoxy)-4- quinolinyl) oxy)-5-fluoro-2-naphthalenyl)-N'-(2, 2, 2- trifluoroethyl) urea 901 N, AO C23H, gF4N205S 510 511 , N, O CH3 p i OF wu O, F CH ;, CH3 N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-5-fluoro-2- naphthaleny1-2, 2, 2-trifluoroethanesulfonamide 902 C2sH24FN304 449 450 N y N--CH3 H3 0 0 CH3 p i O ON CL, 0 N- (6- ( (6, 7-bis (methyloxy)-4-quinolinyl) oxy)-5-fluoro-2- naphthalenyl)-N'-propylurea 903 C32 H3 N3 °6 S 585 586 i w N i o CH3 0 C \3 oJXS oJ oH N- (6- ( (7- ( ( (2R)-2-hydroxy-3- (4-morpholinyl) propyl) oxy)- 6- (methoxy)-4-quinolinyl) oxy)-2-naphthalenyl)-2- thiophenecarboxamide 904 s C32H3, N3 06 S 585 586 N CH3 0 0 YY 0 OH 0 OH N-(6-((7-(((2S)-2-hydroxy-3-(4-morpholinyl) propyl) oxy) 6- (methoxy)-4-quinolinyl) oxy)-2-naphthalenyl)-2- thiophenecarboxamide 905 C25Hl7FN204 S460 461 fi-S\ i i N cH o I o OX 3 Off 0 N- (5-fluoro-6- ( (7-hydroxy-6- (methyloxy)-4- uinolin 1 ox-2-na hthalen 1-3-thio henecarboxamide 906 C32 H3oFN306 S603 604 S i i N cH3 0 o 0 F 6t KOH ou oh N- (5-fluoro-6- ( (7- ( ( (2R)-2-hydroxy-3- (4- morpholinyl) propyl) oxy)-6- (methoxy)-4-quinolinyl) oxy)- 2-naphthalenyl)-3-thiophenecarboxamide 907 C32H30FN306S 603 604 rr N "3 f 3 CXJW top, OH3 0 0 0 F N- (5-fluoro-6- ( (7- ( ( (2S)-2-hydroxy-3- (4- morpholinyl) propyl) oxy)-6- (methoxy)-4-quinolinyl) oxy)-2- naphthalenyl)-3-thiophenecarboxamide Other compounds included in this invention are set forth in Tables 3-6 below.

Table 3

&num R 914.4-CF3-phenyl 915. 4-fluorophenyl 916.3-CF3-phenyl 917.3-chlorophenyl 918.4-chloro-3-methylphenyl 919.4-F-3-CF3-phenyl 920. 2-pyridyl 921.3-isoxazolyl 922.2-thiazolyl 923. cyclopropyl 924. methoxyethyl 925. H 926. methyl Table 4

&num R 927. 4-Cl-phenyl 928.4-fluorophenyl 929.4-CF3-phenyl 930.2-pyridyl 931.3-isoxazolyl 932.2-thiazolyl 933. cyclopropyl 934. methoxyethyl 935. H 936. methyl Table 5 &num R 937.3-CH3-phenyl 938.4-chlorophenyl 939.3-CF3-phenyl 940. 4-F-3-Cl-phenyl 941. phenyl-NH- 942.4-methylphenylamino Table 6

Table 6

Table 6

Table 6

Preparationof-schloro-NI-(3-(dimethylamino) propyl)-Nl-methyl-4 (trifluoromethyl) benzene-1, 2- diamine A heterogeneous mixture of 1-chloro-2-fluoro-3-nitro-5- (trifluoromethyl) benzene (1.25 mL, 8.2 mmol), K2CO3 (3.44 g, 24.6 mmol), N', N', N'-trimethylpropane-1, 3-diamine (1.26 mL, 8.61 mmol) and THF were allowed to stir at RT for 45 min. The THF was removed under reduced pressure and reconstituted in EtOAc (50 rnl). The organic layer was washed with water (20 ml), brine (20 ml), dried over anhydrous sodium sulfate, filtered and concentrated to an oil. The concentrated oil was taken up in EtOH (20 ml) to which Raney nickel (2.5 g wet, washed) was added. The reduction was monitored and after 1 h, another portion of Raney nickel (3.8 g, wet, washed) was added. The reaction was allowed to stir for an additional 30 min. , and filtered through Celite, washed with EtOH (10 mL) and concentrated.

The crude residue was purified via flash chromatography (silica gel, gradient elution 0 to 25% MeOH in CH2CI2) to afford 6-chloro-Nl-(3-(dimethylamino) propyl)-»-methyl4-(trifluoromethyl) benzene-1, 2- diamine as a yellow oil. MS m/z = 310.1 [M+H] +. Calc'd for Cl3HlgCIF3N3 : 309.8.

Preparation lof 1- (6-amino-3, 3-dimethylindolin-1-yl) ethanone The title compound was prepared according to a procedure described in U. S. Patent Publication No. 2003/0203922.

Preparation of 4-(2-nitro-4-(trifluoromethyl) phenyl) thiomorpholine To a solution of 1-fluoro-2-nitro-4- (trifluoromethyl) benzene (7.00 g, 33.48 mmol) in THF (250 ml) at RT was added thiomorpholine (3.45 g, 33.48 mmol) and sodium bicarbonate (3.66 g, 43.52 mmol).

The vessel was purged with nitrogen and stirred at RT for 48 h. After removal of solvent under reduced pressure, the mixture was taken up in EtOAc and filtered. The organics were washed with water, then brine and dried with magnesium sulfate. Filtration and concentration provided the title compound as a bright orange solid. MS m/z: 293.1 (M+H+) ; calc MW = 292. 28.

Preparation of the sulfoxide of 4- (2-nitro-4- (trifluoromethyl) phenyl) thiomorpholine To a solution of 4- (2-nitro-4- (trifluoromethyl) phenyl) thiomorpholine (2.0 g, 6.84 mmol) in MeOH (60 mL) and water (15 ml) was added NaI04 (1.61 g, 7. 53 mmol). The mixture was allowed to stir at RT for 12 h, at which time it was filtered to remove white solid precipitates. Concentration afforded the title compound as an orange solid. MS m/z : 309 (M+H+) ; calc'd MW = 308.28.

Preparation of sulfone of 4- (2-nitro-4- (trifluoromethyl) phenyl) thiomorpholine To a solution of the sulfoxide of 4- (2-nitro-4- (trifluoromethyl) phenyl) thiomorpholine (170 mg, 0.55 mmol) in MeOH (50 mL) was added KMnO4 (96 mg, 0.61 mmol). The reaction was stirred at RT for 15 min and then quenched by the addition of aqueous saturated sodium bisulfate (20 mL). The reaction was filtered and concentrated to provide the sulfone product. MS m/z : 325 (M+H) ; calc'd MW 324.28.

The nitro groups of Examples 625-627 were reduced to the corresponding amine by conventional methods, such as be hydrogenation in the presence of a palladium catalyst. The reduction product of Example 625 was found to have a MS (m/z) = 263.1 (M+H) ; calc'd MW = 262.30, and the reduction product of Example 627 was found to have a MS (m/z) = 295.1 (M+H+) ; calc'd MW = 294.30.

Preparation of (4-methylpiperazin-1-yl) (3-nitro-5-trifluoromethyl) phenyl) -methanone A solution of thionyl chloride (30 ml) and 3-nitro-5- (trifluoromethyl) benzoic acid (10 g) was heated to reflux for 2 h. The reaction mixture was concentrated under reduced pressure and treated with toluene (10 ml) which was then removed under reduced pressure to afford 3-nitro-5- (trifluoromethyl) benzoyl chloride.

To a solution of 3-nitro-5- (trifluoromethyl) benzoyl chloride (2.35 g, 9.3 mmol) in CH2C12 (40 mL) at RT was added N-methylpiperazine (1.26 mL, 9.3 mmol) and the mixture was allowed to stir for 30 min. The reaction was concentrated under reduced pressure, taken up in 1 M HCI (50 ml) and the aqueous layer was washed with Et2O (2 x 20 ml). The aqueous layer was basified to a pH of about 9 with 6 N NaOH, and the aqueous layer was extracted with Et20 (3 x 50 mL). The organic extracts were combined and washed with water (1 x 20 mL) followed by brine (1 x 20 mL), and dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to afford (4-methylpiperazin-1-yl) (3-nitro-5- trifluoromethyl) phenyl) -methanone as an tan oil, which was used without further purification.

Preparation of (3-amino-5- (trifluoromethyl) phenyl) (4-methylpiperazin-1-yl) methanone To an argon purged solution of (4-methylpiperazin-1-yl (3-nitro-5-trifluoromethyl) phenyl)- methanone (1.03 g, 3.25 mmol) was added Pd/C (344 mg, 0.32 mmol, 10%). The mixture was placed under an atmosphere of H2 for 5 h. The reaction was purged with argon and filtered through Celite. The filtrate was concentrated under reduced pressure to afford (3-amino-5- (trifluoromethyl) phenyl) (4- methylpiperazin-l-yl) methanone as an off-white solid. MS m/z= 288.1 [M+H] +. Calc'd for C, 3H, 6F3N30 : 287.3.

Preparation of tert-butyl 7-amino-4, 4-dimethyl-3, 4-dihydroisoquinoline-2 (lH)-carboxylate The title compound was prepared according to the procedure in WO 2004085425.

Preparation of tert-butyl 3, 3-dimethyl-6-nitroindoline-1-carboxylate To a cooled (ice-bath) solution of 3, 3-dimethyl-6-nitroindoline (U. S. Patent Publication No.

2003/0203922) (846 mg, 4.4 mmol) in CH2CI2 (6 mL), triethylamine (2.45 mL, 17.6 mmol) and BOC anhydride (1.01 mL, 4.4 mmol) were added. The reaction mixture was stirred and allowed to warm to RT for 18 h. The mixture was washed with water and brine, dried with Na2SO4, filtered and evaporated. The mixture was purified by column chromatography (using EtOAc: hexanes as the eluent) and the title compound isolated as a brown solid.

Preparation of tert-butyl 6-amino-3, 3-dimethylindoline-1-carboxylate tert-butyl 6-amino-3, 3-dimethylindoline-1-carboxylate To a mixture of tert-butyl 6-amino-3, 3-dimethylindoline-1-carboxylate (500 mg, 1.9 mmol) in MeOH (25 mL), under nitrogen, Pd/C (wet w/MeOH) was added and the atmosphere changed to hydrogen. The reaction mixture was stirred at RT for 3 h. The reaction mixture was filtered through a pad of celite and evaporated to give the title compound as a thick liquid.

Preparation of 1-isopropyl-4- (4-nitrophenyl) piperazine.

To a vial was added 4-fluoronitrobenzene (1.41 g, 1.06 mL, 0.01 mol), DIEA (1.92 mL, 0.011 mmol), isopropylpiperazine (1. 41g, 0. 011 mmol), and DMF (10 mL). Mixture was heated at 100 °C for 48 h in a sealed tube. The reaction mixture was cooled to RT and concentrated. The residue was purified via silica gel column chromatography (gradient elution with 0 to 10% MeOH in DCM) to afford 1-isopropyl- 4- (4-nitrophenyl) piperazine.

Preparation of 4- (4-isopropylpiperazin-1-yl) benzenamine.

10% Palladium on carbon (0.05 g) was added to a solution of the nitroaniline (0. 001 mol) in EtOH (50 mL) under a H2 (g) atmosphere (via balloon). The reaction mixture stirred at RT overnight and was then filtered through celite. The filtrate was concentrated to afford a dark yellow oil, purified on silica column chromatography using isocratic 100% (90/10/l) (CH2CI2/CH30H/NH40H). MS m/z = 220 M+H. Calc'd for C, 3H2, N3 : 219.3.

Preparation of 2-tert-butyl-5-nitrobenzenamine Concentrated sulfuric acid (1 L) was cooled to-10 °C with a dry ice-isopropanol bath in a 2 L 3- necked round bottom flask fitted with a mechanical stirrer and temperature probe. The 2-t-butylaniline (109 g, 730 mmol) was added, giving a clumpy solid. Once the temperature of the mixture was stabilized at-10 °C, the potassium nitrate (101 g, 1001 mmol) was added portion wise, as a solid, over a 4-hour period, maintaining the temperature between-20 and-5 °C. Once all of the potassium nitrate was added, the reaction was left to stir overnight with gradual warming to RT. The reaction was quenched by diluting with water and then extracting three times with EtOAc. The EtOAc extracts were washed multiple times with saturated NaHC03, until gas evolution ceased, then with brine. The EtOAc extracts were then combined, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure giving a black oil. The oil was eluted through a column of silica gel with EtOAc: hexanes gradient 5-50%. Solvent evaporation afforded 2-tert-butyl-5-nitrobenzenamine as a red solid.

Preparation of 2-bromo-N- (2-tert-butyl-5-nitrophenyl) acetamide 2-tert-Butyl-5-nitrobenzenamine (70 g, 359 mmol) and a catalytic amount of DMAP were dissolved into THF (1.5 L) under N2. Triethylamine (109 g, 1077 mmol) was added and the solution was

cooled to 0 °C. Bromoacetyl bromide (207 g, 1023 mmol) was then added and the reaction was stirred at RT for 16 h. The reaction was then partially concentrated under reduced pressure, treated with water, and extracted three times with EtOAc. The EtOAc extracts were washed with brine, combined, dried over Na2SO4 and concentrated to a black oil. This oil was purified using silica chromatography, 95: 5: 0.5 CH2CI2 : MeOH: NH40H, giving 2-bromo-N- (2-tert-butyl-5-nitrophenyl) acetamide as a brown solid.

Preparation of N- (2-tert-butyl-5-nitrophenyl)-2- (dimethylamino) acetamide 2-Bromo-N- (2-tert-butyl-5-nitrophenyl) acetamide (80 g, 253, mmol) and potassium carbonate (70 g, 506 mmol) were combined in THF (1.75 L), and the mixture was cooled to 0 °C. N, N-Dimethylamine (40 ml of a 2 M solution in THF, 800 mmol) was then added to the mixture through an addition funnel over a 30-min period. The mixture was then stirred at RT for 16 h. The mixture was then filtered and the filtrate was concentrated. The crude material was purified by silica chromatography using 50% EtOAc: hexanes as the eluent to give N- (2-tert-butyl-5-nitrophenyl)-2- (dimethylamino) acetamide as a brown solid.

Preparation of N- (5-amino-2-tert-butylphenyl)-2-dimethylamino) acetamide To a solution of N- (2-tert-butyl-5-nitrophenyl)-2- (dimethylamino) acetamide (25,8 g, 02 mmol) in 1,4-dioxane (200 ml) was added 10 % Pd/C (2.5 g) as a slurry in a minimal amount of EtOH. The mixture was evacuated and purged with H2, and then stirred at RT for 16 h. The reaction was then purged with N2 and filtered through celite. The filtrate was concentrated and purified using silica chromatography, 97.5 : 2.5 : 0.25 to 95: 5: 0. 5 CHzClMeOHOH, to afford N- (5-amino-2-tert-butylphenyl)-2- dimethylamino) acetamide as a brown solid. MS (m/z) = 250.2 (M+H) ; Calculated forCl4H23N30 : 249.4.

Preparatioon of 1- (2-Fluoro-4-nitrophenyl)-4-methylpiperazine N-Methylpiperazine (30 mL, 27.1 g, 0.268 mol) was cooled in ice/water while adding 3,4- difluoronitrobenzene (2.0 g, 0. 0126 mol) with stirring. The mixture was then heated at 100 °C overnight, evaporated to remove all excess N-methylpiperazine and the residue dissolved in 1M-hydrochloric acid (30 mL). After washing twice with 20 mL portions of DCM the solution was basified with 5 M-sodium hydroxide (10 mL). The product was extracted into DCM (twice with 20 mL), dried over sodium sulphate and evaporated giving 1.50 g yellow oil which solidified on standing Preparation of 1- (2-Fluoro-4-aminophenyl)-4-methylpiperazine The title compound was obtained by hydrogenation over 10% Pd/C of 1- (2-Fluoro-4- nitrophenyl)-4-methylpiperazine in EtOH.

Preparation of l-methyl-4- [ (4-nitrophenyl) acetyl] piperazine 4-Nitrophenylacetic acid (2.00 g, 0.011 mol) was dissolved in anhydrous THF (20 mL) with gradual addition of thionyl chloride (1.03 mL, 0. 0143 mol) and a catalytic amount of DMF (2 drops) at RT and stirred for 24 h. On completion, the reaction was quenched in situ with N-methylpiperazine (3.85 g, 0.038 mol) added dropwise in a solution of DCM (20 mL) at RT and stirred overnight to give a beige suspension. The solvent was removed in vacuo and the residue partitioned between DCM (30 mL) and sodium hydroxide (1N, 30 mL). The organic layer was washed twice, dried over sodium sulphate and filtered. Removal of the solvent in vacuo yielded the title compound as an amber oil, 1.50 g (solidified on standing).

Preparation of 4- (4-methylpiperazin-1-yl) carbonylmethylaniline A solution of 1-methyl-4- [ (4-nitrophenyl) acetyl] piperazine (1. 5 g, 5.70 mmol) in EtOH (30 mL) was reduced over palladium/charcoal (10% wt, 50% wet, 150 mg) with hydrogen under atmospheric pressure and RT for 18 h. The catalyst was separated by filtration through Celite and the solvent evaporated to the title compound as a brown oil, 1.12g.

Preparation of 4- [2- (4-methyl-piperazin-1-yl) ethyl] aniline 4- (4-Methylpiperazin-l-yl) carbonylmethylaniline (596 mg, 2.55 mmol) was treated in anhydrous THF (20 mL) under nitrogen with lithium aluminum hydride (291 mg, 2.67 mmol) overnight. The reaction was quenched with water (3 x 0. 29mL), 15% sodium hydroxide (3 x 0.29 mL) and again water (3 x 0.29 mL). The resulting precipitate was removed by filtration. Evaporation of the filtrate afforded the title compound as an orange oil, 380 mg.

Preparation of 3- (2- (dimethylamino) ethyl) benzenamine The title compound was prepared using a procedure similar to that described in Example 444.

Preparation of N-(2-dimethylaminoethyl)-3-nitrobenzamide 3-Nitrobenzoyl chloride (2 g, 10.77 mmol) was loaded into a round bottomed flask, placed under a N2 atmosphere and dissolved in anhydrous DCM (10 mL). The mixture was cooled to 0 °C and N, N- dimethylethylenediamine (0.98 mL, 8.98 mmol) was added to the reaction. The reaction was allowed to warm to RT and left to stir for 18 h. After 18 h the reaction had given a precipitate which was isolated by filtration and washed with DCM to give 2.28 g of a white solid, which was partitioned between DCM and a saturated aqueous NaHC03 solution. The organic layer was removed under reduced pressure and the aqueous layer was then re-extracted DCM. The organic layers were combined, dried over Na2SO4 and the solvent was removed under reduced pressure to afford the title compound as a yellow solid.

Preparation of 3-(N-(2-dimethylaminoethylcarbamoyl)) aniline Palladium on carbon (200 mg, 10% w/w) was loaded to a three-necked flask and EtOH (1 mL) was added. This was then fitted with a three-way tap with balloon. The flask was then placed under vacuum then purged with nitrogen, this was repeated twice more. The amide (2.0 g, 8.4 mmol) was dissolved in EtOH (20 mL), this was then added to the reaction. The reaction was then placed under vacuum and purged with nitrogen three more times. It was then placed under vacuum again then purged with hydrogen, this was repeated once more leaving the balloon filled with hydrogen. The reaction was left at RT overnight under a hydrogen atmosphere. The reaction solution was then filtered through a Celitee plug washing with EtOH. The filtrates were combined and solvent removed to give the title compounds as a clear colourless oil.

Preparation of tert-butyl 4-(3-amino-5-(trifluoromethyl) phenyl)-5, 6-dihydropyridine-1 (2H)- carboxylate Into a 50 mL round bottom flask was placed 3-bromo-5- (trifluoromethyl) benzenamine (1 g, 4.16 mmol) and DMF (10 mL). To this was added tert-butyl 4- (4, 4,5, 5-tetramethyl-1, 3,2-dioxaborolan-2-yl)- 5, 6-dihydropyridine-1 (2H)-carboxylate (1.67 g, 5.4 mmol), palladium dichlorodiphenylphosphinoferrocene (183 mg, 0.24 mmol), potassium carbonate (2.29 g, 16.6 mmol).

Allowed to heat at 80 °C with stirring for 20 h. Work up: Reaction cooled to RT, solvents removed under reduced pressure. Purified via silica column using 0 to 8% MeOH gradient in DCM. Best fractions pooled, solvents removed under reduced pressure. Affords a clear oil. LC-MS (+) shows mass 343 (M+H) as expected for C, 7H2, F3N202, mw 342.36.

Preparation of 3- (1-methyl-1, 2,3, 6-tetrahydropyridin-4-yl)-5- (trifluoromethyl) benzenamine Into a 100 mL round bottom flask was placed LAH (1. 518g, 40 mmol) and suspended in THF (30 mL). Flask placed into an ice bath. Tert-butyl 4- (3-amino-5- (trifluoromethyl) phenyl) -5,6- dihydropyridine-1 (2H) -carboxylate (1.368g, 4 mmol) is added to THF (10 mL) and this solution is in turn added dropwise to the LAH suspension at 0 °C. 15 min after addition was complete, flask is equipped with reflux condensor and allowed to reflux 15 h with stirring. Work up: Water (1. 5g) is added dropwise, then 15% NaOH (aq) (w/w) (1. 5g), followed by water (3g). White precipitate forms after 20 h of stirring, filtered solids, removed solvent under reduced pressure. No further purification done. LC-MS (+) shows mass 257 (M+H), as expected for C, 3H, 5F3N2, mw 256.27.

Preparation of 3-(1-methylpiperidin-4-yl)-5-(trifluoromethyl) benzenamine Into a 100 mL round bottom flask was placed 3- (1-methyl-1, 2,3, 6-tetrahydropyridin-4-yl)-5- (trifluoromethyl) benzenamine (2.05 g, 8 mmol) and EtOH (40 mL). Flask sparged with argon, then 10% Palladium on carbon (100 mg) is added. Argon removed and replaced with hydrogen via balloon, stirs overnight at RT. Work up: Filtered reaction mixture through Celite under inert atmosphere. Removed

solvents under reduced pressure. Purified via silica column using 0 to 100% 90/10/1 (DCM/MeOH/NH40H) gradient in DCM. Affords a pale yellow oil. LC-MS (+) shows mass 259 (M+H), as expected for Cl3H, 7F3N2, mw 258.28.

Preparation of N2, N2-dimethylpyridine-2, 5-diamine 2-Chloro-5-nitropyridine (3.57 g, 22.5 mmol), dimethylamine hydrochloride (5.50 g, 67.5 mmol) and diisopropylethylamine (13.7 mL, 78.7 mmol) were combined in DMSO (15 mL) and the reaction mixture was heated at 80 °C for 4 h. After cooling to RT, water was added and the desired N, N-dimethyl- 5-nitropyridin-2-amine was isolated by filtration and used in the next step without further purification.

Palladium on carbon (200 mg) was added to a solution of N, N-dimethyl-5-nitropyridin-2-amine (1.29 g, 7.75 mmol) in EtOH (40 mL) and EtOAc (40 mL). The resulting mixture was stirred for 16 h under a H2 atmosphere, filtered and concentrated in vacuo to give the title compound.

Preparation of N, l-dimethyl-N- (2-nitro-4- (trifluoromethyl) phenyl) piperidin-4-amine To a solution of 1-fluoro-2-nitro-4- (trifluoromethyl) benzene (7.5 g, 36 mmol) in THF (180 mL) was added N, l-dimethylpiperidin4-amine (5.5 g, 43 mmol) and NaHC03 (6.0 g, 71 mmol). The mixture was stirred at RT and monitored by LCMS for disappearance of starting material. The reaction was filtered, concentrated, and partitioned between H2O and CH2CI2. The aqueous layer was extracted several times with CH2CI2, and the organics combined. The organics were washed with brine, dried with MgS04, filtered, and concentrated to afford the desired product.

Preparation of Nl-methyl-Nl-(l-methylpiperidin-4-yl)-4-(trifluoromethyl) benzene-1, 2-diamine To a solution ofN, l-dimethyl-N (2-nitro-4- (trifluoromethyl) phenyl) piperidin-4-amine (11.3 g, 35.6 mmol) in MeOH (260 mL) at RT was added 10% Pd/C (1.89 g). H2 gas was bubbled through the solution for 5 minutes and the reaction was stirred under an atmosphere of H2 gas. The reaction was monitored by LCMS, and H2 gas was added periodically until consumption of starting material. The mixture was filtered through Celite with MeOH and concentrated to afford the desired product.

Preparation of 1-Methylcyclopropylamine hydrochloride The title compound was prepared according to the method described in patent WO 02/010116 A2.

Preparation of 4-methoxy-3-nitrobenzoyl chloride 4-methoxy-3-nitrobenzoic acid (10.0 g, 0.051 mol), and thionyl chloride (25 g, 0.212 mol), were refluxed together for 24 h. The reaction mixture was cooled to RT and concentrated to dryness. The off- white solid was carried onto the next step.

Preparation of 4-methoxy-3-nitro-N- (pyridin-2-yl) benzamide 4-methoxy-3-nitrobenzoyl chloride (1.08 g, 0.005 mol), 2-aminopyridine (0.94 g, 0.01 mol) and DIPEA (1.8 mL, 0. 01 mol) were allowed to stir in DCM (10 mL) for 48 h to form 4-methoxy-3-nitro-N- (pyridin-2-yl) benzamide. Intermediate was purified via silica column chromatography using 0 to 100% EtOAc in hexane.

Preparation of 3-aminoffimethoxy-N-(pyridine-3-yl) benzamide Into a 100 mL round bottom flask was placed 4-methoxy-3-nitro-N- (pyridin-2-yl) benzamide (0.735 g, 2.69 mmol), 10% Palladium on carbon (250 mg), EtOH (50 mL), and acetic acid (10 mL) under inert atmosphere. Atmosphere then exchanged with hydrogen (via balloon) and allowed to stir 24 h at RT.

Reaction mixture was filtered through Celite@, concentrated under reduced pressure, then purified via silica column chromatography using 0 to 100% EtOAc in hexane. MS m/z = 244 [M+H] +. Calc'd for C, 3H, 3N302 : 243.3.

Preparation of l-methyl-4-(2-nitro-4-(trifluoromethyl) phenoxy) piperidine l-methylpiperidin4-ol (2.99 mmol, 344.4 mg) was added to a suspension of potassium tert- butoxide in THF (5 mL) and stirred at RT for 30 minutes. 2-fluoro-5-trifluorometyl nitrobenzene (2.39 mmol, 500 mg) was then added and the reaction mixture was stirred an additional 5 h at RT, at which time LC-MS showed complete conversion to the desired product. The reaction mixture was concentrated and the dark brown residue was taken up in methylene chloride (25 mL). This was washed with water (3 x 20 mL), dried over sodium sulfate, filtered and concentrated to give the crude product as a yellow oil. Crude material (> 90% purity) was taken to the next step without further purification LC-MS: 305.1 (M+H) Preparation of 2- (1-methylpiperidin-4-yloxy)-5- (trifluoromethyl) benzenamine 10% Palladium on carbon (100 mg) was put into a 100 mL round bottom flask and flushed thouroughly with nitrogen. EtOAc (30 mL) was slowly added to the flask, followed by addition of 1- methyl-4- (2-nitro-4- (trifluoromethyl) phenoxy) piperidine (800mg crude) as a solution in MeOH (3 mL).

The flask was evacuated and purged with hydrogen gas several times and then allowed to stir at RT under hydrogen for 18 h. The flask was then evacuated and purged with nitrogen several times. The reaction mixture was filtered through celite and concentrated to give 2-(1-methylpiperidin4-yloxy)-5- (trifluoromethyl) benzenamine as a yellow solid. (> 90% purity) was used without further purification (617.4mg, 94% for 2 steps). LC-MS: 275.1 (M+H) Synthesis of 3- ( (4-methylpiperazin-1-yl) methyl)-5- (trifluoromethyl)-benzenamine To LAH (1. 84 g, 48.5 mmol) in THF (50 ml) at RT was added (4-methylpiperazin-1-yl) (3-nitro- 5-trifluoromethyl) phenyl) -methanone (1.54 g, 4.85 mmol) in THF (10 mL). The resulting mixture was refluxed for 5 h. The reaction mixture was cooled to 0 °C at which point water (1.84 mL), 15% aq. NaOH

(1.84 mL and water (3.68 mL) were successively added. The resulting mixture was allowed to stir at RT for 1 h. The mixture was filtered through celite, concentrated under reduced pressure and purified via flash chromatography (silica gel, 0 to 25% MeOH in CH2CI2, gradient elution) to afford 3- ( (4- methylpiperazin-l-yl) methyl)-5- (trifluoromethyl) benzenamine as a colorless oil. MS m/z = 274 [M+H] +.

Calc'd for C, 3H, 8F3N3 : 273.3.

Preparation of 1- (3-amino-5- (trifluoromethyl) phenyl) pyrrolidin-2-one. Into a 16 by 100 mm vial sparged with argon was added 3-amino-5-bromobenzotrifluoride (1 g, 4.16 mmol), 2-pyrrolidinone (425 mg, 5 mmol), N, N'-dimethylethylenediamine (37 mg, 0.416 mmol), potassium carbonate (1.15 g, 8. 33 mmol), copper (l) iodide (80 mg, 0.416 mmol), and toluene (1 mL). Vial capped, heated with stirring at 85 °C for 24 h. Reaction cooled to RT, solvent removed under reduced pressure, reconstituted in DCM and filtered through silica. Affords a gray solid. MS m/z = 245 [M+H] +. Calc'd for C"H"F3N2O : 244.2 Preparation of 3-chloro-2, 2-dimethyl-N- (2-nitro-4- (trifluoromethyl) phenyl) propanamide.

To a solution of 2-nitro-4- (trifluoromethyl) benzenamine (3.00 g, 14.9 mmol, 1.0 equiv) in CH2CI2 (90 mL) at 25°C, was added 3-chloro-2,2-dimethylpropanoyl chloride (3.9 mL, 29.8 mmol, 2.0 equiv) followed by triethylamine (4.2 mL, 29.8 mmol, 2.0 equiv). The solution was heated to 40 °C.

After 48 h, the solution was washed with water (50 mL), and brine (50 mL). After concentration in vacuo, the residue was purified by silica gel chromatography (1: 10 hexanes: EtOAc to 1 : 5 hexanes: EtOAc) to afford 3-chloro-2, 2-dimethyl-N- (2-nitro-4- (trifluoromethyl) phenyl) propanamide. MS-No (MH+) observed.

Preparation of 3, 3-dimethyl-1-(2-nitro-4-(trifluoromethyl) phenyl) azetidin-2-one To a mixture of 3-chloro-2, 2-dimethyl-N- (2-nitro-4- (trifluoromethyl) phenyl) propanamide (3.24 g, 10.0 mmol, 1.0 equiv) in acetone (100 mL) was added K2CO3 (3.5 g, 25.0 mmol, 2.5 equiv). The mixture was heated to 50°C for 48 h. After filtering, the solvent was removed in vacuo and the resulting residue purified by silica gel chromatography (1: 10 hexanes: EtOAc to 1 : 5 hexanes: EtOAc) to afford lactam 3.

MS (MH+) 289.1 ; Calculated 289.1 for C, 2H, 2F3N203.

Preparation of 1- (2-amino-4- (trifluoromethyl) phenyl-3, 3-dimethylazetidin-2-one A mixture of 3, 3-dimethyl-1-(2-nitro4-(trifluoromethyl) phenyl) azetidin-2-one (1.67 g, 5.8 mmol, 1.0 equiv) and 10% Pd/C (300 mg) in MeOH (30 mL) was exposed to an atmosphere of H2. After consumption of the starting material, the mixture was filtered and concentrated to afford 1- (2-amino-4- (trifluoromethyl) phenyl-3,3-dimethylazetidin-2-one, which was advanced without further purification. MS (MH+) 259.1 ; Calculated 259.1 for C, 2H, 4F3N20.

Preparation of (R)-1-(2-nitro-4-(trifluoromethyl) phenyl} N, N-dimethylpyrrolidin-3-amine To a solution of 1-fluoro-2-nitro-4- (trifluoromethyl) benzene (0.67 mL, 4.78 mmol) in THF (25 mL) was added (R) -N, N-dimethylpyrrolidin-3-amine (0.66 g, 5.74 mmol) and NaHC03 (1. 1 g, 13.15 mmol). The reaction was stirred at RT and monitored by LCMS for disappearance of starting material and formation of product. The mixture was concentrated, diluted with CH2C12, washed with H2O and then brine. Drying with MgS04 was followed by filtration and concentration to afford the product as an orange oil.

Preparation of R)-1-(2-amino-4-(trifluoromethyl) phenyl)-N, N-dimethylpyrrolidin-3-amine To a solution of (R)-N, N-dimethyl-1-(2-nitro-4-(trifluoromethyl)phenyl)pyrrolidin-3 -amine (1.75 g, 5.77 mmol) in MeOH (60 mL) was added 10% Pd/C (0.30 g, 0.29 mmol). H2 gas was bubbled through the solution for 5 minutes, and the reaction was stirred at RT under an atmosphere of H2 gas. The reaction was monitored by LCMS for disappearance of starting material and formation of product. The mixture was filtered through celite with MeOH, and concentrated to afford the product as an orange/red oil.

Preparation of 1- (thiazol-2-yl) ethanamine To a solution 1-(thiazol-2-yl) ethanone (5 g, 0.039 mol) in MeOH (100 mL) ammonium acetate (37.88 g, 0.492 mol) was added at RT and stirred for 20 min. To the resulting mixture, sodium cyanoborohydride (1.73 g, 0.028 mol) was added and the solution was stirred for 1 week at RT. Upon quenching with 6 M HCl (30 mL), the crude product was extracted with CH2CI2 and purified through column chromatography using 100% CH2CI2 h 20% 90: 10: 1 CH2CI2 : MeOH: NH40H. The solution was concentrated in vacuo to give the title compound. MS (ESI, pos. ion) m/z : 129 (M+1). Mass calc'd for CSNZS, HB : 128.2.

Although the pharmacological properties of the compounds of Formulas I-VII vary with structural change, in general, activity possessed by compounds of Formulas I-VII may be demonstrated in vivo. The pharmacological properties of the compounds of this invention may be confirmed by a number of pharmacological in vitro assays. The exemplified pharmacological assays which follow have been carried out with the compounds according to the invention and their salts. Compounds of the present invention showed inhibition of Lck kinase at doses less than 10 p1M. Compounds of the present invention showed inhibition of c-Met kinase at doses less than 10 uM. Compounds of the present invention also showed inhibition of VEGFR kinase at doses less than 10 u. M.

BIOLOGICAL TESTING The efficacy of the compounds of the invention as inhibitors of Lck, VEGFR and/or HGF related activity are demonstrated as follows.

c-Met receptor assay Cloning, Expression and Purification of c-Met Kinase Domain A PCR product covering residues 1058-1365 of c-Met (c-Met kinase domain) is generated from Human Liver QuickCloneT cDNA (Invitrogen) using forward primer 5'- ATTGACGGATCCATGCTAAATCCAGAGCTGGTCCAGGCA-3' (SEQ ID NO. 1) and reverse primer 5'-ACAACAGAATTCAATACGGAGCGACACATTTTACGTT-3' (SEQ ID NO. 2). The PCR product is cloned into a modified pFastBac I expression vector (harboring the gene for S. japonicum glutathione S- transferase immediately upstream of the multiple cloning site) using standard molecular biological techniques. The GST-c-Met kinase domain fusion (GST-Met) gene is transposed into full-length baculovirus DNA using the BacToBacTM system (Invitrogen). High5 cells are infected with the recombinant baculovirus for 72 h at 27 °C. The infected cells are harvested by centrifugation and the pellet is stored at-80 °C. The pellet is resuspended in buffer A (50 mM HEPES, pH 8.0, 0.25 M NaCI, 10 mM 2-mercaptoethanol, 10% (w/v) glycerol, 0.5 % (v/v) protease inhibitor cocktail (Sigma P8340), stirred at 4 °C to homogeneity, and the cells are disrupted by microfluidization (Microfluidics) at 10,000 psi. The resulting lysate is centrifuged at 50,000 x g for 90 min at 4 °C, and the supernatant is adsorbed onto 10 mL of glutathione sepharoseT 4B (Amersham) by batch method. The slurry is rocked gently overnight at 4 °C. The glutathione resin is harvested by centrifugation and washed three times with 40 mL buffer A by batch method. The resin is washed three times with buffer B (buffer A adjusted to 0.1 M NaCI, less protease inhibitors). The protein is eluted with buffer B containing 25 mM reduced glutathione. Eluted fractions are analyzed by SDS-PAGE and concentrated to <10 mL (-10 mg/mL total protein). The concentrated protein is separated by Superdex 200 (Amersham) size exclusion chromatography in buffer C (25 mM Tris, pH 7.5, 0.1 M NaCI, 10 mM 2-mercaptoethanol, 10% glycerol).

The fractions are analyzed by SDS-PAGE and the appropriate fractions are pooled and concentrated to-1 mg/mL. The protein is aliquotted and stored at-80 °C.

Alternative purification of human GST-cMET from Baculovirus cells Baculovirus cells are broken in 5x (volume/weight) of Lysis Buffer (50 mM HEPES, pH 8.0, 0.25 M NaCI, 5 mM mercaptoethanol, 10% glycerol plus Complete Protease Inhibitors (Roche (&num 10019600), 1 tablet per 50 mL buffer). The lysed cell suspension is centrifuged at 100,000 x g (29,300 rpm) in a Beckman ultracentrifuge Ti45 rotor for 1 h. The supernatant is incubated with 10 ml of Glutathione Sepharose 4B from Amersham Biosciences (&num 27-4574-01). Incubation is carried out overnight in a cold room (approximately 8 °C). The resin and supernatant is poured into an appropriately sized disposable column and the flow through supernatant was collected. The resin is washed with 10 column volumes (100 mL) of Lysis Buffer. The GST-cMET is eluted with 45 mL of 10 mM Glutathione (Sigma &num G-4251) in Lysis Buffer. The elution is collected as 15 mL fractions. Aliquots of the elution fractions are run on

SDS PAGE (12% Tris Glycine gel, Invitrogen, &num EC6005BOX). The gel is stained with 0.25% Coomassie Blue stain. Fractions with GST-cMET are concentrated with a Vivaspin 20 mL Concentrator (#VS2002 ; 10,00 MW cutoff) to a final volume less than 2.0 ml. The concentrated GST-cMET solution is applied to a Superdex 75 16/60 column (Amersham Biosciences &num 17-1068-01) equilibrated with 25 mM Tris, pH 7.5, 100 mM NaCI, 10 mM mercaptoethanol, 10% glycerol. The GST-cMET is eluted with an socratic run of the above buffer, with the eluent collected in 1.0 mL fractions. Fractions with significant OD280 readings are run on another 12% Tris Glycine gel. The peak tubes with GST-cMET are pooled and the OD2eo is read with the column buffer listed above as the blank buffer.

Phosphorylation of the purified GST-cMET is performed by incubating the protein for 3 h at RT with the following: Final concentration a) 100 mM ATP (Sigma #A7699) 25 mM b) 1. 0MMgCl2 (Sigma#M-0250) 100 mM c) 200 mM Sodium Orthovanadate (Sigma #S-6508) 15 mM d) 1. 0 M Tris-HCI, pH 7. 00 (in house) 50 mM e) H20 f) GST-cMET 0.2-0. 5 mg/mL After incubation, the solution is concentrated in a Vivaspin 20 mL Concentrator to a volume less than 2.00 mL. The solution is applied to the same Superdex 75 16/60 column used above after re- equilibration. The GST-cMET is eluted as described above. The elution fractions corresponding to the first eluted peak on the chromatogram are run on a 12% Tris Glycine gel, as above, to identify the fractions with GST-cMET. Fractions are pooled and the OD280 is read with the column buffer used as the blank.

A Kinase reaction Buffer is prepared as follows: Per 1 L 60 mM HEPES pH 7. 4 1 M stock 16.7 X 60 mL 50 mM NaCI 5 M stock 100 X 10 mL 20 mM MgCl2 1 M stock 50 X 20 mL 5 mM MnCl2 1 M stock 200 X 5 mL When the assay is carried out, freshly add: 2 mM DTT 1 M stock 500 X 0.05 % BSA 5 % stock 100 X 0.1 mM Na30V4 0.1 M stock 1000 X

The HTRF buffer contains: 50 mM Tris-HCI (pH 7.5), 100 mM NaCI, 0.1 % BSA, 0.05 % Tween 20, 5mM EDTA Fresh add SA-APC (PJ25S Phycolink Streptavidin-Allophycocyanin Conjugate, Prozyme Inc. ) and Eu- PT66 (Eu-W1024 labeled anti-phosphorotyrosine antibody PT66, AD0069, Lot 168465, Perkin-Elmer Inc. ) to reach the final concentration: 0. 1 nM final Eu-PT66 11 nM final SA-APC Methods: 1. Dilute GST-cMet (P) enzyme in kinase buffer as follows: Prepare 8 nM GST-cMet (P) working solution (7.32 uM to 8 nM, 915 X, 10 L to 9. 15 mL). In a 96 well clear plate [Costar # 3365] add 100 FL in eleven columns, in one column add 100 uL kinase reaction buffer alone.

2. Assay plate preparation: Use Biomek FX to transfer 10 I1L 8 nM GST-cMet (P) enzyme, 48. 4 µL kinase reaction buffer, 1. 6 uL compound (in DMSO) (Start concentration at 10 mM, 1 mM and 0.1 mM, sequential dilution 1: 3 to reach 10 test points) in a 96 well costar clear plate [Costar # 3365], mix several times. Then incubate the plate at RT for 30 min.

3. Prepare Gastrin and ATP working solution in kinase reaction buffer as follows: Prepare 4 uM Gastrin and 16 uM ATP working solution Per 10 mL Gastrin 4 uM stock (500 pM to 4 IlM, 125 X) 80 IlL ATP 16 uM stock (1000 µM to 16 µM, 62. 5 X) 160 L Use Biomek FX to add 20 ut ATP and Gastrin working solution to the assay plate to start reaction, incubate the plate at RT for 1 h.

4. Transfer 5 IlL reaction product at the end of 1 h into 80 p. L HTRF buffer in black plate [Costar # 3356], read on Discover after 30 min incubation.

Assay condition summary: KM ATP *-6 FM [ATP] - 4 µM KMGastrin/p (EY)-3. 8 FM [gastrin] 1 pM µM [enzyme]-1 nM KM ATP, KM gastrin for various enzymes were determined by HTRF/33P labeling and HTRF methods. c-Met cell-based autophosphorylation assay Hunan PC3 and mouse CT26 cells are available obtained from ATCC. The cells were cultured in a growth medium containing RPMI 1640, penicillin/streptomycin/glutamine (IX) and 5% FBS. 2x104 cells in medium were plated per well in a 96 well plate and incubated at 37 °C overnight. The cells were serum-starved by replacing the growth media with basic medium (DMEM low glucose + 0. 1 BSA, 120 IlL per well) at 37 °C for 16 h. Compounds (either 1 mM and 0.2 mM) in 100% DMSO were serially diluted (1: 3) 3333 fold on a 96 well plate, diluting 1: 3 with DMSO from column 1 to 11 (columns 6 and 12 receive no compound). Compound samples (2.4 p1L per well) were diluted with basic medium (240 pL) in a 96 well plate. The cells were washed once with basic medium (GIBCO, DMEM 11885-076) then compound solution was added (100 uL). The cells were incubated at 37 °C for 1 h. A (2 mg/mL) solution of CHO-HGF (7.5 pL) was diluted with 30 mL basic medium to provide a final concentration of 500 ng/mL. This HGF-containing media (120 IL- was transferred to a 96 well plate. Compounds (1.2 uL) was added to the HGF-containing media and mixed well. The mixture of media/HGF/compound (100 liL) was added to the cells (final HGF concentration-250 ng/mL) then incubated at 37 °C for 10 min. A cell lysate buffer (20 mL) was prepared containing 1% Triton X-100,50 mM Tris pH 8.0, 100 mM NaCl, Protease inhibitor (Sigma, #P-8340) 200 1L, Roche Protease inhibitor (Complete, # 1-697- 498) 2 tablets, Phosphatase Inhibitor II (Sigma, #P-5726) 200 1L, and a sodium vanadate solution (containing 900 IlL PBS, 100 gL 300 mM NaVO3, 6 uL H20z (30% stock) and stirred at RT for 15 min) (90 pL). The cells were washed once with ice cold 1X PBS (GIBCO, #14190-136), then lysis buffer (60 pL) was added and the cells were incubated on ice for 20 min.

The IGEN assay was performed as follows: Dynabeads M-280 streptavidin beads were pre- incubated with biotinylated anti-human HGFR (240 aL anti-human-HGFR (R&D system, BAF527 or BAF328) @ 100 ug/mL + 360 gL Beads (IGEN #10029 + 5.4 1L buffer-PBS/1% BSA/0.1% Tween20) by rotating for 30 min at RT. Antibody beads (25 IlL) were transferred to a 96 well plate. Cell lysate solution (25 uL) was transferred added and the plate was shaken at RT for 1 h. Anti-phosphotyrosine 4G10 (Upstate 05-321) (19.7 gL antibody + 6 mL 1X PBS) (12.5 IlL) was added to each well, then incubated for 1 h at RT. Anti-mouse IgG ORI-Tag (ORIGEN #110087) (24 uL Antibody + 6 mL buffer) (12.5 gel) was added to each well, then incubated at RT for 30 min. 1X PBS (175 I1L) was added to each

well and the electrochemiluminescence was read by an IGEN M8. Raw data was analyzed using a 4- parameter fit equation in XLFit. ICso values are then determined using Grafit software. Examples 3-4,9, 25-27,37-38, 41,85, 91-93,87-88, 90,107-108, 111, 114-115 and 133 exhibited activity in PC3 cells with ICso values less than 1.0 I1M. Examples 1,3-4, 9,25-27, 38,40, 46,50-51, 53-54,64, 66,70, 73,76, 85,88-91, 92-93,87-90, 104-105,107 and 109-111 exhibited activity in CT26 cells with ICso values less than 1.0 uM.

HUVEC Proliferation Assay Human Umbilical Vein Endothelial cells are purchased from Clonetics, Inc. , as cryopreserved cells harvested from a pool of donors. These cells, at passage 1, are thawed and expanded in EBM-2 complete medium, until passage 2 or 3. The cells are trypsinized, washed in DMEM + 10% FBS + antibiotics, and spun at 1000 rpm for 10 min. Prior to centrifugation of the cells, a small amount is collected for a cell count. After centrifugation, the medium is discarded, and the cells are resuspended in the appropriate volume of DMEM + 10% FBS + antibiotics to achieve a concentration of 3 x 105 cells/mL. Another cell count is performed to confirm the cell concentration. The cells are diluted to 3 x 104 cells/mL in DMEM + 10% FBS + antibiotics, and 100 uL of cells are added to a 96-well plate. The cells are incubated at 37 °C for 22 h.

Prior to the completion of the incubation period, compound dilutions are prepared. Five-point, five-fold serial dilutions are prepared in DMSO, at concentrations 400-fold greater than the final concentrations desired. 2.5 piL of each compound dilution are diluted further in a total of 1 mL DMEM + 10% FBS + antibiotics (400x dilution). Medium containing 0.25% DMSO is also prepared for the 0 uM compound sample. At the 22 h timepoint, the medium is removed from the cells, and 100 IlL of each compound dilution is added. The cells are incubated at 37 °C for 2-3 h.

During the compound pre-incubation period, the growth factors are diluted to the appropriate concentrations. Solutions of DMEM + 10% FBS + antibiotics, containing either VEGF or bFGF at the following concentrations: 50,10, 2,0. 4,0. 08, and 0 ng/mL are prepared. For the compound-treated cells, solutions of VEGF at 550 ng/mL or bFGF at 220 ng/mL for 50 ng/mL or 20 ng/mL final concentrations, respectively, are prepared since 10 uL of each will be added to the cells (I 10 ptL final volume). At the appropriate time after adding the compounds, the growth factors are added. VEGF is added to one set of plates, while bFGF is added to another set of plates. For the growth factor control curves, the media on wells B4-G6 of plates 1 and 2 are replaced with media containing VEGF or bFGF at the varying concentrations (50-0 ng/mL). The cells are incubated at 37 °C for an additional 72 h.

At the completion of the 72 h incubation period, the medium is removed, and the cells are washed twice with PBS. After the second wash with PBS, the plates are tapped gently to remove excess PBS, and the cells are placed at-70 °C for at least 30 min. The cells are thawed and analyzed using the CyQuant fluorescent dye (Molecular Probes C-7026), following the manufacturer's recommendations. The plates

are read on a Victor/Wallac 1420 workstation at 485 nm/530 nm (excitation/emission). Raw data are collected and analyzed using a 4-parameter fit equation in XLFit. ICso values are then determined.

Examples 114-117 and 120-121 inhibited VEGF-stimulated HUVEC proliferation at a level below 500 nM.

Rat Corneal Neovascularization Micropocket Model In Life Aspects: Female Sprague Dawley rats weighing approximately 250 g were randomized into one of five treatment groups. Pretreatment with the vehicle or compound was administered orally, 24 h prior to surgery and continued once a day for seven additional days. On the day of surgery, the rats were temporarily anesthetized in an Isofluorane gas chamber (delivering 2.5 liters/min oxygen + 5% Isofluorane). An othoscope was then placed inside the mouth of the animal to visualize the vocal cords.

A tip-blunted wire was advanced in between the vocal cords and used as a guide for the placement of an endotracheal Teflon tube (Small Parts Inc. TFE-standard Wall R-SWTT-18). A volume-controlled ventilator (Harvard Apparatus, Inc. Model 683) was connected to the endotracheal tube to deliver a mixture of oxygen and 3% Isofluorane. Upon achieving deep anesthesia, the whiskers were cut short and the eye areas and eyes gently washed with Betadine soap and rinsed with sterile saline. The corneas were irrigated with one to two drops of Proparacaine HCI ophthalmic topical anesthetic solution (0.5%) (Bausch and Lomb Pharmaceuticals, Tampa FL). The rat was then positioned under the dissecting microscope and the corneal surface brought into focus. A vertical incision was made on the midline of the cornea using a diamond blade knife. A pocket was created by using fine scissors to separate the connective tissue layers of the stroma, tunneling towards the limbus of the eye. The distance between the apex of the pocket and the limbus was approximately 1.5 mm. After the pocket had been made, the soaked nitrocellulose disk filter (Gelman Sciences, Ann Arbor MI. ) was inserted under the lip of the pocket. This surgical procedure was performed on both eyes. rHu-bFGF soaked disks were placed into the right eye, and the rHu-VEGF soaked disks were placed into the left eye. Vehicle soaked disks were placed in both eyes. The disk was pushed into position at the desired distance from the limbal vessels.

Ophthalmic antibiotic ointment was applied to the eye to prevent drying and infection. After seven days, the rats were euthanized by CO2 asphyxiation, and the eyes enucleated. The retinal hemisphere of the eye was windowed to facilitate fixation, and the eye placed into formalin overnight.

Post Mortem Aspects: After 24 h in fixative, the corneal region of interest was dissected out from the eye, using fine forceps and a razorblade. The retinal hemisphere was trimmed off and the lens extracted and discarded. The corneal dome was bisected and the superfluous cornea trimmed off. The iris, conjunctiva and associated limbal glands were then carefully teased away. Final cuts were made to generate a square 3x3 mm containing the disk, the limbus, and the entire zone of neovascularization.

Gross Image Recording: The corneal specimens were digitally photographed using a Sony CatsEye DKC5000 camera (A. G. Heinz, Irvine CA) mounted on a Nikon SMZ-U stereo microscope (A. G. Heinz). The corneas were submerged in distilled water and photographed via trans-illumination at

approximately 5.0 diameters magnification.

Image analysis: Numerical endpoints were generated using digital micrographs collected from the whole mount corneas after trimming and were used for image analysis on the Metamorph image analysis system (Universal Imaging Corporation, West Chester PA). Three measurements were taken: Disk placement distance from the limbus, number of vessels intersecting a 2.0 mm perpendicular line at the midpoint of the disk placement distance, and percent blood vessel area of the diffusion determined by thresholding.

General Formulations: 0.1% BSA in PBS vehicle: 0.025 g of BSA was added to 25.0 mL of sterile 1X phosphate buffered saline, gently shaken until fully dissolved, and filtered at 0.2 uM. Individual 1.0 mL samples were aliquoted into 25 single-use vials, and stored at-20 °C until use. For the rHu-bFGF disks, a vial of this 0. 1% BSA solution was allowed to thaw at RT. Once thawed, 10 IlL of a 100 mM stock solution of DTT was added to the 1 ml BSA vial to yield a final concentration of 1 mM DTT in 0. 1% BSA. rHu-VEGF Dilutions: Prior to the disk implant surgery, 23. 8 uL of the 0.1% BSA vehicle above was added to a 10 pg rHu-VEGF lyophilized vial yielding a final concentration of 10 uM. rHu-bFGF: Stock concentration of 180 ng/» L : R&D rHu-bFGF : Added 139 uL of the appropriate vehicle above to the 25 pg vial lyophilized vial. 13.3 IlL of the [180 ng/pL] stock vial and added 26.6 uL of vehicle to yield a final concentration of 3.75 uM concentration.

Nitro-cellulose disk preparation: The tip of a 20-gauge needle was cut off square and beveled with emery paper to create a punch. This tip was then used to cut out-0. 5 mm diameter disks from a nitrocellulose filter paper sheet (Gelman Sciences). Prepared disks were then placed into Eppendorf microfuge tubes containing solutions of either 0. 1% BSA in PBS vehicle, 10 JIM rHu-VEGF (R&D Systems, Minneapolis, MN), or 3. 75 uM rHu-bFGF (R&D Systems, Minneapolis, MN) and allowed to soak for 45-60 min before use. Each nitrocellulose filter disk absorbs approximately 0.1 uL of solution.

In the rat micropocket assay, compounds of the present invention will inhibit angiogenesis at a dose of less than 50 mg/kg/day.

Tumor model A431 cells (ATCC) are expanded in culture, harvested and injected subcutaneously into 5-8 week old female nude mice (CD1 nu/nu, Charles River Labs) (n = 5-15). Subsequent administration of compound by oral gavage (10-200 mpk/dose) begins anywhere from day 0 to day 29 post tumor cell challenge and generally continues either once or twice a day for the duration of the experiment.

Progression of tumor growth is followed by three dimensional caliper measurements and recorded as a function of time. Initial statistical analysis is done by repeated measures analysis of variance (RMANOVA), followed by Scheffe post hoc testing for multiple comparisons. Vehicle alone (Ora-Plus, pH 2.0) is the negative control. Compounds of the present invention will be active at doses less than 150 mpk.

Human glioma tumor cells (U87MG cells, ATCC) are expanded in culture, harvested and injected subcutaneously into 5-8 week old female nude mice (CD1 nu/nu, Charles River Labs) (n=10).

Subsequent administration of compound by oral gavage or by IP (10-100 mpk/dose) begins anywhere from day 0 to day 29 post tumor cell challenge and generally continues either once or twice a day for the duration of the experiment. Progression of tumor growth is followed by three dimensional caliper measurements and recorded as a function of time. Initial statistical analysis is done by repeated measures analysis of variance (RMANOVA), followed by Scheffe post hoc testing for multiple comparisons.

Vehicle alone (captisol, or the like) is the negative control. Compounds of the present invention will be active at doses less than 100 mpk.

LCK-Homogeneous Time Resolved Fluorescent (HTRF) Kinase Assay: The LCK HTRF assay begins with LCK in the presence of ATP phosphorylating the biotinylated peptide Gastrin. The reaction incubates for 90 min. To quench the assay detection reagents are added which both stop the reaction by diluting out the enzyme and chelating the metals due to the presence of EDTA. Once the detection reagents are added the assay incubates for 30 min to allow for equilibration of the detection reagents.

The LCK HTRF assay is comprised of 10 IlL of compound in 100% DMSO, 15 RL of ATP and biotinylated Gastrin, and 15 pL of LCK KD GST (225-509) for a final volume of 40 pL. The final concentration of gastrin is 1.2 uM. The final concentration of ATP is 0. 5uM (Km app= 0.6 +/-0. 1) and the final concentration of LCK is 250 pM. Buffer conditions are as follows: 50mM HEPES pH 7.5, 50 mM NaCI, 20 mM MgCI, 5mM MnCI, 2mM DTT, 0.05% BSA.

The assay is quenched and stopped with 160 liL of detection reagent. Detection reagents are as follows: Buffer made of 50 mM Tris, pH 7.5, 100 mM NaCI, 3mM EDTA, 0.05% BSA, 0. 1 % Tween20.

Added to this buffer prior to reading is Steptavidin allophycocyanin (SA-APC) at a final conc in the assay of 0.0004 mg/mL, and europilated anti-phosphotyrosine Ab (Eu-anti-PY) at a final conc of 0.025 nM.

The assay plate is read in either a Discovery or a RubyStar. The eu-anti-PY is excited at 320 nm and emits at 615 nm to excite the SA-APC which in turn emits at 655 nm. The ratio of SA-APC at 655 nm (excited due to close proximity to the Eu-anti-PY because of phosphorylation of the peptide) to free Eu-anti-PY at 615 nm will give substrate phosphorylation.

Human mixed lymphocyte reaction (huMLR) : The purpose of this assay is to test the potency of T cell activation inhibitors in an in vitro model of allogeneic T cell stimulation. Human peripheral blood lymphocytes (hPBL ; 2 x 105/well) are incubated with mitomycin C-treated B lymphoblastoid cells (JY cell line; 1 x 105/well) as allogeneic stimulators in the presence or absence of dilutions of potential inhibitor compound in 96-well round-bottom tissue culture plates. These cultures are incubated at 37 °C in 5% CO2 for 6 days total. The proliferative response of the hPBL is measured by 3H-thymidine incorporation overnight between days 5 and 6 after

initiation of culture. Cells are harvested onto glass fiber filters and 3H-thymidine incorporation into DNA is analyzed by liquid scintillation counter. Examples 289,314, 325,342, 467,541, 583, 589,611, 657, 732, and 816, for example, inhibited T-cell activation with ICso's below 100 nM.

Jurkat proliferation/survival assay: The purpose of this assay is to test the general anti-proliferative/cytotoxic effect of compounds on the Jurkat human T cell line. Jurkat cells (1 x 105/well) are plated in 96-well flat-bottom tissue culture plates with or without compound dilutions and cultured for 72 h at 37 °C in 5% CO2. Viable cell number is determined during the last 4 h of culture by adding 10 eL/well WST-I dye. WST-1 dye conversion relies on active mitochondrial electron transport for reduction of the tetrazolium dye. The dye conversion is read by OD at 450-600 nm.

Anti-CD3/CD28-induced T cell IL-2 secretion and proliferation assay: The purpose of this assay is to test the potency of T cell receptor (TCR; CD3) and CD28 signaling pathway inhibitors in human T cells. T cells are purified from human peripheral blood lymphocytes (hPBL) and pre-incubated with or without compound prior to stimulation with a combination of an anti- CD3 and an anti-CD28 antibody in 96-well tissue culture plates (1 x 105 T cells/well). Cells are cultured for ~20 h at 37 °C in 5% CO2, then secreted IL-2 in the supernatants is quantified by cytokine ELISA (Pierce/Endogen). The cells remaining in the wells are then pulsed with 3H-thymidine overnight to assess the T cell proliferative response. Cells are harvested onto glass fiber filters and 3H-thymidine incorporation into DNA is analyzed by liquid scintillation counter. For comparison purposes, phorbol myristic acid (PMA) and calcium ionophore can be used in combination to induce IL-2 secretion from purified T cells. Potential inhibitor compounds can be tested for inhibition of this response as described above for anti-CD3 and-CD28 antibodies.

Other compounds described in the following patents and patent applications can be used in combination therapy: US 6, 258,812, US 2003/0105091, WO 01/37820, US 6, 235,764, WO 01/32651, US 6,630, 500, US 6,515, 004, US 6,713, 485, US 5,521, 184, US 5,770, 599, US 5,747, 498, WO 02/68406, WO 02/66470, WO 02/55501, WO 04/05279, WO 04/07481, WO 04/07458, WO 04/09784, WO 02/59110, WO 99/45009, WO 00/59509, WO 99/61422, US 5,990, 141, WO 00/12089 and WO 00/02871.

In some embodiments, the combination comprises a composition of the present invention in combination with at least one anti-angiogenic agent. Agents are inclusive of, but not limited to, in vitro synthetically prepared chemical compositions, antibodies, antigen binding regions, radionuclides, and combinations and conjugates thereof. An agent can be an agonist, antagonist, allosteric modulator, toxin or, more generally, may act to inhibit or stimulate its target (e. g., receptor or enzyme activation or inhibition), and thereby promote cell death or arrest cell growth.

Exemplary anti-tumor agents include HERCEPTINTM (trastuzumab), which may be used to treat breast cancer and other forms of cancer, and RITUXANw (rituximab), ZEVALINTM (ibritumomab

tiuxetan), and LYWHOCIDETM (epratuzumab), which may be used to treat non-Hodgkin's lymphom and other forms of cancer, GLEEVACTM which may be used to treat chronic myeloid leukemia and gastrointestinal stromal tumors, and BEXXARTM (iodine 131 tositumomab) which may be used for treatment of non-Hodgkins's lymphoma.

Exemplary anti-angiogenic agents include ERBITUX (IMC-C225), KDR (kinase domain receptor) inhibitory agents (e. g. , antibodies and antigen binding regions that specifically bind to the kinase domain receptor), anti-VEGF agents (e. g. , antibodies or antigen binding regions that specifically bind VEGF, or soluble VEGF receptors or a ligand binding region thereof) such as AVASTRM or VEGF- TRAP, and anti-VEGF receptor agents (e. g. , antibodies or antigen binding regions that specifically bind thereto), EGFR inhibitory agents (e. g. , antibodies or antigen binding regions that specifically bind thereto) such as ABX-EGF (panitumumab), IRESSATM (gefitinib), TARCEVATM (erlotinib), anti-Angl and anti- Ang2 agents (e. g. , antibodies or antigen binding regions specifically binding thereto or to their receptors, e. g. , Tie2/Tek), and anti-Tie2 kinase inhibitory agents (e. g. , antibodies or antigen binding regions that specifically bind thereto). The pharmaceutical compositions of the present invention can also include one or more agents (e. g. , antibodies, antigen binding regions, or soluble receptors) that specifically bind and inhibit the activity of growth factors, such as antagonists of hepatocyte growth factor (HGF, also known as Scatter Factor), and antibodies or antigen binding regions that specifically bind its receptor"c-met".

Other anti-angiogenic agents include Campath, IL-8, B-FGF, Tek antagonists (Ceretti et al. , US Publication No. 2003/0162712; US Patent No. 6,413, 932), anti-TWEAK agents (e. g., specifically binding antibodies or antigen binding regions, or soluble TWEAK receptor antagonists; see, Wiley, US Patent No.

6,727, 225), ADAM distintegrin domain to antagonize the binding of integrin to its ligands (Fanslow et al., US Publication No. 2002/0042368), specifically binding anti-eph receptor and/or anti-ephrin antibodies or antigen binding regions (US Patent Nos. 5,981, 245; 5,728, 813; 5,969, 110; 6,596, 852; 6,232, 447; 6,057, 124 and patent family members thereof), and anti-PDGF-BB antagonists (e. g., specifically binding antibodies or antigen binding regions) as well as antibodies or antigen binding regions specifically binding to PDGF-BB ligands, and PDGFR kinase inhibitory agents (e. g. , antibodies or antigen binding regions that specifically bind thereto).

Additional anti-angiogenic/anti-tumor agents include : SD-7784 (Pfizer, USA); cilengitide. (Merck KGaA, Germany, EPO 770622); pegaptanib octasodium, (Gilead Sciences, USA); Alphastatin, (BioActa, UK); M-PGA, (Celgene, USA, US 5712291); ilomastat, (Arriva, USA, US 5892112) ; emaxanib, (Pfizer, USA, US 5792783); vatalanib, (Novartis, Switzerland); 2-methoxyestradiol, (EntreMed, USA); TLC ELL-12, (Elan, Ireland); anecortave acetate, (Alcon, USA); alpha-D148 Mab, (Amgen, USA); CEP- 7055, (Cephalon, USA); anti-Vn Mab, (Crucell, Netherlands) DAC: antiangiogenic, (ConjuChem, Canada); Angiocidin, (InKine Pharmaceutical, USA); KM-2550, (Kyowa Hakko, Japan); SU-0879, (Pfizer, USA); CGP-79787, (Novartis, Switzerland, EP 970070); ARGENT technology, (Ariad, USA); YIGSR-Stealth, (Johnson & Johnson, USA); fibrinogen-E fragment, (BioActa, UK); angiogenesis inhibitor, (Trigen, UK) ; TBC-1635, (Encysive Pharmaceuticals, USA); SC-236, (Pfizer, USA); ABT-567, (Abbott, USA); Metastatin, (EntreMed, USA); angiogenesis inhibitor, (Tripep, Sweden); maspin, (Sosei, Japan); 2-

methoxyestradiol, (Oncology Sciences Corporation, USA); ER-68203-00.

Labs, USA); Tz-93, (Tsumura, Japan); TAN-1120, (Takeda, Japan); FR-111142, (Fujisawa, Japan, JP 02233610); platelet factor 4, (RepliGen, USA, EP 407122); vascular endothelial growth factor antagonist, (Borean, Denmark); cancer therapy, (University of South Carolina, USA); bevacizumab (pINN), (Genentech, USA); angiogenesis inhibitors, (SUGEN, USA); XL 784, (Exelixis, USA); XL 647, (Exelixis, USA); MAb, alpha5beta3 integrin, second generation, (Applied Molecular Evolution, USA and MedImmune, USA); gene therapy, retinopathy, (Oxford BioMedica, UK); enzastaurin hydrochloride (USAN), (Lilly, USA); CEP 7055, (Cephalon, USA and Sanofi-Synthelabo, France); BC 1, (Genoa Institute of Cancer Research, Italy); angiogenesis inhibitor, (Alchemia, Australia); VEGF antagonist, (Regeneron, USA); rBPI 21 and BPI-derived antiangiogenic, (XOMA, USA); PI 88, (Progen, Australia); cilengitide (pINN), (Merck KGaA, German; Munich Technical University, Germany, Scripps Clinic and Research Foundation, USA); cetuximab (INN), (Aventis, France); AVE 8062, (Ajinomoto, Japan); AS 1404, (Cancer Research Laboratory, New Zealand); SG 292, (Telios, USA); Endostatin, (Boston Childrens Hospital, USA); ATN 161, (Attenuon, USA); ANGIOSTATIN, (Boston Childrens Hospital, USA); 2-methoxyestradiol, (Boston Childrens Hospital, USA); ZD 6474, (AstraZeneca, UK); ZD 6126, (Angiogene Pharmaceuticals, UK); PPI 2458, (Praecis, USA); AZD 9935, (AstraZeneca, UK) ; AZD 2171, (AstraZeneca, UK) ; vatalanib (pINN), (Novartis, Switzerland and Schering AG, Germany); tissue factor pathway inhibitors, (EntreMed, USA); pegaptanib (Pinn), (Gilead Sciences, USA); xanthorrhizol, (Yonsei University, South Korea); vaccine, gene-based, VEGF-2, (Scripps Clinic and Research Foundation, USA); SPV5.2, (Supratek, Canada); SDX 103, (University of California at San Diego, USA); PX 478, (ProlX, USA); METASTATIN, (EntreMed, USA); troponin I, (Harvard University, USA); SU 6668, (SUGEN, USA); OXI 4503, (OXiGENE, USA); o-guanidines, (Dimensional Pharmaceuticals, USA); motuporamine C, (British Columbia University, Canada); CDP 791, (Celltech Group, UK); atiprimod (pINN), (GlaxoSmithKline, UK); E 7820, (Eisai, Japan); CYC 381, (Harvard University, USA); AE 941, (Aeterna, Canada); vaccine, angiogenesis, (EntreMed, USA); urokinase plasminogen activator inhibitor, (Dendreon, USA); oglufanide (pINN), (Melmotte, USA); HIF-lalfa inhibitors, (Xenova, UK); CEP 5214, (Cephalon, USA); BAY RES 2622, (Bayer, Germany); Angiocidin, (InKine, USA); A6, (Angstrom, USA); KR 31372, (Korea Research Institute of Chemical Technology, South Korea); GW 2286, (GlaxoSmithKline, UK); EHT 0101, (ExonHit, France); CP 868596, (Pfizer, USA); CP 564959, (OSI, USA); CP 547632, (Pfizer, USA); 786034, (GlaxoSmithKline, UK); KRN 633, (Kirin Brewery, Japan); drug delivery system, intraocular, 2-methoxyestradiol, (EntreMed, USA); anginex, (Maastricht University, Netherlands, and Minnesota University, USA); ABT 510, (Abbott, USA); AAL 993, (Novartis, Switzerland); VEGI, (ProteomTech, USA); tumor necrosis factor-alpha inhibitors, (National Institute on Aging, USA); SU 11248, (Pfizer, USA and SUGEN USA); ABT 518, (Abbott, USA); YH16, (Yantai Rongchang, China); S-3APG, (Boston Childrens Hospital, USA and EntreMed, USA); MAb, KDR, (ImClone Systems, USA); MAb, alpha5 betal, (Protein Design, USA); KDR kinase inhibitor, (Celltech Group, UK, and Johnson & Johnson, USA); GFB 116, (South Florida University, USA and Yale University, USA); CS 706, (Sankyo, Japan); combretastatin A4 prodrug, (Arizona State University,

USA); chondroitinase AC, (IBEX, Canada); BAY RES 2690, (Bayer, Germany); AGM 1470, (Harvard University, USA, Takeda, Japan, and TAP, USA); AG 13925, (Agouron, USA); Tetrathiomolybdate, (University of Michigan, USA); GCS 100, (Wayne State University, USA) CV 247, (Ivy Medical, UK); CKD 732, (Chong Kun Dang, South Korea); MAb, vascular endothelium growth factor, (Xenova, UK) ; irsogladine (INN), (Nippon Shinyaku, Japan); RG 13577, (Aventis, France); WX 360, (Wilex, Germany); squalamine (plNN), (Genaera, USA); RPI 4610, (Sirna, USA); cancer therapy, (Marinova, Australia); heparanase inhibitors, (InSight, Israel); KL 3106, (Kolon, South Korea); Honokiol, (Emory University, USA); ZK CDK, (Sobering AG, Germany); ZK Angio, (Schering AG, Germany); ZK 229561, (Novartis, Switzerland, and Schering AG, Germany); XMP 300, (XOMA, USA); VGA 1102, (Taisho, Japan); VEGF receptor modulators, (Pharmacopeia, USA); VE-cadherin-2 antagonists, (ImClone Systems, USA); Vasostatin, (National Institutes of Health, USA); vaccine, Flk-1, (ImClone Systems, USA); TZ 93, (Tsumura, Japan); TumStatin, (Beth Israel Hospital, USA); truncated soluble FLT 1 (vascular endothelial growth factor receptor 1), (Merck & Co, USA); Tie-2 ligands, (Regeneron, USA); and, thrombospondin 1 inhibitor, (Allegheny Health, Education and Research Foundation, USA).

FORMULATIONS Also embraced within this invention is a class of pharmaceutical compositions comprising the active compounds of Formula I-VII in association with one or more non-toxic, pharmaceutically- acceptable carriers and/or diluents and/or adjuvants (collectively referred to herein as"carrier"materials) and, if desired, other active ingredients. The active compounds of the present invention may be administered by any suitable route, preferably in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended. The compounds and compositions of the present invention may, for example, be administered orally, mucosally, topically, rectally, pulmonarily such as by inhalation spray, or parentally including intravascularly, intravenously, intraperitoneally, subcutaneously, intramuscularly intrasternally and infusion techniques, in dosage unit formulations containing conventional pharmaceutically acceptable carriers, adjuvants, and vehicles.

The pharmaceutically active compounds of this invention can be processed in accordance with conventional methods of pharmacy to produce medicinal agents for administration to patients, including humans and other mammals.

For oral administration, the pharmaceutical composition may be in the form of, for example, a tablet, capsule, suspension or liquid. The pharmaceutical composition is preferably made in the form of a dosage unit containing a particular amount of the active ingredient. Examples of such dosage units are tablets or capsules. For example, these may contain an amount of active ingredient from about 1 to 2000 mg, preferably from about 1 to 500 mg. A suitable daily dose for a human or other mammal may vary widely depending on the condition of the patient and other factors, but, once again, can be determined using routine methods.

The amount of compounds which are administered and the dosage regimen for treating a disease condition with the compounds and/or compositions of this invention depends on a variety of factors,

including the age, weight, sex and medical condition of the subject, the type of disease, the severity of the disease, the route and frequency of administration, and the particular compound employed. Thus, the dosage regimen may vary widely, but can be determined routinely using standard methods. A daily dose of about 0. 01 to 100 mg/kg, or between about 0. 01 and about 20 mg/kg, or between about 0. 01 and about 10 mg/kg body weight may be appropriate. The daily dose can be administered in one to four doses per day.

For therapeutic purposes, the active compounds of this invention are ordinarily combined with one or more adjuvants appropriate to the indicated route of administration. If administered per os, the compounds may be admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration. Such capsules or tablets may contain a controlled-release formulation as may be provided in a dispersion of active compound in hydroxypropylmethyl cellulose.

In the case of psoriasis and other skin conditions, it may be preferable to apply a topical preparation of compounds of this invention to the affected area two to four times a day.

Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin (e. g. , liniments, lotions, ointments, creams, or pastes) and drops suitable for administration to the eye, ear, or nose. A suitable topical dose of active ingredient of a compound of the invention is 0.1 mg to 150 mg administered one to four, preferably one or two times daily. For topical administration, the active ingredient may comprise from 0.001% to 10% w/w, e. g., from 1% to 2% by weight of the formulation, although it may comprise as much as 10% w/w, but preferably not more than 5% w/w, and more preferably from 0. 1 % to 1 % of the formulation.

When formulated in an ointment, the active ingredients may be employed with either paraffinic or a water-miscible ointment base. Alternatively, the active ingredients may be formulated in a cream with an oil-in-water cream base. If desired, the aqueous phase of the cream base may include, for example at least 30% w/w of a polyhydric alcohol such as propylene glycol, butane-1, 3-diol, mannitol, sorbitol, glycerol, polyethylene glycol and mixtures thereof. The topical formulation may desirably include a compound which enhances absorption or penetration of the active ingredient through the skin or other affected areas. Examples of such dermal penetration enhancers include DMSO and related analogs.

The compounds of this invention can also be administered by a transdermal device. Preferably transdermal administration will be accomplished using a patch either of the reservoir and porous membrane type or of a solid matrix variety. In either case, the active agent is delivered continuously from the reservoir or microcapsules through a membrane into the active agent permeable adhesive, which is in contact with the skin or mucosa of the recipient. If the active agent is absorbed through the skin, a controlled and predetermined flow of the active agent is administered to the recipient. In the case of microcapsules, the encapsulating agent may also function as the membrane.

The oily phase of the emulsions of this invention may be constituted from known ingredients in a known manner. While the phase may comprise merely an emulsifier, it may comprise a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil. Preferably, a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabilizer. It is also preferred to include both an oil and a fat. Together, the emulsifier (s) with or without stabilizer (s) make-up the so-called emulsifying wax, and the wax together with the oil and fat make up the so-called emulsifying ointment base which forms the oily dispersed phase of the cream formulations. Emulsifiers and emulsion stabilizers suitable for use in the formulation of the present invention include Tween 60, Span 80, cetostearyl alcohol, myristyl alcohol, glyceryl monostearate, sodium lauryl sulfate, glyceryl distearate alone or with a wax, or other materials well known in the art.

The choice of suitable oils or fats for the formulation is based on achieving the desired cosmetic properties, since the solubility of the active compound in most oils likely to be used in pharmaceutical emulsion formulations is very low. Thus, the cream should preferably be a non-greasy, non-staining and washable product with suitable consistency to avoid leakage from tubes or other containers. Straight or branched chain, mono-or dibasic alkyl esters such as di-isoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2- ethylhexyl palmitate or a blend of branched chain esters may be used. These may be used alone or in combination depending on the properties required. Alternatively, high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils can be used.

Formulations suitable for topical administration to the eye also include eye drops wherein the active ingredients are dissolved or suspended in suitable carrier, especially an aqueous solvent for the active ingredients. The active ingredients are preferably present in such formulations in a concentration of 0.5 to 20%, advantageously 0.5 to 10% and particularly about 1.5% w/w.

Formulations for parenteral administration may be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. These solutions and suspensions may be prepared from sterile powders or granules using one or more of the carriers or diluents mentioned for use in the formulations for oral administration or by using other suitable dispersing or wetting agents and suspending agents. The compounds may be dissolved in water, polyethylene glycol, propylene glycol, EtOH, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, tragacanth gum, and/or various buffers. Other adjuvants and modes of administration are well and widely known in the pharmaceutical art. The active ingredient may also be administered by injection as a composition with suitable carriers including saline, dextrose, or water, or with cyclodextrin (ie. Captisol), cosolvent solubilization (ie. propylene glycol) or micellar solubilization (ie. Tween 80).

The sterile injectable preparation may also be a sterile injectable solution or suspension in a non- toxic parenterally acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending

medium. For this purpose any bland fixed oil may be employed, including synthetic mono-or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

For pulmonary administration, the pharmaceutical composition may be administered in the form of an aerosol or with an inhaler including dry powder aerosol.

Suppositories for rectal administration of the drug can be prepared by mixing the drug with a suitable non-irritating excipient such as cocoa butter and polyethylene glycols that are solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum and release the drug.

The pharmaceutical compositions may be subjected to conventional pharmaceutical operations such as sterilization and/or may contain conventional adjuvants, such as preservatives, stabilizers, wetting agents, emulsifiers, buffers etc. Tablets and pills can additionally be prepared with enteric coatings. Such compositions may also comprise adjuvants, such as wetting, sweetening, flavoring, and perfuming agents.

The foregoing is merely illustrative of the invention and is not intended to limit the invention to the disclosed compounds. Variations and changes which are obvious to one skilled in the art are intended to be within the scope and nature of the invention which are defined in the appended claims.

From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.

No unacceptable toxological effects are expected when compounds of the present invention are administered in accordance with the present invention.

All mentioned references, patents, applications and publications, are hereby incorporated by reference in their entirety, as if here written.